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Lysosomal glycosidases: inherited deficiency, molecular 
aspects, and novel chemical probes 
  




    
arbohydrates are the most abundant biomolecules on earth and they are besides 
nucleic acids, proteins, and lipids one of  the four major macromolecules essential 
for life.1 They are structurally very diverse as the result of  the occurrence of  
different monosaccharide building blocks, and different linkages among these. The most utilized 
monosaccharides are pentose and hexose (five- or six- carbon sugars), whose ketone or aldehyde 
can spontaneously react with one of  its own hydroxyl, forming a stable five-membered ring 
(furanose, e.g. fructose and ribose) or a six-membered ring (pyranose, e.g. glucose). This is 
accompanied by two possible stereochemical outcomes (α- or a β-anomer, where the hemiacetal 
hydroxyl points to opposite directions from the ring plane). In addition, the monomers can have 
different hydroxyl configurations (e.g. glucose, galactose, and mannose), and their hydroxyl(s) 
may be substituted with other types of  functional group (e.g. N-acetyl, carboxylic acid, sulfate). 
The ten commonly utilized monosaccharide building blocks in life are glucose, galactose, 
mannose, glucuronic acid, L-iduronic acid, neuraminic acid, N-acetylglucosamine (GlcNAc), N-
acetylgalactosamine (GalNAc), L-fucose, and xylose (Fig. 1A).2 When these are linked together 
through glycosidic linkages at different hydroxyl positions (on the reducing-end sugar), a large 
number of  possible polymeric structures (oligosaccharides and polysaccharides) can be formed. 
For example, a simple hexasaccharide constituting of  a single type of  hexose can form 1.05 x 
1012 different isomers.3 Finally, carbohydrates can also linked to other biomolecules, such as 
protein and lipids, forming glycoconjugates that are also structurally diverse (Fig 1B). These 
entail specific cellular functions such as energy storage (i.e. glycogen and starch), structural 
integrity (i.e. cellulose and chitin), and a plethora of  fundamental cellular processes in eukaryotes, 
ranging from glycoprotein folding and targeting, inter- and intra-cellular signaling, and cellular 
interaction/recognition events underlying infection, immune response, and cancer.1 In 
vertebrates, glycan synthesis is carried out by ~200 glycosyltransferases, mostly are Golgi 
enzymes that transfer monosaccharides to the glycans’ non-reducing end using high-energy 
nucleotide sugar donors.2, 6 
 In contrast, glycan degradation largely takes place in lysosomes. The lysosomes are 
ubiquitous cellular organelles with an acid interior; they contain a range of  acid hydrolases 
fragmenting macromolecules that may enter lysosomes through endocytosis and autophagy. 
Degradation products are exported from lysosomes via specific transporters for re-use in the 






glycosidic bonds presented on the structurally diverse glycoconjugates. These lysosomal 
glycosidases are proficient catalytic machines that can accelerate the hydrolysis of  glycosidic 
bonds by a factor of  1017.7 Most of  them hydrolyze a specific type of  reducing-end 
monosaccharide with either α- or β-anomeric linkage, from glycans presented on 
glycosphingolipids or liberated from other types of  glycoconjugate. Paradoxically, the impressive 
substrate specificity and high catalytic efficiency of  lysosomal glycosidases forms the basis of  a 
number of  inherited metabolic diseases in man (Part I). Deficiency of  a single lysosomal 
glycosidase can cause major disturbances in metabolism, ultimately translating in clinical  
 
Figure 1. Structures of A) monosaccharide building blocks and B) a selected set of 
glycoconjugates with their main cellular functions. 
Figure 1
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symptoms. Research on lysosomal glycosidases and corresponding diseases have prompted the 
design of  mechanism-based chemical probes for enzyme profiling to facilitate investigations on 
glycosidases in health and disease in an unprecedented manner (Part II). 
Part I. Glycosidases and inherited metabolic diseases 
Pioneering work in the 50’s and 60’s revealed that inborn deficiencies of  particular 
lysosomal glycosidases are the molecular basis of  a number of  inherited metabolic disorders, 
collectively coined as lysosomal storage disorders (LSDs).8–10 Individual LSDs are rare, and the 
combined incidence rate is about 1 in 5,000–8,000 newborns.11, 12 The prevalence of  some LSDs 
can be however high in specific populations: for example, the prevalence of  Gaucher disease 
among Ashkenazi Jewish individuals is reported to be 1 in 450–850 newborns.13, 14 To date, more 
than 50 discrete LSDs are recognized. Lysosome dysfunction may result from defects in 
formation of  lysosomes, stability of  the cell organelle, export of  degradation products and 
failure of  fragmentation processes. Most LSDs are caused by primary defects in enzymes: about 
one-third of  the LSDs is caused by deficiencies of  lysosomal glycosidases (Table 1). 
The best studied LSD is Gaucher disease (GD), where deficiency of  lysosomal β-
glucosidase (glucocerebrosidase; GBA) leads to prominent accumulation of  the substrate 
glucosylceramide in lysosomes of  tissue macrophages that transform into lipid-laden Gaucher 
cells. These viable storage macrophages are thought to underlie characteristic symptoms of  GD 
patients such as hepatosplenomegaly and pancytopenia (shortage of  red blood cells and 
platelets).15 In the case of  GD, the progression and severity of  disease, and occurrence of  
particular signs and symptoms varies greatly among patients, even homozygotic twins.16, 17 The 
cause for this phenotypic variation of  GD is presently largely unclear, hypothetically being 
attributed to modifier genes and other factors. 18–22 More severely affected GD patients (type 2 
and type 3) develop marked skeletal disease, fatal neurological symptoms and impaired skin 
permeability. The pathophysiological mechanisms driving the latter symptoms have not been 
elucidated yet.14 Alternative excessive metabolism of  glucosylceramide by the cytosolic β-
glucosidase GBA2 as well as the formation of  toxic glucosylsphingosine from accumulating 
glucosylceramide in lysosomes is considered to contribute to particular symptoms of  GD 
patients.15, 21 Mutations in the GBA gene are at present also the highest known risk factor for  
developing Parkinson’s disease23 and Dementia of  Lewy Bodies.24, 25 The surprising link between 





Table 1. Selected lysosomal glycosidases and underlying lysosomal storage diseases. 
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dosis type IVB, 
MPS 4B)
(OMIM #  253010)
Type I (infantile):
Pyschomotor deterioration, 
central nervous system 
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hepatosplenomegaly, 
macular cherry-red spot, 
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dysmorphism
Type II (late infantile/juvenile):
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Table 1.  (Continued) 
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Pompe disease is another relatively common LSD caused by deficiency of  a lysosomal 
glycosidase, in this case the acid α-glucosidase (GAA).26 Affected patients are characterized by 
abnormal lysosomal accumulation of  undegraded glycogen in muscle and bone cells, leading to 
progressive muscle weakness, respiratory failure, and in the severe cases death in early childhood 
(Table 1).26 GM1 gangliosidosis is an LSD in the subgroup of  (glyco)sphingolipidosis, in which 
the primary accumulating substrate is the  (glyco)sphingolipid GM1 ganglioside. It is caused by 
deficiency in the lysosomal β-galactosidase (GLB1).27 The lysosomal accumulation of  GM1 
ganglioside affects both the central and peripheral nervous system, resulting in 
neurodegeneration in affected patients (Table 1).28 Hurler syndrome (Mucopolysaccharidosis 
Type I, MPS 1)29 and Sly syndrome (MPS 7)30 are mucopolysaccharidoses, in which enzyme 
deficiency (α- L-iduronidase and β-glucuronidase, respectively) causes accumulation of  
glycosaminoglycans (GAGs, or mucopolysaccharides). Patients typically exhibit abnormality in 
bone and connective tissues, as well as in the brain (Table 1), due to impaired GAG metabolism. 
Finally, the oligosaccharidoses α- and β-mannosidosis are caused by deficiency in lysosomal α- 
or β-mannosidases.31, 32 Both diseases are characterized by the accumulation of  undegraded 
oligosaccharides deriving from N-linked glycoproteins and lipid carriers of  the N-linked glycan, 
which manifests in clinical features such as mental retardation and facial dysmorphism (Table 
1).  
Enzyme replacement therapy The realization that a single enzyme deficiency underlies 
specific LSD has prompted the design of  therapeutic approaches that aim to either replace the 
defective enzyme with a normal one, to stabilize and activate the residual mutant enzyme, or to 
reduce the accumulating substrates for reducing their cytotoxic effects (Fig. 2).12 Gaucher disease, 
in particular the non-neuropathic type 1 variant, has been the frontrunner in development of  
therapy approaches. Building on the finding that bone marrow transplantation of  GD patients, 
replacing the white blood cell lineage with hematopoietic stem cells capable of  producing GBA 
competent macrophages, renders major clinical improvements, correction of  macrophages in 
type 1 GD patients by enzyme supplementation, so-called enzyme-replacement therapy (ERT) 
has been actively studied.33 First conceived by Brady and co-workers in 1960s,34 ERT with 
macrophage-targeted GBA results in remarkable reduction of  hepatosplenomegaly, anemia, and 
thrombocytopenia in Gaucher patients.35, 36 The originally approved therapeutic enzyme was 
isolated from human placenta, and its complex-type N-glycans were chemically modified into 
terminal high-mannose N-glycans,35 resulting in efficient uptake by (affected) macrophages  




Figure 2. Lysosomal storage diseases and current therapeutic strategies. A) Substrate hydrolysis 
by glycosidases in normal individuals. B) Enzyme defects in lysosomal storage disease (LSD) patients 
lead to lysosomal dysfunction. C) Therapeutic strategies for LSDs. ERT, enzyme replacement therapy; 
PCT, pharmacological chaperon therapy; SRT, substrate reduction therapy; BMT, bone-marrow 
transplantation; HSCT, hematopoietic stem cell transplantation. 
expressing the mannose receptors. Later therapeutic enzymes were produced in Chinese hamster 
ovary (CHO) cells (Imiglucerase, Cerezyme®). Now several therapeutic glucocerebrosidase 
preparations, produced in various cell types including carrot cells, are registered for therapeutic 
use in type 1 GD patients.37, 38 The success of  ERT for type 1 Gaucher disease, aided with the 
passing of  Orphan Drug Act in the US in 1983, prompted the development of  ERT for other 
diseases by the pharmacological industry. Approved by the Food and Drug Administration (FDA) 
in the USA or similar agencies in other parts of  the world are therapeutic enzymes for Pompe 




















































and Agalsidase beta, Replagal®), Hurler syndrome (Laronidase, Aldurazyme®),32 and recently Sly 
syndrome (Vestronidase alfa, Mepsevii®)39 and α-mannosidosis (Velmanase alfa, Lamzede®).40  
Other therapeutic options A caveat of  presently registered therapeutic enzymes is their poor 
penetration to certain types of  tissue (including bone, muscle), but most particular the brain. At 
present, bone marrow transplantation or hematopoietic stem cells transplantation is investigated 
for Gaucher disease41 and remain the only viable therapeutic options for some LSDs affecting 
the central nervous system, such as Krabbe disease and GM1 gangliosidosis.27, 42, 43 Two other 
major therapeutic strategies for LSDs based on small molecules are now available on the market, 
namely pharmacological chaperon therapy (PCT) and substrate reduction therapy (SRT). The 
former makes use of  small chemicals that interact with enzymes with folding defects, which 
stabilize the enzyme in during its maturation and promote their correct transportation to the 
lysosomes.44 Such therapy is currently only available for Fabry disease,45 while other types of  
chaperone therapy, such as induction of  heat-shock proteins to stabilize glycosidase folding and 
function, are also under development.46 For SRT, the aim is not to correct for the defective 
enzyme, but to reduce the amount of  accumulating substrates by inhibiting the enzymes 
accounting for their synthesis.47, 48 To date, Gaucher disease is the only LSD with lysosomal 
glycosidase deficiency with approved SRT options based on orally administered inhibitors of  
glucosylceramide synthase: the iminosugar Miglustat (N-butyl-deoxynojirimycin)49 and the more 
potent and specific ceramide mimic Eliglustat.50 Another actively pursued therapeutic approach 
for LSDs is gene therapy. Studied are several approaches, in modifying patients’ hematopoietic 
stem cells ex vivo with lentiviral vectors encoding wild-type enzymes, or injecting the patient with 
engineered adeno-associated viral (AAV) vectors encoding the enzyme.51, 52 The promotor and 
the site of  injection for the later approach can be tailored according to the disease and affected 
tissue types, and the treatment would only require one-time injection—an obvious advantage 
compared to the life-long treatment regimen for ERT, PCT, and SRT. Safety remains the major 
concern, which has translated to strict manufacturing regulation and thus high pricing—the 
current major hurdle for developing such therapy. 
Diagnosis Traditionally, the diagnosis of  an LSD is made based on clinical symptoms, and later 
confirmed by genetic and biochemical analyses. However, due to the rarity and associated poor 
awareness of  LSDs, as well as their considerable heterogeneity in clinical presentation, in most 
countries their correct diagnosis remains challenging.22, 53 This prompts new-born screening 




(NBS) programs in many parts of  the world, aiming to detect patients before they show the first 
symptoms. Early treatment of  many LSDs is increasingly considered to be essential to achieve 
maximum therapeutic outcome. The first-line screening sometimes builds on genetic testing. 
However, many LSDs show poor genotype-phenotype correlations, and in addition it remains 
challenging to interpret novel (mild) mutations as being a polymorphism or disease-causing 
trait.54 Detection of  biomarkers (surrogate biochemical markers of  disease manifestation and/or 
progression) assist diagnosis, but for many LSD these are unavailable.15, 55 In the case of  LSDs 
caused by enzyme deficiencies, biochemical activity assays are viewed as the gold standard. In 
many cases these indeed allow reliable confirmation of  diagnosis. Traditionally, enzyme activity 
assays involve measurement of  residual activity in cultured patients’ fibroblasts or collected white 
blood cells using artificial fluorogenic substrates, such as 4-methylumbelliferyl (4-MU) glycosides. 
Such assays may suffer from low dynamic range,56 cross activity from other enzymes, and 
inability to multiplex with other enzyme assays. More recently, microfluidic-based 4-MU assay 
platform57, 58 and an MS-based multiplex method using deuterium natural substrates59, 60 have 
been developed and implemented in several NBS programs in the USA and other parts of  the 
world, using dried-blood spots collected from patients as enzyme source. A major obstacle is the 
need for specialized laboratories employing validated measurements, still unavailable in most 
parts of  the world. Furthermore, each method has its own limitations, as the microfluidic 
method does not solve the low-dynamic range issue intrinsic to the 4-MU assay, and the MS-
based method requires laborious procedures and considerable technical know-how.54 
Part II. Lysosomal glycosidases: from molecular understanding to novel chemical tools 
 Fundamental research in the last decades on lysosomal enzymes, including glycosidases, 
has revealed some commonalities among these enzymes. The hydrolases show optimal activity 
at acid pH, coinciding with the low lysosomal pH value. In general, lysosomal glycosidases are 
relatively resistant against proteolytic degradation and survive for more than one day in the lytic 
lysosome environment. For many of  the lysosomal glycosidase the 3D-structure has been 
determined by means of  crystallography and X-ray diffraction. 
Life cycle of  lysosomal glycosidases It is now well-established that lysosomal 
glycosidases are formed at the endoplasmic reticulum and are subsequently are routed to the 
lysosomes via the mannose-6-phosphate (M6P)-dependent pathway. Nascent lysosomal 





(typically 20-25 amino acids), which is cleaved from the nascent preproproteins by the ER-
resident signal peptidase.61 The resulting proproteins are glycosylated at selective Asn residues 
(Asn-X-Ser/Thr, where X cannot be Pro or Asp) with the pre-synthesized Glc3Man9GlcNac2 
glycans transferred en bloc from the dolichol carrier (Fig. 3, step 1).62 N-glycans prove to be 
crucial for the correct folding of  many glycoproteins in the ER. Only after successful folding, 
successive trimming of  terminal glucoses and of  one terminal mannose in N-glycans takes place 
(by processing α-glucosidase I (MOGS), II (GANAB) and ER α-mannosidase (MAN1B1)). Next, 
the  N-glycoproteins are transported to the Golgi apparatus for further modification and 
sorting (Fig. 3, step 2−4).63 In the Golgi, the terminal α-1,2-linked mannoses in the N-glycans 
of  lysosomal proteins are cleaved by the processing mannosidases (Fig. 3, step 5). This enables 
the terminal α-1,6-linked mannose to be modified at the 6 position with a N-acetylglucosamine 
(GlcNAc)-1-phosphate group, catalyzed by GlcNAc-1-phospotransferase (Fig. 3, step 6).64 Next, 
the GlcNAc residue on the GlcNAc-1-phosphate group is released at the trans-Golgi network 
(TGN) by GlcNAc phosphodiesterase (i.e. uncovering enzyme), exposing the mannose-6-
phosphate (M6P) group.65 Two dedicated M6P receptor proteins (MPR300 in particular and 
MPR47 to far lesser extent) recognize the M6P groups presented on the glycosidases, and shuttle 
them via clathrin-coated vesicles to the early or late endosomes (Fig. 3, step 7−9).61  
 Some lysosomal glycosidases are co-transported to the lysosomes in a protein complex, 
such as the β-galactosidase (GLB1)-neuraminidase (Neu1)-cathepsin A complex.66 
Glucocerebrosidase (GBA) does not acquire M6P moieties in its glycans and contrary to other 
lysosomal glycosidases uses an M6P-independent lysosomal targeting pathway involving its 
hydrophobic association with the lysosomal integral protein 2 (LIMP2) (Fig. 3, step a−b).67, 68, 
69 As the early/late endosomes mature into lysosomes, gradual acidification of  the lumen from 
pH 6.0 to below 5.0 facilitates (partial) dissociation of  GBA from LIMP2 and dissociation of  
other lysosomal glycosidases from the MPRs (in particular MPR300) (Fig. 3, step c). LIMP2 
stays in lysosomes, while MPRs are recycled back to the TGN via retrograde transport (Fig. 3, 
step 10).61 An estimated 10 % of  the total cellular MPRs reside at the plasma membrane, where 
they function in “fishing back” the secreted lysosomal glycosidases (both from the same cell or 
from other cells) to the lysosomes via endocytosis (Fig. 3, step 11−13).61 In the lysosome, most 
of  the glycosidases (e.g. α-galactosidase, α- L-fucosidase, α-glucosidase, β-glucuronidase, α- L-
iduronidase, α-mannosidase, β-galactosidase, and galactocerebrosidase) undergo proteolytic  





Figure 3. Lysosomal targeting of glycosidases. TGN, trans-Golgi network. MPR, mannose-6-
phosphate receptor. GBA, glucocerebrosidase. LIMP2, lysosomal integral protein 2. P, phosphate group. 
Dashed lines, retrograde transport of MPR from early and late endosomes to TGN. Glycosylation on GBA 
is omitted for clarity. 
cleavage (Fig. 3, step 14), producing the final mature enzymes.70 
Catalytic mechanisms It has been observed in the first half  of  20th century that most 
glycosidases can be categorized into two groups according to the stereochemistry outcome of  
their hydrolysis—either into inverting glycosidases or retaining glycosidases. These groups utilize 
distinct catalytic mechanisms, as firstly described by Daniel E. Koshland Jr. in 1953.71 Inverting 
glycosidases typically possess a catalytic pocket 10.5 Å in width, which allow the accommodation 
of  the glycoside substrate plus a water molecule.72 When correctly orientated, the catalytic base 
deprotonate the water molecule, which attacks the electron-poor anomeric carbon by the 
assistance of  the catalytic acid that attracts electrons from the glycosidic oxygen, distorting the 
glycosidic bond and disrupt the exo-anomeric effect that stabilizes the glycosidic linkage (Fig. 
4A).73 The reaction proceeds through a transient oxocarbenium-like transition state adopted by 
the substrate glycon (the sugar part), and completes in one-step where the hydroxyl replaces the 
aglycon (the rest of  the reducing-end structures linked to the anomeric carbon) situated on the 
opposing side of  the symmetric plane in a typical SN2 mechanism, resulting a product with the 
inversion of  stereochemistry (Fig. 4A). For retaining glycosidases, which include most lysosomal 
glycosidases, the SN2 mechanism occurs twice (Koshland double-displacement mechanism), 
resulting in the net retention of  stereochemistry on the product. The catalytic pocket is narrower 
(typically 5.5 Å apart), and the reaction occurs with protonation of  the glycosidic oxygen by the 
Figure 3























































catalytic acid/base (typically aspartic acid/aspartate or glutamic acid/glutamate) and 
simultaneous nucleophilic attacks at the anomeric carbon by the catalytic nucleophile (aspartate 
or glutamate). This results in a transient oxocarbenium transition state, followed by a covalent 
substrate-enzyme intermediate (Fig. 4B).72 Next, the catalytic acid/base deprotonates a water 
molecule, which displaces the nucleophile in a similar reaction sequence adopted by the inverting 
glycosidases, producing a product with retained stereochemistry (Fig. 4B). 
 
Figure 4. Reaction mechanism of exo-glycosidases towards a β-glucoside. A) Inverting mechanism. 
B) Retaining double-displacement mechanism. *, transition state. R, aglycon. 
It is also known that glycosidases distort their sugar substrates during the course of  their 
catalysis, and typical sets of  conformational changes on the substrate’s glycon during the reaction 
itinerary can be assigned for each glycosidase class (CAZy classification, discussed later).74, 75 For 
example, the glucose on a β-glucoside, such as the β-glucose presented on a glucosylceramide, 
initially adopts a lowest-energy 1C4 conformation, but as it accommodates in the active-site 
pocket of  a retaining β-glucosidase, such as glucocerebrosidase, it is distorted to a skew-boat 
conformation (1S3) that facilitates both protonation by the acid/base and the nucleophilic attack 
by the nucleophile (Fig. 5). The glycon is further distorted to a half-chair conformation (4H3) 
during the transient transition state, and upon the formation of  the new glycosidic bond with 
the nucleophile the glycon adopts a 4C1 chair conformation, becoming an α-glucose (Fig. 5).74, 
75 The second half  of  the reaction distorts the glycon conformation in a reverse order, producing 































Figure 5. Distortion of substrate conformation by retaining β-glucosidase. Bold, conformation 
adopted by the glycon. *, transition state. R, aglycon. 
 Glycosidase can be additionally classified based on the site of  hydrolysis in the substrate. 
Exo-glycosidase releases terminal monosaccharide from the reducing end of  the substrate. Their 
catalytic sites is typically pocket-shaped, allowing interactions with only monosaccharide at the 
reducing end.76 In contrast, endo-glycosidase have a wider cleft- or tunnel-shaped catalytic site, 
which can accommodate multiple sugar residues at the reducing end of  the to-be-hydrolyzed 
glycosidic bond.76 
Sequence-based classification  In order to study glycosidases in a systematic approach, a 
framework named Carbohydrate-Active Enzyme (CAZy) database has been setup, which groups 
glycosidases into over 100 Glycoside Hydrolase (GH) families.77 This classification system is 
based on amino acid sequence homology, instead of  grouping glycosidases solely by their 
catalytic activity (the Enzyme Commission (E.C.) system). Using this system, it turns out that 
glycosidases classified into the same GH family usually possess similar structural features and 
reaction mechanisms. This in turn proves to be useful in predicting catalytic activities by proteins 
with known sequence, as well as the activity of  a known active-site-interacting molecules towards 
enzymes in the same GH family. The second implication has greatly facilitated the design of  
glycosidase active-site interactors as well as inhibitors, and has assisted the development of  
activity-based probes (ABPs), as discussed in the next section. 
Mechanism-based profiling Enzymes with known reaction mechanism invite the design of  
chemical probes that would react covalently with the enzyme’s active site catalytic amino acids, 
allowing the detection of  the enzymes through reporter moiety grafted on the probe. If  the 













based probe (ABP). Crucial for an ABP is its ability to form covalent linkage to the target enzyme, 
for a period long enough to allow their detection. Key structural elements include a reactive 
“warhead”—typically an electrophile, a recognition element that confers specificity towards the 
target enzyme(s), and a reporter group for detection (or a chemical handle for subsequent 
installation of  reporter group) (Fig. 6A).78 
 Known covalent inhibitors of  GBA have been successfully used as scaffolds to design the 
desired ABPs for the enzyme. The suicide inhibitor conduritol B epoxide (CBE, Fig. 6B) 
irreversibly inactivates β-glucosidases and (with lower potency) other glycosidases in a 
mechanism-based manner.79, 80 It has been exploited for the generation of  a Gaucher-like mouse 
model,81 and for the identification of  active sites of  both retaining β- and α-glucosidases.80, 82 
Cyclophellitol, a later discovered natural suicide inhibitor83 and now synthetically available84, 85, 
also reacts with β-glucosidases in a mechanism-based manner and with higher potency (Fig. 
6C).86, 87 Even superior potency is observed by the synthetic compound cyclophellitol aziridine, 
in which the epoxide on cyclophellitol is replaced by an aziridine group (Fig. 6B).88 
 Based on the cyclophellitol scaffold, the first true ABP for lysosomal glycosidase has been 
generated.89 It was synthesized by installing an azide group at the methoxy carbon (C6 by 
glucopyranoside numbering; C8 by cyclophellitol numbering (Fig. 6B)) and the subsequent 
Cu(I)-catalyzed “click” reaction with a BODIPY-alkyne, which generates a BODIPY-substituted 
cyclophellitol (Fig. 6D, ABP 1).89 The ABPs (two BODIPY variants) label glucocerebrosidase 
(GBA) in a mechanism-based manner and with high potency and specificity, allowing detection 
of  endogenous glucocerebrosidase by SDS-PAGE, fluorescence-activated cell sorting (FACS), 
and fluorescence microscopy, and were demonstrated to be useful in the study of  GBA life cycle, 
inhibitor screening (for potential PCT), and diagnosis of  Gaucher disease.89 Later, a suite of  
cyclophellitol and cyclophellitol aziridine-based ABPs containing fluorophores and biotin have 
been developed for retaining β-glucosidases (GBA, non-lysosomal glucosylceramidase (GBA2), 
cytosolic β-glucosidase (GBA3), and lactase phlorizin hydrolase (LPH)) (Fig. 6D, ABP 2, 3),90 
GH27 α-galactosidases,91 GH29 α- L-fucosidases,92 and galactocerebrosidase (GALC).93 The 
designing principle relies on tuning the cyclophellitol scaffold to match the configuration of  the 
substrates from the target glycosidase, and this approach indeed has proved to be successful in 
the specific detection of  enzymes in particular GH family.94 Structural-activity-relationship (SAR)  




Figure 6. Mechanism-based activity profiling for retaining exo-glycosidases. A) Structural elements 
of activity-based probe (ABP). B) Structures of selected irreversible glycosidase inhibitors. C) Mechanism-
based inactivation by cyclophellitol- and cyclophellitol aziridine-based structures. D) Structures of 
glycosidase activity-based probes (ABPs) based on cyclophellitol- (upper) and cyclophellitol aziridine 
(lower) scaffolds. ABP 1, epoxide ABP for glucocerebrosidase89; ABP 2 and 3, aziridine ABPs for β-
glucosidases90, 96. Color scheme same as in A). E) Workflow for activity-based protein profiling (ABPP). 
studies has confirmed this observation, as deleting the C2- or C4-hydroxyls on the aziridine ABP 
render the probes unselective towards specific glycosidase family.95 SAR study also revealed that 
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synthetically tractable and more stable during their synthesis and purification96 Meanwhile, this 
designing strategy has been extended for other (lysosomal) retaining glycosidases, for example 
GH31 α-glucosidases (Chapter 4, this thesis),97 GH2 β-glucuronidases (Chapter 4, this thesis),98 
GH39 α- L-iduronidases (Chapter 5, this thesis),99 GH38 α-mannosidases (Chapter 6, this thesis), 
GH2 β-mannosidases (Chapter 6, this thesis), and GH59 and GH35 β-galactosidases (Chapter 
7, this thesis).  
Applications of  glycosidase activity-based probes Developed applications for the 
mechanism-based glycosidase inhibitors and ABPs include specific visualization of  endogenous 
glycosidases in complex samples such as cell lysates and tissue homogenates based on their 
distinct pH range and molecular weight using SDS-PAGE and fluorescence scanning,100 in intact 
cells using fluorescent microscopy100 and fluorescence-activated cell sorting (FACS),89 and in 
whole tissue sections by fluorescent microscopy (Fig. 6E).93, 101, 102 These methods should prove 
to be useful in diagnostic conformation of  LSDs, in investigations on outcome of  lysosomal 
glycosidase mutations, and in the present development of  LSD therapies such as PCT and gene 
therapy. Therapeutic enzymes for LSDs can also be pre-labeled by the ABPs, which allows their 
detection by these mentioned methods99, 103—crucial in monitoring ERT efficacy in pre-clinical 
and clinical settings. The ABPs can also be used to assess potency and specificity of  known 
glycosidase inhibitors in intact cells or animals (Chapter 2, this thesis)104 or in an in vitro high-
throughput setup such as the fluorescence polarization (FluoPol) assay for discovering potential 
glycosidase interactors (inhibitors/stabilizers/activators) for PCT (Fig. 6E).105 The covalent 
nature of  labeling also allow structural analysis of  (mutant) glycosidase (with or without ABP) 
by protein crystallography93, 97-99 or NMR106, which would offer structural insights crucial for the 
development of  small-molecule chaperones for PCT (Fig. 6E). On the other hand, mechanism-
based inhibitors, owing to their substrate specificity, can also be used to generate LSD cell and 
animal models (Chapter 3, this thesis).107 Last but not least, ABPs appended with a biotin moiety 
would allow affinity-enrichment and identification of  the labeled targets by LC-MS(/MS) based 
proteomics, which is useful in identification of  glycosidase catalytic residues108 or of  unknown 
glycosidases (Chapter 7, this thesis) (Fig. 6E), with the later has already been exploited in 
plants.109, 110 This thesis aims to illustrate a number of  applications by the mechanism-based 
inhibitors and ABPs in the LSD field, as well as to present detailed biochemical characterization 
of  novel ABPs targeting other (LSD-relevant) retaining exo-glycosidases (Chapter 4–7, this 
thesis).  
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Scope of the thesis 
The general goal of  the thesis investigations was to apply newly designed and generated 
ABPs in fundamental research on lysosomal glycosidases. Described is the characterization of  a 
large number of  novel ABPs targeting various glycosidases as well as a broad scale of  
applications for ABPs in research. 
Chapter 1 briefly reviews current research on Gaucher disease and applications of  activity-based 
probes (ABPs) targeting lysosomal glucocerebrosidase (GBA). It provides detailed protocols for 
in vitro and in situ visualization of  active GBA molecules. 
Chapter 2 reports on the use of  a suite of  ABPs in a gel-based competitive activity-based protein 
profiling (cABPP) approach to investigate the in vivo glycosidase targets of  the widely applied 
GBA inhibitor conduritol B epoxide (CBE), and its close structural analogue cyclophellitol (CP). 
Off-target glycosidases are identified for both cyclitols, and the selectivity windows for selective 
GBA inactivation by both inhibitors are assessed. 
Chapter 3 demonstrates the use of  novel modified CPs for selective GBA inactivation and 
generation of  neuropathic Gaucher zebrafish models. These new compounds containing a 
biphenyl or adamantly group installed at the C8 position of  CP, and when orally administered 
the adamantyl compound selectively and potently inactivates GBA in visceral organs and brain 
of  adult zebrafish. 
Chapter 4 reports on the biochemical and structural investigation of  CP aziridine ABPs toward 
GH31 α-glucosidase and GH2 β-glucuronidase. These ABPs allow mechanism-based 
inactivation/labeling of  their target glycosidases in vitro and in cells. This enables the profiling 
of  the endogenous active enzymes across biological samples, including fibroblasts from Pompe 
patients for diagnostic purposes. 
Chapter 5 documents the design and characterization of  CP aziridine ABPs towards GH39 α-





mechanism-based labeling of  iduronidase, allowing detailed structural investigation on the 
conformational itinerary of  the cleavage reaction. In addition, the Cy5 ABP assists monitoring 
of  cellular uptake of  pre-labeled therapeutic iduronidase by fluorescent microscopy. 
Chapter 6 presents the development and characterization of  CP aziridine ABPs targeting GH38 
α-mannosidases or GH2 β-mannosidase. For this purpose use was made of  SDS-PAGE-based 
fluorescence detection, measurement of  inhibitory potency and kinetic studies, structural 
analysis, and chemical proteomics. Obtained data on labeling potency and glycosidase selectivity 
for both sets of  compounds, provide a basis for application in mannosidase ABPPs across a 
range of  biological samples as well as their use in screening of  compound libraries for inhibitors. 
Chapter 7 investigates the labeling mechanism, potency, inhibition kinetics, and glycosidase 
targets of  the β-galactose configured CP aziridine compounds and ABPs. This allows the 
activity-based profiling of  both lysosomal β-galactosidase (GLB1) and galactocerebrosidase 
(GALC) in biological samples. Chemical proteomics also identified other GLB1-like proteins, 
whose biological functions and implication in GM1-gangliosidosis or Krabbe disease should be 
explored in the future. 
In the General discussion and future prospects section, the design and applications of  
cyclophellitol and cyclophellitol aziridine ABPs reacting with lysosomal glycosidases are 
reviewed, with a focus on their application in LSD research. The present limitations of  current 
ABPs and future prospects are discussed. 
This thesis is concluded with Appendices that include a List of  publications and Curriculum 
vitae of  the author.  












Development of  activity-based protein profiling methods 
for in vitro and in situ visualization of  glucocerebrosidase 
Manuscript published as: 
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Glycosidases mediate the fragmentation of  glycoconjugates in the body, including the vital 
recycling of  endogenous molecules. Several inherited diseases in men concern deficiencies in 
lysosomal glycosidases degrading glycosphingolipids. Prominent is Gaucher disease caused by 
an impaired lysosomal β-glucosidase (glucocerebrosidase; GBA) and resulting in pathological 
lysosomal storage of  glucosylceramide (glucocerebroside) in tissue macrophages. GBA is a 
retaining glucosidase with a characteristic glycosyl–enzyme intermediate formed during 
catalysis. Using the natural suicide inhibitor cyclophellitol as lead, mechanism-based 
irreversible inhibitors of  GBA equipped with a fluorescent reporter was developed. These 
covalently link to the catalytic nucleophile residue of  GBA and permit specific and sensitive 
visualization of  active enzyme molecules. The amphiphilic activity-based probes (ABPs) allow 
in situ detection of  active glucocerebrosidase in cells and organisms. Furthermore, they may be 
used to biochemically confirm the diagnosis of  Gaucher disease and they might assist 
screening for small compounds interacting with the catalytic pocket. While the focus of  this 
chapter is ABPs for β-glucosidases and Gaucher disease, the described concept has meanwhile 







he human body contains a huge number of  glycoconjugates that are ongoingly 
synthesized and degraded by glycosidases. As first described by Daniel E. Koshland, 
the hydrolysis of  the glycosidic bond by glycosidases results in inversion or retention 
of  the anomeric stereochemistry in the glycon.1 Inverting glycosidases employ two 
carboxylic acid residues, typically spaced 6–11 Å apart and positioned on opposing sides of  the 
substrate glycoside, allowing joint entry of  substrate and a water molecule.2 The reaction 
proceeds through a single oxocarbenium ion-like transition state. In contrast, retaining 
glycosidases use a double-displacement mechanism that proceeds via a glycosyl–enzyme 
intermediate, flanked by two oxocarbenium ion-like transition states, preserving the initial 
configuration at the anomeric center. Two adjacent carboxylic acid residues, spaced 5.5 Å apart, 
function as the catalytic nucleophile and acid/base residue.3 Variations on the classical Koshland-
type mechanisms have been identified.4 
Among the many cellular glycoconjugates are glycosphingolipids (GSLs), consisting of  
ceramide lipid backbones extended with oligosaccharides.5 Their recycling involves 
fragmentation in lysosomes through sequential action of  glycosidases and acid ceramidase. A 
genetic deficiency of  a lysosomal glycosidase involved in GSL degradation causes accumulation 
of  the corresponding lipid substrate.6 Most prominent among these inherited 
glycosphingolipidoses are Gaucher disease (GD), Krabbe disease, Tay-Sachs disease and Fabry 
disease. Albeit monogenetic, the lysosomal disorders show remarkable variation in nature of  
symptoms, age of  onset and progression of  clinical presentations.  
Over the years, GD has acted as frontrunner in fundamental research on lysosomal 
glycosidases and subsequent development of  rational therapies for enzymopathies.7 One and a 
half  century ago Ernest Gaucher described a patient with a markedly enlarged spleen showing 
accumulation of  lipid-laden phagocytes. It was soon recognized that this patient represented a 
distinct disease entity, subsequently referred to as Gaucher disease.8 The accumulating lipid in 
the lysosomes of  storage macrophages (Gaucher cells) of  GD patients was identified as 
glucosylceramide (glucocerebroside). Next, Roscoe Brady and co-workers demonstrated that 
deficiency of  glucocerebrosidase (GBA, acid β-glucosidase; EC. 3.2.1.45) is the molecular cause 
of  GD.9 Over 200 mutations in the GBA gene (locus 1q21) have meanwhile been linked to the 
disease.10 The clinical manifestation of  GD is remarkably heterogeneous, ranging from lethal 
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neonatal complications to an almost asymptomatic course.8 The most prevalent manifestation, 
type 1 GD, does not involve pathology of  the central nervous system. Major symptoms are 
enlargement of  spleen and liver, infiltration of  the bone marrow by storage cells, 
thrombocytopenia, anemia and bone disease. GD types 2 and 3 are accompanied by fatal 
neurological symptoms developing in the first years of  life or at later age, respectively. The most 
severe manifestation is the so-called collodion baby, born with lethal skin permeability.11 For 
several GBA genotypes considerable variability in disease severity has been documented, even 
among monozygotic twins.12, 13 Deficiency of  GBA has recently been recognized as a risk factor 
for multiple myeloma.14 Intriguingly, carriers of  a mutant GBA allele are also at markedly 
increased risk for developing Parkinsonism.15 
The life cycle and structural features of  GBA have been studied in great detail. The 
acquired fundamental knowledge has been translated to (experimental) therapeutic interventions. 
Given the success of  bone marrow transplantation, presently gene therapy of  GD is pursued, 
aiming at macrophage-specific expression of  GBA in genetically modified hematopoietic stem 
cells.16 Small compound glycomimetics (chemical chaperones) promoting folding and/or 
increasing the structural stability of  GBA are searched and designed.17 Substrate reduction 
therapy inhibiting biosynthesis of  glucosylceramide through oral administration of  inhibitors of  
glucosylceramide synthase has already been registered as treatment of  GD (Miglustat, Actelion; 
Eliglustat, Sanofi-Genzyme).18, 19 Moreover, intravenous supplementation of  macrophage-
targeted recombinant GBA results in major visceral improvements in type 1 GD patients, but 
fails to prevent neurological manifestations in type 2 and 3 GD patients.20 Currently, several 
enzyme preparations have been registered for enzyme replacement therapy of  type 1 GD.7 The 
success of  enzyme replacement therapy has led to similar approaches for other lysosomal 
enzymopathies in the lysosomal turnover of  GSL, mucopolysaccharides and glycogen. 
Glycosidases, particularly those implicated in rare lysosomal storage diseases, receive 
consequently great attention. New tools to visualize active glycosidases in living cells and 
organisms are warranted. 
GBA is a retaining β-glucosidase with E340 as nucleophile and E325 as acid/base residue 
(Fig. 1.1, upper panel).21 Cyclophellitol 1 (Fig. 1.1, lower panel), isolated from the Phellinus sp. 
mushroom, is a mechanism-based inhibitor of  GBA, reacting far more potently and specifically 





successfully used as a lead for the development of  high affinity ABPs for retaining β-glucosidases, 
in particular for the human enzyme GBA.24, 25 Grafting an azide group onto the C6 position of  
cyclophellitol 1 (glucopyranose numbering) yielded azido-cyclophellitol 2 (Fig. 1.1, lower panel). 
When 2 was covalently extended at C6 with BODIPY fluorophore moieties, the resulting 
compounds 3 and 4 were even 100-fold more potent inhibitors for GBA than parent 
cyclophellitol 1.24 The fluorescent ABPs, green-fluorescent β-epoxide 3 (MDW933) and red-
fluorescent β-epoxide 4 (MDW941) allow immediate fluorescence scanning of  SDS-PAGE gels 
with ABP-labeled proteins.24 The attachment of  the bulky BODIPY moiety at the C6-position 
in cyclophellitol enhanced the potency and specificity of  the inhibitor for GBA. 
Figure 1.1. Catalytic mechanism of retaining glycosidases and ABPs. Upper panel: Catalytic 
mechanism of a retaining β-glycosidase, characterized by a covalent glycosyl–nucleophile adduct, flanked 
by two oxocarbenium ion-like transition states (*). The transition states are stabilized by hydrogen bonding 
(finely dotted line) between the C-2 hydroxyl group of the substrate and the nucleophile. Lower panel: 
Structures of cyclophellitol β-epoxide 1, azido-cyclophellitol 2 (KY170), fluorescent β-epoxide 3 (MDW933, 
green fluorescent) and β-epoxide 4 (MDW941, red fluorescent). 
 Active GBA can be labeled in lysates of  cells with 3 or 4 and subsequently visualized by 
fluorescence scanning following SDS-PAGE electrophoresis. Fig. 1.2 shows ABP-labeled GBA 
in lysates of  human fibroblasts. Multiple molecular weight isoforms are detected, reflecting 
variations in the N-linked glycan composition of  GBA.26 Active GBA can also be labeled in 
living cells thanks to the cell permeability of  the amphiphilic ABPs.24 Fig. 1.3 Shows the in situ  
Acid/base
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Figure 1.2. In vitro MDW933 (3) and MDW941 (4) labeling of GBA in human fibroblast lysates. 
Different amounts of samples were labeled with 100 nM MDW933 or MDW941 for 30 min at 37 °C, 
denatured, resolved using 7.5 % polyacrylamide SDS-PAGE, and scanned for BODIPY green or red 
fluorescence (upper and lower panel respectively). Coomassie Brilliant Blue G250 (CBB) staining was 
used to visualize total protein. No ABP was added to the negative control sample (- ABP). 2 % SDS was 
added to one sample (+SDS) and incubated for 5 min at 98°C prior to ABP addition. 1 mM CBE was 
added to one sample (+CBE) for 30 min at 37 °C prior to ABP addition. 
labeling with 4 of  GBA in human fibroblasts as visualized by confocal fluorescence microscopy. 
The β-glucosyl configured cyclophellitols find broad applications as inspired by the 
seminal work by Cravatt and co-workers with ABPs.27, 28 It has been earlier reported that they 
can be used in biochemical confirmation of  the diagnosis GD through the demonstration of  
reduced ABP-labeled GBA in fibroblasts.24, 29 The ABPs can be employed across species to 
visualize active GBA.24, 30, 31 In situ ABP-labeling of  active GBA in cultured cells and mice is 
feasible. In the case of  cells, the ABP can be applied to the medium. In the case of  mice, it needs 
to be intravenously infused.32 Since BODIPY-tagged ABPs poorly penetrate the brain, in situ 
visualization of  GBA in this tissue requires intrathecal administration of  the ABP.33 The use of  
the ABPs in correlative light and electron microscopy (CLEM) is presently pursued. Equipping 







Figure 3. In situ labeling with MDW941 detects GBA in human fibroblasts by confocal fluorescence 
microscopy. A) In situ labeling with MDW941 for 2 h at 5 nM followed by immunostaining of GBA showing 
significant co-localization of active GBA (red) with total GBA (green). B) Active GBA is detected with 
MDW941, while pre-incubation with CBE followed by MDW941 results in loss of the fluorescent signal. 
Scale bars, 10 μm. 
configured cyclophellitol with a biotin at C6 drastically decreased its activity against GBA24 and 
was not suitable for streptavidin-bead pull down application, but novel biotin ABPs with longer 
linker are currently being developed for GBA (General Discussion and Future Prospects, this 
thesis). In principle, proteins strongly interacting with GBA could be enriched in this manner 
and identified by proteomics. 
Another future application of  the ABPs could be (ABPP) screening of  compound libraries 
for structures showing affinity for the catalytic pocket of  GBA. Such compounds may be of  
interest to be developed further as therapeutic chemical chaperones.17 The β-glucosyl configured 
cyclophellitol ABP has been also used to study the interaction of  isofagomine with GBA in 
intact cells.24 Finally, the BODIPY-equipped ABPs, not penetrating the brain possibly due to 
active Pgp-mediated removal, may be used to pharmacologically generate a visceral model of  
Figure 1.3




Gaucher disease without the fatal neuropathology in GBA-deficient mice. 
Here, a detailed protocol for GBA detection using ABPs 3 and 4 is presented in this 
chapter. The first section lists the equipment and materials (1.2); the second section details the 
protocol for in vitro ABP labeling and SDS-PAGE-based fluorescence detection for GBA (1.3); 
the third section concerns the protocol for in situ ABP labeling of  GBA in intact cells followed 
by SDS-PAGE-based fluorescence detection (1.4); and the fourth section reports on the protocol 
for in situ ABP labeling of  GBA in intact cells followed by detection using fluorescent 
microscopy (1.5). Meanwhile, the concept of  cyclophellitol-type ABPs has been extended to 
other retaining glycosidases (General introduction, this thesis). Thus, this protocol can also be 
used as a basis for activity-based protein profiling using other cyclophellitol-based or 
cyclophellitol-aziridine-based ABPs targeting different disease-relevant glycosidases. 






1.5-mL Microcentrifuge tubes 
200-μL PCR tubes 
15- and 50-mL Centrifuge tubes 
Micropipettors 
Micropipettor tips 
SDS-PAGE equipment and glass plates 
Fluorescence imager or scanner (with settings for BODIPY green or red fluorescence) 
Sterile 6-well and 12-well plates 
Coverslips 
Incubator at 37 °C with 5 % CO2 
Parafilm 








a. 25 mM Potassium phosphate buffer (KPi) pH 6.5 (1 L) 
 
Component   Final concentration  Stock concentration Amount 
K2HPO4   7.5 mM    1 M    7.5 mL 
KH2PO4   17.5 mM    1 M    17.5 mL 
*Add 950 mL of  ultrapure-H2O, adjust the pH to 6.5 and add H2O to a total volume of  1 L 
b. Cell lysis buffer (50 mL) 
Component   Final concentration  Stock concentration Amount 
KPi buffer pH 6.5  25 mM    25 mM   49.5 mL 
Protease inhibitor -     -     1 tablet 
cocktail tablet (Roche) 
Triton X-100  0.1 % (v/v)    10 % (v/v)   0.5 mL 
*Note: Store at -20 °C in 1 mL aliquots 
c. 750 mM McIlvaine buffer pH 5.2 (40 mL) 
Component   Final concentration  Stock concentration Amount 
Citric acid   0.27 M    0.5 M    21.4 mL 
Na2HPO4   0.46 M    1 M    18.6 mL 
*Note: 0.01% (w/v) NaN3 can be added to both Na2HPO4 and citric acid stocks as bacteriostatic 
agent 
d. 150 mM McIlvaine buffer pH 5.2 (40 mL) 
Component   Final concentration  Stock concentration Amount 
Citric acid   0.054 M    0.1 M    21.4 mL 
Na2HPO4   0.093 M    0.2 M    18.6 mL 
*Note: 0.01% (w/v) NaN3 can be added to both Na2HPO4 and citric acid stocks as 
bacteriostatic agent 
 




e. 5x Laemmli sample buffer (10 mL) 
Component   Final concentration  Stock concentration Amount 
Tris-HCl pH=6.8  0.3 M     1.25 M   2.5 mL 
Glycerol   50% (v/v)    100% (v/v)   5 mL 
Sodium dodecyl sulfate 10% (v/v)    -    1 g 
Bromophenol blue 0.1% (v/v)    1% (w/v)   1 mL 
*Add ultrapure-H2O to a total volume of  10 mL 
1.3 Protocol: Fluorescent detection of  ABP-labeled GBA on wet slab gels 
MDW933 (3) and MDW941 (4) are dissolved in DMSO and stored in small aliquots at -
20 °C until use. The labeling can be performed on samples in vitro or directly in intact cells (in 
situ). For the in vitro labeling procedure, the samples and ABP are diluted separately in McIlvaine 
buffer pH 5.2 and combined for a 30 min incubation at 37 °C, and denatured for SDS-PAGE. 
For the in situ labeling procedure, MDW933 or MDW941 is diluted in culture medium and 
applied to the cell culture for a 2 h incubation at 37 °C. Subsequently, the cells are washed three 
times in PBS and lysed in lysis buffer. Proteins from both in vitro and in situ labeled samples are 
resolved by SDS-PAGE and wet slab gels are scanned for BODIPY green or red fluorescence 
using a fluorescence scanner. 
Storage of  ABPs 
Aliquots of  MDW933 and MDW941 are made in either 1 mM or 50 μM concentrations, in a 
volume of  1–2 μL. 
1. To make the 1 mM stock, add 100 μL DMSO to the tube containing 100 nmol lyophilized 
MDW933 or MDW941, vortex to dissolve and transfer to a 1.5 mL Eppendorf  tube. 
2. Make 1 μL or 2 μL aliquots for the 1 mM stock in PCR tubes (200 μL volume). 
3. To make the 50 μM stock, add 38 μL DMSO to one tube of  the 2 μL 1 mM stock, vortex to 
dissolve and make aliquots of  1 μL in PCR tubes. 
4. Place the PCR tubes into containers or 50 mL centrifuge tubes and store them at -20°C. 






One tube of  1 μL 50 μM MDW933 or MDW941 is sufficient for the in vitro labeling of  66 
samples at 100 nM labeling concentration (SDS-PAGE loading volume = 20 μL), or 1 x 6-well 
plate of  culture cells at 5 nM labeling concentration (1 mL culture medium per well). 
**Caution 
1. Avoid freeze-thawing the ABP stocks (in DMSO) more than twice. 
2. Do not store and re-use ABPs that have been diluted in H2O or buffer. 
3. Protect the ABPs from light. 
In vitro labeling and in-gel detection 
1. Prepare lysates and homogenates in lysis buffer and measure protein concentration by the 
BCA assay (Pierce, BCA protein assay kit). 
2. On ice, prepare 2–5 μL samples in 1.5 mL tubes, containing 5–50 μg total protein, or 0.5–50 
fmole GBA molecules of  purified enzyme stock. 
3. Add McIlvaine buffer (pH 5.2) to the samples, to a total volume of  10 μL, and incubate on 
ice for 5 min. Use 150 mM McIlvaine buffer for lysate volumes ≤ 2 uL, and 750 mM for lysate 
volumes of  2–5 μL. 
4. Prepare 300 nM MDW933 or MDW941 diluted in McIlvaine buffer (pH 5.2, 150 mM or 750 
mM) using the 50 μM MDW933 or MDW941 stock (e.g. 1 μL 50 μM stock + 166 μL McIlvaine 
buffer). 
5. Add 5 μL 300 nM MDW933 or MDW941 to each sample (10 μL) and incubate at 37°C on a 
thermoshaker or in a waterbath for 30 min. 
6. After the incubation, add 3.75 μL 5x Laemmli sample buffer to the sample, and incubate at 
98 °C for 5 min. 
7. Resolve the proteins by SDS-PAGE (7.5 % or 10 % polyacrylamide gels) and quantify the 
labeling on a Typhoon scanner (GE Healthcare) using the following fluorescence settings: green 




BODIPY: λex = 488 nm, λem = 500–550 nm; red BODIPY: λex 594 nm, λem = 605–645 nm. 
*Tip 
1. For optimal labeling and fluorescence detection in lysates and homogenates, the protein 
concentration in the prepared cell lysates or tissue homogenates is best kept at 10-20 μg/μL. 
2. When performing labeling on purified GBA, supplement the McIlvaine buffer with 0.1% (v/v) 
Triton X-100 and 0.2% (w/v) sodium taurocholate. 
3. Optimal labeling visualization is achieved with 0.5–50 fmole GBA per sample. 
4. Include one sample without MDW933 or MDW941 treatment as negative control for 
assessing autofluorescence from the samples. 
1.4 Protocol: In situ labeling and in-gel detection 
Cells are treated with 5 nM MDW933 or MDW941 at 37 °C for 2 h, washed three times 
with PBS, lysed in lysis buffer and detached by scraping. The homogenate is resolved by SDS-
PAGE and the fluorescent signal on the gel is quantified by fluorescent scanning.  
1. Maintain normal human dermal fibroblasts (Lonza) in DMEM containing 4.5 g/L glucose, 
sodium pyruvate and sodium bicarbonate (Sigma, D6546), or F-12 Ham/DMEM (Sigma, 
D8062), both supplemented with 10% (v/v) FBS, 100,000 units/L penicillin, 100 mg/L 
streptomycin and 2 mM glutamax. 
Transfer the fibroblasts to 6-well plates and let them grow until at least 80 % confluency. 
2. In a 15 mL centrifuge tube, combine 10 mL pre-warmed culture medium (37 °C) with 1 μL 
of  50 μM MDW933 or MDW941. 
3. Aspirate the culture medium from the cell culture plate and add 1 mL of  the prepared 5 nM 
MDW933 or MDW941 diluted in the pre-warmed culture medium.  
4. Incubate for 2 h in a 37 °C incubator. 
5. After the incubation, aspirate the MDW933 or MDW941-containing medium and wash the 





6. Aspirate the PBS, place the culture plate on ice and add 50 μL pre-chilled 25 mM KPi buffer 
pH 6.5 (+0.1% (v/v) Triton X-100 and protease inhibitor cocktail) to each well of  the plate. 
7. Use a cell scraper or the back of  a P200 pipette tip to detach the fibroblasts from the plate 
and collect the cells in 1.5 mL Eppendorf  tubes. 
8. Vortex, store the samples at -80 °C for 1 h, and thaw the samples on ice. 
9. Determine the protein concentrations using the BCA assay (Pierce BCA protein assay kit) and 
a spectrophotometer (absorption set at 562 nm). The typical protein concentration for in situ 
treated fibroblast lysates is between 1–2 μg/μL. 
10. For SDS-PAGE, samples containing the same amount of  protein (typically 5-30 μg protein) 
are diluted in 25 mM KPi buffer (+0.1% (v/v) Triton X-100 and protease inhibitor cocktail), in 
a total volume of  15 μL, denatured by incubation with 3.75 μL 5x Laemmli sample buffer at 98 
°C for 5 min, and resolved by SDS-PAGE. 
11. Quantify fluorescence on wet slab gel using a Typhoon scanner (GE Healthcare). 
*Tip 
For ABP labeling experiment involving different ABP concentrations, or treatment at different 
time points, an alternative labeling method can be followed. For this method, first pre-dilute the 
ABP stock (1 mM or 50 μM) in DMSO into 1000x of  the desired labeling concentrations in 
sterile 1.5 mL tubes, then directly pipette 1 μL of  the prepared ABP dilutions per well to the 6-
well plate (containing 1 mL refreshed medium per well). It is important to ensure proper mixing 
of  the ABP in the culture medium. 
1.5 Protocol: In situ labeling of  GBA for fluorescence microscopy 
To localize active GBA, the cells are in situ labeled with MDW941 by applying the ABP to 
the culture medium. It is important to include controls for autofluorescence, i.e. DMSO treated 
cells, and for the specificity of  the ABP signal. For the latter, the cells are incubated with CBE 
prior to the in situ labeling with ABP. This compound will bind to the active GBA molecules, 
thereby blocking all binding by the ABP. Any remaining signal will represent unbound ABP. 
 




1. The day before the experiment, transfer normal human dermal fibroblasts to four wells of  a 
12-well plate that contain autoclaved coverslips (Menzel, 15 mm diameter). Allow the cells to 
adhere to the coverslips by incubating them overnight in a humidified incubator at 37 °C with 5 
% CO2. 
2. The cells should have reached ~70 % confluency on the day of  the in situ labeling. Remove 
the culture medium and place 1 mL of  fresh medium in each well.  
3. Two wells are treated with CBE as a control for the specificity of  the signal. Dissolve CBE 
(Enzo Life Sciences Inc.) in ultrapure-H2O at a concentration of  150 mM, e.g. by adding 200 μL 
ultrapure-H2O to 5 mg CBE. Add 2 μL of  CBE per well (final concentration will be 0.3 mM) 
and incubate the cells at 37°C for 16 h.  
4. After the 16 h incubation, remove the culture medium from the wells and wash twice with 
PBS. Subsequently, place 1 mL of  culture medium in each well.  
5. Dilute MDW941 in DMSO to a concentration of  5 μM, e.g. by adding 1 μL of  the 1 mM 
stock to 200 μL DMSO. Subsequently, add 1 μL of  the 5 μM dilution to one well that was pre-
incubated with CBE and to one untreated well. This final concentration of  5 nM will label ~50 
% of  total endogenous GBA in these cells, but optimal concentrations should be determined 
for each cell line. Add 1 μL of  DMSO to the second untreated well as a control for 
autofluorescence. From this step onwards it is important to protect the cells from light. 
6. Incubate the cells for 2 h at 37 °C. 
7. At the end of  the incubation, remove the culture medium from the wells and wash 3 times 
with 1 mL PBS. 
8. Fix the cells by placing 1 mL of  4 % (w/v) formaldehyde/PBS in each well and incubate for 
25 min at RT. A stock of  16 % formaldehyde/H2O can be made as described in Slot & Geuze, 
2007.34 Dilute this stock 1:4 in PBS, e.g. by mixing 4 mL of  16 % formaldehyde with 1.6 mL 10x 
concentrated PBS and 10.4 mL distilled H2O. 
9. Remove the fixative and wash the coverslips with PBS by placing 1 mL in each well. Remove 
the PBS and repeat this wash two times. To stain all GBA in the cells (active and inactive) for 





steps 10-14 and proceed with step 15. 
10. Prepare a piece of  parafilm with 200 μL drops of  2 % (w/v) bovine serum albumin/ 0.1% 
(w/v) saponin in PBS (= permeabilization buffer). Incubate the coverslips onto these drops, 
with the cells facing the drop, for 10 min. Cover the coverslips with a petri dish wrapped in 
aluminum foil to protect from light and evaporation. 
11. Incubate the coverslips for 1 h at RT onto 100 μL drops of  1:500 diluted mouse anti-GBA 
monoclonal antibody 8E4 (generated in the Aerts lab) in permeabilization buffer. 
12. Transfer the coverslips to 200 μL drops of  permeabilization buffer and incubate for 10 min. 
Repeat this washing step twice. 
13. Incubate the coverslips for 1 h at RT onto 100 μL drops of  1:500 diluted Alexa Fluor 488-
coupled donkey anti-mouse IgG (H+L) (Invitrogen). 
14. Wash the coverslips three times on 200 μL drops of  permeabilization buffer. 
15. Wash the coverslips quickly by dipping them in distilled H2O. 
16. Drain off  the H2O from the coverslips and mount them on a microscope slide (VWR) with 
ProLong Diamond antifade reagent containing DAPI (Molecular Probes). Allow the coverslips 
to dry overnight, seal with nail polish and store at 4°C. 
17. Image the cells under a Leica SP8 confocal microscope with a 63x/1.40 NA HC Plan Apo 
CS2 oil immersion objective and equipped with a hybrid detector (HyD). Image MDW941 with 
excitation at 552 nm, emission 590–650 nm, Alexa Fluor 488 with excitation at 488 nm, emission 
500–540 nm and DAPI with excitation at 405 nm, emission 420–480 nm. 
*Tip 
The concentration of  in situ applied MDW933 or MDW941 can be adjusted from 5 nM to 100 
nM, according to cell types and confluency, and it is advisable to validate the percentage of  GBA 
inhibition by in vitro 4-methylumbelliferyl substrate assay.35  
 
 





 Deficiency of  GBA leads to Gaucher disease and constitutes a risk factor for multiple 
myeloma and Parkinsonism. The biochemical and clinical study on Gaucher disease has enabled 
tremendous therapeutic development in the past decades, which has encouraged the research 
and therapeutic development on other lysosomal storage diseases involving glycosidases. The 
availability of  the here-described ABPs specifically labeling GBA in a mechanism-based manner 
offer new valuable tools for research on the enzyme, diagnosis and therapy development. 
Detailed protocols for in vitro and in situ detection of  GBA using these ABPs were described in 
this chapter, which should also serve as a basis for ABP detection of  other glycosidases relevant 
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Glucocerebrosidase (GBA) is a lysosomal β-glucosidase catalyzing the hydrolysis of  
glucosylceramide into glucose and ceramide. Its deficiency causes Gaucher disease (GD), the 
most common lysosomal storage disorder (LSD). Carrying a genetic abnormality in GBA also 
constitutes at present the largest genetic risk factor for Parkinson’s disease (PD). Conduritol B 
epoxide (CBE) is a commonly used pharmacological agent to generate cell and animal models 
for investigations on GD and PD, due to its perceived specificity towards GBA. It’s inhibition 
towards GBA is mechanism-based and irreversible, but it may have additional in vivo 
glycosidase targets besides GBA, depending on the applied dose and treatment duration. In 
this chapter, the first in vivo target engagement study for CBE is presented. A suite of  activity-
based probes and gel-based fluorescence detection was employed, allowing visualization of  
the covalent catalytic pocket occupancy by CBE on candidate off-target glycosidases in 
cultured cells, zebrafish larvae, and brain of  mice, at various CBE concentrations and fixed 
incubation time. Comparatively studied is the in vivo target engagement of  cyclophellitol 
(CP)—another structurally related GBA inhibitor that has been used for generate GD animal 
model. The results revealed that only at significantly higher CBE concentrations, non-
lysosomal glucosylceramidase (GBA2) and lysosomal α-glucosidase (GAA) were identified as 
major off-targets in cells and zebrafish larvae. A tight, but acceptable window for selective 
inhibition of  GBA in the brain of  mice was observed. On the other hand, CP, a closer glucose 
mimic, was found to inactivate with equal affinity GBA and GBA2 and therefore is not suitable 







he lysosomal enzyme glucocerebrosidase (GBA, EC 3.2.1.45) is a retaining β-
glucosidase that degrades the glycosphingolipid, glucosylceramide. Inherited 
deficiency of  GBA is the cause of  autosomal recessive Gaucher disease (GD).1 
Most GD patients display heterogeneous symptoms including spleen and liver 
enlargement, bone deterioration, anaemia, leukopenia, and thrombocytopenia. Some patients 
also develop fatal neurological symptoms.2 The GBA genotype poorly predicts the onset and 
severity of  disease in individual GD patients, even in monozygotic twins.3, 4 Carriers of  a GBA 
defect do not develop GD but show a markedly increased risk for Parkinson’s disease (PD) and 
Lewy-body dementia.5, 6 The molecular basis for this risk is unknown and a subject of  research. 
Because complete genetic abrogation of  GBA results in premature death in mice, research 
models of  GBA deficiency are often generated with conduritol B epoxide (CBE) (Figure 
2.1A).7–9 CBE is a cyclitol epoxide that covalently and irreversibly reacts with the catalytic 
nucleophile of  GBA and thus inactivates irreversibly the enzyme (Fig. 2.1B). The crystal 
structure of  GBA with bound CBE confirmed the covalent linkage of  the compound to the 
catalytic nucleophile Glu340.10, 11 Building on the initial work by Kanfer and co-workers, a 
regimen using different doses of  CBE has been established to generate a phenotypic copy of  
neuronopathic GD in mice.9–12 This pharmacological model is now widely used to study the 
nature of  neuropathology resulting from GBA deficiency, including Parkinsonism.13–15 
A major advantage of  CBE’s pharmacological use in cultured cells and mice is its tunability: 
the extent of  GBA inactivation can be adjusted by variation of  the inhibitor concentration 
and/or exposure time.9 However, this has led to use of  distinct treatment regimens across studies: 
exposure of  cells ranging from 50 µM to 100 mM CBE for 2 hours up to 60 days16–22 and daily 
exposure of  mice from 25 to 300 mg kg−1 body weight during 2 hours up to 36 days.9 The use 
of  a high CBE concentration raises concerns about specificity since the compound has been 
reported to inhibit at high concentration other glycosidases than GBA. Examples are in vitro 
inhibition of  retaining α-glucosidases (EC 3.2.1.20)23–26, in vitro27 and in situ28 cell inhibition of  
the non-lysosomal glucosylceramidase (GBA2, EC 3.2.1.45), and inhibition of  the lysosomal β-
glucuronidase (GUSB, EC 3.2.1.31) in mice29. The reactivity of  CBE towards both β- and α-
glucosidases can be explained by the C2-symmetry found in its structure26 (Fig. 2.1B), which 
T 




Figure 2.1. Structures of compounds used in this study and inactivation of β-glucosidases by CBE. 
A) Chemical structure of CBE 1 and cyclophellitol (CP) 2. B) Reaction coordinates of CBE during inhibition 
of β-glucosidases. C) Activity-based probes (ABPs) used in this study: GBA ABPs 3a and 3b, GBA and 
GBA2 ABPs 4a-c, GUSB ABP 5c, and GAA and GANAB ABPs 6a and 6c.
allows reaction with the catalytic nucleophile of  both classes of  enzymes. Another structurally 
related cyclitol epoxide, cyclophellitol (CP, Fig. 2.1A), is a structurally closer β-glucose mimic 
and inhibits GBA with far higher affinity than CBE.30, 31 It exhibits selectivity over α-glucosidases 
due to the C5-hydroxymethyl group30–32, and was also shown to induce Gaucher phenotypes in 
mice.30 Its reactivity in vivo towards GBA2 and other glycosidases is unknown. 
The aim of  this chapter is to systematically study the in vivo selectivity of  CBE and CP in 
cells and animal models. It is envisioned that besides the traditional enzymatic assays employing 
fluorogenic substrates, activity-based probes (ABPs) could be superior tools for this study. 
Unlike enzymatic substrate assays, which do not easily distinguish similar enzymatic activities 
such as GBA vs GBA2, ABPs would allow direct and unambiguous visualization of  respective 
target glycosidases that are not occupied/inactivated by CBE or CP at the active site pocket. 





proteases and lipases in a competitive activity-based protein profiling (ABPP) approach to 
identify in vivo target engagement of  small compounds.33–35 Used ABPs in this study are 
cyclophellitol-epoxide tagged with a fluorophore that labels specifically GBA32, and 
appropriately configured cyclophellitol-aziridines tagged with a fluorophore that label multiple 
β-glucosidases, (GBA and GBA2)36, β-glucuronidase (GUSB) (descried in Chapter 4, this 
thesis)37 and α-glucosidases (GAA and GANAB) (descried in Chapter 4, this thesis)38 (Fig. 2.1C, 
ABPs 3−6). Through parallel application of  both the competitive ABPP method and enzymatic 
assay in lysates of  cultured cells, zebrafish (Danio rerio) larvae, and brains of  mice treated in vivo 
with a relevant range of  concentrations of  CBE or CP, the in vivo off-targets and selectivity 
windows for GBA by both CBR and CP in vivo was systematically studied and reported. 
2.2 Results 
2.2.1 A competitive ABPP method to determine GBA target engagement of  CBE and CP 
ABPs specifically label GBA have been reported, in which their use in profiling GBA in 
cells and identifying active-site pocket interactors have been demonstrated (Fig. 2.1C, ABP 3 
and 4).32, 39 Here, they were employed to visualize GBA target engagement of  CBE 1 and CP 2 
using a competitive ABPP method, by which the irreversible occupancy of  the catalytic 
nucleophile of  GBA by the inhibitors during pre-incubation is assessed. As a validation, 
competition of  ABP labeling by CBE and CP was compared to the loss of  GBA activity 
measured using 3.75 mM 4-methylumbelliferyl-β-glucoside as substrate.40 For this, recombinant 
human GBA (rGBA) was pre-incubated with CBE across a range of  concentrations at 37 °C for 
0, 30 or 180 minutes in McIlvaine buffer (pH 5.2) containing 0.2 % taurocholate and 0.1 % 
Triton X-100, a condition optimal for enzymatic activity.41 Subsequent labeling of  GBA by ABP 
4c was quantified by SDS-PAGE and fluorescence scanning. IC50 values (concentrations of  
inhibitor yielding a 50 % reduction of  ABP 4c labeling) were determined and found to be 26.6 
µM at 30 min CBE pre-incubation, and 2.30 µM at 180 min pre-incubation (Fig. 2.2A, Table 
2.1). These values match the ones determined by measurement of  residual enzymatic activity of  
GBA assay (Fig. 2.2A lower right panel, Table 2.1), validating the competitive ABPP 
methodology. 
Next, CP was comparably studied and its IC50 values determined by ABPP were 0.15 µM 
at 30 min pre-incubation and 0.03 µM at 180 min pre-incubation, comparable to values  




Figure 2.2. Effect of pre-incubation with CBE or CP on ABP labeling of recombinant GBA. A) 
Representative gel images (1 set from n = 3 biological replicates) of rGBA pre-incubated with CBE for 30 
min or 180 min and fluorescently labeled with ABP 4c. Fluorescent signals were quantified and normalized 
to the untreated sample (ctrl, 0 µM CBE) (bottom left), and compared to the inhibition curves obtained 
with enzymatic assay (bottom right). B) Same as A), with CP at 10–0.001 µM. Error ranges in enzymatic 
assay = ± SD, n = 3 (technical replicates). 
Table 2.1. In vitro inhibition of CBE or CP towards human recombinant GBA. Apparent IC50 values 
(µM) were derived from the average of 3 individual experiments as measured by either enzymatic assays 
(Enz. assay) or quantification of ABP labeling on residual active enzymes (ABP). Error ranges = ± SD, n 




determined by enzymatic assay (Fig. 2.2B, Table 2.1). 
2.2.2 In vivo targets of  CBE 
 Next analysed were the targets of  CBE in intact human cells, zebrafish larvae, and brain 
of  treated mice. These biological materials contain besides GBA the candidate off-target 
glycosidases: GBA2, α-glucosidases (GAA and GANAB), and lysosomal β-glucuronidase GUSB. 
For each of  these enzymes ABPs have been designed, and enzymatic activity assays with 
fluorogenic substrates established.36–38 Of  note, ABP 4 allows simultaneous visualization of  
CBE 1 CP 2
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active GBA (58-66 kDa) and GBA2 (110 kDa) following SDS-PAGE analysis. HEK293T cells 
expressing GBA2 were exposed for 24 h to different concentrations of  CBE (0.1 µM–10 mM) 
after which the residual amount of  GBA, GBA2, GAA, GANAB and GUSB in cell lysates that 
can still be labeled with the appropriate ABPs (Fig. 2.1C) was determined (Fig. 2.3A). 
Competitive ABPP showed that besides GBA, all other candidate off-target enzymes are 
inactivated by CBE but with marked lower affinity: GBA (IC50 = 0.59 µM), GBA2 (IC50 = 315 
µM), GAA (IC50 = 249 µM), GANAB (IC50 = 2900 µM) and GUSB (IC50 = 857 µM). (Fig. 2.3B,  
Table 2.2). Comparable results were obtained by determination of  residual enzyme activities: 
GBA (IC50 = 0.33 µM), GBA2 (IC50 =272 µM), GAA (IC50 = 309 µM), GANAB (IC50 = 1580 
µM) and GUSB (IC50 = 607 µM) (Fig. 2.3C, Table 2.2). Next, cultured human fibroblasts, rich 
in lysosomal enzymes, were used to analyse a panel of  additional glycosidases (α- and β-
mannosidase, N-acetyl α-galactosidase, β-hexosaminidase, α-fucosidase, α-iduronidase, α- and β-
galactosidase) for their possible inactivation by CBE. At the highest concentration of  CBE (10 
mM) tested, no significant loss of  activity was observed for any of  these additional lysosomal 
enzymes (Fig. 2.S1). In addition, in vivo competitive ABPP experiments were also performed. 
For this, the appropriate ABPs were added to the culture medium of  HEK293T cells during 4 
hours prior to their harvesting. The outcome of  this in vivo ABP labeling was comparable to that 
of  in vitro ABP labeling in the lysates of  harvested cells (Fig. 2.S2, Table 2.S1). 
Figure 2.3. In vivo glycosidase targets of CBE in cultured cells. A) Representative gel images (1 set 
from n = 3 biological replicates) showing fluorescent ABP labeling of GBA, GBA2, GAA, GANAB, and 
GUSB in lysates of cells treated in vivo for 24 h with CBE. B) Quantification of relative ABP labeling. C) 
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Figure 2.3




Table 2.2. In vivo inhibition of CBE or CP towards glycosidases in cultured cells. Apparent IC50 
values (µM) were derived from the average of biological triplicates as measured by either in vitro 
enzymatic assays (Enz. assay) or quantification of in vitro ABP labeling on residual active enzymes (ABP). 









Next, CBE target engagement was investigated in intact zebrafish larvae. Fertilized 
zebrafish eggs (0 dpf) were exposed to CBE (1 µM–100 mM) in the egg water for five days. The 
larvae were collected, lysed, and analysed by the competitive ABPP method. Exposure to 100 
mM CBE was found to reduce ABP labeling of  all five glycosidases (Fig. 2.4A, Fig. 2.S3A). The 
IC50 values determined by the competitive ABPP method were: GBA (IC50 = 44.1 µM), GBA2 
(IC50 = 890 µM), GAA (IC50 = 9550 µM), GANAB (IC50 = 4700 µM) and GUSB (IC50 = 6470 
µM) (Table 2.3). Thus, inactivation of  GBA in zebrafish larvae takes place 20-fold more avidly 
than that of  GBA2 and 100- to 200-fold more potently than that of  GAA, GANAB and GUSB. 
Analysis of  residual enzymatic activity of  the various enzymes gave similar results (Table 2.3, 
Fig. 2.S3B). Analysis by enzymatic assay revealed that exposure of  the animals to 10 mM CBE 
did not lead to significant inactivation of  other glycosidases (α- and β-mannosidase, N-acetyl α-
galactosidase, β-hexosaminidase, α-fucosidase and α-iduronidase) except for β-galactosidase 
(IC50 = 11.2 mM) and α-galactosidase (IC50 = 22.5 mM) (Fig. 2.S3B). 
CBE 1 CP 2
































Inhibition of CBE and CP in cultured cells
Apparent IC50 alues (µM) were derived from the average of
3 biological replicates as measured by either in vitro
enzymatic assays (Enz. Assay) or quantification of in vitro
ABP labeling on residual active enzymes (ABP). -, value







Figure 2.4. In vivo glycosidase targets of CBE in animal models. A) Effect of CBE incubation in 
zebrafish to ABP labeling of glycosidases in zebrafish lysates. B) Effect of CBE injection in mice to ABP 
labeling of glycosidases in mice brain homogenates. C) Quantification of labeled bands in B). D) Residual 
activity of glycosidases in brain homogenates of CBE-injected mice. Error ranges = ± SD, n = 3 (biological 
replicates). Two-tailed unpaired t-test was used to derive statistical significance (* p < 0.05, ** p < 0.01, 
NS = not significant). 
Finally, in vivo targets of  CBE was also investigated the in brain of  mice treated daily from 
day 8 to either day 25 with 37.5 mg CBE kg−1 body weight or to day 14 with 100 mg CBE kg−1 
body weight.9 Brain homogenates were prepared from three individuals of  each treatment group 
and the untreated group. As above, both competitive ABPP and measurement of  residual 
enzymatic activity was performed. Interestingly, GBA was found to be the only enzyme 
significantly targeted by CBE in the brain of  mice treated with both CBE dosages (Fig. 2.4B). 
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Table 2.3. In vivo inhibition of CBE or CP towards glycosidases in zebrafish larvae. Apparent IC50 
values (µM) were derived from measurements from lysates made with n = 48 individuals. Enz. assay, 








mice treated with 100 mg CBE kg−1 body weight (Fig. 2.4C), but this reduction (30 %) is far 
less pronounced than the complete reduction of  GBA labeling in the same mice. Measurement 
of  residual enzymatic activities in these samples yielded comparable results (Fig. 2.4D), showing 
that besides GBA the other enzymes GBA2, GAA, GANAB, and GUSB were not affected in 
the brains of  CBE-treated mice. Taking together these results, it can be confirmed that there is 
a therapeutic window for selective inactivation of  GBA with CBE. However, when using higher 
CBE concentration, looking whether concomitant inhibition of  GBA2 takes place is 
warranted.2.2.3 In vivo targets of  CP  
CP has been previously used to generate a GD mouse model.30 Compared to CBE, CP is 
a much more potent inhibitor of  GBA30 and reported to inhibit poorly α-glucosidases in vitro.31 
However, its in vivo reactivity towards other glycosidases has not been thoroughly investigated. 
The in vivo targets of  CP were therefore comparatively studied in cultured cells and zebrafish 
larvae using the competitive ABPP methodology and measurement of  the residual enzymatic 
activities. To compare the selectivity windows of  CP to the ones of  CBE, the concentration 
range of  CP in living models was chosen at 0.001–10 µM for cultured cells and 0.001–100 µM 
for zebrafish, so that it would match the extent of  GBA inhibition by CBE in vitro (Fig. 2.2A, 
B). As determined by the competitive ABPP method, CP was found to inhibit GBA2 on a par 
with GBA in HEK293T cells upon incubation with varying inhibitor concentrations (0.1−10 
µM) for 24 hours. IC50 values of  CP for blocking ABP labeling were 0.063 µM for GBA and 
0.154 µM for GBA2 (Fig. 2.5A, B, Table 2.2). No reduction of  ABP labeling of  GAA, GANAB 
Inhibition of CBE and CP in Danio rerio larvae
Apparent IC50 values (µM) were derived from either duplo
measurements (enzymatic assay, Enz.) or single
mea urement (ABP labeling, ABP) from lysates made with n
= 48 individuals. -, v lue cannot be calculated (no inhibition
in the tested concentrations).
CBE 1 CP 2
Enzyme Enz. Assay ABP Enz. assay ABP
GBA 58.50 44.1 0.130 0.083
GBA2 1160 890 0.176 0.059
GAA 5010 9550 - -
GANAB 4550 4700 - -






Figure 2.5. In vivo glycosidase targets of CP. A) Representative gel images (1 of 3 biological replicates) 
showing fluorescent ABP labeling of GBA, GBA2, GAA, GANAB, and GUSB in lysates of cells treated in 
vivo for 24 h with CP. B) Quantification of relative ABP labeling of GBA and GBA2. C) Residual activities 
of GBA and GBA2 in cell lysates treated in vivo with CP. Error ranges = ± SD, n = 3 (technical replicates). 
D) Effect of CP incubation in zebrafish to ABP labeling of glycosidases in zebrafish lysates.  
and GUSB was observed in lysates of  cells incubated for 24 h with the highest concentration of  
CP (10 µM) (Fig. 2.5A). As determined by enzymatic assay, the apparent IC50 values for 
inactivation were quite comparable, being 0.086 µM for GBA and 0.198 µM for GBA2 (Fig. 
2.5C, Table 2.2). For the other enzymes the IC50 values exceeded at least 10 µM (Fig. 2.S1, 
Table 2.2). 
 Exposure of  zebrafish to CP (5 days at 1–100 µM) also comparably competed GBA and 
GBA2 labeling, but not that of  GUSB, GAA and GANAB (Fig. 2.5D). This finding was again 
supported by results obtained from measurement of  residual enzymatic activities (Table 2.3, 
Fig. 2.S3). From the noted lack of  selectivity of  CP with respect to inactivation of  GBA and 
GBA2, it is obvious that CP does not allow generation of  specific GBA-deficiency in cell and 
animal models. 
2.2.4 Inhibitor sensitivity of  GBA3 
 Besides GBA and GBA2, there exists in humans and zebrafish another β-glucosidase 
named GBA3 (EC 3.2.1.21).42 This is a cytosolic enzyme able to degrade a variety of  glycoside 
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expressed in cells and tissues, for example being particularly high in kidney and absent in 
fibroblasts, and its activity can be visualized by labeling with nanomolar concentrations of  ABP 
4.36 In lysates of  mice brain (Fig. 2.4B) and 5 dpf  zebrafish larvae (Fig. 2.4A, 2.5D), the 
presence of  GBA3 could not be detected (expected m.w. = 45–53 kDa42) by labeling with 200 
nM ABP 4c. Therefore, HEK293T cells over-expressing GBA3 were generated to study the 
inhibitor sensitivity of  the enzyme. In these cells the in vivo interaction of  CBE and CP with 
GBA3 could be measured by ABP detection (ABP 4c) (Fig. 2.6A, B). The apparent IC50 values 
towards GBA3 for CBE and CP were 485 μM and > 10 μM, respectively (Table 2.4). The 
inhibition of  GBA3 by the two compounds was also measured by enzymatic assays, and similar 
results were obtained (apparent IC50 values for CBE and CP were 474 μM and > 10 μM) (Fig. 
Figure 2.6. In vivo GBA3 inhibition by CBE and CP in cultured cells. A) Representative fluorescent 
gel images (1 of 3 biological replicates) of ABP labeling of GBA3 in lysates of HEK293T cells treated with 
CBE or CP for 24 h. B) Quantification of ABP gels . C) Residual activities of GBA3 by enzymatic assay. 






































































































































































































































































































































































































































































Table 2.4. Overview of apparent IC50 values (µM) determined in this study. Enz. assay, enzymatic 















2.6C, Table 2.4). Hence, both compounds show selectivity towards GBA over GBA3; the ratio 
of  IC50 values for GBA3/GBA by ABP detection were 816 for CBE and > 159 for CP (Table 
2.4). 
2.2.5 Impact of  CBE and CP on glycosphingolipids in exposed zebrafish larvae 
 Next studied were the functional impact of  exposing fish embryos for 5 days to CBE or 
CP. It is known that in vivo inactivation of  GBA leads to compensatory formation of  
glucosylsphingosine (GlcSph) by acid ceramidase- mediated conversion of  accumulating GlcCer 
Table 2.4
CBE 1 (μM) CP 2 (μM)













































883 530 2.30 2.44
GAA
/GBA
934 418 >116 >159
GBA3
/GBA




GBA 58.5 44.1 0.130 0.083
GBA2 116 890 0.176 0.059




19.8 20.2 1.35 0.710
GAA
/GBA
85.6 226 >769 >1200
IC50 values and GBA selectivity among tested compounds, in vitro and in vivo
Enz. Assay, enzymatic assay. ABP, ABP labeling results. Values from Hek293T cells
overexpressing GBA2 were used in the cultured cells. N/A, not determined. -, value cannot be
calculated.




in lysosomes.40, 43 In other words, formation of  GlcSph is a biomarker of  the inactivation of  
GBA. The exposure of  zebrafish larvae to CBE and CP led to pronounced accumulation of  
GlcSph (4-fold increase in the case of  1000 μM CBE; 6-fold increase at 10 μM CP) (Fig. 2.7). 
Thus, the observed in vivo GBA inhibition by both compounds according to ABP detection was 






Figure 2.7. C18-Glc-Sphingosine levels in zebrafish larvae treated for five days with CBE or CP. 
Error ranges ± SD,  n = 3 (biological replicates). Two-tailed unpaired t-test was used to derive statistical 
significance (* p < 0.05, ** p < 0.01, *** p < 0.001). N/A, not determined
2.3 Discussion 
 Our present study demonstrates that gel-based fluorescence ABPP can be appropriately 
used to determine in vivo target engagement of  irreversible glycosidase inhibitors such as CBE 
and CP. This method provides important insights on dose-dependent off-targets of  the tested 
compounds. The off-targets may vary among cells and organismal models. From our findings, it 
is concluded that it is wise to test pharmacologically induced Gaucher disease models with 
respect to selectivity of  GBA inactivation. 
 In this chapter, the in vivo target engagement of  CBE is assessed in cells and zebrafish 
model, and compared to that of  CP. Table 2.4 provides an overview of  the IC50 values observed 
for CBE and CP across rGBA, cultured cells, and zebrafish larvae. The table highlights that 
although CBE has in vivo off-targets such as GBA2 and the lysosomal α-glucosidase GAA, it is 
still selective towards GBA in cells (GBA2/GBA inhibition ratio = 530; GAA/GBA inhibition 
ratio = 418; ABP detection) and in zebrafish larvae (GBA2/GBA inhibition ratio = 20.2; 
GAA/GBA inhibition ratio = 226; ABP detection). Thus, a selective window for in vivo GBA 
inactivation by CBE exists (in cells: 0.6−315 μM; in zebrafish larvae: 44−890 μM; ABP detection) 
























































































































Figure 2.8. Windows for selective GBA inhibition by CBE and CP in cultured cells and zebrafish 
larvae. Inhibition curves for CBE or CP towards GBA and other glycosidases were derived from the results 
of ABP detection (average of n = 3 biological replicates). GBA selective window is shown in blue area, 
defined as the concentration range for CBE or CP between its IC50 values towards GBA and the next 
major glycosidase target (in all cases, GBA2).
with 37.5 or 100 mg CBE kg−1 body weight (Fig. 2.4B). It therefore can be concluded that the 
CBE treatment generates a valuable neuronopathic Gaucher disease model. It should however 
be stressed that the use of  higher CBE concentrations or longer incubation periods may cause 
undesired inhibition of  other glycosidases. 
The presented investigation also reveals that CP is a more potent GBA inactivator. 
However, CP inhibits GBA2 on a par with GBA in both cultured cells and zebrafish larvae 
(Table 2.4), and therefore does not offer a window for selective GBA inactivation (Fig. 2.8). In 
other words, CP seems of  little use to generate a Gaucher disease model. Previous work showed 
that a CP functionalized at C6 with a BODIPY moiety is an ABP that inactivates potently and 
selectively GBA.32 This compound was found not to penetrate well into the brain, likely by active 







































































































































































































































































































































































































































































































































































































































































































































0.063 0.154 0.059 0.083




with higher selectivity and concomitantly are brain-permeable. Such compounds might create 






2.4 Experimental procedures 
2.4.1 General materials and methods  
Cyclophellitol (CP) and the ABPs were synthesized as described earlier.32, 36–38, 45 Chemicals were 
obtained from Sigma-Aldrich (St. Louis, MO, USA) if  not otherwise indicated. Conduritol B-
epoxide (CBE) was purchased from Enzo Life Sciences (Farmingdale, NY, USA). Recombinant 
GBA (rGBA, imiglucerase) was obtained from Sanofi Genzyme (Cambridge, MA, USA). Human 
fibroblasts (CC-2511) were obtained from Cambrex-Lonza (East Rutherford, NJ, USA). 
HEK293T (CRL-3216) and RAW-264.7 (TIB-71) cell lines were purchased from ATCC 
(Manassas, VA, USA). HEK293T cells overexpressing human GBA2 and GBA3 were generated 
as previously described46. Cell lines were cultured in HAMF12-DMEM medium (Sigma-Aldrich) 
for fibroblasts or DMEM medium (Sigma-Aldrich) for HEK293T cell line, supplied with 10 % 
(v/v) FCS, 0.1% (w/v) penicillin/streptomycin, and 1 % (v/v) Glutamax, under 5 % CO2 
(fibroblasts) or 7 % CO2 (HEK293T). Zebrafish (Danio rerio) were handled and maintained 
according to standard protocols (zfin.org). Adult zebrafish were housed at a density of  40 per 
tank, with a cycle of  14 h of  light and 10 h of  dark. Adults, embryos and larvae were kept at a 
constant temperature of  28.5 °C. Embryos and larvae were raised in egg water (60 μg L–1 sea 
salt, Sera marin). Synchronized wild-type ABTL zebrafish embryos were acquired after mating 
of  single male and female couples (both > 3 months old). Frozen brain samples from wild-type 
and CBE-treated mice were obtained from a previous study.9 Protein concentration was 
measured using Pierce BCA assay kit (Thermo Fisher Scientific, Waltham, MA, USA). 
2.4.2 Enzymatic assays  
All assays were performed in 96-well plates at 37 °C for human, zebrafish, and mice material. 
Samples were diluted with McIlvaine buffer (150 mM citric acid—Na2HPO4) to a final volume 
of  25 µL, at pH appropriate for each enzyme. Assays were performed by incubating the samples 
with 100 µL 4-MU- (4-methylumbelliferyl-) substrates diluted in McIlvaine buffer (with 0.1% 
(w/v) bovine serum albumin (BSA)) for a period of  30 min to 2 h. After stopping the substrate 
reaction with 200 µL 1M NaOH-glycine (pH 10.3), 4-MU-emitted fluorescence was measured 
with a fluorimeter LS55 (Perkin Elmer, Waltham, MA, USA) using λEX 366 nm and λEM 445 
nm.32 Measured activities were subtracted with background values (from samples without 
enzyme), normalized with the average values from the control samples (no inhibitor), and curve-




fitted to inhibitor concentrations using Prism 7.0 (GraphPad Software, San Diego, CA, USA) by 
the [inhibitor] vs response—various slope (four parameters) method to obtain IC50 values. The 
substrate mixtures used for each enzyme are listed as follows: GBA, 3.75 mM 4-MU-β-D-
glucopyranoside (Glycosynth, Warrington Cheshire, UK) at pH 5.2, supplemented with 0.2% 
(w/v) sodium taurocholate and 0.1% (v/v) Triton X-100, and 25 nM N-(5-adamantane-1-yl-
methoxy-pentyl)-deoxynojirimycin (AMP-DNM), a GBA2-specific inhibitor47; GBA2, 3.75 mM 
4-MU-β-D-glucopyranoside at pH 5.8, with pre-incubation with 1 µM ABP 3a for 30 min to 
specifically inhibit GBA activity; α-glucosidases, 3 mM 4-MU-α-D-glucopyranoside at pH 4.0 
(GAA) or at 7.0 (GANAB), GUSB, 2 mM 4-MU-β-D-glucuronide at pH 5.0; α-galactosidases, 2 
mM 4-MU-α-D-galactopyranoside at pH 4.6; β-galactosidases, 1 mM 4-MU-β-D-
galactopyranoside at pH 4.3 with 0.2 M NaCl; α-mannosidases, 10 mM 4-MU-α-D-
mannopyranoside at pH 4.0; β-mannosidases, 2 mM 4-MU-β-D-mannopyranoside (Glycosynth) 
at pH 4.2; β-hexosaminidase HexA, 5 mM 4-MU-β-D-6-sulpho-2-acetamido-2-deoxy-
glucopyranoside at pH 4.4; β-hexosaminidases HexA/B, 5 mM 4-MU-β-N-acetyl-glucosaminide 
at pH 4.5; α-N-acetyl-galactosaminidase, 1 mM 4-MU-α-N-acetyl-galactosaminide at pH 4.5; α-
L-fucosidase, 1 mM 4-MU-α-L-fucopyranoside at pH 5.0, α-L-iduronidase, 2 mM 4-MU-α-L-
iduronide (Glycosynth) at pH 4.0; GBA3, 3.75 mM 4-MU-β-D-glucopyranoside at pH 6.0. 
2.4.3 Fluorescent ABP labeling and detection 
Residual active, not irreversibly inhibited glycosidases were labeled with excess fluorescent ABPs 
in the optimum McIlvaine buffer, if  not otherwise stated (see above). ABP labeling was 
performed at 37 °C for 30 min for all materials, in a total sample volume of  20–40 µL and 0.5–
1 % DMSO concentration. GBA was labeled with 200 nM ABP 3b (pH 5.2, 0.1 % (v/v) Triton-
100, 0.2 % (w/v) sodium taurocholate), or labeled together with GBA2 using 200 nM β-aziridine 
ABP 4c at pH 5.5. GBA2 was labeled with 200 nM β-aziridine ABP 4a, 4b or 4c. The α-
glucosidases GAA and GANAB were first pre-incubated with 200 nM ABP 4a for 30 min (pH 
4.0 for GAA and pH 7.0 for GANAB), followed by labeling with 500 nM ABP 6a or 6c at pH 
4.0 or 7.0. The β-glucuronidase GUSB was pre-incubated with 200 nM ABP 4a for 30 min, 
followed by labeling with 200 nM β-aziridine ABP 5c. After ABP incubation, proteins were 
denatured by boiling the samples with 5× Laemmli buffer (50 % (v/v) 1 M Tris-HCl, pH 6.8, 50 
% (v/v) 100 % glycerol, 10 % (w/v) DTT, 10 % (w/v) SDS, 0.01 % (w/v) bromophenol blue) 





running continuously at 90V.32, 36–38 Wet slab-gels were scanned on fluorescence using the 
Typhoon FLA 9500 (GE Healthcare) at λEX 473 nm and λEM ≥ 510 nm for green fluorescent 
ABP 4a and 6a; at λEX 532 nm and λEM ≥ 575 nm for ABP 3b and 4b; and at λEX 635 nm and 
λEM ≥ 665 nm for ABP 4c, 5c and 6c. ABP-emitted fluorescence was quantified using 
ImageQuant software (GE Healthcare, Chicago, IL, USA) and curve-fitted using Prism 7.0 
(GraphPad Software). After fluorescence scanning, SDS-PAGE gels were stained for total 
protein with Coomassie G250 and scanned on a ChemiDoc MP imager (Bio-Rad, Hercules, CA, 
USA). 
2.4.4 In vitro effects of  inhibitors on rGBA 
For IC50 measurements using enzymatic assay, 3.16 ng (53 fmole) of  rGBA was prepared in 12.5 
μL McIlvaine buffer (150 mM, pH 5.2) supplemented with 0.1 % (v/v) Triton X-100, and 0.2 % 
(w/v) sodium taurocholate, and incubated with 12.5 μL of  inhibitors (CBE or CP) diluted in 
McIlvaine buffer at 37 °C for various time periods. Residual activity of  rGBA was measured as 
described in previous section. For assessing the occupancy of  active site pocket by the inhibitors 
using ABP labeling, same amount of  rGBA was prepared in 10 μL of  the same McIlvaine buffer, 
incubated firstly with 2.5 μL inhibitor dilutions prepared in McIlvaine buffer at 37 °C for various 
time periods, then with 2.5 μL ABP dilutions prepared in McIlvaine buffer; detection of  ABP-
labeled rGBA follows the procedures described in the previous section. 
2.4.5 In vivo effects of  CBE and CP in intact cultured cells 
Confluent HEK293T stably expressing human GBA2 were cultured in 12-well plates in 
triplicates with(out) CBE (0.01−10,000 μM) or CP (0.001−10 μM) for 24 h at 37 °C. In addition, 
confluent human fibroblasts were similarly treated in 15 cm dishes for 2, 24, and 72 h. For lysis, 
cells were washed three times with PBS, subsequently lysed by scraping in potassium phosphate 
buffer (K2HPO4−KH2PO4, 25 mM, pH 6.5, supplemented with 0.1 % (v/v) Triton X-100 and 
protease inhibitor cocktail (Roche, Basel, Switzerland)), aliquoted, and stored at –80 °C. After 
determination of  the protein concentration, lysates containing equal protein amount (5−20 μg 
total protein per measurement) were adjusted to 12 μL with potassium phosphate buffer and 
subjected to residual activity measurements using enzymatic assay (n = 3 technical replicates for 
each biological triplicate at each treatment condition) or ABP detection (n = 3 biological 
replicates). For in vivo ABP labeling, HEK293T cells expressing GBA2 were incubated with 




culture medium containing CBE (0.015–15,000 μM) or CP (0.001−10 μM) for 24 hours. Medium 
was removed and cells were incubated for 4 hours with culture medium containing a mixture of  
200 nM ABP 4b, 1 μM ABP 5c, and 500 nM ABP 6c, or with DMSO only (negative control). 
Lysates were prepared and measured for protein concentration as described above, and samples 
containing 60 μg total protein (diluted with potassium phosphate buffer to 15 µL total volume) 
were subjected to ABP detection (n = 3 biological replicates). 
2.4.6 In vivo effects of  inhibitors in living zebrafish larvae 
Adult zebrafish were not sacrificed for this study; all experiments were performed on 
embryos/larvae before the free-feeding stage (120 h, i.e. 5 days post-fertilization) and did not 
fall under animal experimentation law according to the EU Animal Protection Directive 
2010/63/EU. For in vivo inhibitor treatment, a single fertilized embryo was seeded in each well 
of  a 96-wells plate, and exposed to 200 μL CBE (1−100,000 μM), or CP (0.001−100 μM) for 
120 hours at 28.5 °C. Per condition, n = 48 embryos were used. At 120 hours (5 dpf), larvae 
were collected, rinsed three times with egg water, fully aspirated, snap-frozen in liquid nitrogen 
and stored at –80 °C until homogenization in 200 μL 25 mM potassium phosphate buffer per 
48 individuals. Lysis was conducted by sonication with a Polytron PT 1300D sonicator 
(Kinematica, Luzern, Switzerland) on ice at 20 % power for three seconds, and repeated three 
times. Samples containing 20–45 μg total protein were subjected to ABP detection or enzymatic 
assay. 
2.4.7 In vivo effects of  CBE in brain of  mice 
Brain hemispheres were obtained from mice injected daily with CBE at either 37.5 mg or 100 
mg kg−1 body weight, or PBS, from day 8 until day of  sacrifice (day 24 for the 37.5 mg CBE kg−1 
group; day 14 for the 100 mg CBE kg−1 group) as previously described.9 Brain hemispheres were 
homogenized in 4x volumes of  tissue wet weight in 25 mM potassium-phosphate buffer (4x 
volume/wet tissue weight) with 1.0 mm glass beads using a Fastprep-24 instrument (MP 
Biomedicals, Santa Ana, CA, USA) set at 6 m s–1 for 20 seconds, repeated three times, while 
chilling samples on ice for 2 min between separate runs. Crude lysates were isolated from the 
glass beads by pipetting into sterile Safe-Lock Eppendorf  tubes. Homogenates were measured 
for protein concentration, aliquoted, and snap-frozen in liquid nitrogen. Samples containing 50 





was performed in Prism 7.0 software (GraphPad) to derive statistical significance, where p < 
0.05 was considered significant. 
2.4.8 In vivo effects of  inhibitors towards GBA3 in cells 
HEK293T cells expressing human GBA3 were cultured, treated (triplicate sets), and lysed in an 
identical setup as described with GBA2-expressing HEK293T cells. Lysates (12 μg protein) were 
subjected to ABP detection using 200 nM ABP 4c at pH 6.0. For enzymatic assay, lysates were 
separated from GBA2 and GBA by centrifugation (16,000 g for 10 min at 4°C) and incubation 
of  the resulting supernatant with 20 μL concanavalin A sepharose beads (Sigma-Aldrich) in 200 
μL of  binding buffer (0.1 M Sodium acetate, 0.1 M NaCl, 1 mM MgCL2, 1 mM MnCl2, 1 mM 
CaCl2, pH 6.0) for 1 h at 4°C on a rotor. Next, beads were removed from the supernatant by 
centrifugation. 5 μL of  the supernatant was added with 20 μL McIlvaine buffer (pH 6.0), and 
subjected to enzymatic assays for GBA3 activity. Measured activity was normalized with the 
corresponding protein concentration of  each sample, and data were processed as earlier 
described. 
2.4.9 Sphingolipid extraction and analysis by mass spectrometry in zebrafish larvae 
Zebrafish embryos at 8 hours post fertilization were seeded in 12-well plates (15 fish/well, 3 mL 
egg water/well) and treated with CBE (10–1,000 µM) or CP (0.01–10 µM)) for 112 hours at 28 
°C. Thereafter, zebrafish larvae were washed three times with egg water, and collected in clean 
screw-cap Eppendorf  tubes (three tubes of  three larvae per inhibitor concentration). Lipids were 
extracted and measured according to methods described previously.48 Briefly, after removing of  
the egg water, 20 µL of  13C-GlcSph49 from concentration 0.1 pmol µL–1 in MeOH, 480 µL 
MeOH, and 250 µL CHCl3 were added to the sample, stirred, incubated for 30 min at RT, 
sonicated (5 x 1 min in sonication water bath), and centrifuged for 10 min at 15,700 g. 
Supernatant was collected in a clean tube, 250 µL CHCl3 and 450 µL 100 mM formate buffer 
(pH 3.2) were added. The sample was stirred and centrifuged, the upper phase was transferred 
to a clean tube. The lower phase was extracted with 500 µL MeOH and 500 µL formate buffer. 
The upper phases were pooled and taken to dryness in a vacuum concentrator at 45 °C. The 
residue was extracted with 700 µL butanol and 700 µL water, stirred and centrifuged. The upper 
phase (butanol phase) was dried and the residue was dissolved in 100 µL MeOH. 10 µL of  this 
sample was injected to the LC-MS for lipid measurement. Two-tailed unpaired t-test was 




performed in Prism 7.0 software (GraphPad) to derive statistical significance, where p < 0.05 
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Figure 2.S1. Effect of in vivo incubation with CBE and CP on enzymatic activity of glycosidases in 
cultured cells. Confluent cultured human fibroblasts were treated in vivo with different concentrations of 
CBE (blue) and CP (red) for 2 h, 24 h, or 72 h, before harvested and lysed in potassium phosphate buffer. 
Residual activities of glycosidases were measured by in vitro enzymatic assay using appropriate glycoside 
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Figure 2.S2. Effect of in vivo incubation with CBE and CP on in vivo ABP labeling of glycosidases 
in cultured cells. A) Schematic representation of the experimental procedure. B) Overlay of fluorescence 
channels showing in vivo ABP labeling of glycosidases that have not been inactivated by CBE or CP; one 
representative image is selected from n = 3 biological replicates. C) Individual fluorescence channels of 
B); one representative image is selected from n = 3 biological replicates. *GBA labeling by ABP 4b was 
not used for analysis, due to the presence of an unidentified off-target by ABP 4b in living cells. ABP 5 
labels both GUSB and GBA.37 D) Quantification of ABP labeling. Error ranges = ± SD, n = 3 (biological 
replicates). 
A
CBE 1 or CP 2















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.S3. Effect of in vivo incubation with CBE and CP on glycosidases in zebrafish larvae. 
Zebrafish embryos (n = 48) were incubated with CBE or CP from 8–120 hpf before lysed in potassium 
phosphate buffer. A) Quantification of gels from Fig. 2.4A and 2.5D. B) Residual activity of glycosidases 
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Table 2.S1 Effect of in vivo incubation with CBE and CP on in vivo ABP labeling of glycosidases 
in cultured cells. Apparent IC50 values (µM) were derived from the average of biological triplicates as 
measured by quantification of in vivo ABP labeling on residual active enzymes (ABP). -, value cannot be 
calculated (no inhibition at the tested concentrations). Error ranges = ± SD, n = 3 biological replicates. 
  
Inhibition of CBE and CP in cultured cells by In vivo ABP
labeling
Apparent IC50 values (µM) were derived from the average of
3 biological replicates as measured by quantification of in
vivo ABP labeling on residual active enzymes (ABP). -, value































Functionalized cyclophellitols are improved 
glucocerebrosidase inhibitors for generating neuropathic 
Gaucher model in zebrafish 
Manuscript published as: 
Artola M, Kuo CL, Lelieveld LT, Rowland RJ, van der Marel GA, Codée JDC, Boot RG, Davies DJ, Aerts 
JMFG, Overkleeft HS (2019) Functionalized Cyclophellitols Are Selective Glucocerebrosidase Inhibitors 
and Induce a Bona Fide Neuropathic Gaucher Model in Zebrafish. J Am Chem Soc 141, 4214–4218.  





Gaucher disease is caused by inherited deficiency in glucocerebrosidase (GBA, a retaining β-
glucosidase), and deficiency in GBA constitutes the largest known genetic risk factor for 
Parkinson disease. In the past, animal models of  Gaucher disease have been generated by 
treatment with the mechanism-based GBA inhibitors, conduritol B epoxide (CBE) and 
cyclophellitol. Both compounds however also target other retaining glycosidases, rendering 
generation and interpretation of  such chemical knockout models complicated. Here it is 
demonstrated that cyclophellitol derivatives carrying a bulky hydrophobic substituent at C8 
(cyclophellitol numbering) are potent and selective GBA inhibitors and that an unambiguous 







lucocerebrosidase (acid glucosylceramidase, GBA, E.C. 3.2.1.45,) is a lysosomal 
retaining β-glucosidase that belongs to the glycoside hydrolase (GH) 30 
(www.cazy.org)1 family and degrades the glycosphingolipid, glucosylceramide 
through a two-step Koshland double displacement mechanism (Fig. 3.1A). 
Inherited deficiency in GBA causes the most common autosomal recessive lysosomal storage 
disorder, Gaucher disease.2 Individuals carrying heterozygous mutations in the gene coding for 
GBA do not develop Gaucher disease but have a remarkable increased risk for developing 
Parkinson disease (PD) and Lewy-body dementia.3–5 Appropriate animal models linking 
impaired GBA functioning to Gaucher disease and Parkinson’s disease are imperative both for 
understanding the pathophysiology of  these diseases and for the development of  effective 
treatments for these. Because complete genetic abrogation of  GBA hampers animal viability due 
to skin permeability problems,6 research models have been generated in the past in a chemical 
knockdown strategy by making use of  the mechanism-based, covalent and irreversible retaining 
β-glucosidase inhibitor, conduritol B epoxide (CBE, 1, Fig. 3.1B) or its close structural analogue, 
cyclophellitol (2, Fig. 3.1B).7, 8 One complication in the use of  these compounds is their relative 
lack of  selectivity.9 It has been found that cyclophellitol 2 is unsuited for creating a reliable 
Gaucher animal model because it targets GBA and GBA2 with about equal efficiency.9 On the 
other hand, CBE 1 exhibits some GBA selectivity but it also inhibits lysosomal α-glucosidase 
(GAA),10–13 non-lysosomal glucosylceramidase (GBA2),14, 15 and lysosomal β-glucuronidase 
(GUSB)16. Effective mouse models can be generated with CBE 1, but the therapeutic window is 
rather narrow and varies in cellular and animal models.  
Recent research from the Aerts and Overkleeft group has revealed that functionalized 
cyclophellitol derivatives carrying a BODIPY substituent at C8 (cyclophellitol numbering, the 
primary carbon corresponding to C6 in glucose) are very potent and very selective activity-based 
probes (ABPs) for monitoring GBA activity in vitro, in situ, and in vivo.17,18 The presence of  a 
bulky and hydrophobic substituent at this position at once proved beneficial for GBA 
inactivation (ABPs 3 and 4, (Fig. 3.1C, D)) proved to inhibit GBA in the nanomolar range, 
whereas cyclophellitol 2 is a high nanomolar to micromolar GBA inactivator and detrimental to 
inhibition of  other retaining β-glucosidases. Following these studies, Vocadlo and co-workers 
designed a set of  fluorogenic substrates featuring a fluorophore at C6 of  a β-glucoside, the 
G 




aglycon of  which carried a fluorescence quencher, compounds that proved to be very selective 
GBA substrates in situ.19 These results altogether evoked the question whether cyclophellitols 
bearing a simple, hydrophobic moiety at C8, such as compounds 6 and 7 (Fig. 3.1D), would be 
suitable compounds for generating chemical knockdown Gaucher animal models. The validity 
of  this reasoning is shown in the generation of  a GBA-deficient Dario rerio zebrafish model, as 
revealed by the accumulation of  elevated levels of  the Gaucher harbinger lysolipid, 
glucosylsphingosine, using cyclophellitol derivatives 6 and 7.
Figure 3.1. Structures and reaction mechanism of compounds in this chapter. A) 
Glucocerebrosidase (GBA) hydrolyses glucosylceramide in a two-step double displacement mechanism 
to yield glucose and ceramide. B) Chemical structure of CBE 1 and cyclophellitol 2. C) Mechanism-based 
inactivation of GBA by glucopyranoside-configured cyclitol epoxides (shown for cyclophellitol). D) 
Structures of C6-extended cyclophellitol derivatives used in the here-presented studies: GBA1 activity-
based probes ABPs 3-5 and selective inhibitors 6 and 7 (see for the full chemical structures of ABPs 3-5 
and 8-14 in Fig. 3.S1). 
3.2 Results and Discussion 
3.2.1 Structural support for inhibitor design 
At the onset of  the studies, structural support was sought for the design of  compounds 6 
and 7. The Cy5-functionalized cyclophellitol 5 was synthesized (Department of  Bio-organic 
Chemistry, Leiden University) and a crystal structure of  human recombinant GBA soaked with 
this ABP was obtained (University of  York). As expected (Fig. 3.2A), the active site nucleophile 
(in both molecules of  the asymmetric unit) had reacted with the epoxide to yield the covalently 






















ABP 3 (R = BODIPY green)
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one molecule of  the asymmetric unit (the differences may reflect crystal packing constraints in 
a soaking experiment) accommodated by a hydrophobic pocket in GBA. Previous studies on the 
bacterial glycoside hydrolase, Thermoanaerobacterium xylanolyticum TxGH116 β-glucosidase, a close 
homologue of  human GBA2 with a conserved active site, instead showed an “inwards” position 
of  O6 (Fig. 3.S2A) and a narrower and less hydrophobic pocket) (Fig. 3.S2B), which may 
partially mitigate against the binding of  O6-functionaised probes, thus allowing sufficient 
discrimination for GBA over GBA2.20, 21 
 
Figure 3.2. Structure of GBA reacted with ABP 5 and adamantyl-cyclophellitol 7. A) GBA dimer, with 
the cyclophellitol and linker moiety of 5 shaded in yellow, and a single observed Cy5 in pink. B) Zoomed 
view of a GBA monomer reacted with ABP 5. C) Structure of GBA with adamantyl-cyclophellitol 7. The 
linker-adamantyl moiety of 7 is observed in slightly different positions in the two molecules of the 
asymmetric unit (PDB Code 6Q6L, Fig. 3.S2) reflecting its binding through predominantly hydrophobic 
interactions. 
Biphenyl-cyclophellitol 6 and adamantyl-cyclophellitol 7 were synthesized following 
adaptations of  literature cyclophellitol syntheses (see Appendix section 3.S2 for synthesis 
details) to generate superior selective GBA inhibitors for the generation of  a Gaucher model 
zebrafish.22, 23 
Although soaking of  GBA crystals with 6 did not yield suitable structures for structural 








hydrophobic moiety (here, the adamantane) to the same hydrophobic cavity and pocket occupied 
by the O6 linker on Cy5 ABP 5. Several hydrophobic residues, including Tyr313, Phe246, and 
Trp348 provide the wide cavity that is able to accommodate different hydrophobic O6 
substituents which is absent in other human β-glucosidases and which provides the structural 
basis for the inhibitory (and substrate) preferences of  GBA. 
3.2.2 In vitro and in vivo activity of  inhibitors 
 The in vitro activity and selectivity of  compounds 6 and 7 towards GBA and the two major 
off-target glycosidases of  CBE 1 (GBA2 and GAA)9 were evaluated, by pre- incubating the 
inhibitors with recombinant human GBA (rGBA, Cerezyme), human GBA2 (from lysates of  
GBA2 overexpressed cells), and recombinant human GAA (rGAA, Myozyme) for 3 h, followed 
by enzymatic activity measurement. Both compound 6 and 7 were nanomolar inhibitors of  
rGBA (apparent IC50 values = 1.0 nM), which were 4,000-fold more potent than CBE 1 (apparent 
IC50 values = 4.28 µM) (Fig. 3.3A, 3.S3) with improved lipophilic ligand efficiencies (LipE) 
(Table 3.S2). Both compounds 6 and 7 were rather inactive towards GBA2 and GAA (apparent 
IC50 values > 100 µM), similar to ABP 3 and 5 (Fig. 3.3A, 3.S4). When comparing their selectivity 
towards GBA, both compounds 6 and 7 exhibited IC50 ratio (GBA2/GBA and GAA/GBA) of 
> 100,000, thus making them 4,000-times and 200-times more selective than CBE 1 (IC50 ratio 
= 23.6 for GBA2/GBA and 444 for GAA/GBA) (Fig. 3.3A).  
 To evaluate the in vivo activity of  compound 6 and 7, compounds were added to the egg-
water containing zebrafish (Danio rerio) embryos, and incubated for 5 days at 28 °C before 
subsequent homogenization and enzyme selectivity analysis by appropriate ABP labeling.9, 24 
Quantification of  ABP-labeled bands revealed that compounds 6 and 7 had in vivo apparent IC50 
values towards GBA of  4 to 6 nM, and that they were 5- to 70-fold more potent than ABP 3 or 
5 and 7,500 fold more potent than CBE 1 (Fig. 3.3B, 3.S5) in the zebrafish larvae. More 
importantly, an improved selective inactivation of  GBA was achieved with both compounds 6 
and 7. At a concentration of  0.1-10 µM of  compound 6 or 7, ABP labeling of  GBA with broad-
spectrum retaining β-glucosidase ABP 8 (Fig. 3.S1) and GBA-specific ABP 5 was abrogated 
(Fig. 3.3C), while other enzymes such as GBA2 and LPH (Figure 3.3C), GAA, ER α-






Figure 3.3. In vitro and in vivo activity of compounds used in this study. A) Apparent IC50 values for 
in vitro inhibition of GBA, GBA2 and GAA in recombinant enzymes (rGBA and rGAA) or overexpressed 
cell lysates (GBA2) by compounds 1, 2, 3, 5, 6 and 7. Error ranges depict standard deviations from 
biological duplicates. B) Apparent IC50 values for in vivo inhibition in 5-day treated zebrafish embryo with 
compounds 1, 2, 3, 5, 6, and 7. Error ranges depict standard deviations from n = 12−24 individuals. C) 
Competitive ABPP in lysates of zebrafish treated in vivo with compounds 6 and 7 using broad-spectrum 
retaining β-glucosidase ABP 8 and selective GBA ABP 5 as readout. D) Glucosylsphingosine levels 
produced in zebrafish embryos treated for 5 days with inhibitors 6, 7 or CBE 1.9 Error ranges depict 
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At 0.1-10 µM of  inhibitor 6 or 7, a 10- to 30-fold elevation in the level of  
glucosylsphingosine (GlcSph) was observed, which is known to be formed by acid ceramidase-
mediated conversion of  accumulating GlcCer in lysosomes.25, 26 Therefore, this observation also 
strongly points to in vivo inactivation of  lysosomal GBA. For comparison, reaching similar 
GlcSph levels in the zebrafish with CBE required 1,000 to 10,000-fold higher concentration in 
contrast with compounds 6 or 7 (Fig. 3.3D), concentrations at which GBA2 and GAA may also 
be targeted. 
3.2.3 Brain permeability of  inhibitors 
Finally, the brain permeability of  these new inhibitors was investigated, a crucial feature 
for their future application in the study of  neuropathic Gaucher disease and Parkinson disease. 
Adult zebrafish of  3 months’ age were treated with DMSO, ABP 3 or compound 7 (1,6 
nmol/fish, approximately 4 μmol/kg) administered via food intake, and after 16 h brains and 
other organs were isolated, homogenized, and analyzed by ABP labeling using ABP 5 (GBA), 
ABP 8 (GBA2 + GBA), ABP 11 (GAA at pH 4.0 and ER α-glucosidase GANAB at pH 7.0), 
and ABP 13 (lysosomal β-glucuronidase GUSB) (Fig. 3.S1). Labeling of  brain homogenate of  
adult zebrafish with ABP 5 resulted in considerable GBA labeling in control and ABP 3-treated 
fish, but no labeling in brain homogenates from fish treated with compound 7 (Fig. 3.4). 
Labeling by the broad-spectrum β-glucosidase ABP 8 showed that GBA2 was not a target of  
compound 7, nor was the lower running band (48 kDa), which is hypothesized to be the cytosolic 
β-glucosidase, GBA3 (E.C. 3.2.1.21).27 It could be labeled (in lysates of  zebrafish larvae) with 
the broad spectrum β-glucosidase ABP 8 at 0.1 µM28 optimally at pH of  6.0 (Fig. 3.S8) and 
could be competed away by pre-incubating the lysates with another broad spectrum β-
glucosidase ABP—ABP 10, while not showing reactivity with the GBA-specific epoxide ABP 5 
(Fig. 3.S8). It is noted that the expression level of  this protein is likely variable among individual 
fish, as four out of  six fish in the control group lacked this band (Fig. 3.4). In the visceral organs 
(both liver and spleen), both ABP 3 and compound 7 selectively abrogated GBA, while not 






Figure 3.4. In vivo targets of ABP 3 and 7 in brains of adult zebrafish. Competitive ABPP in adult 
zebrafish homogenates with selective GBA ABP 5 or broad-spectrum retaining -glucosidase ABP 8 as 
read-out.
3.3 Conclusion 
To summarize, crystallographic studies aided the rational design of  novel cyclophellitol 
analogues 6 and 7, that turned out to be very potent and selective GBA inhibitors, also in 
zebrafish embryos and adult zebrafish (GBA2/GBA inhibition ratio > 1,000). Compound 7, 
which also completely block GBA activity in the brain, should be superior to CBE 1 and CP 2 
for generating GBA deficiency on demand in zebrafish, thus to create zebrafish models for 
neuropathic Gaucher disease, to assist research in the context of  neuropathic GD and PD. 
  
Figure 3.4
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3.4 Experimental procedures 
3.4.1 General materials and methods  
Cyclophellitol (CP) 1 and the ABPs 3, 4 and 8–14 were synthesized as described earlier17, 27–30. 
Conduritol B-epoxide (CBE) was purchased from Enzo Life Sciences (Farmingdale, NY, USA). 
Recombinant human GBA (rGBA, imiglucerase, Cerezyme®) and recombinant human GAA 
(rGAA, alglucosidase alfa, Myozyme) were obtained from Sanofi Genzyme (Cambridge, MA, 
USA). HEK293T (CRL-3216) cell lines were purchased from ATCC (Manassas, VA, USA). Cell 
lines were cultured in DMEM medium (Sigma-Aldrich, St. Lois, MO, USA), supplied with 10% 
(v/v) FCS, 0.1 % (w/v) penicillin/streptomycin, and 1 % (v/v) Glutamax, under 7 % CO2 at 
37°C. Zebrafish (Danio rerio) were handled and maintained as previously described.9 Protein 
concentration was measured using Pierce BCA assay kit (Thermo Fisher Scientific, Waltham, 
MA, USA). 
3.4.2 Preparation of  cell lysates containing human GBA2  
HEK293T cells overexpressing human GBA2 were generated as previously described20. For 
preparing lysates, cell pellets from two 15-cm culture dishes were resuspended in 1200 μL of  
lysis buffer (25 mM KH2PO4–K2HPO4, pH 6.5, protease inhibitor cocktail (EDTA-free, Roche, 
Basel, Switzerland), 2.5 U/mL benzonase) and incubated for 30 min on ice. The suspension was 
passed through a 30-gauge needle 10 times using a 1 mL syringe, and stored at –80°C.  
3.4.3 In vitro activity of  inhibitors on glycosidases measured by 4-MU substrates 
In vitro apparent IC50 measurements with compounds (ABP 3, ABP 5, 6, and 7) in GBA (rGBA) 
followed the fluorogenic substrate methods described9 previously at 3 h incubation time and 2 
nM enzyme. For in vitro apparent IC50 measurements with compounds (CBE 1, CP 2, ABP 3, 
ABP 5, 6, and 7) in GBA2, 8 volumes of  cell lysates (7 μg total protein/μL) containing 
overexpressed human GBA2 were firstly pre-incubated with 1 volume of  ABP 4 (100 nM final 
concentration, 0.5% (v/v DMSO)) for 30 min at 37°C to selectively inhibit GBA activity. After 
which, lysates were incubated with 1 volume of  compounds at various concentrations for 3 h at 
37°C, before subsequent enzymatic assay for GBA2 activity described earlier.9 For measurement 
in rGAA, 2.1 ng rGAA was prepared in 12.5 μL assay buffer (150 mM McIlvaine buffer, pH 4.0, 





3, ABP 5, 6, and 7) for 3 h at 37°C and subjected to GAA activity readout as described earlier 
([enzyme] =19 nM during incubation).9 All assays were performed in duplicate sets, each set with 
3 technical replicates at each inhibitor concentration. DMSO concentration was kept at 1 % (v/v) 
in all assays during incubation with compounds. In vitro apparent IC50 values were calculated by 
fitting data with [inhibitor] vs response—various slope (four parameters) function using 
GraphPad Prism 7.0 software, and the average values and standard deviations were calculated 
from the two sets for each compound. 
3.4.4 Zebrafish housing and breeding 
Zebrafish were housed and maintained at the University of  Leiden, the Netherlands, at a density 
of  40-50 adults per tank, on a cycle of  14 hours of  light, 10 hours of  darkness and at constant 
temperature of  28°C. The breeding of  fish lines was approved by the local animal welfare 
committee (Instantie voor dierwelzijn, IvD) of  the University of  Leiden (license number: 10612). 
Experiments with embryos and larvae were performed before the free-feeding stage, not falling 
under animal experimentation law according the EU animal Protection Directive 2010/63/EU. 
Embryos and larvae were grown and incubated in egg water (60 µg/mL Instant Ocean Sera 
marin TM aquarium salts (Sera; Heinsberg, Germany) at constant temperature of  28 °C. 
3.4.5 In vivo activity of  inhibitors and fluorescent ABP labeling and detection in zebrafish larvae 
For in vivo treatment of  compounds (ABP 3, ABP 5, 6, and 7), a single fertilized embryo was 
seeded in each well of  a 96-wells plate, and exposed to ABP 3 (0.001−10 μM), ABP 5 (0.0001−10 
μM), 6 (0.001−10 μM) and 7 (0.001−10 μM) diluted in 200 μL egg water (0.5% (v/v) DMSO) 
for 120 hours at 28.5 °C. Per condition, n = 24 embryos were used. At 120 hours (5 dpf), larvae 
were collected, rinsed three times with egg water, fully aspirated, snap-frozen in liquid nitrogen 
and stored at –80 °C until homogenization in lysis buffer (without benzonase) at 4 μL/fish. Lysis 
was conducted by sonication with a Polytron PT 1300D sonicator (Kinematica, Luzern, 
Switzerland) on ice at 20% power for three seconds, and repeated three times. Samples 
containing 20–45 μg total protein were diluted in 14 μL lysis buffer, added with McIlvaine buffer 
at various pHs, and subjected to ABP detection at a final volume of  32 μL for 30 min at 37 °C 
using the following conditions: GBA with McIlvaine buffer pH 5.2 (with 0.1 % (v/v) Triton X-
100 and 0.2 % (w/v) sodium taurocholate (Sigma)), and 200 nM ABP 4 or ABP 5; β-glucosidases 
(GBA, GBA2, GBA3, LPH) with McIlvaine buffer pH 5.5 and 100 nM ABP 8 or ABP 9; GAA 




with McIlvaine buffer pH 4.0 and pre-incubation with 200 nM ABP 10, before incubation with 
500 nM ABP 11 or 3 μM ABP 12; GANAB with McIlvaine buffer pH 7.0 and pre-incubation 
with 200 nM ABP 10, before incubation with 500 nM ABP 11 or ABP 12; GUSB with McIlvaine 
buffer pH 5.0 and pre-incubation with 200 nM ABP 10, before incubation with 200 nM ABP 13 
or ABP 14. After ABP incubation, proteins were denatured and separated by SDS-PAGE, and 
analysed according to the previously described method.9 Coomassie staining was used to assess 
total protein loading. 
3.4.6 In vivo activity of  inhibitors in adult zebrafish 
Surplus wild-type adult zebrafish of  3 months of  age were administrated with a single dose of  
food grain mixed with DMSO, ABP 3 or 7 (1.6 nmol/fish, approximately 4 μmol/kg, n = 3 for 
each treatment) in n = 2 sets, according to project license AVD1060020184725,1-04 held by Dr. 
R.G. Boot. An initial experiment was performed with 3 adult zebrafish and the effect was 
confirmed by additional 3 individuals per experimental condition. Zebrafish were sacrificed after 
24 h using Tricaine (250 mg/L), organs were harvested, snap-frozen in liquid nitrogen and stored 
at -80°C until use. Food grain consisted of  Gemma micro mixed with Gemma diamond 
(Skretting, Stavanger, Norway). Lysis was performed with 50 μL lysis buffer (without benzonase) 
per sample, and lysates containing 20–60 μg total protein were analyzed by ABP method for 
GBA, GBA2, GAA, GANAB, and GUSB, as described in the previous section. 
3.4.7 Sphingolipid extraction and analysis by mass spectrometry in treated zebrafish larvae 
Zebrafish embryos at 8 hours post fertilization were seeded in 12-well plates (15 fish/well, 3 mL 
egg water/well) and treated with CBE 1 (10–1,000 µM)9, 6 (0.001−10 μM) or 7 (0.001−10 μM) 
for 112 hours at 28 °C. Thereafter, zebrafish larvae were washed three times with egg water, and 
collected in clean screw-cap Eppendorf  tubes (three tubes of  three larvae per inhibitor 
concentration). Lipids were extracted and measured according to methods described 
previously.31 Briefly, after removing of  the egg water, 20 µL of  13C-GlcSph32 from concentration 
of  0.1 pmol µL–1 in MeOH, 480 µL MeOH, and 250 µL CHCl3 were added to the sample, stirred, 
incubated for 30 min at RT, sonicated (5 x 1 min in sonication water bath), and centrifuged for 
10 min at 15,700 g. Supernatant was collected in a clean tube, where 250 µL CHCl3 and 450 µL 
100 mM formate buffer (pH 3.2) were added. The sample was stirred and centrifuged, the upper 





450 µL formate buffer. The upper phases were pooled and taken to dryness in a vacuum 
concentrator at 45 °C. The residue was extracted with 700 µL butanol and 700 µL water, stirred 
and centrifuged. The upper phase (butanol phase) was dried and the residue was dissolved in 
100 µL MeOH. 10 µL of  this sample was injected to the LC-MS for lipid measurement. Two-
tailed unpaired t-test was performed in Prism 7.0 software (GraphPad) to derive statistical 
significance, where p < 0.05 was considered significant. 
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Figure 3.S1. Chemical structures of ABPs 8-14 used in this work. Code for each ABP: ABP 8 
(JJB367), ABP 9 (JJB75), ABP 10 (JJB70), ABP 11 (JJB383), ABP 12 (JJB347), ABP 13 (JJB392), and 
ABP 14 (JJB391). 
  
Figure 3.S1
8: X = CH2, R = Cy5
9: X = CO, R = BODIPY red
10: X = CO, R = BODIPY green
11: R = Cy5
12: R = BODIPY red
13: R = Cy5
14: R = BODIPY red






Figure 3.S2.  Accommodation of O6-derivatized ligands in GBA1 and GBA2. A) Overlay of the 
bacterial GBA2 homology TxGH116 (PDB 5NCX, carbon-atoms colored lavender, aziridine complex 
bound to Glu441 in yellow) with the GBA1 complex with 5 reported here (grey carbons). Of note is the 
“inwards” orientation of O6, via interactions with Arg786 and Glu777 and the constricted space by virtue 
of the position of Asp593. B) Partial electrostatic surface of TxGH116 overlaid with the ligand coordinates 
for 5 bound to GBA1 (this work) overlaid (indicating potential steric clashes were the ligand bound exactly 
as in GBA1). Together these overlays suggest that TXGH116 is less able to accommodate O6 substituted 
ligands, at least to the extent that O6 substituted ligands gain sufficient discriminatory power for 
GBA1/GBA2. C) Structure of GBA reacted with biphenyl-cyclophellitol 6 and adamantyl-cyclophellitol. The 
biphenyl moiety is not visible and just the cyclophellitol-GBA complex structure is observed (PDB Code 
6Q6N). D) The linker-adamantyl moiety of 6 is observed in slightly different positions in the two molecules 
of the asymmetric unit (PDB Code 6Q6L) reflecting its binding through predominantly hydrophobic 
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Figure 3.S4. In vitro inhibition curves of CBE 1, CP 2, ABPs 3 and 5, and inhibitors 6 and 7 on 








Figure 3.S5. Inhibition curves for in vivo GBA inactivation in zebrafish larvae by ABPs 3 and 5, 
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Figure 3.S6. In vivo targets of A) inhibitor 6, B) inhibitor 7, C) ABP 3, and D) ABP 5 in zebrafish 
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Figure 3.S7. In vivo targets of ABPs 3 and inhibitor 7 of treated adult zebrafish revealed by 
competitive ABPP. A), B) labeling in brain homogenates C), D) Labeling in liver and spleen homogenates. 
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Figure 3.S8. Detection of GBA3 in lysates of zebrafish larvae. A) Labeling using ABP 5 (ME569) or 
ABP 8 (JJB367) at various ABP concentrations. B) Labeling using ABP 8 (JJB367) in lysates at various 










ABP 5 (μM) ABP 8 (μM)
Cy5 Fluor. (pH 6.0)
DMSO ABP 10 (1 μM)
























Table 3.S1. Data collection and refinement statistics for rGBA in complex with ABP 5 and inhibitors 6 and 
7. 





 5 6 7 
Data collection    
Space group C 2 2 21 C 2 2 21 C 2 2 21 
Cell dimensions    
a, b, c (Å) 110.6, 285.9, 92.3 110.4, 285.2, 91.9 110.2, 285.1, 92.0 
α, β, γ () 90, 90, 90 90, 90, 90 90, 90, 90 






Rmerge 0.161 (1.623) 0.101 (1.609) 0.132 (1.661) 
Rpim 0.064 (0.647) 0.047 (0.735) 0.061 (0.757) 
I / σI 6.5 (1.1) 8.8 (1.1) 7.7 (1.0) 
Completeness (%) 99.9 (99.8) 99.9 (98..8) 100.0 (98.7) 
Redundancy 8.3 (8.1) 6.49 (6.50) 6.53 (6.58) 
    
Refinement    
Resolution (Å) 77.52-1.92 72.13-1.63 71.98-1.81 
No. reflections 925691 1167262 859243 
Rwork / Rfree 0.18/0.22 0.18/0.21 0.18/0.21 
No. atoms    
Protein 7939 7870 7960 
Ligand/ion 354 273 334 
Water 699 966 936 
B-factors (Å2)    
Protein 39 26 28 
Ligand/ion 65 52 55 
Water 47 39 39 
R.m.s. deviations    
Bond lengths (Å) 0.009 0.012 0.010 
Bond angles () 1.60 1.67 1.63 
Ramachandran Plot Residues     
In most favourable regions (%) 94.5 94.7 94.6 
In allowed regions (%) 4.3 4.2 4.3 
PDB code  6Q6K 6Q6N 6Q6L 
    




Table 3.S2. Lipophilic ligand efficiency (LipE) values of CBE 1, CP 2, ABP 3, ABP 5 and new 
functionalized cyclophellitol 6 and 7 for rGBA activity. LipE = pIC50 – cLogP. cLogP values were 
calculated using the ChemDraw version 16 software. 
 
 CBE 1 CP 2 ABP 3 ABP 5 6 7 
cLogP -1.76 -2.77 2.47 1.66 1.16 1.60 
pIC50 GBA 5.37 7.52 9.00 8.52 9.00 9.00 







3.S1 Crystallographic data collection and refinement statistics (University of  York) 
3.S1.1 Deglycosylation, Purification and Crystallization  
Prior to crystallization, Cerezyme (3.4 mg mL-1, NEB) was deglycosylated with PNGase F (20 
µL, NEB) for 5 days at room temperature. The digested material was purified by size exclusion 
chromatography on an S75 16/600 column. Crystals were obtained using hanging-drop vapor 
diffusion, based on parent conditions outlined by Dvir et al. (2003).1 Drops contained 1 μL 
purified Cerezyme (9.1 mg mL-1) and 1 μL mother liquor (1.1 M (NH2)2SO4, 0.19 M guanidine 
HCl, 0.04 M KCl, 0.1 M Na acetate, pH 4.6). Crystals were grown for 1 week at 18 °C.  
3.S1.2 Inhibitor Complexes 
Inhibitors were prepared at 20 mM in HEPES buffer (20 mM, pH 7.0) and diluted to 2 mM in 
mother liquor comprising 1.1 M (NH2)2SO4, 0.19 M guanidine HCl, 0.04 M KCl and 0.1 M Na 
acetate (pH 4.6). Crystals were soaked in 5 µL of  inhibitor-mother liquor solution for 4 hours at 
18 °C. Crystals were transferred to a lithium sulfate cryoprotectant (0.2 M Li2SO4, 0.17 M 
guanidine HCl, 0.04 M KCl, 0.1 M Na acetate, pH 4.6) before freezing in liquid nitrogen. 
3.S1.3 Structure Solution and Refinement  
For the ABP 5 complex, data were collected at the i04_1 beamline of  the Diamond Light Source 
Facility to 1.79 Å. Data were collected at the i24 beamline to 1.81 Å and 1.63 Å for the inhibitors 
6 and 7 complexes respectively. For all complexes, data were processed using the XIA22, 3 and 
AIMLESS data reduction pipelines through the CCP4i2 software.4 The structures were solved 
by molecular replacement using MOLREP5 with the previous GBA1 PDB (2NT0)6 as the 
homologous search model. Refinement was performed using REFMAC7 followed by several 
rounds of  manual model building with COOT.8 Idealised coordinate sets and refinement 
dictionaries for the ligands were generated using JLIGAND9 and sugar conformations were 
validated using Privateer.10 Crystal structure figures were generated using ccp4mg.11 For ABP 5, 
the structure could be traced from residues 1–497 in chain A and chain B. In chain A, residue 
344 is disordered in density and has been omitted. In chain B residues 29–31 and 346–348 are 
disordered in density and have been omitted. For inhibitor 6, the structure could be traced from 
residues 1–497 in chain A and chain B. In chain B, residues 344–345 are disordered in density 
and have been omitted.  




For inhibitor 7 the structure could be traced from residues 1–497 in chain A and chain B. In 
chain A, residue 345 is disordered in density and has been omitted. In chain B, residues 316–
318 and residues 344–347 are disordered in density and have been omitted. 
3.S2 Synthesis of  ABP 5 and Compounds 6 and 7 (Department of  Bio-organic Synthesis, 
Leiden University) 
 
Scheme 3.S1. Synthesis of C-8 functionalized cyclophellitol ABP 5 and inhibitors 6 and 7. Reagents 
and conditions: (i) CuSO4·H2O, sodium ascorbate, DMF, RT, 18 h, 5: 38%, 6: 78%, 7: 89%. 
3.S2.1 4-((pent-4-yn-1-yloxy)methyl)-1,1'-biphenyl (15)  
[1,1'-biphenyl]-4-ylmethanol (689 mg, 3.74 mmol), tetrabutyl ammonium iodide (1.38 g, 3.74 
mmol) and NaH (204 mg, 5.10 mmol) were added to a cooled (0 °C) solution of  5-bromopent-
1-yne (500 mg, 3.74 mmol) in DMF (15 mL). The reaction mixture was allowed to warm to room 
temperature and stirred 24 h and subsequently poured into ice, extracted with EtOAc (20 mL), 
and washed with water (20 mL) and saturated aqueous NaCl (10 mL). The organic phase was 
dried (MgSO4), filtered and concentrated. The residue was purified by silica gel column 
chromatography with Pentane/EtOAc (from 10:0 to 8:2, v/v) to give the desired product as a 







CH Ar), 7.49 – 7.28 (m, 5H, 5 x CH Ar), 4.54 (s, 2H, CH2O), 3.59 (t, J = 6.1 Hz, 2H, CH2O), 
2.33 (td, J = 7.1, 2.7 Hz, 2H, CH2), 1.94 (t, J = 2.7 Hz, 1H, CH), 1.91 – 1.78 (m, 2H, CH2); 13C-
NMR (101 MHz, CDCl3) δ 141.0, 140.6, 137.6, 128.9, 128.7, 128.4, 128.2, 127.4, 127.3, 127.2, 




Azido cyclophellitol12 (4.4 mg, 0.022 mmol) was dissolved in DMF (1 mL) and CuSO4·5H2O 
(0.1 M, 50 µL, 4.4 μmol, 0.2 eq.) and sodium ascorbate (0.1 M, 50 µL, 4.4 μmol, 0.2 eq.) were 
added to the solution under argon atmosphere. Then, a solution of  biphenyl alkyne (4.4 mg, 26 
μmol, 1.2 eq.) was added and the reaction mixture was stirred at room temperature for 18 h. The 
crude was purified by column chromatography (DCM to DCM/MeOH 9:1) to afford the desired 
compound 6 (7.7 mg, 0.017 mmol, 78%). Rf: 0.20 (DCM/MeOH 9:1). 1H-NMR (400 MHz, 
CD3OD) δ 7.65 – 7.55 (m, 4H, 4 x CH Ar), 7.43 (t, J = 7.7 Hz, 4H, 4 x CH Ar), 7.32 (t, J = 7.4 
Hz, 1H, CH Ar), 5.49 (s, 1H, CH=N), 4.81 (d, J = 14.3 Hz, 1H, CHH-7), 4.69 – 4.56 (m, 1H, 
CHH-7), 4.55 (s, 2H, CH2O), 3.65 – 3.48 (m, 3H, CH2O, CH-2), 3.21 (t, J = 8.8 Hz, 1H, CH-3), 
3.17 – 3.06 (m, 1H, CH-4), 3.02 – 2.97 (s, 2H, CH-1, CH-6), 2.85 (br s, 2H, CH2), 2.40 – 2.35 (t, 
J = 7.3 Hz, 1H, CH-5), 2.03 (br s, 2H, CH2); 13C-NMR (101 MHz, CD3OD) δ 142.1, 141.8, 
138.93 (3 x C Ar), 131.1, 129.9, 129.4, 128.4, 127.9 (9 x CH Ar), 78.2 (CH-4), 73.6 (CH2O), 72.5 
(CH-2), 70.1 (CH2O), 68.7 (CH-3), 57.5, 55.5 (CH-1/CH-6), 51.1 (CH2), 44.5 (CH-5), 30.2 (CH2). 
HRMS: calculated for C25H30N3O5+ [M+H]+ 452.21855, found: 452.21759. 
3.S2.3 (1S,2R,3S,4R,5R,6R)-5-((4-(3-(((1s,3S)-adamantan-1-yl)methoxy)propyl)-1H-1,2,3-
triazol-1-yl)methyl)-7-oxabicyclo[4.1.0]heptane-2,3,4-triol (7)  
Azido-cyclophellitol12 (4.4 mg, 0.022 mmol) was dissolved in DMF (1 mL) and CuSO4·5H2O 
(0.1 M, 50 µL, 4.4 μmol, 0.2 eq.) and sodium ascorbate (0.1 M, 50 µL, 4.4 μmol, 0.2 eq.) were 
added to the solution under argon atmosphere. Then, a solution of  adamantane alkyne (6.10 mg, 
26 μmol, 1.2 eq.) was added and the reaction mixture was stirred at room temperature for 18 h. 
The crude was purified by column chromatography (DCM to DCM/MeOH 9:1) to afford the 
desired compound 7 (8.4 mg, 0.019 mmol, 89%). Rf: 0.20 (DCM/MeOH 9:1). 1H-NMR (400 
MHz, CD3OD) δ 4.82 (dd, J = 13.7, 3.9 Hz, 1H, CHH), 4.62 (dd, J = 13.8, 8.5 Hz, 1H, CHH), 




3.62 (d, J = 8.1 Hz, 1H, CH-2), 3.42 (t, J = 5.4 Hz, 2H, CH2), 3.23 (dd, J = 10.0, 8.1 Hz, 1H, 
CH-3), 3.13 (t, J = 9.8 Hz, 1H, CH-4), 3.03 (s, 2H, CH-1, CH-6), 2.97 (s, 2H, CH2O), 2.80 (br s, 
2H, CH2), 2.39 (td, J = 9.0, 3.5 Hz, 1H, CH-5), 1.95 (br s, 4CH, 4 x CH adamantane), 1.85 – 1.63 
(m, 6H, 3 x CH2 adamantane), 1.57 (br s, 6H, 3 x CH2 adamantane); 13C-NMR (101 MHz, 
CD3OD) δ 83.0 (CH2O), 78.2 (CH-3), 72.5 (CH-2), 71.4 (CH2), 68.7 (CH-4), 57.6, 55.5 (CH-
1/CH-6), 44.6 (CH-5), 40.8 (3 x CH2), 38.3 (3 x CH2), 35.1 (C adamantane), 30.3 (CH2), 29.8 (4 
x CH adamantane), 23.2 (CH2); HRMS: calculated for C25H30N3O5+ [M+H]+ 434.26550, found: 
434.26441. 
3.S2.4 Cyclophellitol Cy5 ABP (5) 
Azido-cyclophellitol12 (24.2 mg, 0.12 mmol) and the desired Cy5-alkyne (84 mg, 0.15 mmol) 
were dissolved in BuOH/toluene/H2O (6 mL, 1:1:1, v/v/v). CuSO4 (0.024 mL, 1 M in H2O) 
and sodium ascorbate (0.024 mL, 1 M in H2O) were added and the reaction mixture was heated 
at 80 ºC for 18 h. Then, the solution was diluted with CH2Cl2, washed with H2O, dried over 
MgSO4 and concentrated under reduced pressure. The crude was purified by silica gel column 
chromatography (CH2Cl2 to CH2Cl2/MeOH 9:1), subsequently purified by semipreparative 
reversed-phase HPLC (linear gradient: 45 to 48% B in A, 12 min, solutions used A: 50mM 
NH4HCO3 in H2O, B: MeCN) and lyophilized to yield ABP 5 as a blue powder (33.5 mg, 44 
µmol, 37%). 1H NMR (400 MHz, CD3OD): δ 8.25 (t, J = 13.1 Hz, 2H), 7.91 (d, J = 3.3 Hz, 1H), 
7.49 (d, J = 7.4 Hz, 2H), 7.44 – 7.39 (m, 2H), 7.31 – 7.24 (m, 4H), 6.63 (t, J = 12.4 Hz, 1H), 6.29 
(d, J = 13.8 Hz, 2H), 4.81 (dd, J = 13.9, 3.8 Hz, 1H), 4.61 (dd, J = 13.9, 8.6 Hz, 1H), 4.42 (s, 2H), 
4.09 (t, J = 7.4 Hz, 2H), 3.63 (s, 3H), 3.60 (d, J = 8.0 Hz, 1H), 3.24 – 3.20 (m, 1H), 3.12 (t, J = 
14.9 Hz, 1H), 3.02 – 3.00 (m, 1H), 2.41 – 2.35 (m, 1H), 2.25 (t, J = 7.3 Hz, 2H), 1.91 (s, 6H), 
1.85 – 1.78 (m, 2H), 1.72 (s, 12H), 1.50 – 1.43 (m, 2H) ppm; 13C NMR (101 MHz, CD3OD): δ 
175.8, 175.4, 174.6, 155.5, 155.5, 146.2, 144.2, 143.5, 142.6, 142.5, 129.8, 129.7, 126.7, 126.2, 
126.2, 125.2, 123.4, 123.3, 112.0, 111.8, 104.5, 104.3, 78.2, 72.5, 68.6, 57.6, 55.5, 50.8, 50.5, 50.5, 
44.8, 44.6, 36.5, 35.6, 31.6, 28.1, 28.0, 27.3, 26.4 ppm; HRMS: calculated for C42H53N6O5 [M]+ 
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The lysosomal glycosidases α-glucosidase (GAA) and β-glucuronidase (GUSB) catalyze 
fragmentation of  glycogen and glycosaminoglycans, respectively.. Their deficiency due to 
genetic aberrations leads to the lysosomal storage disorder (LSD) Pompe disease (GAA 
deficiency) and mucopolysaccharidosis type VII (MPSVII; Sly Syndrome), both severe disease 
conditions with still unmet clinical needs. To generate tools to facilitate biochemical and 
biomedical research on these two enzymes, activity-based probes targeting either enzyme 
(GH31 α-glucosidases or GH2 β-glucuronidase) were developed and evaluated for their 
mechanism-of-action, inhibition potency, and target selectivity. Both sets of  ABPs successfully 
label their respective target enzyme class in activity-based manner. They are nanomolar 
irreversible inhibitors with fast inhibition kinetics. At acidic labeling pH and in cells, the 
lysosomal acid α-glucosidase GAA or β-glucuronidase GUSB are labeled by their respective 
ABPs, as revealed by both in-gel fluorescence and chemical proteomics. In the case of  both 
GAA and GUSB ABPs, some minor out-of-class targets are observed. By altering the labeling 
pH or pre-incubating samples with previously generated inhibitors for the off-targets,  GAA 
or GUSB can be visualized with their corresponding ABPs simultaneously with the off-target 
glycosidases. The new ABPs for GH31 α-glucosidases and GH2 β-glucuronidase successfully 
expand the chemical toolbox for lysosomal glycosidases and should find future applications in 








eficiency in lysosomal proteins due to genetic mutations underlies lysosomal 
storage disorders (LSDs) in which undegraded substrate accumulate in the 
lysosomes of  particular cell types in the affected patients, and lead to a complex 
cascade of  downstream pathological events1. An important class of  deficient 
proteins in LSDs are the lysosomal glycosidases (E.C. 3.2.1), accounting for a third of  known 
LSD enzymopathies. Glycosidases can be broadly classified by their substrate preference on the 
glycon part (e.g. sugar configuration, exo-acting vs endo-acting), mechanism of  hydrolysis (e.g. 
retaining, inverting, substrate assisted), or evolutionary similarity by amino acid sequence and 
folding by the glycoside hydrolase (GH) family system.1  
Man expresses at least four exo-acting retaining α-glucosidases that belong to the glycoside 
hydrolase family 31 (GH31): the α-subunit of  ER α-glucosidase II (GANAB) (E.C. 3.2.1.20 and 
3.2.1.84) which plays a role in quality control of  N-glycoprotein synthesis, the two intestinal 
enzymes maltase-glucoamylase (MGAM) (E.C. 3.2.1.20) and sucrase-isomaltase (SI) (E.C. 
3.2.1.20 and 3.2.1.48) degrading dietary glycosides, and the lysosomal acid α-glucosidase (GAA) 
(E.C. 3.2.1.20) degrading glycogen.2 The human GAA is formed as a 110 kDa proenzyme, that 
upon mannose-6-phosphate dependent transport to the lysosome is processed into the 76 kDa 
and 70 kDa active forms.3, 4 Mutations in GAA gene may lead to Glycogen storage disease type 
II, also known as Pompe disease.5 This relatively common LSD (1:40,000 live birth worldwide)6 
is characterized by the intra-lysosomal accumulation of  undegraded glycogen, which causes 
progressive muscle weakness in the heart and skeletal muscles and eventually affects the liver 
and central nervous system.7 Classification of  the disease is based on the age of  onset, and 
patients classified into the infantile form (4 to 8 months of  age) usually do not survive before 
one year of  age.8 Later onset forms (juvenile and adult forms) are characterized by a slower 
progressive decrease in muscle strength, firstly in the legs and then the trunks and the arms, and 
finally to fatality through respiratory failure.9 Severity of  Pompe disease correlates with the extent 
of  lost GAA activity.10 The disease is currently treated by chronic intravenous injection of  
recombinant GAA (rGAA, alglucosidase alpha, Myozyme®), which impressively delays the fatal 
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symptoms in infantile patients.11 However, due to poor correction in muscle cell pathology, it 
only has limited response in adult patients.12  
Another LSD-relevant lysosomal glycosidase, the retaining exo-β-glucuronidase (GUSB), 
belongs to the GH2 family.2 It catalyzes the hydrolysis of  terminal β-glucuronic acid from 
heparan sulfates, dermatan sulfates, and chondroitin-4,6-sulfate—polysaccharides presented in 
glycosaminoglycans (GAGs) which are found in the extracellular matrix that serve structural and 
signaling functions. Deficiency of  GUSB activity due to hereditary genetic mutations forms the 
basis of  another LSD known as mucopolysaccharidosis type VII (MPSVII), or Sly syndrome.13 
Affected individual are characterized by lysosomal accumulation of  GAGs in many tissues, 
which ultimately affects the central nervous system and causes hepatosplenomegaly and bone 
dysplasia.14 No targeted therapy is currently available for this rare disease. Notably, there exists 
another lysosomal enzyme in human that has exhibits β-glucuronidase activity—heparanase 
(HPSE). This is an endo-acting retaining β-glucuronidase, and belongs to the GH79 family, that 
functions in the turnover of  heparan sulfate.2 Interestingly, the bacterial GH79 homologue from 
Acidobacterium capsulatum, that exhibits similar protein fold, is an exo-acting retaining β-
glucuronidase.15 HPSE activity is implicated in disease-related processes such as inflammation, 
tumor metastasis and angiogenesis.16, 17 
In the past, the mechanism-based irreversible β-glucosidase inhibitor cyclophellitol (CP) 
has been used as a scaffold to generate potent and specific inhibitors and ABPs towards the 
lysosomal glucocerebrosidase (GBA).1 The configurational and functional isomers of  CP-
aziridine have been found to inactivate and label other classes of  retaining exo-glycosidases that 
follow the formal Koshland double-displacement mechanism.1 Both GAA and GUSB are 
retaining exo-glycosidases (Fig. 4.1A),18 which makes them possible candidates for activity-based 
probe labeling (Fig. 4.1B). It is therefore hypothesized that the α-glucose and β-glucuronic acid 
configured cyclophellitol epoxides and aziridines may render inhibitors and ABPs targeting 
GH31 retaining exo-α-glucosidases (GAA and GANAB) and GH2 retaining exo-β-
glucuronidase (GUSB), respectively. In this chapter the characterization of  these newly generated 








Figure 4.1. Reaction mechanisms of compounds used in this chapter. A) Koshland double-
displacement mechanism employed by retaining α-glucosidase and β-glucuronidase. B) Proposed 
inhibition mechanism of cyclophellitol aziridine-based α-glucosidase inhibitor (left) and β-glucuronidase 
inhibitor. The corresponding ABPs may be obtained by grafting a detection group (fluorophore or biotin) 











4.2 Results and Discussion 
4.2.1 Synthesis of  α-glucose- and β-glucuronic acid-configured inhibitors and ABPs 
Compounds were synthesized at the at the Department of Bio-organic Synthesis, Leiden 
University. The α-glucose-configured-configured cyclophellitol (1) and cyclophellitol aziridines 
(2) were synthesized (Fig. 4.2) from a cyclohexane diol (17) (see Scheme 4.S1 for synthetic 
strategy, and reference Jiang et al.19 for synthetic and characterization details of compounds). 
Compound 2 was alkylated to give compound 3, which was further reacted with different 
substituted alkynes by copper (I)-catalyzed [2+3] azide-alkyne click reaction to afford ABPs 4–
7 (Fig. 4.2, Scheme 4.S1). 
 
Figure 4.2. Structures of compounds used in this chapter. 
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The β-glucuronic acid-configured cyclophellitol 8 and cyclophellitol aziridine 9 (Fig. 4.2) 
were also synthesized from 17 (Scheme 4.S2). The synthesis of N-alkyl-substituted β-glucuronic 
acid-configured cyclophellitol aziridines utilized the N-alkyl-substituted β-glucose-configured 
cyclophellitol aziridine20 as a precursor, and upon selective oxidation at the primary alcohol, the 
β-glucuronic acid-configured compound 10 was obtained (Fig. 4.2, Scheme 4.S3). Further click 
reaction afforded the N-alkyl-substituted β-glucuronic acid-configured ABPs 11–14 (Fig. 4.2). 
The iminosugar 15 (Fig. 4.2) was synthesized as a putative GUSB inhibitor, according to the 
strategy depicted in Scheme 4.S4. 
4.2.2 In vitro inhibition and labeling of  enzyme targets by compounds 1–14 
At the start of  the evaluation of  the newly generated compounds, the therapeutic 
recombinant human GAA (rGAA) and recombinant GH79 retaining exo-β-glucuronidase 
(AcGH79) from the bacteria Acidobacterium capsulatum were used as enzyme sources. The 
inhibitory activity of  compounds 1–7 towards rGAA, and compounds 8–14 on AcGH79, were 
determined by measuring the apparent IC50 value of each compound at 30 min incubation time 
using fluorogenic 4-methylumblliferyl (4-MU)-glycoside substrate assays. As can be seen in Fig. 
4.3A (top panel), the value for the α-glucose configured cyclophellitol epoxide 1 was at a low-
micromolar apparent range (14.6 ± 1.6 μM) towards rGAA; the values for cyclophellitol aziridine 
2 and its alkyl derivative 3 were at mid-nanomolar range (apparent IC50 = 30–50 nM), and that 
the values for ABPs 4–7 were at high-nanomolar range (apparent IC50 = 200–800 nM). For the 
β-glucuronic-acid-configured compounds 8–14, all exhibited nanomolar apparent IC50 values 
towards AcGH79. The N-alkyl-substituted compound 10 and ABPs 11–14 were the most potent, 
reaching low- to sub-nanomolar potency (Fig. 4.3A, lower panel). The aziridine compound 9 
and the epoxide compound 8 were also nanomolar inhibitors towards AcGH79 (Fig. 4.3A, 
lower panel), but slightly less reactive compared to the N-alkylated compounds.  
Next, the formation of covalent enzyme-ABP complex was examined by fluorescent gel-
based ABPP assay. ABP 4 or ABP 11, both containing a green BODIPY fluorophore, were 
incubated with their respective target enzyme (rGAA or AcGH79) at 1 μM concentration for 30 




minutes. Afterwards, samples were denatured and subjected to SDS-PAGE. The subsequent 
fluorescent scanning on the wet slab-gels containing the rGAA samples (Fig. 4.3B, left panel) 
revealed a clear green band corresponds to the expected molecular weight for rGAA (~100 kDa) 
in the ABP 4-treated lane (second lane of the gel). This band is absent in samples without ABP 
treatment or pre-incubated with compounds 1–3 and 7, the GAA substrate 4-MU-α-glc and 
maltose, and the protein-denaturing agent SDS. In samples pre-incubated with ABP 5 or 6, red 
 
Figure 4.3. In vitro inhibition and labeling on recombinant enzymes by compounds 1–14. A) 
Apparent IC50 values for compounds 1–7 towards rGAA (top) and for compounds 8–14 towards AcGH79 
(bottom). B) Fluorescent gel-based cABPP by compound 1–7 towards rGAA (left) and by compounds 8–
14 towards AcGH79 (right). Enzymes were pre-incubated with inhibitors shown on the top of gels, and 
labeled with ABP 4 or 11. C) pH-dependent labeling of ABP 4 (left) or ABP 11 (right) towards 
corresponding enzymes. The intensity of the labeled bands was quantified, and compared with the activity 
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or Cy5 (shown in blue) fluorescence replaced the green fluorescence, suggesting the labeling of 
these ABP on rGAA competed away for the one from ABP 4. Similarly, the gel containing the 
AcGH79 samples (Fig. 4.3B, right panel) showed a comparable labeling pattern. A green 
fluorescent band at the expected molecular weight of AcGH79 (~50 kDa) was observed in the 
ABP 11-treated sample (second lane), and absent (or replaced by fluorescence of other colors) 
in samples pre-incubated with compounds 8–10 and 12–14 for AcGH79), known substrate (4-
MU-β-glcA), putative competitive enzyme inhibitor (compound 15), or 2 % (w/v) SDS. These 
results suggested that the labeling of ABP 4 or 11 towards their respective enzyme target occurred 
at the active site. To further evaluate whether the labeling by these ABPs occurred in an activity-
based manner, ABP labeling on both enzymes was examined for the pH-dependence. For this, 
enzymes were labeled by ABPs across a range of pH (Fig. 4.3C, top panels), and the intensity 
of ABP labeling were compared to the measured enzymatic activity across the same pH range. 
The comparison revealed that the pH optimum of 5.0 for ABP labeling differed only slightly 
with that for substrate hydrolysis at pH 4.0 (Fig. 4.3C, lower panels). 
Next, the kinetics for ABP labeling was examined. Both ABP 4 and 11 showed time-
dependent labeling on their respective enzyme target, and reached saturation during 10–15 
minutes of  incubation time (Fig. 4.S1). The inhibition kinetic parameters were measured for the 
β-glucuronic acid-configured compound 8–14 on AcGH79 by fluorogenic substrate assay in a 
continuous setup (see 4.S2 Supporting note), and the results revealed that beside the epoxide 
8, all compounds had pseudo-first order rate constant (ki/KI) in the rage of  3.5–25 μM-1 min-1 
(Table 4.1; see Fig. 4.S2 for processing curves and kobs vs [I] data, Fig 4.S3 for Michaelis-
Menton plot). These values were comparably high (i.e. fast in labeling) to the reported values for 
the previously generated cyclophellitol ABPs towards rGBA (0.8–25 μM-1 min-1).21 
Table 4.1. Kinetic parameters for compounds 8–14 towards AcGH79. Error ranges = SD from triplicate 
sets of experiment. 
Table 4.1






3.5 ± 0.2 18.8 ± 0.7 25.0 ± 0.7 18.2 ± 0.9 14.0 ± 0.8 5.5 ± 0.2 




4.2.3 Structural analysis of  compounds in complex with recombinant enzymes 
The mechanistic aspect of  inhibition/labeling by the compounds were further examined 
by using protein crystallography studies (University of  York), which could reveal structural 
insights how compounds bind in the active-site pocket of  an enzyme, such as the formation of  
covalent bond, or the conformation that compounds adopt. For this purpose, crystals of  the 
bacterial GAA homologue CjAgd31B from Cellvibrio japonicus or the bacterial GUSB homologue 
AcGH79 (wild-type or the E287Q nucleophile mutant) were soaked with either compound 3 or 
compound 10, before subjecting to X-ray crystallography and structural determination. The 
results revealed that compound 3 adopted a 1S3 conformation in the active site of  CjAgd31B 
(Fig. 4.4A), identical with the known conformation adopted by other GAA substrates22, 23 (Fig. 
4.1A, third structure in the top panel). It also showed a covalent glycosidic bond between 
anomeric carbon (C1) of  3 and the nucleophile Asp412 of  the enzyme, confirming the predicted 
mechanism-based inhibition/labeling (Fig. 4.1). 
Figure 4.4. Structures of inhibitor-enzyme complex determined by protein crystallography. A) 
Spectroscopic view of compound 3 in the active site of CjAgd31B. B) Structure of compound 10 in the 
active site of AcGH79. C) Structure of compound 10 in the active site of the E287Q catalytic nucleophile 
mutant of AcGH79. 
The structure of  compound 10 coupled to AcGH79 revealed a 4C1 conformation adopted 








On the other hand, the structure of  10 in complex with the E287Q catalytic nucleophile mutant 
of  AcGH79 revealed a 4H3 conformation adopted by the compound, and the absence of  the 
glycosidic linkage between the compound and the enzyme (Fig. 4.4C). This demonstrated that 
the compound is a transition state-mimic of  the substrates of  β-glucuronidase, and that the 
inhibition/labeling followed the expected 4H3  4C1 itinerary from the transition-state to the 
covalent substrate-enzyme intermediate (Fig. 4.1).15 
4.2.4 Glycosidase targets of  ABPs 4–7 in complex biological samples 
Whether the generated ABPs are applicable to detecting GAA or GUSB in complex 
biological samples was tested next. For GAA, lysates of  human fibroblasts were incubated with 
1 μM of  the Cy5 ABP 6 for 30 minutes at 37°C at pH range from 2.5 to 8.0, and subjected to 
gel-based fluorescence detection. The results clearly showed two lower bands (around 75 kDa) 
prominently presented at pH from 3.5 to 6.5, and a higher band (around 100 kDa) seen at pH 
from 5.5 to 7.5 (Fig. 4.5A). These two lower bands had acidic pH optimum and molecular 
weights characteristic of  the two mature lysosomal GAA forms (70 and 76 kDa), while the higher 
band has a neutral pH optimum despite havening similar molecular weight of  pro-GAA (110 
kDa). The amounts of  pro-form of  GAA should be low in cells, and it is—as well as the mature 
forms—active at acidic pH. Hence, this higher running band is likely to be another target, likely 
the α-subunit of  the ER-residing α-glucosidase II (GANAB), which possesses a similar 
molecular weight and a more neutral pH optimum. To identify these ABP targets, chemical 
proteomic method was employed. In this method, the biotin-containing ABP 7 was incubated 
with fibroblasts lysates at 5 μM concentration at either pH 4.0 or 7.0, with or without pre-
incubation of  ABP 4 (5 μM , as a negative control). Samples were subsequently denatured, 
affinity-enriched for biotin-containing molecules using streptavidin beads, subjected to either 
on-bead tryptic digestion or in-gel tryptic digestion, and peptides were analyzed by nano-LC-
MS-based protein identification (Fig. 4.5B). For the in-gel digestion protocol, biotin-enriched 
samples were subjected to SDS-PAGE and silver stained. The resulting bands were excised out 
and subjected to in-gel tryptic digestion and proteomic identification. The silver stain results 
(Fig. 4.5C) showed similar band patterns with those by the labeling of  Cy5 ABP 6 (Fig. 4.5A): 
two prominent bands at around 75 kDa were observed in the sample labeled with the biotin 
ABP 7 at pH 4.0, and one 100 kDa band were detected in the sample labeled with the biotin 




ABP 7 at pH 7.0 (Fig. 4.5C). These band were absent from samples not treated with ABP 7, 
and from samples pre-incubated with the green BODIPY ABP 4 (Fig. 4.5C), suggesting they 
were truly protein targets that were labeled with the biotin-containing ABP 7 and affinity-
enriched. Subsequent proteomic identification revealed that GAA was the 
Figure 4.5. Identification of ABP targets in human fibroblast lysates by chemical proteomics. A) 
Gel-based fluorescent labeling of ABP 6 in lysates of normal human dermal fibroblasts (NHDF) at different 
pHs. B) Schematic representation of the chemical proteomic workflow. C) Silver stain of gels containing 
samples enriched for biotin-containing molecules (left), and the resulting list of identified glycosidases at 
the indicated positions (lane 1–6, band a–d). D) Comparison of relative abundance of glycosidases by 
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prominent glycosidase in position a–c (around 75–50 kDa) in the gel containing samples labeled 
at pH 4.0, while GANAB was exclusively identified in position d (around 100 kDa) in the gel 
containing samples labeled at pH 7.0 (Fig. 4.5C, right). Interestingly, the lysosomal 
glucocerebrosidase (GBA) was also identified as a target at position c of  the pH 4.0 gel (Fig. 
4.5C). To verify the activity of  compound 1–7 towards GBA, compounds were subjected to 
enzymatic assay with the therapeutic recombinant human GBA (rGBA, Imiglucerase, 
Cerezyme®). The results demonstrated that, besides the epoxide compound 2 and the aziridine 
compound 3, all other N-alkylated compounds inhibited GBA at high nanomolar to low 
micromolar range. They were, however, less reactive towards rGBA compared to rGAA (Table. 
4.S1).  
In a parallel experiment, the affinity enriched samples were trypsin-digested in the solution 
(i.e. on-bead digest), and the resulting peptides were comparably analyzed by nano-LC-MS. The 
identified glycosidases in each sample were compared for relative abundance using the Mascot 
search score (Fig. 4.5D, left) and the exponentially modified Protein Abundance Index (emPAI) 
(Fig. 4.5D, right), which is based on comparing the coverage of  matched peptides for each 
protein against the search database. The results were in excellent agreement with the previous 
finding, in which GAA and GBA were the only two ABP glycosidase targets identified at pH 4.0, 
and that GANAB (and its isoform 2) were additionally identified at pH 7.0.  
The chemical proteomic protocol was also applied to tissue extracts from mouse. Labeling 
by ABP 7 in mouse liver homogenates also enabled identification of  GAA and GBA at pH 4.0, 
and GANAB at pH 7.0 (Fig. 4.S4), while labeling by ABP 7 in mouse intestine homogenates 
identified three additional enzymes: maltase-glucoamylase (MGAM, predominantly at pH 4.0), 
sucrase-isomaltase (SI, at both pH 4.0 and 7.0), and lactase-phlorizin hydrolase (LPH, or protein 
Lct, at pH 7.0) (Fig. 4.S5). Thus, compound 7 labeled all four mammalian GH31 α-glucosidases, 
while also reactive towards the retaining exo-β-glucosidases GBA and LPH. 
4.2.5 Glycosidase targets of  ABPs 11–14 in complex human proteome 
Identification of  targets by the β-glucuronic acid configured ABPs was performed in 




homogenates of  human spleen, a material which is predicted to express high GUSB level, 
 
Figure 4.6. Identification of ABP targets in human spleen homogenates. A) Gel-based fluorescent 
labeling of ABP 6 at different pHs. B) Competitive ABPP of GBA-specific ABP 14 or biotin ABP 16 with 
the Cy5 ABP 13 in control (left) or Gaucher (right) spleen homogenates. C) List of glycosidases identified 
at each gel position by chemical proteomics. Albumin and actin were included based on their absence in 
the control samples. D) emPAI values of identified glycosidases. E) Transcriptomic abundance of the 
identified glycosidases in human spleen, based on data from FANTOM5 consortium experiment E-MTAB-
3358. FPKM, Fragments sequenced per kilobase transcript per million reads. 











































































in samples treated with 100 nM Cy5 ABP 13 at various pH showed four prominent bands 
between around 80–60 kDa, all of  which have labeling optimum at around pH 5.0 (Fig. 4.6A). 
Human GUSB is processed from the 78 kDa pro-form into a 60 kDa and a 18 kDa fragment in 
the lysosomes25, 26, while two other isoforms of  70 (isoform 2) and 58 kDa (isoform 3) were 
known. It is likely that three of  the bands were GUSB isoforms, and one was another protein. 
Thus, the two higher bands were likely the pro-form of  GUSB and the isoform 2, and the lowest 
band could be a mixture of  mature GUSB and isoform 3. The identity of  the second-lowest 
band was hypothesized as the mature form of  GUSB, or GBA, which has a similar molecular 
weight as appeared on SDS-PAGE.21 To verify the identity of  this band, gel-based competitive 
ABPP was employed, in which the biotin ABP 14 or the GBA-specific red BODIPY ABP 1621 
(Fig. 4.2) were pre-incubated with the sample at pH 5.0, prior to the addition of  the Cy5 ABP 
13. Indeed, in sample pre-treated with ABP 16, a red band was observed, in place of  the second-
lowest band labeled by ABP 13, suggesting that the second-lowest band was GBA (Fig. 4.6B, 
left). In support of  this, ABP 13 labeling was also performed in homogenates of  human Gaucher 
spleen that is deficient in GBA, where this band was absent from samples labeled with either 
ABP 13 or ABP 16 (Fig. 4.6B, right). In samples pre-treated with ABP 14, all labeling were 
abrogated, which indicated that both ABP 13 and 14 could label at least GBA, and possibly on 
GUSB. 
Similar to the target identification for the α-glucose configured cyclophellitol aziridine 
compound 7, chemical proteomics were applied to further identify the protein targets of  the 
biotin ABP 14. Human spleen homogenates were pre-incubated with or without the GBA-
specific ABP 16, and labeled with ABP 14 at 10 μM concentration. Upon denaturation and 
affinity-purification of  biotinylated molecules, samples were again divided for in-gel tryptic 
digestion and on-bead tryptic digestion. As expected, in-gel digestion protocol resulted in the 
identification of  GUSB and GBA at the indicated positions (Fig. 4.6C) in samples treated with 
ABP 14, while pre-incubation of  ABP 16 abrogated the identification of  GBA by both in-gel 
(Fig. 4.6C, left) and on-bead digestion protocol (Fig. 4.6D). Also identified were the human 
GH79 retaining endo-β-glucuronidase heparanase (HPSE, at around 50 kDa) and the lysosomal 




acid β-galactosidase (GLB1, at around 60 kDa). However, the abundance of  GBA, HPSE, and 
GLB1 were all much lower compared to the level of  GUSB, based on emPAI value (Fig. 4.6D). 
Analysis of  transcript abundance of  the identified proteins in human spleen (based on data from 
the FANTOM5 consortium experiment E-MTAB-3358) showed that GUSB and GLB1 
transcripts are much more abundant compared to the GBA and HPSE transcripts. In 
combination, these results suggested that GUSB is the major target by ABP 14, and that GLB1 
is a minor target. GBA and HPSE could also be major targets of  ABP 14, given sufficient 
expression levels in the labeled tissue. 
4.2.5 GAA and GUSB labeling in intact cells 
The applicability of  the ABPs to inhibit and label their target glycosidases in intact cells 
were next investigated. For inhibition, confluent human fibroblasts were treated with the ABPs 
in a range of  different concentrations for 2 hours, washed and lysed, and the lysates were 
measured for the relative loss of  GAA or GUSB activity. For most of  the α-glucose-configured 
compounds, it was observed that their in situ apparent IC50 values towards the endogenous GAA 
in intact cells were similar to their in vitro apparent IC50 values towards rGAA (mid- to high 
nanomolar) (Fig. 4.7A, left). The epoxide compound 1 and the biotin ABP 7 were the only two 
exceptions, showing no inhibition at the highest applied concentration (50 or 10 μM). This was 
in contrast to the β-glucuronic acid configured compounds, in which only the red BODIPY ABP 
12 and the Cy5 ABP 13 showed moderate activity towards GUSB (apparent in situ IC50 value = 
1.7 and 1.8 μM, respectively), and other compounds did not show inhibition up to the highest 
applied concentration (15 μM) (Fig. 4.7A, right). This suggested that installation of  the biotin 
moiety on the α-glucose-configured cyclophellitol aziridine, as well as the presence of  carboxylic 
acid at the C8 position of  the cyclophellitol aziridine, are detrimental for in situ inhibition of  the 
two lysosomal glycosidases. 
 To visualize the in situ labeling, the α-glucose-configured Cy5 ABP 6 was treated to cells at 
100 nM concentration for various time periods (10 minutes to 4 hours), and the fluorescence in 
cell lysates was visualized by gel-based ABPP. Another set of  cells were identically treated, but 





possible labeling of  GAA by ABP 6 during cell lysis. The gel-based ABPP analysis showed three 
prominent bands corresponding to the molecular weight of  GANAB (~100 kDa) and GAA (76 
and 70 kDa), as identified previously, and that the labeling intensity increased with incubation 
time (Fig. 4.7B, left). Addition of  the green BODIPY ABP 4 resulted in a band with overlapping 
molecular weight as the putative GANAB, and another lower band at around 55 kDa that was 
not labeled by the Cy5 ABP 6—likely to be GBA according to its appeared molecular weight.21 
Because the addition of  ABP 4 in the lysis buffer did not change the labeling pattern of  the in 
situ treated Cy5 ABP 6, it can be concluded that ABP 6 labeling on GANAB and GAA was most 
likely taken place in intact cells. The higher band labeled by ABP 4 in the lysis buffer was also 
  
Figure 4.7. Glycosidase inhibition and labeling in intact cells by compounds 1–14. A) In situ IC50 
values towards GAA by compounds 1–7 (left) or GUSB by compounds 8–14 (right). B) In situ labeling by 




1 (JJB307) > 50,000
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ABP 6 labeling in cells. 
putatively assigned to GANAB, as the in situ treated ABP 6 at 100 nM seemed not to reach 
saturate labeling of  that protein at 4 h incubation time. This is in contrast to the labeling on the 
GAA bands, which were saturated at around 2 h incubation. In another experimental setup, 
chloroquine was added at various dosage and incubation time to the cells, prior to ABP 6 
incubation and the subsequent lysis with or without an excess of  ABP 4. Chloroquine is a 
chemical agent that is known to raise lysosomal pH and thereby disrupt lysosomal functions27, 
and its presence could inhibit GAA activity in the lysosome and therefore abrogate ABP labeling. 
As predicted, it was clearly observed that the labeling by ABP 6 on the putative GAA bands was 
abrogated in the presence of  chloroquine, while that the labeling on GANAB was not affected 
(Fig 4.7C). This result confirmed the ability of  ABP 6 to inhibit and label the lysosomal GAA 
in intact cells in an activity-based manner, and demonstrated the applicability of  this ABP in 
monitoring GAA activity in cells. 
4.2.6 Visualizing GAA deficiency in patient fibroblasts 
 As ABP 6 was shown to allow specific detection of  active GAA in gel-based assays, it’s 
applicability for GAA labeling in a diagnostic setup was examined. Fibroblasts from healthy 
donors or Pompe disease patients were cultured, and cell lysates were labeled with 1 μM ABP 6 
for 30 minutes, at either pH 4.0 or 7.0. The results showed the marked loss of  GAA labeling by 
ABP 6 at pH 4.0 in samples of  Pompe patients (Fig. 4.8A), but not on those of  GANAB at pH 
7.0 (Fig. 4.8B). This loss of  active GAA in patient samples correlated with the loss of  GAA 
proteins, as determined by the subsequent Western blot detection of  GAA from the 
same gel (Fig. 4.8A and B, lower panels). This result therefore demonstrated the 





Figure 4.8. ABP 6 labeling in fibroblasts lysates of control or Pompe patients. A) Labeling at pH 4.0. 
B) Labeling at pH 7.0. The same gels were subjected to subsequent Western blot detection of GAA and 
β-actin (protein loading control). 
4.3 Discussion 
Activity-based protein profiling has emerged in the past decade allowing unprecedented 
studies on active enzymes such as quantitative visualization and enrichment. Glycosidases 
possessing the Koshland double-displacement mechanism have been shown to be applicable for 
activity-based protein profiling through the appropriate designing of  small molecules grafted 
with an electrophilic trap and exhibit sufficient substrate mimicry. Functionalization and tuning 
the configuration of  cyclophellitol epoxide and cyclophellitol aziridine was found to offer a 
viable strategy for generating ABPs against a number of  retaining glycosidases.20, 21, 28–30 In this 
chapter, the α-glucose- and β-glucuronic acid-configured cyclophellitol and (N-tagged) 















































action in recombinant enzymes and selectivity in complex proteomes and in intact cells. 
Both sets of  compounds inhibit recombinant enzymes in a pH- and time-dependent 
manner, and generally with high (nanomolar) potency. Protein crystallographic studies reveals 
that they react with the nucleophile of  their respective target enzyme, and adopting identical 
conformation as the true substrates. Targets of  these ABPs have been identified qualitatively by 
gel-based fluorescent detection, and quantitatively by chemical proteomics. For α-glucose-
configured cyclophellitol aziridine ABPs in human and mouse samples these encompass four 
GH31 retaining exo-α-glucosidases, including GAA, GANAB, and the intestinal dietary enzymes 
MGAM and SI. Intriguingly, the retaining β-glucosidases GBA and LPH are also identified as 
targets by chemical proteomics. As these two enzymes exhibit no α-glucosidase activity towards 
artificial 4-MU substrates, the labeling mechanism of  ABP 14 towards the retaining β-
glucosidases remains to be explored in the future. The β-glucuronic acid-configured 
cyclophellitol aziridine ABP labels the intended target GUSB with exceptionally high potency. It 
nevertheless shows additional minor targets in GBA, HPSE, and GLB1. Labeling of  the GUSB 
ABPs of  HPSE, as well as pro-HPSE, has been further demonstrated by chemical proteomics 
and protein crystallography in the published article based on the results from this chapter.31 
Because GUSB and HPSE have distinct molecular weights, the β-glucuronic acid configured 
cyclophellitol aziridine ABPs should also be viable tools to specifically detect HPSE activity in 
complex biological samples using an SDS-PAGE setup. Altogether, the in vitro labeling results 
suggest that tuning the glycon configuration of  the cyclophellitol aziridine ABP is a viable 
strategy to target the intended glycosidase class, but labeling of  other out-of-class glycosidases 
can in some cases still occur. Nevertheless, by identifying the off-target glycosidases, specific 
visualization of  target glycosidases, such as GAA or GUSB, can be achieved by varying the 
labeling pH, ABP concentration, and/or pre-incubation of  known ABPs/inhibitors for the off-
target glycosidases, as demonstrated in this chapter. 
It is shown that the α-glucose-configured cyclophellitol aziridine compounds are cell-
permeable, and that the Cy5 ABP 6 at 100 nM specifically labeled GAA over GBA in cells. The 





exhibit at least 1000-fold reduction in apparent potency in cells when compared to in vitro assay. 
Nevertheless, the red BODIPY ABP 12 and Cy5 ABP 13 should be applicable for in situ GUSB 
labeling, given enough incubation time and prior incubation with a GBA inhibitor or ABP. In 
the future, the ability of  the ABPs to label active lysosomal enzymes in lysates/homogenates and 
in intact cells should assist important studies such as those on processing and distribution of  
therapeutic enzymes, and the efficacy of  other LSD therapeutic approaches that aim to promote 
the lysosomal activity of  deficient enzymes at target tissues/organs like gene therapy and 
chaperone therapy. 
Finally, in this chapter the applicability of  the GAA ABP in the laboratory diagnosis of  
Pompe disease is demonstrated. Common biochemical diagnosis methods for Pompe disease 
rely on GAA ativity measurement using the 4-MU-α-glc substrate assay from lysates of  cultured 
fibroblasts, muscle biopsy, urine, or blood samples.32 The biggest drawbacks for the substrate 
assay is the low detection dynamic range (typically in the order of  two)33, due to background 
activity from 4-MU, and the presence of  MGAM in blood samples that requires the addition of  
acarbose to relatively block MGAM activity in the assay34. Mass spectrometry-based activity 
assays have improved the detection sensitivity33, 35, but suffer from the associated laborious 
procedures. Therefore, it is envisioned that the gel-based ABPP described in this chapter could 
circumvent these shortcomings, offering rapid and sensitive visualization of  active GAA on a 
simple and rapid SDS-PAGE-based assay. Other possible GAA activity readouts using ABPs are 
fluorescent microscopy (Chapter 1, this thesis) and fluorescence-assisted cell sorting (FACS).21 
However, in both cases, the concomitant labeling on GANAB in intact cells would introduce 
undesirable background fluorescence, which could complicate data interpretation. This issue can 
be overcome by pre-incubation with a GANAB-selective or GAA-selective active-site blocker. 
Although no such inhibitors are currently known, using the ABPs in a gel-based competitive 
ABPP assay (cABPP) or in a fluorescent polarization assay36 would assist identification of  such 
inhibitors. Studies are currently pursued in this direction (Daniel Lahav, Department of  Bio-
organic Synthesis, Leiden University). 
In conclusion, true mechanism-based inhibitors and ABPs for GAA and GUSB have been 




successfully developed and extensively characterized. They enable specific detection of  their 
target enzymes in complex biological samples. The applicability of  the ABP in GAA detection 
has been demonstrated in intact cells, and its value for diagnosis of  Pompe disease has been 
demonstrated. The novel ABPs should find future applications in the study of  lysosomal 
glycosidases in both fundamental and applied research in the context of  Pompe disease, Sly 






4.4 Experimental procedures 
4.4.1 Materials 
Chemicals were obtained from Sigma-Aldrich (St. Louis, MO, USA), if  not otherwise indicated. 
Trypsin and was commercially available from Promega (Madison, WI, USA). Recombinant GAA 
was obtained from Sanofi Genzyme (Cambridge, MA, USA). Fibroblasts were obtained with 
consent from donors. Pompe patients were diagnosed on the basis of  reduced GAA activity. 
Fibroblast cell lines were cultured in HAMF12-DMEM medium (ThermoFisher InvitrogenTM, 
Waltham, MA, USA) supplied with 10% (v/v) FCS. Mouse tissue were isolated according to 
guidelines approved by the ethical committee of  Leiden University (DEC#13191). All the cell 
or tissue lysates were prepared in potassium phosphate (KPi) lysis buffer (25 mM 
K2HPO4/KH2PO4, pH 6.5, supplemented with protease inhibitor cocktail (EDTA-free, Roche, 
Basel, Switzerland) and 0.1 % (v/v) Triton X-100) via homogenization with silent crusher S 
equipped with Typ 7 F/S head (30 rpm x 1000, 3 × 7 sec) on ice. Protein concentration in lysates 
was determined with BCA Protein Assay Kit (ThermoFisher PierceTM). Lysates were stored in 
small aliquots at –80 °C until use. 
4.4.2 Cloning, expression, and purification of bacterial enzymes (University of York) 
CjAgd31B expression and purification was carried out as previously described.37 For AcGH79, 
the coding sequence of the AcGH79 gene was cloned into the pET28a (Novagen, Madison, WI, 
USA) expression vector with an N-terminal His6 tag. The E287N mutant was produced by 
polymerase chain reaction (PCR) using the primer 5’-CCTGACCCAAACGAATTC-3’ (forward 
primer) and 5’-GAATTCGTTTGGGTCAGG-3’ (reverse primer). Both the wild-type and 
mutant proteins were overexpressed in Escherichia coli strain BL21 (DE3) GOLD using LB 
medium. The transformed cells were grown at 37 °C in LB media containing 50 μg mL-1 
kanamycin until the A600 nm reached 0.8. Expression of the recombinant proteins was induced 
by the addition of 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 12 h at 25 °C. The 
cells were harvested by centrifugation at 8000 g for 30 min and resuspended in 50 mL HEPES 
lysis buffer (20 mM HEPES, NaCl 200 mM, imidazole 5 mM, pH 7.0). After 20 min of 




sonication and 30 min of centrifugation at 12000 g, the filtered supernatant containing His6-
AcGH79 was loaded onto a His Trap column (GE Healthcare, Chicago, IL, USA), equilibrated 
with the lysis buffer. The column was washed with HEPES lysis buffer and the His6-AcGH79 
protein was eluted with the same buffer with supplement of 400 mM imidazole over a gradient 
of 100 mL. The fractions containing the His6-AcGH79 were then loaded onto a Hiload 16/60 
Superdex 75 column (GE Healthcare). The fractions containing the His6-AcGH79 were pooled 
and concentrated to the final concentration of 14.5 mg mL-1. 
4.4.3 Enzyme activity assays and in vitro IC50 measurements 
The α-D-glucosidase activity of lysosomal α-D-glucosidase GAA was assayed in individual wells 
of medium-binding flat-bottomed black 96-well plates (Greiner, Kremsmünster, Austria) at 37 
°C by incubating samples with 3.0 mM 4- methylumbelliferyl-α-D-glucopyranoside (4-MU-α-glc) 
as substrate in McIlvaine buffer (150 mM sodium citrate-Na2HPO4, supplemented with 0.01 % 
(w/v) NaN3 as bacteriostatic)38, supplemented with 0.1 % (w/v) BSA, at pH 5.0 for rGAA and 
at pH 4.0 for GAA in cell lysates or tissue homogenates. Activity of rGBA was measured using 
similar conditions but with 3.75 mM 4-methylumbelliferyl-β-D-glucopyranoside (4-MU-β-glc) as 
substrate at pH 5.2, supplemented with 0.1 % (v/v) Triton X-100 and 0.2 % (w/v) sodium 
taurocholate. Activity of AcGH79 and GUSB was performed with 2.5 mM 4-methylumbelliferyl-
β-D-glucuronic acid (4-MU-β-glc) as substrate at pH 5.0, supplemented with 0.1 % (w/v) BSA. 
To determine the apparent in vitro IC50 value, recombinant enzymes (12.5 μL) were firstly pre-
incubated with inhibitor dilutions (12.5 μL) for 30 min at 37 °C, prior to incubation with 
substrates (100 μL) for a further 30 min at 37 °C. The enzymatic reaction was quenched by 
adding 200 μL of Glycine-NaOH (1 M, pH 10.3), after which fluorescence of liberated 4-
methylumbelliferyl was measured with a fluorimeter LS55 (Perkin Elmer, Waltham, MA, USA) 
at λEX = 366 nm and λEM = 445 nm. For experiments with varying pH, enzymes, inhibitors, and 
substrates were prepared in McIlvaine buffer at the indicated pH. All apparent IC50 values were 
determined from biological duplicates. Data was corrected for background fluorescence, then 
normalized to the untreated control condition and finally curve-fitted via one phase exponential 





4.4.4 In vitro ABP labeling for recombinant enzymes  
All enzymes were pre-incubated in McIlvaine buffer at pH 5.0 (or other indicated pH) on ice for 
5 min. In vitro labeling on rGAA was performed by incubating 100 fmol rGAA with(out) prior 
incubation with inhibitors in McIlvaine buffer (pH 5.0 if not otherwise indicated) for 30 min at 
37 °C, and ABP 4 labeling at 1 μM probe concentration for 30 min at 37 °C. For In vitro labeling 
on AcGH79, 200 fmol of the enzyme was incubated with(out) inhibitors with the identical 
conditions as those for rGAA, and ABP incubation was performed with 1 μM ABP 11 for 30 
min at 37 °C. Inhibitor concentrations were: 10 μM for compounds 3, 5–7, 10, and 12–14; 100 
μM for compound 1–2, 8, 9, and 15; 2.5 mM for maltose, 10 mM for 4-MU substrates, and 2 % 
(w/v) for sodium dodecyl sulfate (SDS). After ABP incubation, samples were denatured with 5x 
Laemmli buffer (50 % (v/v) 1.0 M Tris−HCl, pH 6.8, 50% (v/v) 100 % glycerol, 10 % (w/v) 
DTT, 10 % (w/v) SDS, 0.01 % (w/v) bromophenol blue) by boiling for 5 min at 98 °C. 
Denatured samples were separated by SDS-PAGE using 7.5 % or 10% polyacrylamide gels, at 
90 V for 30 min and 200 V for 50–70 min. Wet slab-gels were scanned for ABP-emitted 
fluorescence using a Bio-Rad ChemiDoc MP imager (Bio-Rad, Hercules, CA, USA) using Cy2 
(λEX = 470 nm, bandpass 30 nm; λEM = 530 nm, bandpass 28), Cy3 (λEX = 530 nm, bandpass 28 
nm; λEM = 605 nm, bandpass 50), and Cy5 (λEX = 625 nm, bandpass 30 nm; λEM = 695 nm, 
bandpass 55) channels. Detected fluorescence was quantified by ImageLab Software (Bio-Rad) 
and plotted by Prism 5.0 Software (GraphPad). For labeling kinetics, enzymes and ABPs were 
prepared as earlier described, and incubated at either 4°C or 37 °C for 2 to 60 min. Samples 
without ABP addition were used as the 0 min controls. 
4.4.5 Measurement of inhibition kinetic parameters 
Kinetic parameters for inhibition of AcGH79 were determined using a continuous method 
involving simultaneous exposure of the enzyme to substrates and inhibitor (see Supporting 
Note 4.S2; ref. 39), using fluorogenic substrate assay. During the enzymatic reaction, the 
concentration of enzyme (AcGH79) and substrates were 0.26 nM and 2 mM, respectively. For 
each inhibitor, triplicate sets of eight 2 mL Eppendorf tubes were prepared. These were added 




firstly with 8.13 μL inhibitor at various concentrations (diluted in DMSO, 200x of reaction 
concentration, control = DMSO) and secondly with 154.4 μL McIlvaine buffer (150 mM, pH 
5.0) and 1300 μL substrate mixture (2.5 mM 4-MU-β-GlcA, pH 5.0, 0.1 % (w/v) BSA). The 
reaction tubes were pre-warmed on a thermoshaker at 37 °C for 10 min. For each inhibitor, the 
enzyme (AcGH79) was prepared by diluting with McIlvaine buffer in an Eppendorf tube to a 
volume of 1250 μL and 2.6 nM enzyme concentration. A negative control (enzyme blank) was 
prepared in a separate Eppendorf tube by substituting the enzyme with denatured enzyme 
(boiled at 98 ºC for 5 min). Both were pre-warmed on a thermoshaker at 37 °C for 10 min. Prior 
to the reaction, a black 96-well plate was loaded with 200 μL stop buffer (1 M glycine-NaOH, 
pH 10.3) in each well. The t = 0 samples were prepared by filling the first two columns of the 
plate with 12.5 μL enzyme (or enzyme blank, in the last row) and 112.6 μL of each from the 
substrate-inhibitor mixture (1 concentration per row, in duplicate wells). To start the reaction, 
137.6 μL aliquots of the pre-warmed 26 nM enzyme was transferred to each but the last 
(containing DMSO dilution and substrate mixture) of the pre-warmed 2 mL tube containing the 
substrate-inhibitor mixture, with a time interval of 15 seconds between samples. 137.6 μL 
aliquots from the pre-warmed enzyme blank were similarly transferred to the last 2 mL tube. To 
ensure proper mixing of the components, during the addition of enzyme aliquots the 2 mL tubes 
were continuously incubated in the thermal shaker at 37 °C under constant shaking at 850 rpm. 
At t = 5, 10, 15, 30 and 60 min, duplicates of 125 μL aliquots from each of the reaction tubes 
were transferred to the 96-well plate that contained stop buffer, with a 15-second interval 
between each tube. The plate was vortexed shortly and 4-MU fluorescence was measured 
immediately. The observed pseudo-first order inactivation rate (kobs) was calculated for each 
concentration of each inhibitor by fitting the data with the one-phase exponential association 
function: 4-MU fluorescence = A*(1–e^(−kobs*t)) using GraphPad Prism. The obtained kobs 
values for each concentration of each inhibitor were then plotted against the inhibitor 
concentration, and the resulting plots were fitted using a linear function, which gives the 
combined apparent inhibition parameter kinact/K’I as the slope. kinact/KI was derived from 
kinact/K’I by correcting for the presence of competing 4-MU-β-GlcA substrate, using the 





values from three independent sets measured for each inhibitor were used to calculate the 
average and SD of the kinact/KI value of each inhibitor. 
4.4.6 Protein crystallography (University of York) 
Protein crystals of CjAgd31B were obtained using 1.8 M ammonium sulfate, 0.10 M HEPES 
(pH = 7.0), 2% PEG 400 at 20 °C by the sitting drop vapor diffusion method. Crystal complexes 
with compound 3 was obtained by soaking in mother liquor containing 5.0 mM compound for 
2 h, before cryoprotecting in 2.0 M lithium sulfate, 0.10 M HEPES (pH = 7.0), 2 % (w/v) PEG 
400, and flash freezing in liquid N2 for data collection. AcGH79 was tested against a range of 
commercial crystallization screens. Well diffracting crystals of wild-type AcGH79 were obtained 
by the sitting-drop vapor-diffusion method at 20 °C using 0.8–1.2 M of 0.5:9.5 
NaH2PO4:K2HPO4 (v/v) at a protein:well ratio of 700:500 nL. Crystals of AcGH79 E287Q 
mutant were obtained using 1.2–1.5 M of 1.0:9.0 NaH2PO4:K2HPO4 (v/v) at a protein:well ratio 
of 500:500 nL. Crystals typically appeared after 1 day. Protein complexes with compound 10 
were prepared by supplying the drops containing crystals with 1.0 μL of 5.0 mM compound, in 
the precipitant solution freshly prepared, before soaking procedure for 1 h at 20 °C before 
fishing. Crystals of AcGH79 were cryoprotected using 2 M lithium sulfate before flash freezing 
in liquid N2 for data collection. All data were collected at 100 K on beamline I04 of the Diamond 
Light Source UK. Data were processed manually using XDS3140 and reduced using Aimless41 
(CjAgd31B), or with the xia2 pipeline42 of the CCP4 software suite (AcGH79). Complex 
structures were solved by molecular replacement using MolRep,43 before subsequent rounds of 
manual model building and refinement using Coot44 and REFMAC545 respectively. Refinements 
were carried out using TLS determination of molecular motions.46 Ligand coordinates were built 
using jLigand.47 Ribbon and protein surface diagrams were generated using PyMOL. Crystal 
structure figures were generated using CCP4mg.48 The data processing statistics and structure 
refinement are listed in Table 4.S2. 
 
 




4.4.7 In vitro ABP labeling in cell lysates and tissue homogenates 
All ABP incubation were performed at 37 °C for 30 min. For ABP 6 labeling in human fibroblast 
lysates, 10 μg total protein from the lysates was incubated with McIlvaine buffer at various pH 
in 10 μL of volume for 5 min on ice, followed by incubation with 5 μL ABP 6 (diluted with 
McIlvaine buffer at the matching pH) at a final ABP concentration of 1 μM. For ABP 13 labeling 
in human spleen homogenates, 20 μg total protein from the samples was incubated firstly with 
McIlvaine buffer at various pH and secondly with 5 μL ABP 13 (diluted with McIlvaine buffer 
at the matching pH) at a final ABP concentration of 100 nM, in the same volume and incubation 
time described for ABP 6. For competitive ABPP in human spleen homogenates, samples (40 
μg total protein) were diluted in 10 μL McIlvaine buffer (pH 5.0), pre-incubated with 2.5 μL 
ABP 14, ABP 16, or DMSO (diluted in McIlvaine buffer) at 100 nM ABP concentration during 
reaction. These were followed by incubation with 2.5 μL ABP 13 or DMSO (diluted in McIlvaine 
buffer), at 100 nM ABP 13 during incubation. 
4.4.8 Chemical proteomics  
For target identification of ABP 7, human fibroblast lysates (3 mg total protein), mouse liver 
homogenates (10 mg total protein) or mouse intestine homogenates (6 mg total protein) were 
incubated at pH 4.0 or 7.0 in McIlvaine buffer, at 37 °C in 0.5 mL volume, with either (1) 0.1 % 
(v/v) DMSO for 2 h, (2) firstly with 5.0 μM ABP 4 for 1 h, followed by ABP 7 (5 μM for 
fibroblasts lysates and mouse intestine homogenates; 10 μM for mouse liver homogenates) for 
1 h, or (3) ABP 7 (5 μM for fibroblasts lysates and mouse intestine homogenates; 10 μM for 
mouse liver homogenates) for 1 h. After incubation, samples were denatured by the addition of 
125 μL 10 % (w/v) SDS, and boiling for 5 min at 100 °C. From here on, samples were prepared 
for pull-down with streptavidin beads as published earlier.49 After pull-down procedure, the 
samples were divided, two-thirds for on-bead digestion and one-thirds for in-gel digestion. On-
bead digestion samples were incubated with 400 μL of trypsin digestion buffer (100 mM Tris-
HCl pH 7.8, 100 mM NaCl, 1.0 mM CaCl2, 2% (v/v) acetonitrile (ACN) and 10 ng/μL trypsin) 
at 37 °C overnight under constant shaking. The supernatant was desalted using stage tips, 





95:3:0.1, v:v:v) for LC-MS analysis following previously described procedures.49 For the in-gel 
digestion samples, peptides were eluted from the streptavidin resin by boiling at 100 °C with 30 
μL of 1 x Laemmli buffer (supplemented with 10 μL biotin). The eluted proteins were separated 
on 0.75 mm 10 % protein gels by SDS-PAGE at 200 V for 1 h, and silver-stained using the 
SilverQuest kit (Thermo Fisher). The resulting protein bands were excised and cut into 1 mm3 
cubes with a sterile surgery knife, transferred into 1.5 mL Eppendorf tubes and treated with 30 
μL of in-gel digestion buffer (10 mM NH4HCO3, 5 % (v/v) ACN, 1 mM CaCl2, 10 ng/μL 
trypsin). The supernatant containing the trypsin-digested peptides was extracted, and desalted 
for LC-MS measurement following the published protocol.49 For LC-MS measurement, all 
peptide samples were analyzed with a 2 h gradient of 5 % → 25 % ACN on nano-LC, hyphenated 
to an LTQ-Orbitrap and identified via the Mascot protein search engine, and the Raw data was 
calculated by MaxQuant program against the Uniprot human or mouse proteome database to 
present the protein identification list.49 Mascot identifications were manually validated. The 
identification results were exported as Excel file including protein accession numbers, Mascot 
peptide scores, mass of the protein, % coverage of the protein by amino acids identified by LC-
MS, peptide matches, miss cleavages, C-terminal peptides and protein emPAI values.49 For target 
identification of ABP 14, 3 mg total protein from human spleen or Gaucher spleen homogenates 
was incubated with either (1) 0.1% (v/v) DMSO, (2) firstly with 10 μM ABP 16 followed by 10 
μM 14, or (3) 10 μM 14, each step taking 30 min at 37 °C, in a total volume of 0.5 mL McIlvaine 
buffer at pH 5.0. Subsequent steps were identical to the method describes for target identification 
of ABP 7. 
4.4.9 Determination of in situ apparent IC50 values 
The in situ IC50 value was determined by incubating fibroblast cell lines expressing wild-type 
GAA and GUSB, grown to confluence, with a range of inhibitor dilutions for 2 h. Hereafter, 
cells were washed three times with PBS and subsequently harvested by scraping in KPi lysis 
buffer. In situ apparent IC50 values for each compound were determined by using enzymatic assay 
method described earlier, with GAA activity measured at pH 4.0 to avoid possible readout of 
GANAB activity. 




4.4.10 In situ ABP labeling 
Cultured fibroblasts were cultured in 6-well plates to confluency, and treated with 100 nM ABP 
6 diluted in culture medium, at 1 mL medium per well, for 10 to 240 min. For chloroquine 
treatment experiment, cultured fibroblasts were incubated with chloroquine (10–50 μM, for 1 h 
up to 3 h) and subsequently with ABP 6 (100 nM, for 3 h) in medium. After washing 3 times 
with PBS, cells were scraped from culture dishes in the presence of KPi lysis buffer (50 μL per 
well, with or without 10 μM ABP 4), collected in Eppendorf tubes, incubated on ice for 30 min 
for lysis, and stored at –80 °C until use. Lysates containing 5–10 μg total protein were subjected 
to SDS-PAGE and fluorescence scanning by methods described earlier. Labeling were visualized 
by fluorescent detection using Bio-Rad ChemiDoc MP Imager under the channels Cy5 for ABP 
6 and Cy2 for ABP 4 with the above described settings. For Chloroquine treatment experiment, 
cultured fibroblasts were incubated with chloroquine (10-50 μM, for up to 3 h) and subsequently 
with ABP 6 (100 nM, for 3 h) in medium. Cells were harvested with or without 10 mM ABP 4 
with the above describe methods. Homogenates were denatured, resolved on SDS-PAGE and 
detected for ABP 6 labeling by fluorescent scanning.  
4.4.11 GAA detection in fibroblast lysates of control and Pompe patients 
10 μg protein from each lysate were labeled with 1 μM ABP 4 for 30 min at 37 °C at either pH 
4.0 or 7.0, before subsequent SDS-PAGE and fluorescent scanning using a Typhoon FLA9500 
Imager (GE Healthcare) using λEX = 635 nm laser and λEM ≥ 665 nm filter, and 100 mm as pixel 
size. After scanning, proteins on wet slab gels were transferred to PVDF membranes and 
blocked with 5 % (w/v) BSA in TBST. For GAA detection, the membranes were incubated 
firstly with mouse polyclonal anti GAA (kind gift from the Kornfeld lab, Washington University 
of St. Louis, MO, USA) and subsequently with goat anti mouse Alexa647 (Life Technologies, 
Carlsbad, CA, USA). Blots were scanned on the Typhoon FLA 9500 Imager using 633 nm laser 
and LPR filter, and 100 mm as pixel size. Rabbit anti β-actin (Cell Signaling, Danvers, MA, USA) 
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Figure 4.S1. Labeling kinetics of ABPs towards recombinant enzymes at 4 °C or at 37 °C. A) ABP 4 
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Figure 4.S2. Kinetic parameter measurements for compound 8–14 towards AcGH79. Left panels: 
progressing curves of relative fluorescent unit (RFU) for each sample incubated with the indicated inhibitor 
concentration for different incubation time. Middle panels: inhibition curves for each sample incubated 
with the indicated inhibitor concentration through the indicated incubation time, relative to the activity from 
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Figure 4.S4. Target identification for ABP 6 and 7 using chemical proteomics in mouse liver 
homogenates. A) ABP 6 labeling at various pHs. B) Silver stain of gels containing samples labeled 
with(out) ABPs at pH 4.0 or 7.0, and affinity-enriched for biotin. C) List of identified glycosidases by LC-
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Figure 4.S5. Target identification for ABP 6 and 7 using chemical proteomics in mouse intestine 
homogenates. A) Silver stain of gels containing samples labeled with(out) ABPs at pH 4.0 or 7.0, and 
affinity-enriched for biotin. B) List of identified glycosidases by LC-MS measurement by LC-MS-based 
proteomics at positions shown in A. C) Table of the most abundant glycosidase identified at each gel 
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1 (JJB307) 155,000 ±
1,770
2 (CF21) 41,900 ± 490
3 (CF22) 603 ± 28.0
4 (JJB382) 593 ± 214
5 (JJB347) 1,080 ± 63.6
6 (JJB383) 816 ± 526
7 (JJB384) 2,060 ± 219
Table 4.S3
CjAgd31B–3 AcGH79(wt)–10 AcGH79(E287Q)–10
PDB 5123 5G0Q 5L77
Data collection
Space group P622 C2 C2
Cell dimensions
a, b, c (Å) 198.0, 198.0, 103.0 148.5, 44.9, 82.2 150.2, 45.1, 82.0
α, β, γ () 90, 90, 120 90, 114.8, 90 90, 115.1, 90
Resolution (Å) 85.74-1.95 42.60-1.60 28.90-1.24
Rmerge 0.13 (1.64) 0.058 (0.664) 0.045 (0.489)
I/σI 19.6 (2.3) 12.1 (1.8) 13.7 (1.9)
Completeness (%) 100 (100) 99.5 (99.7) 89.8 (49.7)
Redundancy 20.0 (20.1) 4.0 (3.7) 3.9 (2.7)
Refinement
Resolution (Å) 85.74-1.95 42.60-1.60 28.90-1.24
No. reflections 82110 56355 120177
Rwork/ Rfree 0.17/0.19 0.12/0.17 0.13/0.16
No. atoms
Protein 6299 3434 3477
Ligand/ion 102 36 56
Water 616 294 486
B-factors
Protein 33.8 19.82 17.87
Ligand/ion 64.8 28.07 33.05
Water 39.7 30.29 30.95
R.m.s. deviations
Bond lengths (Å) 0.012 0.020 0.016
Bond angles () 1.57 1.86 1.73




4.S2. Supporting note 
Modeling irreversible enzyme inactivation by ABPs in presence of  substrate. 
Inactivation of  enzyme by ABP is assumed to follow the following model (Main text Ref. 39): 
 
KM is the equilibrium constant for E-S formation (i.e. Michaelis constant; the concentration of  
S in which product formation is at 1/2 Vmax), kcat is the rate constant for P formation, KI is the 
equilibrium constant for E-I formation (i.e. inhibition constant), ki is the rate constant for E-I* 
formation (i.e. inactivation rate constant). 
In the experiments I is the ABP, S is the substrate 4-MU-GlcA, E is AcGH79 and P is the 
measured product 4-MU. [I] and [S] are both >> [Etot] which is fixed at 260 pM ([Etot] = 
[E]+[EI]+[ES]+[EI*]). [S] is 2.5 mM.  
In this model, the substrate and ABP compete reversibly for the enzyme active site, followed by 
irreversible reactions to give either P, or the inactivated enzyme complex E-I*.   
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= 𝑘𝑜𝑏𝑠[𝐸𝑡𝑜𝑡 −  𝐸𝐼
∗]   (3) 
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Here, the appeared equilibrium constant for I is dependent on the type and the amount of  S 








         (6) 
For deriving kobs experimentally, [I] and [S] can be both set at >> [Etot]. Under this condition, 
kobs is a pseudo-first order inactivation rate constant (dependent on [I]). The extent of  enzyme 
inactivation at time t is quantified by the residual activity Vt/V0, where Vt is the enzyme reaction 
rate at time t. Thus, Vt/V0 for each value of  [I] can be described by the first-order rate equation: 
𝑉𝑡
𝑉0
⁄ = 𝑒−𝑘𝑜𝑏𝑠𝑡        (7) 
𝑉𝑡 = 𝑉0𝑒
−𝑘𝑜𝑏𝑠𝑡         (8) 
The amount of  product [P] formed at time t is the integral of  Vt, with respect to t, between the 
interval [0, t]: 






⁄ (1 − 𝑒−𝑘𝑜𝑏𝑠𝑡)    (9) 




Fitting 4-MU fluorescence (which is ∝ [P]) vs. time using (9) allows kobs to be derived for each 
value of  [I]. Next, the derived kobs values at each [I] can be plotted against each [I], and the 
resulting plot of  kobs vs [I] can be fitted using (6), which is an analogue of  Michaelis-Menton 
equation, to derive K’I and ki. 
When [I] << K’I, as observed from the data in this chapter, K’I and ki cannot be accurately 




⁄ [𝐼]        (10) 
Thus, a subsaturated plot of  kobs against [I] is better fitted using linear function (10), allowing an 
estimate of  ki/K’I to be derived from the gradient of  the slope. 
ki/KI is derived from ki/K’I by applying (5), where [S] is known and KM can be derived by a 





4.S3 Synthetic schemes for compounds 1-15 (Department of  Bio-organic synthesis, Leiden 
University) 
For complete synthetic method and characterization data, the reader is directed to the 




Scheme 4.S1. Synthesis of 1,6-epi-cyclophellitol 1, the cyclophellitol aziridine inhibitors 2, 3, and 
ABPs 4−7. Reagents and conditions: (a) (i) Li, NH3, THF, −60  C, 57 %; (ii) PhCH(OMe)2, CSA, DMF, 61 
%. (b) CCl3CN, DBU, DCM, 0  C. (c) NaHCO3, I2, H2O, two step yield 41 %. (d) 37 % HCl aq, dioxane. (e) 
NaHCO3, MeOH, two step yield 63 %. (f) 1-azido-8-iodooctane, K2CO3, DMF, 80  C, 39 %. (g) 4, 5, 6, or 
7, CuSO4, sodium ascorbate, DMF, 38 % 3, 11 % 4, 24 % 5, 23 % 6. (h) m-CPBA, DCM, 40  C, 44 %. (i) 
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4 (aq., 1 M), NaH2PO4 (aq., 1.0 M), DCM, 50 °C, 55 %; (b) BAIB, TEMPO, 
DCM/tBuOH/H2O (4:4:1), 0 °C, 79 %; (c) H2, Pd(OH)2/C, MeOH, 98 %; (d) i) CCl3CN, DBU, DCM, 0 °C; ii) 
I2, NaHCO3, H2O; iii) 37 % HCl aq., dioxane, 60 °C; iv) NaHCO3, MeOH, 45 %; (e) Cbz-Cl, Pyridine, THF, 




Scheme 4.S3. Synthesis of compounds 10-14. Reagents and conditions: (a) K2CO3, DMF, 1-azido-8-
iodooctane, 80 °C, 50 %; (b) TEMPO, NaClO, NaBr, NaOH, H2O, 15 %; (c) CuSO4, sodium ascorbate, 
DMF, 22 % 11, 13 % 12, 17 % 13, 13 % 14. 
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Scheme 4.S4. Synthesis of 2S, 3R, 4R, 5S-trihydroxypipecolic acid 15. Reagents and conditions: (a) 
Supplementary Ref. 1 (b) DMAP, TEA, TrtCl, DCM, 3 h, 75 %; (c) Na, MeOH, 3 h, 91 %; (d) i): (COCl)2, 
DMSO, DCM, –65 °C, 2 h; ii): TEA, -65 to 5 °C, 2 h; iii): NH4HCO3, NaBH3CN, 3 Å mol. sieves, MeOH, 0 
°C, 1 h, then 0 °C to RT, 20 h, 85 %; (e) CbzCl, THF, TEA, RT, 20 h, 72 %; (f) p-TsOH, DCM, 0 °C to RT, 
3 h, 83%; (g) TEMPO, BAIB, DCM/H2O (2/1), 0 °C, 5 h, 41: 71 %; (h) i): TEMPO, BAIB, DCM/H2O (2/1), 
0 °C, 5 h; ii): BnBr, Cs2CO3, DMF, RT, 3 h, 42: 75 %; (i) H2, Pd(OH)2/C, AcOH/H2O(4/1), RT, 16 h, 57 %. 
 
6.S4 Supplementary Reference 
1  La Ferla B, Bugada P & Nicotra F (2006) Synthesis of the dimethyl ester of 1-deoxy-L-idonojirimycin-1-
methylenphosphonate: A new approach to iminosugar phosphonates. J Carb  Chem 25, 151–162.  
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Development and application of  activity-based probes for 
α-L-iduronidase 
Manuscript published as: 
Artola M, Kuo CL, McMahon SA, Oehler V, Hansen T, van der Lienden M, He X, van den Elst H, Florea 
BI, Kermode AR, van der Marel GA, Gloster TM, Codée JDC, Overkleeft HS & Aerts JMFG (2018) New 
Irreversible α-l-Iduronidase Inhibitors and Activity-Based Probes. Chemistry 24, 19081–19088.  





Human α-L-iduronidase is a retaining exo-acting glycosidase responsible for catalyzing the 
lysosomal turnover of  glycosaminoglycans, and its hereditary deficiency underlies the 
lysosomal storage disorder mucopolysaccharidosis type I (MPS I). New covalent inhibitors and 
ABPs of  α-L-iduronidase has been synthesized based on the cyclophellitol scaffold, and these 
were shown to react covalently and irreversibly in an activity-based manner with human 
recombinant α-L-iduronidase (rIDUA, Aldurazyme®), albeit with a lower potency and slower 
inhibitory kinetics compared to earlier generated ABPs towards other retaining glycosidases. 
The structures of  IDUA when complexed with the inhibitors in a noncovalent transition-state-
mimicking form and a covalent enzyme-bound form provide insights into its conformational 
itinerary. Inhibitors 1–3 adopt a half-chair conformation in solution (4H3 and 3H4), as predicted 
by DFT calculations, which is different from the conformation of  the Michaelis complex 
observed by crystallographic studies. Consequently, 1–3 may need to overcome an energy 
barrier in order to switch from the 4H3 conformation to the transition state (2, 5B) binding 
conformation before reacting and adopting a covalent 5S1 conformation, explaining their lower 
potency and slower inhibitory kinetics. Nevertheless, rIDUA can be efficiently labeled with 
fluorescent Cy5 ABP 2, which allows monitoring of  the delivery of  this therapeutic 
recombinant enzyme to lysosomes, as is intended in enzyme replacement therapy for the 







uman α-L-iduronidase (IDUA), which belongs to the GH39 family in the 
Carbohydrate Active EnZyme (CAZy) classification,1, 2 hydrolyzes terminal non-
reducing α-L-iduronic acid residues in glycosaminoglycans (GAGs), including 
dermatan sulfate (DS) and heparan sulfate (HS), through a two-step Koshland double-
displacement mechanism (Fig. 5.1A).3–6 The active site of the enzyme contains a carboxylic 
acid/carboxylate pair that acts as an acid/base (Glu188) and a nucleophilic (Glu299) catalyst. 
Protonation of the exocyclic oxygen by the acid/base residue and concomitant nucleophilic 
attack at the anomeric carbon by Glu299 leads to SN2 displacement of the aglycon, yielding a 
covalent enzyme–substrate complex with inversion of stereochemistry at the anomeric carbon. 
In the next step, a water molecule enters the enzyme active site, where it is deprotonated by the 
acid/base (Glu188) and then hydrolyzes the enzyme–substrate intermediate in a reversal of steps, 
again with inversion of anomeric configuration. The conformational change of IDUA from 
Michaelis complex to transition state (TS) and enzyme–inhibitor covalent complex has recently 
been suggested to follow a 2S0  2, 5B  5S1 itinerary.5, 7, 8 This catalytic pathway was predicted 
on the basis of the structures of Michaelis complexes with (2R, 3R, 4R, 5S)-2-carboxy-3,4,5-
trihydroxypiperidine (IdoA-DNJ) and 5-fluoro-α-L-idopyranosyluronic acid fluoride (5F-IdoAF) 
as reversible inhibitors and the 2-deoxy-2-fluoro-α-L-idopyranosyluronic acid (2F-IdoA)–
enzyme covalent complex intermediate. 
 Mutations in the gene encoding IDUA may result in mucopolysaccharidosis type I (MPS 
I), which is a rare autosomal inherited recessive disease that leads to toxic accumulation of HS 
and DS. MPS I is a devastating disease that affects around 1 in 100,000 individuals and is 
classified as attenuated MPS I and more severe MPS I (traditionally categorized from less to 
more severe form as Scheie, Hurler–Scheie, or Hurler disease) to distinguish between disease 
severity and therapeutic options.8 Children with severe MPS I are treated at a young age by 
hematopoietic cell transplantation (HCT).9 Enzyme replacement therapy (ERT) with 
recombinant human α-L-iduronidase (rIDUA, Aldurazyme®) is considered as a treatment for 
non-neurological manifestations of MPS I.10 There is consensus among treating clinicians that 
H 




the impact of ERT with rIDUA is greatest when the treatment is initiated early in the disease 
progression. An obvious prerequisite for effectiveness is the successful targeting of infused 
rIDUA to lysosomes in multiple cell types, and for this purpose a detailed understanding of 
rIDUA targeting is still urgently needed. Besides MPS I, lysosomal α-L-iduronidase is indirectly 
involved in two other inherited lysosomal storage disorders, mucolipidosis II (ML II) and III 
a/b. Here, a deficiency in the generation of mannose-6-phosphate (M6P) moieties in N-linked 
glycans of newly formed lysosomal enzymes impairs their correct routing to lysosomes and 
therefore these, including α-L-iduronidase, are largely erroneously secreted.11 
Figure 5.1. Reaction mechanisms and structures of compounds used in this chapter. A) Koshland 
double-displacement mechanism employed by retaining α-L-iduronidase, showing the 2S0  
2, 5B  5S1 
conformational reaction itinerary from the Michaelis complex, transition state 1, covalent substrate–
enzyme intermediate, and transition state 2, to the hydrolyzed product. B) Proposed inhibition mechanism 
of aziridine-based inhibitor 1 and ABPs 2 and 3. C) Chemical structures of α-L-iduronic-configured 
mechanism-based irreversible inhibitor 1 and ABPs 2 and 3, and the idose-configured compound 11 and 
12 described in this work. 
Herein, the characterization and application of new irreversible IDUA inhibitors and 
activity-based probes (ABPs) bearing an α-L-iduronic configured cyclophellitol aziridine as an 
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(for gel and/or cell imaging) or biotin (for chemical proteomics studies) afforded valuable tools 
(Fig. 5.1B, C) for the study of α-L-iduronidase in vitro and in situ, structural analysis, and for 
monitoring rIDUA uptake and trafficking to lysosomes, as is revealed in this chapter. 
5.2 Results 
5.2.1 Synthesis of  α-L-iduronic-configured inhibitors and ABPs 
The synthetic strategy for compound 1, ABP 2 and ABP 3 (Fig. 5.1C) (Department of 
Bio-organic Synthesis, Leiden University) is described in detail in section 4.S1.2 in the Appendix. 
Briefly, to obtain the desired α-L-iduronic-configured inhibitors and ABPs, the α-L-iduronic-
configured cyclohexene 8 was produced in three steps, followed by benzylation of  free alcohol 
and aziridination with 3-amino-2-(trifluoromethyl)quinazolin-4(3H)-one (CF3-Q-NHOAc), 
following strategy described by Llebaria and coworkers12 and the Overkleeft group13 (Scheme 
5.S1). After removal of  benzyl and CF3-Q groups, the obtained idose-configured aziridine 11 
(Fig. 5.1C) was alkylated to afford the azide-containing compound 12 (Fig. 5.1C), which was 
further oxidized at C-6 to afford the α-L-iduronic-configured cyclophellitol aziridine compound 
1 (Fig. 5.1C). Finally, click reaction with a Cy5- or biotin-substituted alkyne on compound 1 
afforded the desired ABP 2 or 3 (Fig. 5.1C). 
5.2.2 In vitro inhibition and labeling of  recombinant human α-L-iduronidase with compounds 1–
3 
The in vitro inhibition potencies of  compounds 1–3 was examined by incubating them for 
60 min at various inhibitor concentrations with human recombinant α-L-iduronidase (rIDUA, 
Genzyme) at pH 4.5, followed by 30 min incubation with the fluorogenic substrate 4-
methylumbelliferyl-a-iduronide (4-MU-IdoA). The assay mixture was supplemented with BSA, 
Triton X-100, NaCl, and chloride salt of  divalent cations, by adapting methods described in 
literatures14, 15, which resulted in a 3.5-fold increase in rIDUA activity (Fig. 5.S1). Compounds 
1–3 inhibited rIDUA with apparent half-maximum inhibitory concentrations in the micromolar 
range (Fig. 5.2). Intermediate 11 showed no activity (Fig. 5.2), in line with the role of  the 




carboxylate group at C5 for IDUA binding in a positively charged enzymatic pocket formed by 
the Arg363 and Lys264 side chains and the main-chain NH groups of  Gly305 and Trp306.8 
Surprisingly, alkyl aziridine 12 inhibited rIDUA on a par with compound 1–3 (Fig. 5.2), 
suggesting that the carboxylate group may not be essential for binding if  an N-alkyl group is 
presented. These results are also in line with previous findings that N-alkyl aziridines display 
improved binding potency towards glycosidases.16  
Figure 5.2. In vitro inhibition of recombinant α-L-iduronidase (rIDUA) by compounds 1-3, 11 and 12 
at 1 hour incubation time. Compounds 1-3, 12 = triplicate sets of experiment, each with technical 
triplicates; 11 = duplicate sets of experiment. Error range in inhibition curves = SD from technical triplicates. 
Error range in IC50 values = SD from triplicate (or duplicate) experimental sets. 
Cy5 ABP 2 labeled rIDUA in a concentration- and time-dependent manner, consistent 
with the irreversible inhibition mechanism of  these analogues, with optimal labeling at 50 μM 
and about 120–180 min incubation, as visualized by SDS-PAGE (Fig. 5.3A). The optimum pH 
for labeling with ABP 2 was determined as 4.5–5.0, consistent with the reported optimum pH 
for enzymatic activity (Fig. 5.3B).2 The stability of  the covalent enzyme–inhibitor complex was 
Compound
Apparent IC50
(μM), n = 3 ± SD
1 40.6 ± 17.0
2 58.1 ± 6.66
3 65.5 ± 5.73
11 > 100






also tested, and it was observed that rIDUA remained inactivated for at least 100 h (Fig. 5.3C). 
In addition, competitive activity-based protein profiling (ABPP) showed competition in a  
Figure 5.3. Labeling of rIDUA with ABPs 2. A) Cy5 ABP 2 labels rIDUA (10 ng) in a concentration-
dependent (left, at 4 h incubation time) and time-dependent (right, at 50 μM) manner. Labeling signals 
were quantified (below each gel image) and fitted with a one-phase association equation. Dotted lines 
represent 95 % CI. B) ABP 2 labels rIDUA in a pH-dependent manner. The quantified labeling signals 
were compared to data obtained with 4-MU substrate assay (below; error range =SD from technical 
triplicates). C) Irreversible inhibition of rIDUA by ABP 2. Error range = SD from technical triplicates. D) 
ABP 2 labels rIDUA and negative controls: without rIDUA, without ABP 2 or with SDS (left panel), 
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concentration-dependent manner with 4-MU-IdoA as well as with inhibitor 1, illustrating the 
applicability of  this probe for the screening of  new inhibitors (Fig. 5.3D). 
Next, kinetic parameters for rIDUA labeling/inhibition by ABP 2 was determined. Due 
to the fluorescent nature and the slow labeling on rIDUA by ABP 2 (Fig. 4.3A, right panel), it 
was envisioned that kinetic parameters could be derived by monitoring the progress of  rIDUA 
labeling by ABP 2 at various concentrations (5–60 mm) and different incubation times (30–150 
min) using an SDS-PAGE-based ABPP method. This would simplify the derivatization of  
kinetic parameters commonly applied for irreversible inhibitors (see Experimental procedures 
5.4.9 for more detailed explanation). Indeed, when labeling of  rIDUA by ABP 2 (Fig. 5.S2) was 
quantified (Fig. 5.4A), the initial binding constant (KI) and an inactivation rate constant (kinact) 
could be determined (Fig. 5.4B). The calculated kinact/ KI value was 1.38 x 10-4 μM-1 min-1,  
Figure 5.4. Kinetic parameters for ABP 2 towards rIDUA. A) Percentages of rIDUA labeling at different 
time points and at different concentrations of ABP 2. Data were quantified from three sets of fluorescent 
gels containing rIDUA labeled with ABP 2 under the depicted conditions to derive a rate constant k for 
each ABP 2 concentration. B) Left, k vs. [inhibitor] plot. Data were curve-fitted with the Michaelis–Menten 
equation to obtain kinetic parameters. Right, calculated kinetic parameters for ABP 2 labeling of rIDUA. 
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showing this compound to be a less potent inactivator than other ABPs for related glycosidases, 
such as β-glucuronidases16, β-glucosidases17, 18, α-glucosidases19, and α-galactosidase20. 
 To further demonstrate the covalent binding to the catalytically active amino acid, 
biotinylated ABP 3 was incubated with rIDUA, and peptide mass fingerprinting-based 
proteomic was utilized to detect for the presence of  ABP 3 on the active site peptide of  rIDUA. 
After ABP incubation, rIDUA was denatured and digested by chymotrypsin, and the resulting 
ABP 3-labeled peptides were affinity-enriched and analyzed by nanoscale liquid chromatography 
coupled with tandem mass spectrometry (nano-LC-MS/MS). A fragment of  the IDUA 
nucleophile (Glu299) covalently attached to ABP 3 was detected by MS/MS fragmentation of  
the 7-amino-acid peptide containing the nucleophilic residue (Fig. 5.5, 5.S3 and 5.S4). 
 
Figure 5.5. Proteomic detection of ABP 3-labeled rIDUA peptides. MS/MS pattern of a sample 
containing rIDUA Asn297–Leu303 active site peptide labeled with biotin ABP 3 at Glu299 is shown, and 
peaks corresponding to the detected fragments are annotated. Actx = active site peptide. 
5.2.3 Activity-based protein profiling of  IDUA in homogenates of  fibroblasts 
It was attempted to use ABP 2 to visualize endogenous IDUA in lysates of  cultured 
normal human dermal fibroblasts (NHDF) and concentrated human urine, with and without 
Asn—Asp























































































































pre-purification by concanavalin A beads. Unfortunately, no clear labeling on rIDUA was 
observed with ABP 2 at 1–10 μM concentration, and many non-specific bands were detected at 
higher concentrations, that could not be competed by inhibitor 1 nor ABP 3 (data not shown). 
To investigate whether the lack of  specific IDUA labeling in NHDF lysates is due to low enzyme 
amount, the specific glycosidase activity and ABP labeling of  IDUA vs. β-glucocerebrosidase 
(GBA) with those of  the corresponding Cy5 ABPs (2 vs. ABP JJB36721) was compared in 
recombinant enzymes and NHDF lysates. It was observed that while it is theoretically possible 
to detect IDUA in fibroblast lysates (calculated amount of  IDUA in lysates was only 1.5 lower 
than that of  GBA in the same lysates), its detection in NHDF lysates is still challenging due to 
nonspecific labeling of  other proteins at the required concentration of  ABP 2 (25–50 mm) (Fig. 
5.6). On the other hand, measurement of  ABP 2’s inhibition on IDUA in NHDF lysates showed  
 
Figure 5.6. Detection of endogenous IDUA in human fibroblasts (NHDF) lysates. A) Comparing 
endogenous enzyme amount in human fibroblasts (NHDF) lysates for IDUA vs glucocerebrosidase (GBA), 
by comparing measured specific activity presented in lysates vs from known amount of rIDUA or rGBA 
with 4-methylumbelliferyl-glycoside substrates. B) Comparing ABP labeling of known amounts of rGBA 
and rIDUA vs ABP labeling in NHDF lysates. *10 µg protein was loaded. 
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an apparent IC50 value of  23.5 μM (Fig. 5.S5), comparable to the value towards rIDUA. 
Therefore, it was concluded that direct detection of  IDUA in biological samples by ABP 2 via 
SDS-PAGE is not feasible due to a combination of  this compound’s moderate activity and a 
lack of  relative substrate specificity. Future optimization of  enrichment method for endogenous 
IDUA is warranted for its eventual application in diagnostic purposes. 
5.2.4 Conformations of  α-L-ido-aziridine 11 and α-L-idoA-aziridine by DFT calculations  
The conformational preferences of  α-L-ido-aziridine 11 and α-L-idoA methylated aziridine 
was studied (Department of  Bio-organic Synthesis, Leiden University), as simplified 
representations of  inhibitors 1–3, in order to elucidate the involvement of  conformation on 
inhibitor potency and binding kinetics. A conformer distribution search in Spartan 1422 and 
further optimization with Gaussian 0923 by utilizing B3LYP/6–311G(d, p)/PCM(H2O) (for 
details, see section 5.S3 in the Appendix) showed that the 4H3 conformation of  α-L-ido-aziridine 
11 is greatly favored, with variations in the geometry about the C5–C7 bond (Table 5.S2). 
Conversely, α-L-idoA-aziridine showed both 4H3 and 3H4 (the latter 1.4 kcal mol-1 higher in 
energy) as relevant conformations. Interestingly, the 2, 5B boat conformation was also found as a 
relevant geometry for α-L-idoA-aziridine, albeit with an energetic cost of  8.0 kcal mol-1. In 
addition, coupling constants (J) were calculated for the lowest-energy conformations, and these 
were in excellent agreement with experimental NMR data (Table 5.S3, 5.S4). 
5.2.5 Structural analysis of  IDUA interactions with inhibitors 1–3 
In order to study the mechanism of  action of  inhibitors 1–3, their conformations upon 
binding to IDUA were analyzed by crystallographic studies by collaboration with the Gloster 
group (University of  St Andrews). Compounds were applied in solution for various durations to 
raIDUA crystals (IDUA recombinantly expressed in the seeds of  a cgl (complex glycan deficient) 
mutant of  Arabidopsis thaliana). Data were collected from a crystal soaked with ABP 1 for 24 h 
to 2.02 Å resolution (Table 5.S1), which revealed the structure of  raIDUA in a covalent complex 
with 1 (Fig. 5.7A). The aziridine nitrogen is displaced by nucleophilic attack of  the active site 
carboxylate to form a trans-2-amino ester (with the rest of  the R group not visible in the electron 




density, presumably disordered due to its inherent flexibility; this region of  the structure is 
exposed to the solvent). Interestingly, the pseudo-glycoside was observed in a 5S1 skew-boat 
conformation, which differs slightly from the distorted 2, 5B boat conformation reported for the 
previously described irreversible inhibitor 2-deoxy-2-fluoro-α-L-ido-pyranosyluronic acid 
 
Figure 5.7. Structural insights into raIDUA complexed with ABPs. A) Structure of raIDUA complexed 
with a fragment of compound 1, which is covalently linked to the nucleophile Glu299. The maximum 
likelihood/sA weighted 2Fobs–Fcalc electron density map (gray) is contoured at 1.2 sigma. B) Structure of 
raIDUA covalently complexed with a fragment of compound 1, illustrating the active site residues that 
interact with the pseudo-glycoside. C) Structure of raIDUA complexed with a fragment of ABP 3. The 
nucleophile Glu299 is shown. The maximum likelihood/sA weighted 2Fobs–Fcalc electron density map (gray) 
is contoured at 1.0 sigma. D) Structure of raIDUA complexed with a fragment of ABP 3, illustrating the 
active site residues that interact with the pseudo-glycoside. E) Superposition of raIDUA covalently 
complexed with fragments of compound 1 (green) and 2F-IdoA (pink; PDB code 4KH28). F) Superposition 
(based on alignment of protein main-chain atoms) of raIDUA complexed with a fragment of compound 1 
(covalent, green) and a fragment of ABP 3 (transition state, cyan). G) Superposition (based on alignment 
of C3 and C4 atoms of each molecule) of raIDUA complexed with a fragment of compound 1 (covalent, 










(2F-IdoA) covalently bound to IDUA.8 The observed 5S1 conformation of  the covalent inhibitor 
1–enzyme complex supports predictions for the conformational itinerary followed by α-L-
iduronidase GH39 (Fig. 5.1A).7 The carboxylate group of  the pseudo-iduronic acid forms 
bidentate hydrogen bonds with the main-chain nitrogen atoms of  Gly305 and Trp306, the C4 
hydroxyl group forms hydrogen bonds with Arg363 and Asp349, the C3 hydroxyl group interacts 
with Asp349 and a water molecule, and the C2 hydroxyl group forms hydrogen bonds with 
Asn181 and the nucleophile Glu299 (Fig. 5.7B). In the covalent complex between IDUA and 
2F-IdoA, the nucleophile Glu299 is rotated by around 90 ⁰C compared to the position observed 
in the complex here with the fragment of  1,8 and the fluoro group at C2 may preclude an 
interaction with Oε2 of  Glu299, causing it to rotate. However, the inhibitor 1–IDUA complex 
presented here, bearing a hydroxyl group at C2 and showing an interaction with Glu299, is more 
likely to represent what occurs during catalysis (Fig. 5.7E). 
In an attempt to fully define the conformational inhibition of  compounds 1–3, raIDUA 
crystals were soaked with the ABPs for shorter durations. Data collected to 2.39 Å resolution 
(Table 5.S1) on a crystal soaked with ABP 3 for 45 min revealed electron density in the active 
site of  raIDUA consistent with the unreacted cyclophellitol aziridine 3 (Fig. 5.7C). A methyl 
group on the cyclophellitol aziridine was visible, but the rest of  the R group was not evident and 
presumably disordered. Interestingly, the pseudo-glycoside was observed in a 2, 5B conformation, 
which is the predicted transition state for GH39 α-L-iduronisase.7 The majority of  the 
interactions with active-site residues were the same as those described for the covalent complex 
with raIDUA (Fig. 5.7D), although a shift in position of  the glycoside indicated that the 
carboxylate group additionally interacted with Lys264. The hydroxyl group at C2 forms a 
hydrogen bond with the nucleophile Oε2 of  Glu299, but at a surprisingly short distance of  2.4 
Å, suggesting a tight interaction. This close proximity results in a distance between the pseudo-
anomeric carbon and Oε1 of  only 2.9 Å. These tight interactions, together with the2, 5B 
conformation of  the pseudo-glycoside, suggest that the pseudo-glycoside at the transition state 
was being observed; such structural observations are rare using wild-type enzymes, but here it 
was possible due to the slow inactivation kinetics of  3. The importance of  the interaction 




between the glycoside and the C2 hydroxyl group supports work by others;24, 25 indeed, 
interactions at the 2-position were estimated to contribute 18 kJ mol-1 binding energy to 
stabilization of  the transition state for a β-glucosidase during the glycosylation step of  the 
catalysis.24 Based on this work, it was postulated that a hydrogen bond formed between the C2 
hydroxyl group and the nucleophile would be optimal at the transition state, as the two groups 
come into close proximity during formation of  the covalent glycosyl–enzyme bond.24 
Superimposition of  the main chain atoms for the two complexes revealed a shift in the 
position of  the cyclophellitol aziridine to accommodate formation of  the covalent bond (Fig. 
5.7F). This engendered movement of  between 0.2 and 0.4 Å at C5, C4 and C3, 0.5 Å at C2, 0.6 
Å at the carbon at the position of  the endocyclic oxygen, and 1.1 Å at the pseudo-anomeric 
carbon. These structures, together with the previously reported structure of  IDUA in complex 
with the inhibitor IdoA-DNJ, in which the pseudo-glycoside was observed in a 2S0 conformation 
(predicted Michaelis complex conformation), allows the full conformational itinerary for IDUA 
to be structurally defined. The structures of  IDUA with IdoADNJ (Michaelis complex) and 3 
(transition state complex) and the fragment of  compound 1 (covalent complex) were overlapped 
at the C3 and C4 atoms (Fig. 5.7G). This clearly shows the electrophilic migration from the 
Michaelis complex in a 2S0 conformation, through the transition state in a 2,5B conformation, to 
the covalent intermediate in a 5S1 conformation. At the pseudo-anomeric carbon, there is a 
displacement of  0.74 Å from the Michaelis complex to the covalent intermediate. This is 
accompanied by a small (0.23 Å) movement at C2, but larger movement at C5 (0.72 Å) and the 
atom at the position of  the endocyclic oxygen (0.70 Å), presumably to bring about the required 
migration at the anomeric position. 
5.2.6 Visualizing rIDUA uptake in normal and patient cells 
 Finally, the question whether ABP 2 could be used to study rIDUA cellular uptake and 
lysosomal internalization was investigated. The majority of  therapeutic glycosidases are amended 
with mannose 6-phosphate (M6P) residues for their recognition by M6P receptors (MPRs) on 





within cells, NHDF and fibroblasts of  MPS I and ML II patients were fed with pre-labeled 
rIDUA-ABP 2, and after fixation, cells were analyzed by confocal fluorescence microscopy. After 
16 h incubation, punctate fluorescence structures were observed, which colocalized with the 
signals from the antibody-labeled lysosomal-associated membrane protein 1 (LAMP1), 
indicating lysosomal uptake of  labeled rIDUA by all analyzed fibroblast models (Fig. 5.8A). The 
fluorescence from labeled rIDUA was absent in cells without the addition of  rIDUA, as well as 
cells pre-incubated with M6P, which blocks M6P receptors (Fig. 5.8A). This finding was 
recapitulated in a parallel experiment, in which identically treated cells were lysed and detected 
for Cy5 fluorescence by SDS-PAGE and fluorescent scanning, revealing that only cells treated 
with ABP 2-labeled rIDUA and without M6P pre-incubation contained bands corresponding to 
rIDUA (Fig. 5.8B). Interestingly, two extra bands that were smaller than the original rIDUA (85 
kDa) were observed in the NHDF lysates, whereas only one band of  74 kDa and one band of  
85 kDa was observed in lysates of  MPS I or ML II fibroblasts, respectively. The 74 kDa and 
lower molecular bands were possibly rIDUA processed in the lysosomes of  NHDF,26 and this 
difference in labeling patterns could therefore indicate difference in the lysosomal function or 
endosomal uptake between normal and patient cells. Altogether, these results clearly 
demonstrated that rIDUA lysosomal uptake is mediated by MPRs, in agreement with earlier 
literature,27 and that ABP 2 can be used to study the trafficking, localization, and lysosomal 
processing of  rIDUA within cells derived from MPSI and MLII patients. 
5.3 Discussion 
 In this chapter, the characterization and application of  newly synthesized α-L-iduronidase 
inhibitors and ABPs were discussed. α-L-ido-configured cyclophellitol aziridine was synthesized 
as a key intermediate for generation of  the first α-L-iduronidase ABPs. The α-L-ido-configured 
cyclohexene 8 could be an interesting starting point for the development of  new IDUA 
inhibitors or chaperones. With the inhibitors described herein, ABPP studies on rIDUA has been 
conducted, showing that ABP 2 irreversibly labels rIDUA in a concentration- and time-
dependent manner, with optimum labeling at pH 4.5–5.0. The covalent rIDUA inhibition has 
been further demonstrated by nano-LC-MS/MS, detecting a 7-amino-acid peptide fragment of     




Figure 5.8. rIDUA visualization in human fibroblasts by confocal fluorescence microscopy and 
SDS-PAGE. A) From top to bottom: NHDF, human normal dermal fibroblasts; MPS I, patient fibroblasts 
with mucopolysaccharidosis type I, and ML II, patient fibroblasts with mucolipidosis type II. From left to 
right: cells were incubated without (Ctrl) or with ABP 2-prelabeled rIDUA (+rIDUA, with successive 
zoomed-in images from areas within the indicated white squares), or pre-treated with man-nose-6-
phosphate prior to rIDUA incubation (+M6P +rIDUA). Color legend: nuclei were stained with DAPI (blue), 
lysosomes with immunostaining of lysosomal-associated membrane protein 1 (LAMP1) (green), and 
rIDUA was labeled with ABP 2 (red). Scale bar =25 mm. B) Lysates of cells with identical treatment, 
detected for Cy5 fluorescence by fluorescent scanning on the wet slab gel, after samples were resolved 
by SDS-PAGE (left panel) The same gel was stained for Coomassie Brilliant Blue (CBB) for analysis of 
protein loading amount (right panel).
rIDUA containing the nucleophilic residue bound to ABP 3.  
 It was found that the α-L-iduronidase inhibitors and ABPs exhibited much lower inhibitory 
potency and slower binding kinetics compared to earlier generated cyclophellitol aziridines 
conformers, such as the β-gluco-aziridine ABP JJB367 for GBA20. This was explained by DFT 
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calculations, which showed that inhibitors 1–3 adopt mainly a half-chair conformation (4H3 and 
3H4) in solution, with the 2, 5B conformation also as relevant geometry at an extra cost of  8.0 
kcal mol-1. Furthermore, crystallographic studies showed that compounds 1–3 bind IDUA in a 
2, 5B boat conformation in the Michaelis complex. As a consequence, the half-chair 
conformations (4H3 and 3H4) of  inhibitors 1–3, as predicted by DFT calculations, differ from 
any of  the reaction itinerary conformations of  α-L-iduronidase depicted in Fig. 5.1A, and thus 
inhibitors 1–3 may need to overcome this 8.0 kcal mol-1 energetic barrier to adopt the Michaelis 
complex transition state (2, 5B) conformation. Therefore, it is likely that the lower potency and 
slower inhibition kinetics of  α-L-idoA-aziridine analogues on rIDUA is a manifestation of  this 
energetic barrier. 
Structural evidence for covalent addition of  the ABPs to the nucleophilic residue of  
raIDUA was also provided by crystallographic studies. In the process, the conformation of  the 
cyclophellitol aziridine at the transition state and in the covalent intermediate was defined, which 
supports earlier predictions concerning the conformational itinerary followed by α-L-
iduronidase.7 The insights gained through these studies should help in the design of  closer 
conformational 2, 5B analogues by the use of  different electrophilic traps or reactive species for 
the generation of  improved inhibitors or molecular chaperones, with the end goal being the 
future provision of  improved therapies for MPS I patients.  
IDUA labeling with ABP 2 in complex biological samples—such as cell lysates, was not 
successful due to lower potency and lack of  relative selectivity of  this analogue at the applied 
concentration (low μM) compared with previously reported glycosidase probes. Future 
optimization on ABP labeling conditions and IDUA purification procedures from the desired 
sample are warranted, in order to utilize the ABPs for studying endogenous IDUA from clinical 
or laboratory samples. On the other hand, it was demonstrated that ABP 2 can be used to study 
the localization and trafficking of  therapeutic rIDUA within cultured cells. It was shown that 
the rIDUA–ABP 2 complex is recognized by MPRs and internalized in lysosomes, and possibly 
processed differently between normal and patient fibroblasts. 




5.4 Experimental procedures 
5.4.1 Materials 
Recombinant human iduronidase (rIDUA) was obtained from Genzyme (Aldurazyme®). 
Normal human dermal fibroblasts (NHDF) were obtained from Lonza. Human patient 
fibroblasts (MPS-I and ML-II) were obtained with consent from donors from the Academic 
Medical Center in Amsterdam, the Netherlands. 4-methylumbelliferyl α-L-iduronide (4-MU-α-L-
IdoA) was purchased from Glycosynth. PierceTM Bicinchoninic acid (BCA) protein assay kit and 
Pierce™ Polyacrylamide Spin Desalting Columns 7K MWCO was acquired from Thermo Fisher 
Scientific. All other chemicals were obtained from commercial sources. 
5.4.2 Cell culture and lysate preparation 
Fibroblasts were cultured in Dulbecco’s modified Eagle’s medium: Nutrient Mixture F-12 
(DMEM/F-12, Invitrogen), containing 10 % (v/v) heat-inactivated fetal calf  serum, 200 µg/mL 
penicillin, 200 µg/mL streptomycin, at 37 °C and 5 % CO2. Confluent Fibroblasts were 
subcultured at a ratio of  1:4 each week. To prepare lysates, cells were washed three times with 
phosphate-buffered saline (PBS), detached by scraping in the presence of  ice-cold lysis buffer 
(25 mM K2HPO4/KH2PO4 pH 6.5, supplemented with 0.1 % (v/v) Triton X-100 and protease 
inhibitor cocktail tablet (Roche ,version 12)), and collected in Eppendorf  tubes. The collected 
suspension was vortexed vigorously, incubated on ice for 1 h, freeze-thawed once using liquid 
nitrogen, and stored at –80 °C. Concentration of  lysates was determined using BCA kit. 
5.4.3 Iduronidase activity assay using 4-MU-α-L-IdoA as substrate 
Samples containing enzyme were diluted in assay buffer (150 mM citrate/Na2HPO4, pH 4.5, 
supplemented with 0.1 % (v/v) Triton X-100, 0.15 M NaCl, 33 mM CaCl2, 33 mM MgCl2), and 
load onto a black flat-bottom 96-well plate (Greiner) in triplicates of  25 µL per well. Negative 
controls (blank) were prepared by substituting enzyme samples with buffer. For reaction, 
samples were added with 25 µL of  360 µM 4-MU-α-L-IdoA28 (prepared in assay buffer 





min to 4h. Reaction was stopped by adding 200 µL 1 M Glycine-NaOH (pH 10.3), and 
fluorescence was measured using a LS-55 fluorometer (PerkinElmer) at λex = 366 nm and λem = 
445 nm. 
5.4.4 Apparent IC50 values of  inhibitors and ABPs on recombinant human iduronidase and 
cell lysates 
Inhibitors and ABPs were diluted at various concentrations in 12.5 µL assay buffer and incubated 
with 12.5 µL rIDUA (5.8 ng, or 70 fmol) or fibroblast lysates (50 µg protein), both diluted in 
assay buffer, at 37°C for 1 h (rIDUA) or 4 h (fibroblasts lysates), at 1 % (v/v) DMSO 
concentration. This was followed by iduronidase activity assay (30 min incubation time) 
described in the previous section. The detected 4-MU fluorescence at each concentration for 
each compound were normalized to the fluorescence from the control sample without inhibitor, 
and data were fitted with [inhibitor] vs response – variable slope (four parameters) function in 
GraphPad Prism 7.0 software to obtain apparent IC50 values. 
5.4.5 Labeling and SDS-PAGE of  recombinant human iduronidase 
To prepare for labeling, rIDUA stock (0.58 µg/µL in PBS) was diluted with assay buffer to final 
concentration of  10 ng (120 fmol) in 14 µL assay buffer, if  not otherwise specified. ABP 2 stock 
(15 mM in DMSO) was diluted subsequently with DMSO and then assay buffer, to 8x of  
intended assay concentration obtaining 4 % (v/v) DMSO. For labeling, 2 µL of  ABP 2 dilution 
was incubated with 14 µL enzyme dilution at 37 °C for the intended time periods. Labeling was 
terminated by denaturing samples with 4 µL sample buffer (5x Laemmli buffer, containing 0.3 
M Tris-HCl pH 6.8, 50 % (v/v) 100 % glycerol, 8 % (w/v) dithiothreitol (DTT), 10 % (w/v) 
sodium dodecyl sulfate (SDS), 0.01 % (w/v) bromophenol blue) and heated at 98 °C for 5 
minutes. SDS-PAGE and fluorescence detection procedures followed the previously described 
methods.21 
5.4.6 Labeling of  recombinant human iduronidase at different pH 
Assay buffers with pH 2.5–8.0 were used to dilute rIDUA and ABP 2. The experiment was 




performed with 10 ng rIDUA at 10 µM ABP 2 (assay concentration) in 16 µL volume and 1 h 
incubation time, followed by denaturation, SDS-PAGE, and fluorescence scan. 
5.4.7 Reversibility of  labeling of  ABP 2 on recombinant human iduronidase 
5 µL rIDUA stock (0.58 µg/µL in PBS) was diluted with 20 µL assay buffer without Triton X-
100, and incubated with either 25 µL ABP 2 (150 µM and 1 % (v/v) DMSO) or 25 µL assay 
buffer containing 0.1 % (w/v) DMSO for 1 h at 37 °C. Thereafter, 45 µL of  sample was passed 
through a desalting column, and diluted with 216 µL assay buffer (with Triton X-100) to a final 
enzyme concentration of  1 ng/µL. For assessing the reversibility of  labeling/inactivation of  
ABP 2 on rIDUA, both samples were kept at 4 °C until subjecting to iduronidase activity assay 
using 4-MU-α-IdoA at the following time points after desalting: 0.5, 28, and 100 h. Iduronidase 
activity assay was performed with 1 µL sample in triplicates, and assay buffer was used as blank. 
5.4.8 Competitive ABPP experiments 
For the competitive ABPP (cABPP) experiment using 4-MU-α-IdoA as an active-site directed 
inhibitor, 10 ng rIDUA, or no-enzyme blank (PBS), was prepared in 7 µL assay buffer (pH 4.5). 
This was pre-incubated with 7 µL assay buffer containing 4-MU-α-IdoA (0.2 -20 mM) on ice for 
5 min, then incubated with 1 µL ABP 2 (750 µM, 8 % (v/v) in assay buffer) or DMSO control 
(8 % (v/v) in assay buffer) at 37 °C for 2 h. In the same experiment, 7 µL SDS (4 % (w/v)) was 
added to the 7 µL enzyme, pre-incubated at 98 °C for 2 min, and incubated with ABP 2 at 37 °C 
for 2 h. For the cABPP experiment with compound 1, 10 ng rIDUA was prepared in 12 µL assay 
buffer, pre-incubated with 2 µL compound 1 (2.8 mM – 70 µM, 18.6% DMSO in assay buffer) 
at 37 °C for 2 h, then incubated with 2 µL ABP 2 (100 µM, 4 % DMSO in assay buffer) at 37 °C 
for 2 h. Samples were then denatured, and subjected to SDS-PAGE and fluorescence scan. 
5.4.9 Kinetic parameters of  ABP 2 
The kinetic parameters of  ABP 2 for rIDUA was determined by an SDS-PAGE-based assay, in 
which the intensity of  fluorescent signal from ABP 2-labeled rIDUA on the wet slab gel is 





control group with saturate labeled rIDUA. rIDUA was labeled with ABP 2 for different time 
periods and at different ABP 2 concentrations (which were >> enzyme concentration), and the 
kinetic parameters kinact (pseudo first-order inactivation rate constant) and KI (inhibition constant) 
were obtained using non-linear curve fitting. To perform the experiment, three sets of  rIDUA 
were diluted in series of  1.5 mL Eppendorf  tubes to 10 ng (120 fmol) per 14 µL, and labeled 
with 2 µL ABP 2 (diluted in DMSO and assay buffer to various concentrations and [DMSO] 
fixed at 8 % (v/v)) for 30, 60, 90, 120, or 150 min. Concentrations in assay were 5 µM, 10 µM, 
20 µM, 30 µM, 40 µM, 50 µM, or 60 µM for ABP 2, 7.5 nM for rIDUA, and 1 % (v/v) for 
DMSO. Reaction was terminated by incubating samples with sample buffer at 98°C for 5 min. 
Samples were subjected to SDS-PAGE and fluorescence scan, and Cy5 fluorescence from the 
ABP 2-labeled rIDUA was quantified using ImageQuant software (GE Healthcare). The 
incubation condition for maximum labeling (complete inactivation) on rIDUA for ABP 2 was 
determined to be 60 µM and 150 min, and a control sample with this condition was loaded on 
every gel to allow normalization of  signals form samples in the same gel. After normalization, 
the value at each ABP 2 concentration were plotted in a time vs % labeling (inactivation) graph, 
and the plotted data were fitted with one-phase exponential association function to obtain the 
rate constant k at each ABP 2 concentration. Finally, in a second plot the obtained k values were 
plotted against ABP 2 concentrations, and the data were fitted with a Michaelis-Menten equation 
to obtain kinact and KI values for ABP 2 on rIDUA for each set (n = 3). All non-linear curve-
fitting was performed using GraphPad Prism 7.0 software. 
5.4.10 LC-MS/MS identification of  rIDUA active site peptide 
A total of  10 µg rIDUA was diluted in assay buffer and incubated with either 75 µM ABP 3 or 
DMSO (negative control) for 1 h at 37 °C in 100 µL volume ([DMSO] = 0.5 % (v/v)). The 
samples were then added with 100 µg BSA (100 µL), and followed by chloroform/methanol 
precipitation and reduction/alkylation procedures described previously.29 Consequently, the 
samples were dissolved in 2 % (w/v) SDS and diluted with 50 mM Tris-HCl (pH 7.8) to a final 
SDS concentration of  0.05 % (w/v). The samples were then concentrated with size exclusion 
columns (Amicon 10 k) to a volume of  74 µL, and digested O/N at 25 ºC with 1.1 µg 




Chymotrypsin (Promega) in the presence of  10 mM CaCl2. Digested peptides were pulled-down 
using 50 µL of  Streptavidin paramagnetic beads (MyOne T1, ThermoFisher) in 1 mL of  pull-
down buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5 % (w/v) SDS) for 1 h at RT under 
vigorous shaking. The beads were washed stringently following previously described 
procedures29 and eluted with 100 µL of  elution buffer (25 % (v/v) acetonitrile, 5 % (v/v) formic 
acid, 70 H2O, 10 µM biotin) for 30 min at 37°C. Afterwards, acetonitrile in the supernatant were 
evaporated using a Speedvac at 45°C, and this was followed by desalting using StageTips. The 
eluate was evaporated and reconstituted in 20 µL of  LC-MS sample solution (95: 3: 0.1, H2O: 
acetonitrile: formic acid) for LC-MS/MS analysis. Peptide samples were analyzed with a two-
hour gradient of  5 % to 25 % acetonitrile on nano-LC, hyphenated to an LTQ Orbitrap and 
identified by manual search for the theoretical m/z values of  the active site peptide and its 
MS/MS fragments labeled with ABP 3. 
5.4.11 Comparing specific activity and ABP labeling between GBA and IDUA 
For measurement of  GBA activity, 100 fmol of  rGBA (Cerezyme/Imiglucerase, Genzyme) or 
NHDF lysates (10 μg protein) were diluted in 25 μL of  GBA buffer (150 mM citric 
acid/Na2HPO4, 0.1 % (v/v) Triton X-100, 0.2 % (w/v) sodium taurocholate) and incubated with 
100 μL GBA substrate mixture (3.75 mM 4-MU-β-D-glucopyranoside (Glycosynth), in GBA 
buffer, 0.1 % (w/v) BSA) for 30 min at 37 °C. IDUA activity was measured following the 
methods described in previous section. For ABP labeling of  GBA, rGBA (100 – 0.1 fmol) or 
NHDF lysates (10 μg protein) were diluted in 14 μL GBA buffer, and incubated with 0.5 μM 
JJB36721 for 30 min at 37 °C ([DMSO] = 0.5 (v/v)). For ABP labeling of  IDUA, rIDUA (1–100 
fmol) or NHDF lysates (10 μg protein) were diluted in 14 μL assay buffer and incubated with 
either 50 μM or 25 μM ABP 2 for 4 h at 37 °C ([DMSO] = 0.5 % (v/v)). Samples were denatured, 
and proceeded to SDS-PAGE and fluorescent detection. 
5.4.12 Recombinant expression and purification of  IDUA in seeds of  Arabidopsis thaliana 
(University of  St Andrews) 





obtained from Genzyme) was produced in seeds of  Arabidopsis thaliana cgl (complex glycan 
deficient) line A4.730 in which the seeds (T3 generation) accumulated raIDUA to 7.2 ± 0.6 % 
total soluble protein (9.8 μg/mg dry seeds). raIDUA was purified to homogeneity from the T3 
seeds using concanavalin A-sepharose and anti-IDUA affinity chromatography as described 
previously31, 32. In human IDUA, there are six N-linked glycosylation sites. The oligosaccharide 
structures at each site of  rIDUA secreted from a Chinese hamster ovary (CHO) cell line have 
been determined by mass spectrometry33. The raIDUA expressed in the seeds of  the cgl mutant 
of  Arabidopsis has much reduced complexity in these N-linked glycans, the majority of  which are 
non-matured, high mannose N-glycans30, 34. 
5.4.13 Crystallization of  raIDUA (University of  St Andrews) 
raIDUA was further purified by size exclusion chromatography using an S200 10/300 column 
(GE Healthcare) equilibrated in 20 mM Tris, pH 7.0, 500 mM NaCl, and 0.02 % sodium azide. 
The fractions containing raIDUA were buffer exchanged using a PD10 desalt column (GE 
Healthcare) into 20 mM dimethylglutaric acid, pH 6.0, 0.2 M NaCl, 5 % (v/v) glycerol, and 5 % 
(v/v) ethanol and concentrated to 10 mg/ml for crystallization. Crystallization was performed 
in a 24 well plate using hanging-drop vapor diffusion. The rhomboid-plate shaped crystals grew 
at room temperature from 0.1 M HEPES, pH 7.5, 0.26 M sodium potassium tartrate, 20 % (w/v) 
polyethylene glycol 3350 (optimized from the crystallization condition reported by Bie et al.8). 
Crystals were soaked in mother liquor containing a minute amount of  solid 1 for 24 hours or 3 
for 45 minutes, before being harvested. Crystals were cryo-protected in a solution containing the 
mother liquor plus 30 % glycerol prior to vitrification in liquid nitrogen. 
5.4.14 Data collection and processing for raIDUA crystals (University of  St Andrews) 
X-ray diffraction data were collected at Diamond Light Source (DLS) on beamlines I03 and I04; 
the data processing and refinement statistics can be found in Table 4.S1. Diffraction data were 
processed either using the FastDP pipeline35 (which utilizes XDS36 with Aimless37) or Xia238 
(also with XDS36 with Aimless37). Molecular replacement was performed using Phaser39 with 
Protein Data Bank (PDB) entry 4JXO as the search model. Refinement was performed using 




REFMAC540 and manual model building was done using Coot41. Structures were validated using 
PDB_REDO42. Models for the fragments of  1 and 3 were built in JSME43 and the libraries 
generated with PRODRG44. 
5.4.15 Fibroblasts uptake of  ABP 2-labeled rIDUA 
rIDUA was diluted to 58 ng/µL and labeled with ABP 2 at 75 µM for 1 h at 37 °C in a volume 
of  40 μL. After incubation, unbound ABP 2 in solution was removed by passing through 
desalting columns (Pierce™ Polyacrylamide Spin Desalting Columns 7K MWCO), and the 
eluate were diluted in assay buffer without Triton X-100, to a final rIDUA concentration of  10 
ng/µL. For the uptake experiment, human normal and patient fibroblasts were sub-cultured 1 
day before treatment in 12-well plates (1 mL culture medium per well) with or without glass 
coverslips. Cells were then pre-treated with 4 mM mannose-6-phosphate (M6P, diluted in water) 
or same volume of  water for 1 h, followed by treating with ABP 2-labeled rIDUA (100 ng/mL 
culture medium) for 20 h, without removing M6P. A control group was included for each cell 
type, treated only with water and assay buffer. Confocal microscopy analysis was carried out 
following a previously described procedure45, where samples were fixed with 4 % formaldehyde, 
permeabilized with 0.1 % (w/v) saponin and 2 % (w/v) BSA, and immuno-stained for the 
lysosomal membrane protein LAMP1 using mouse anti human LAMP1 (Southern Biotech) as 
primary antibody, and donkey anti mouse Alexa488 (Molecular Probes) as secondary antibody. 
The coverslips were mounted to microscopy slides using ProLong™ Diamond Antifade 
Mountant with DAPI (Thermo Fisher), and scanned using a Leica SP8 confocal microscope for 
DAPI, Alexa488, and Cy5 fluorescence with a 40x oil-immersed objective. Pictures at each 
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2: BSA (0.1 %)
3: BSA (0.1 %) + TX-100 (0.1 %) + NaCl (0.15 M)
4: BSA (0.1 %) + TX-100 (0.1 %) + NaCl (0.15 M) + MgCl2 (33 mM)
5: BSA (0.1 %) + TX-100 (0.1 %) + NaCl (0.15 M) + CaCl2 (33 mM)
6: BSA (0.1 %) + TX-100 (0.1 %) + NaCl (0.15 M) + MgCl2 (33 mM) + CaCl2 (33 mM)
Experimental
Enzyme (E) = 0.1 U/L  (7 nM or 7 fmole/L or 0.58
ng/L )
-diluted from 100 U stock in McIlvaine buffer (150 mM,
pH 4.5) or with various additives (#2 - #6)
Substrate mixture (S) = 360 M 4MU--L-IdoA in
McIlvaine buffer (150 mM, pH 4.5, 0.1% (w/v) BSA) with
various additives (#2 - #6)
-diluted from 3.6 mM stock (made in McIlvaine buffer
with BSA)
E + S incubation (triplicates) = 25 L enzyme dilution
(175 fmole or 14.9 ng; #1 - #6) + 25 L substrate
mixture (#1 - #6), 37C for 1 h (end [E] = 3.5 nM; end
[S] = 180 M)









































































Lysate (E) = NHDF lysate (12.63 g/L)
-made in KPi buffer (25 mM K2HPO4 / KH2PO4, ,0.1 %
(w/v) TX-100, Protease Inhibitor cocktail (Roche version
12, no EDTA)), sonicated 3x 10 sec at 20% amplitute,
no pelleting
-diluted in McIlvaine buffer (150 mM, pH 4.5; ctrl) or in
optimized buffer (McIlvaine buffer (150 mM, pH 4.5) with
additives (0.15 M NaCl, 0.1% TX-100, 33 mM MgCl2, 33
mM CaCl2))
Substrate mixture (S) = 360 M 4MU--L-IdoA in
McIlvaine buffer (150 mM, pH 4.5, 0.1% (w/v) BSA) with
or without additives (0.15 M NaCl, 0.1% TX-100, 33 mM
MgCl2, 33 mM CaCl2)
-diluted from 3.6 mM stock (made in McIlvaine buffer with
BSA)
E + S incubation (triplicates) = 25 L lysate dilution + 25
L substrate mixture, 37C for 1 h (end [S] = 180 M)
-Blank = replace E with the corresponding buffer








Figure 5.S2. SDS-PAGE gels used for labeling kinetic studies of ABP 2 with rIDUA. rIDUA was 
labeled at different incubation time periods (30–150 min) and at different ABP 2 concentrations (5–60 µM), 
before SDS-PAGE and fluorescent detection and quantification. The labeling experiment was performed 
in triplicate sets. 
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20 µM (set #1) 30 µM (set #1)
40 µM (set #1) 50 µM (set #1)
60 µM (set #1) 60 µM (set #2)
Incubation 
time (min)
20 µM (set #2) 30 µM (set #2)
40 µM (set #2) 50 µM (set #2)
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Figure 5.S3. Chromatogram of sample containing rIDUA active site peptide labeled without (Ctrl) 







Figure 5.S4. LC-MS/MS identification of IDUA peptides labeled with ABP 3. A) Mass spectrum of 
sample containing rIDUA active site peptide labeled with ABP 3. B) Theoretical and experimental m/z 
values for rIDUA active site peptide labeled with ABP 3. 














































































































































































































z Theoretical Experimental Delta ppm
1 1509.725 1510.729 1509.723 1510.740 0.9999 1.52 7.28
2 755.3663 755.868 755.3578 755.8612 0.0534 11.25 9.00
























































5.S2 Synthesis of α-L-iduronic-configured inhibitors and ABPs (Department of Bio-organic 
Synthesis, Leiden University) 
5.S2.1 General experimental details 
All reagents were of  a commercial grade and were used as received unless stated otherwise. 
Dichloromethane (DCM), tetrahydrofuran (THF) and N,N-dimethylformamide (DMF) were 
stored over 4 Å molecular sieves, which were dried in vacuo before use. Triethylamine was dried 
Table 4.S1




over KOH and distilled before using. All reactions were performed under an argon atmosphere 
unless stated otherwise. Solvents used for flash column chromatography were of  pro analysis 
quality. Reactions were monitored by analytical thin-layer chromatography (TLC) using Merck 
aluminum sheets pre-coated with silica gel 60 with detection by UV absorption (254 nm) and by 
spraying with a solution of  (NH4)6Mo7O24·H2O (25 g/L) and (NH4)4Ce(SO4)4·H2O (10 g/L) in 
10 % sulfuric acid followed by charring at ~150 ˚C or by spraying with an aqueous solution of  
KMnO4 (7 %) and K2CO3 (2 %) followed by charring at ~150 °C. Column chromatography was 
performed manually using either Baker or Screening Device silica gel 60 (0.04 - 0.063 mm) or a 
Biotage Isolera™ flash purification system using silica gel cartridges (Screening devices SiliaSep 
HP, particle size 15-40 µm, 60A) in the indicated solvents. 1H NMR and 13C NMR spectra were 
recorded on Bruker DMX-600 (600/150 MHz) and Bruker AV-400 (400/100 MHz) 
spectrometer in the given solvent. Chemical shifts are given in ppm relative to the chloroform 
residual solvent peak or tetramethylsilane (TMS) as internal standard. Coupling constants are 
given in Hz. All given 13C spectra are proton decoupled. The following abbreviations are used 
to describe peak patterns when appropriate: s (singlet), d (doublet), t (triplet), qt (quintet), m 
(multiplet), br (broad), ar (aromatic), app (apparent). 2D NMR experiments (HSQC, COSY and 
NOESY) were carried out to assign protons and carbons of  the new structures and assignation 
follows the general numbering shown in cyclohexene 9. High-resolution mass spectra (HRMS) 
of  intermediates were recorded with a LTQ Orbitrap (Thermo Finnigan) and final compounds 
were recorded with an apex-QE instrument (Bruker). Optical rotations were measured on a 
Anton Paar MCP automatic polarimeter (Sodium D-line, λ = 589 nm). LC/MS analysis was 
performed on an LCQ Advantage Max (Thermo Finnigan) ion-trap spectrometer (ESI+) 
coupled to a Surveyor HPLC system (Thermo Finnigan) equipped with a C18 column (Gemini, 
4.6 mm x 50 mm, 3 μm particle size, Phenomenex) equipped with buffers A: H2O, B: acetonitrile 
(MeCN) and C: 1% aqueous TFA, or an Agilent Technologies 1260 Infinity LCMS with a 6120 
Quadrupole MS system equipped with buffers A: H2O, B: acetonitrile (MeCN) and C: 100 mM 
NH4OAc. For reversed-phase HPLC-MS purifications an Agilent Technologies 1200 series prep 
LCMS with a 6130 Quadrupole MS system was used equipped with buffers A: 50 mM 





5.S2.2 Synthetic strategies 
Synthetic strategies to assemble cyclophellitol derivatives often involve different configurations 
of functionalized cyclohexenes as starting materials. Based on the synthesis of D-galacto- and L-
fuco-configured cyclohexenes described by Llebaria and coworkers1 and the Overkleeft group,2 
it was reasoned that reaction of debenzylated aldehyde 53 with chiral Evans’ oxazolidinone 4 
should provide the L-ido-configured cyclohexene by syn-aldol addition (Scheme 4.S1). Indeed, 
asymmetric aldol condensation catalyzed by dibutylboryl triflate at low temperatures (–78 °C to 
–20 °C) proceeded stereo-selectively to provide the desired aldol product 6 in 60 % yield. During 
the reaction, the non-reactive terminal alkene derived from isomerization of acrylamide 4 was 
observed as a major side product. Reduction of oxazolidinone 6 with LiBH4 followed by Grubbs 
II-catalyzed metathesis afforded the desired L-ido-configured cyclohexene 8 in excellent yield.
 
  
Scheme 5.S1. Synthesis of α-L-iduronic-configured inhibitors and ABPs 1–3. Reagents and 
conditions: a) DBBT, Et3N, CH2Cl2, –78 °C to –20 °C, 5 h, 60 %; b) LiBH4, THF, RT, 2 h, 99 %; c) Grubbs 
II catalyst, CH2Cl2, 40 °C, 18 h, 98 %; d) BnBr, TBAI, NaH, DMF, RT, 18 h, 79 %; e) PhI(OAc)2, CH2Cl2, 
RT 48 h, 43 %; f) Li, NH3, THF, –60 °C, 1 h, 93 %; g) 8-azido-1-iodooctane, K2CO3, DMF, 55 °C, 24 h, 12: 
22 %; h) TEMPO, NaBr, NaOCl, H2O, 0 °C, 3 h, 14 %; i) CuSO4, NaAsc, RT, 18–48 h, 2: 22 %, 3: 34 %.
 
Thereafter, olefin aziridination of L-ido-configured cyclohexene 8 was attempted, with the 
specific aim of obtaining the α-stereoisomer. Llebaria and co-workers have recently reported the 
first N-aminoaziridine covalent glycosidase inhibitors, which were prepared by stereoselective 
hydrogen-bonding-guided aziridination using 3-amino-2-ethylquinazolin-4(3H)-one (Et-Q-
NH2).2 Because such hydrogen-bond-mediated aziridination of cyclohexene 8 would generate 
4 5 6 7 8: R = H
9: R = Bn
9
10 11 12 1 2: R = Cy5
3: R = biotin
a b c
d








the undesired β-diastereoisomer, the free alcohol groups in 8 were benzylated with benzyl 
bromide and sodium hydride to generate cyclohexene 9. When the direct azidirination of 9 was 
performed with in situ generated CF3-Q-NHOAc complex, the desired a-aziridine 10 was 
obtained in 43% yield together with 32% recovered starting material (Scheme 4.S1). This result 
implied that hydrogen bonding is not required for a productive aziridination, provided that the 
double bond is freely accessible. Removal of the CF3-Q and benzyl groups was achieved in one 
step by Birch reduction using lithium and liquid ammonia at –78 °C. After quenching the 
reaction with H2O, CF3-Q-derived impurities precipitated and were filtered off. Aziridine 11 was 
purged of lithium hydroxide by cation-exchange chromatography with Amberlite H+ resin, and 
the fully deprotected cyclitol aziridine was obtained in 93 % yield (Scheme 4.S1). The α-L-
configuration of aziridine 11 was established by 1H NMR analysis (Section 4.S2), and the 
experimental coupling constants were compared with the corresponding calculated values 
obtained from DFT calculations (Section 4.S3). Aziridine 11 was then alkylated with 8-azido-1-
iodooctane and K2CO3 or acylated with 8-azidooctanoic acid and EEDQ to afford intermediates 
12 or 13, respectively, which were purified by reversed-phase column chromatography. 
Oxidation of C-6 proved to be challenging due to instability of the aziridine under acidic or basic 
conditions. Aziridine 1 was obtained in 14 % yield by oxoammonium-catalyzed oxidation, 
maintaining the reaction and HPLC-MS purification at basic pH. Final click reaction with Cy5- 
and biotin-substituted alkynes afforded the desired ABPs 2 and 3. 
5.S2.3 Synthesis and characterization data of compounds 1–3 










5.S3. DFT Calculations (Department of Bio-organic Synthesis, Leiden University) 
5.S3.1 Geometry optimization 
By using the conformer distribution search option included in the Spartan 14 program5, 
exclusively the 4H3 conformation of  the structure was found. Only notable variations of  the 
geometry were found at the C5-C7 bond, including multiple rotamers which were significant 
higher in terms of  energy. For α-L-idoA aziridine the 4H3 conformation was also found as lowest 
energy conformer, but in this case the 3H4 was only 1.4 kcal/mol higher in terms of  energy. 
All calculations were performed with DFT as level of  theory in combination with the 
B3LYP hybrid functional. A conformer distribution search option included in the Spartan 14 
program5, in gas-phase with the use of  6-31G(d) as basis set, was used as starting point for the 
geometry optimization. All generated structures were further optimized with Gaussian 096 at 6-
311G(d, p). Optimization was done in gas-phase and subsequently corrections for solvent effects 
were done by the use of  a polarizable continuum model using water as solvent parameter. The 
free Gibbs energy of  the computed conformations was calculated using Equation (1) in which 
∆𝐸𝑔𝑎𝑠 is the gas-phase energy (electronic energy), ∆𝐺𝑅𝑅𝐻𝑂 
𝑇  (T= 298.15 K and pressure= 1 
atm.) is the sum of  corrections from the electronic energy to free Gibbs energy in the rigid-
rotor-harmonic-oscillator approximation (RRHO) also including zero-point-vibrational energy, 
and ∆𝐺𝑠𝑜𝑙𝑣
𝑇  is their corresponding free solvation Gibbs energy. 
∆𝐺𝑎𝑞
𝑇 =  ∆𝐸𝑔𝑎𝑠 +  ∆𝐺𝑔𝑎𝑠,𝑅𝑅𝐻𝑂
𝑇 +  ∆𝐺𝑠𝑜𝑙𝑣             (1) 
=  ∆𝐺𝑔𝑎𝑠
𝑇 +  ∆𝐺𝑠𝑜𝑙𝑣 
The used free energies include unscaled zero-point vibrational energies. Visualization of  the 









Table 5.S2. Geometry optimization of compound 11 and the N-methylated α-L-iduronic configured 
cyclophellitol aziridine performed by of DFT calculation. 
 
 
5.S3.2 NMR calculations  
Based on the optimized lowest energy structure the spin-spin coupling constants were calculated 
according to the work of  Rablen and Bally8 with the use of  6-311g(d, p) u+1s as basis set and 
PCM(H2O) as solvent model and a scaling factor of  0.92. The calculated total nuclear spin-spin 








Table 5.S3. Experimental coupling constants of α-idose configured cyclophellitol aziridine 12 
compared to DFT calculated coupling constants. 
 
Coupling constants were determined by 1H NMR experiments (exp.). n.d.: values not determine due to very small 

















Table 5.S4. Experimental coupling constants of 1 compared to DFT calculated coupling constants 
of the methylated α-iduronic configured cyclophellitol aziridine. 
 


















5.S4 Supplementary References 
 
1 Hansen FG, Bundgaard E & Madsen R (2005) A short synthesis of  (+)-cyclophellitol. J Org Chem 70, 10139–10142. 
2 Harrak Y, Barra CM, Delgado A, Castaño AR & Llebaria A (2011) Galacto-configured aminocyclitol 
 phytoceramides are potent in vivo invariant natural killer T cell stimulators. J Am Chem Soc 133, 12079–12084. 
3 Jiang J, Kallemeijn WW, Wright DW, van den Nieuwendijk AMCH, Rohde VC, Folch EC, van den Elst  H, Florea 
BI, Scheij S, Donker-Koopman WE, Verhoek M, Li N, Schürmann M, Mink D, Boot RG, Codée JDC, van der Marel 
GA, Davies GJ, Aerts JMFG & Overkleeft HS (2015) In vitro and in vivo comparative and competitive activity-
based protein profiling of  GH29 α-l-fucosidases. Chem Sci 6, 2782–2789. 
4 Artola M, Kuo CL, McMahon SA, Oehler V, Hansen T, van der Lienden M, He X, van den Elst H, Florea BI, 
Kermode AR, van der Marel GA, Gloster TM, Codée JDC, Overkleeft HS & Aerts JMFG (2018) New Irreversible 
α-l-Iduronidase Inhibitors and Activity-Based Probes. Chemistry 24, 19081–19088. 
5 Spartan ’10 [Computer software]. (2010) Irvine, CA: Wavefunction Inc. 
6 Gaussian 03 [Computer software]. (2004) Gaussian, Inc., Wallingford CT. 
7 Legault CY (2009) CYLview 1.0b [Computer software]. Québec, Montreal, Canada: Univ Sherbrooke.  Retrieved 
from http//www.cylview.org). 
8 Bally T & Rablen PR (2011) Quantum-chemical simulation of  1H NMR spectra. 2. Comparison of  DFT-based 
procedures for computing proton-proton coupling constants in organic molecules. Org. Chem 76, 4818–4830.  
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Mannosidases are key enzymes in eukaryotic N-linked glycan synthesis and degradation. Among 
these hydrolases, retaining exo-α-mannosidases (Glycoside Hydrolase (GH) family 38) and exo-
β-mannosidase (GH family 2) are implicated in pathologies such as cancer and lysosomal storage 
diseases. To generate tools to profile these enzymes, mechanism-based suicide inhibitors and 
activity-based probes (ABPs) were synthesized and characterized. These compounds, based on 
α-mannose or β-mannose configured cyclophellitol scaffolds, are micromolar inactivators of  
their expected target enzymes. The ABPs label the target mannosidases in mechanism-based 
manner, as confirmed by SDS-PAGE-based fluorescent detection, kinetic studies, and protein 
crystallography. Proteomics revealed that the α-mannose configured ABP equipped with biotin 
labels all five GH38 retaining exo-α-mannosidases in mouse tissue extracts. Similarly, the α-
mannose configured Cy5 ABP labels all five human GH38 α-mannosidases cloned and 
individually expressed in human cell lines. The unique molecular weight and pH optimum of  
each α-mannosidase allows their simultaneous activity-based profiling in complex biological 
samples such as cell lysates and tissue extracts. β-Mannose configured ABP labels the GH2 β-
mannosidase (MANBA) in mouse kidney extracts. It additional labels retaining β-glucosidases, 
but specific visualization of  MANBA is still feasible by pre-incubating the samples with β-
glucosidase inhibitors. In conclusion, the novel ABPs described here enable the simultaneous 
visualization of  all retaining exo-mannosidases in complex biological samples. They should assist 
future screening for small molecule inhibitors/activators of  these highly relevant enzymes.  





rotein N-linked glycosylation takes place in all domains of life. In the ER of 
eukaryotes, it plays essential roles in folding ,quality control and subsequent 
transport of newly formed N-linked glycoproteins to the Golgi apparatus.1, 2 This 
finely orchestrated process is carried out by lectins recognizing specific glycan 
structures, and by glycosidases residing at various subcellular locations that modify the glycans. 
A key component of the N-linked glycan is mannose. This sugar is abundant in the 
Glc3Man9GlcNAc2 glycan that is transferred from the dolichol donor to nascent polypeptide in 
the ER (Fig. 6.1, step 1−2). Maturation of N-linked glycoprotein is accompanied by removal of 
specific mannose residues from their N-linked glycans. Several mannosidases are involved in this 
process. These enzymes differ in subcellular location and substrate specificity, and are classified 
into Glycoside Hydrolase (GH) family 2, 38, 47, and 99 (Fig. 6.1, bottom right) based on the 
Carbohydrate active enzyme (CAZy) database3. 
In man, the GH47 family comprises four inverting exo-α-1,2-mannosidases located in the 
ER and Golgi complex, and three additional ER-dependent α-mannosidase-like proteins 
(EDEMs) that have putative α-mannosidase activity. The ER-α-mannosidase I (MAN1B1) trims 
one mannose from the protein N-linked glycan, which signals the protein to either pass the ER 
quality control checkpoint (Fig. 6.1, step 3−4)4, 5 or enter the ER-associated degradation 
pathway in a process facilitated by the EDEMs (Fig. 6.1, step 5−6).6, 7 The three Golgi GH47 
mannosidases, Ia (MAN1A1)8, Ib (MAN1A2)9, and Ic (MAN1C1)10 further trim the α-1,2-linked 
mannoses from glycans of glycoproteins arriving at the cis-Golgi (Fig. 6.1, step 7−8), enabling 
downstream processes such as protein N-linked hybrid- or complex-type glycan synthesis (Fig. 
6.1, step 11−12 and below) or the mannose-6-phosphate mediated endosomal/lysosomal 
targeting (Fig. 6.1, step 13 and below)11. The GH99 endo-α-1,2-mannosidase (MANEA) is also 
residing at the cis-Golgi. It recognizes glycoproteins that still contain terminal glucose residues 
and catalyzes the one-step endo-glycosidic hydrolysis of these glucoses together with the 
adjacent mannose. This provides an additional pathway for glycoprotein maturation (Fig. 6.1, 
step 9−10).12, 13  
 The other two mannosidase families are GH38 α-mannosidase (MAN2A1, MAN2A2, 
MAN2B1, MAN2B2, MAN2C1) and GH2 β-mannosidase (MANBA), both composed of  
P 




Figure 6.1. Human mannosidases in N-linked glycoprotein synthetic and degradation pathways. 
1−4, trimming of glucoses and one mannose on correctly folded proteins in the ER. 5−6, mannosidases 
responsible for initiating the ER-associated degradation (ERAD) pathway. 7−8, mannose trimming in the 
cis-Golgi. 9−10, action of the endo-mannosidase on glycoproteins arriving at the Golgi with terminal 
glucoses. 11−12, mannose trimming by Golgi mannosidase II and IIx (MAN2A1, A2) for complex-type 
glycan formation. 13, glycan processing for the mannose-6-phophate (M6P)-dependent protein targeting 
pathways. 14−15, glycan degradation by cytosolic mannosidase (MAN2C1). 16−19, actions of lysosomal 
retaining exo-mannosidases (MAN2B1, B2, and MANBA) on glycans from the cytosol or endosomal 
compartments. UPS, ubiquitin-proteasome system; MOGS, ER α-glucosidase I; GANAB, ER α-
glucosidase II; UGGT, UDP-glucose:glycoprotein glucosyltransferase; GNPTAB/GNPTG, GlcNAc-
phosphotransferase α, β/γ subunits; NAGPA, GlcNAc1-1-phosphodiesterase; MGAT1, α-1,3-mannosyl-
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retaining glycosidases. The human GH38 α-mannosidase family consists of five members, all of 
which require metal ions (zinc or cobalt) for catalysis but differ in subcellular location and 
substrate specificity. Two of these, Golgi mannosidase II14 and IIx15 (MAN2A1 and MAN2A2, 
E.C. 3.2.1.114), remove the two outer α-1,3- and α-1,6-linked mannoses on the protein 
GlcNAcMan4GlcNAc2 glycans, thus allowing further synthesis of complex-type glycans (Fig. 
6.1, step 11−12).16 These two enzymes arose from a recent mammalian gene duplication event, 
exhibiting overlapping substrate specificity17 but differ in expression levels depending on tissue 
type.18, 19 The neutral α-mannosidase (MAN2C1) is a cytosolic enzyme degrading soluble N-
linked glycans released from glycoprotein or glycolipids into Man5GlcNac, thus allows the 
trimmed glycan to be further degraded in the lysosome (Fig. 6.1, step 14−15).20, 21 It depends 
on Co2+ for catalysis, but is also activated by Fe2+ and Mn2+.22 The lysosomal GH38 α-
mannosidase MAN2B1 acts on α-1,2- and α-1,3-linked mannoses on glycans derived from 
protein N-linked glycans or glycolipids (E.C.3.2.1.24),23 as well as on glycans attached to 
glycoproteins (Fig. 6.1, step 16 and 19).24 It does not cleave the core α-1,6-linked mannose,24 
which is specifically hydrolyzed by the lysosomal GH38 core-specific α-mannosidase (MAN2B2, 
E.C. 3.2.1.114) (Fig. 6.1, step 17 and 19),25, 26 also known as the epididymis α-mannosidase.27 
Finally, the lysosomal GH2 β-mannosidase (MANBA) releases the last mannose residue from 
GlcNAc (E.C. 3.2.1.25) and completes the mannose catabolism (Fig. 6.1, step 18 and 19).28, 29 
 Both the GH38 and GH2 mannosidases receive continuous interest as therapeutic 
targets for human diseases. The Golgi α-mannosidase MAN2A1 has been linked to the 
progression of several cancers.30 Clinical trials had been conducted using the inhibitor 
swainsonine, albeit unsuccessful due to adverse side effects attributed to its concomitant 
inhibition of other mannosidases 31, 32 Inherited deficiency of the lysosomal α-mannosidase 
MAN2B1 deficiency underlies the lysosomal storage disorder α-mannosidosis (OMIM: 248500) 
in man.33 Affected individuals accumulate in lysosomes undegraded mannose-containing 
oligosaccharides, causing variable degree and progression of mental and respirational impairment, 
hearing loss, Hurler-like facial distortion, and reoccurring infections among paitents.33 A 
recombinant α-mannosidase-based enzyme replacement therapy has been recently approved in 
the EU.34, 35 Deficiency in the lysosomal β-mannosidase MANBA also causes a lysosomal storage 
disorder, β-mannosidosis (OMIM: 248510). This disease is firstly described in goat36 and is rare 
in human. Human patients generally have milder symptoms (e.g. mental retardation) compared 
to the affected lifestock.37 Last but not least, the cytosolic neutral α-mannosidase MAN2C1 is 




involved in tumorigenesis.38, 39 The cause for this process is believed to be independent of 
MAN2C1’s catalytic activity, but rather through its direct association with tumor suppressive 
proteins and thereby causes their inactivation during tumorigenesis.40, 41  
 In the past, GH38 α-mannosidase activities are distinguished from those of GH47 α-
mannosidases based on their different cation preference (Zn2+ or Co2+ for GH38 vs Ca2+ for 
GH47) and inhibitor sensitivity (furanose-based inhibitors such as swainsonine and mannostatin 
A for GH38; pyranose-based inhibitors such as 1-deoxymannojirimycin for GH47).42 Because 
GH38 and GH2 mannosidases are retaining glycosidases employing the Koshland double 
displacement catalytic mechanism (Fig. 6.2A, B),43−45 it is envisioned that their activity can be 
selectively measured over the GH47 enzymes (which are inverting glycosidases) by activity-based 
protein profiling with compounds harboring a mannose-configured scaffold that covalently 
becomes trapped at the catalytic nucleophile of the enzyme upon the initial nucleophilic attack 
(Fig. 6.2C, D). Similar approaches using configurational isomers of cyclophellitols and 
cyclophellitol aziridines have been recently demonstrated to be useful tools in labeling their 
targeted glycosidases (General Introduction and Chapter 6, this thesis). This chapter presents 
the characterization of the α- or β-mannose configured cyclophellitol aziridines inhibitors and 
ABPs in their inhibitory potency and labeling towards GH38 and GH2 mannosidases, and 
discusses the potential application of the ABPs in the study of mannosidase biology and 
associated diseases. 
6.2 Results 
6.2.1 Synthesis of  compounds used in this chapter 
The synthesis of  compounds 1−7 and 8−13 was performed at the Department of  Bio-
organic Synthesis at Leiden University and followed the strategies reported for the α- and β-
mannose configured cyclophellitols 1 and 8,46 the β-mannose configured cyclophellitol aziridine 
9,46 and the α-mannose configured cyclophellitol aziridine 247 (Fig. 6.3 and Scheme 6.S1−2). 
N-alkylation of 2 or 9 with 1-azido-8-iodooctane yielded compound 3 and 10, which were 
subsequently appended with either a BODIPY, Cy5, or a biotin tag (compounds 4−6 and 11−13) 
using the Cu(I)-catalyzed azide-alkyne Huisgen [2 + 3]-cycloaddition (“click” reaction).48, 49 N-
acylation of 3 was also attempted,48 with which successfully yielded the Cy5 compound 7. 





Figure 6.2. Reaction mechanisms of retaining exo-mannosidases. A) Reaction itinerary by GH38 α-
mannosidases. B) Reaction itinerary by GH382 β-mannosidase. C) Proposed reaction mechanism for α-
mannose configured cyclophellitol aziridine. D) Proposed reaction mechanism for β-mannose configured 
cyclophellitol aziridine. Numbers shown correspond to pyranose numbering of the carbons. 
6.2.2 In vitro activity of  compound 1−7 on GH38 α-mannosidases 
 The α-mannose configured compounds 1−7 were tested for in vitro inhibitory potency 
by enzymatic assay of  commercially available Jack bean (Canavalia ensiformis) GH38 α-
mannosidase (E.C. 3.2.1.24). This enzyme exhibits a similar catalytic profile and zinc ion 
dependency to the human lysosomal broad-specificity α-mannosidase (MAN2B1).50 The assay 
was performed at an acidic pH of  4.5 and at 37 °C, by means of  a 30 min incubation of  enzyme 

















It turned out that all the tested compounds were α-mannosidase inhibitors, exhibiting low- to 
mid-micromolar apparent IC50 values (Table 6.1, Fig. 6.S1A). The most potent of  the series 
were the biotin 6, Cy5 5, and N-alkyl azide compound 3 (apparent IC50 = 2−4 μM); they were 
followed by the unsubstituted α-mannose configured cyclophellitol aziridine 2, and the epoxide 
1, with the later having similar value to the one reported by Tatsuta et al.51 BODIPY ABP 4 was 
the least potent of  the series, having apparent IC50 value over 50 μM. The N-acylated Cy5 ABP 
7 required more steps to synthesize but was equally potent as the N-alkylated Cy5 ABP 5, similar 
 
Figure 6.3. Structures of compounds used in this study. 
Figure 8.3
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Table 6.1 Apparent IC50 values of α-mannose configured cyclophellitol and aziridines towards Jack 
bean GH38 α-mannosidase. A) Apparent IC50 values at 30 min compound incubation time. B) Apparent 
IC50 values of 5 at different incubation time. 
to the general trend observed on earlier reported ABPs towards other glycosidases.52 Next, time 
dependency of  inhibition by ABP 5 was examined. The apparent IC50 values for the N-alkyl 
ABP 5 gradually were found to decrease from 4.94 μM to 1.13 μM with incubation times 
increasing from 10 min to 120 min (Table 6.1B, Fig. 6.S1B), hinting to irreversible inhibition. 
 Next, SDS-PAGE-based fluorescent readout was used to directly visualize the covalent 
ABP labeling of  Jack bean α-mannosidase. In the first experiment, 3 μM ABP 5 was incubated 
with the enzyme for 30 min at 37 °C at various pHs. The results showed that the ABP covalently 
labeled the enzyme in a pH-dependent manner: one band between 60 and 70 kDa was found to 
be most prominently labeled at acidic pHs (Fig. 6.4A, left), corresponding to the known size of  
the large subunit (66 kDa) of  Jack bean α-mannosidase bearing the active site.51 Removing zinc 
ion from the reaction mixture did not affect the ABP labeling during the 30 min incubation time 
(Fig. 6.4A, left). Compared to enzymatic activity, the ABP labeling had a slight shift in pH 
optimum (0.5−1 unit)—with maximal enzymatic activity occurring at pH 4.5−5.0 and maximal 
ABP labeling at pH 5.0−6.0 (Fig. 6.4A, right). The labeling potency of  ABP 5 was next 
compared to that of  ABP 7 (N-acyl Cy5) at pH 5.5: both labeled the enzyme and were equally 
potent (Fig. 6.4B). Saturation of  labeling occurred at around 3 μM for both ABPs, with the 
calculated concentration for 50 % labeling being 0.3 μM (Fig. 6.4B, right). This value was ten-
fold lower than the apparent IC50 values (around 3 μM), which might be resulted from different 
assay pHs (5.5 during ABP labeling vs 4.5 during inhibitory IC50 determination). Time-
dependency of  labeling by ABP 5 was next examined, at 3 μM ABP 5 and pH 5.5. It was found   
Compounds IC50 ( M)
1 (TB440) 35.4 ± 6.70
2 (TB450) 7.19 ± 0.12
3 (TB481) 3.54 ± 0.48
4 (TB521) > 50
5 (TB482) 3.43 ± 0.68
6 (TB484) 2.22 ± 0.24





10 4.94 ± 0.13
30 2.84 ± 0.17
120 1.13 ± 0.06
A B




Figure 6.4. In vitro labeling of compounds towards Jack bean (Canavalia ensiformis) GH38 α-
mannosidase. A) pH-dependent labeling of 5 (left) and comparison of quantified ABP labeling with 
measured 4-MU activity across different pHs. Error ranges = ± SD from technical triplicates. B) Labeling 
of 5 and 7 at different ABP concentrations (left) and band quantification (right). C) Time-dependent 
labeling of 5 at two different temperatures (left) and band quantification (right). D) Competitive ABP 
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that labeling increased with incubation time, and reached saturation within 10 min at 37 °C (60 
min for labeling at 4 °C) (Fig. 6.4C). Finally, to determine if  the labeling occurred at the enzymes’ 
active site pocket, the enzyme was pre-incubated with two known GH38 α-mannosidase 
inhibitors, swainsonine and mannostatin A, followed by a short ABP labeling period of  10 min. 
As expected, labeling of  ABP 5 towards the enzyme was abolished by both inhibitors, suggesting 
active-site pocket occupancy of  the ABPs in the enzyme (Fig. 6.4D). 
 The active site occupancy and labeling of  the compound towards GH38 α-mannosidase 
was further examined in detail by structural analysis perform at the University of  York. For this 
experiment, protein crystals of  the Drosophila melanogaster GH38 MAN2A1 (Golgi α-
mannosidaseII) homologue (dGMII)30 were incubated with the bare aziridine compound 2, and 
solved for structure by protein X-ray crystallography. In the resolved structure, a covalent 
glycosidic bond was clearly visible between the C1 of  compound 2 and the catalytic nucleophile 
Asp204 (Fig. 6.5) of  dGMII. Compound 2 adopted an 1S5, conformation (Fig. 6.5, right), 
matching the known substrate conformation at the covalent enzyme-substrate intermediate (Fig. 
6.2A, middle).45 
 
Figure 6.5. Structure of Drosophila melanogaster GH38 α-mannosidase (dGMII) in complex with 
compound 2. Right, skeletal structure of compound 2 bound to the nucleophile, showing the conformation 
observed from the crystal structure (left). 
6.2.3 Target detection and identification of  the α-mannose configured ABPs in complex 
biological samples 
 Activity-based protein profiling (ABPP) was performed with ABP 5 in mouse tissue 
















spleen, kidney, and testis enabled the detection of  distinct bands in these samples. At 1−3 μM 
ABP 5, a sharp band around 140 kDa was detected in liver and testis extracts, whilst two bands 
around 50 kDa and 45 kDa were clearly visible in spleen, kidney, and testis extracts (Fig. 6.6A). 
As testis extracts contain multiple bands, a pH titration was performed herewith from pH 3.0 to 
8.0. The experiment revealed that the labeling of  the different bands had a distinct pH optimum; 
the 140 kDa band was optimally labeled at pH 6.0, while the 50 and 45 kDa bands were optimally 
labeled at pH 4.5 (Fig. 6.6B). Several other minor bands were also detected, most of  which also 
showed a pH optimum of  4.5. To determine whether these bands were GH38 α-mannosidases, 
a competitive ABPP (cABPP) experiment was employed. Mouse testis extracts were pre- 
incubated with swainsonine or mannostatin A for 30 min at pH 4.5, and then incubated with 3 
μM ABP 5 for 10 min. The 140 kDa, 50 kDa, 45 kDa, and an additional 76 kDa bands were 
abolished by swainsonine pre-incubation, and the 45 kDa band was additionally competed away 
Figure 6.6. ABPP in mouse tissue extracts with ABP 5. A) Concentration titration of ABP 5 in 
homogenates of liver, spleen, kidney, and testis. B) Titration of labeling pH with ABP 5 in mouse testis 
homogenates. C) cABPP of swainsonine or mannostatin A with ABP 5 in mouse testis homogenates. 
Arrows, bands that were abolished by swainsonine pre-incubation. 
with 1 mM mannostatin A (Fig. 6.6C). The other minor bands were not abolished by inhibitor 
Figure 8.8
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pre-incubation, pointing to non-specific labeling (Fig. 6.6C). MANB1 is cleaved in the lysosome 
into five fragments that contain the 42 kDa peptide A (with catalytic active site), the 10 kDa 
peptide B, the 24 kDa peptide C, and peptide D and E; the latter two do not form disulfide 
bridges to the other three fragments. 23, 32 Thus, the 76, 50, and 45 kDa bands, all showing a 
labeling pH optimum of  4.5, could correspond to MAN2B1’s peptide ABC, AB, and A, 
respectively. The 140 kDa with a labeling pH optimum of  6.0 and being abolished by 
swainsonine pre-incubation is likely MAN2A1 and/or A2. 
A parallel experiment using the biotin ABP 6 was performed in mouse testis extracts to 
verify the labeling of  GH38 enzymes. Samples incubated with ABP 6 at either pH 4.5 or 6.0 
were subjected to biotin affinity enrichment and tryptic digestion (both on-bead digestion and 
in-gel digestion), and finally LC-MS-based protein identification. While silver stain of  the gel 
containing the affinity-enriched samples yielded few, if  any, distinct bands (data not shown), the 
on-bead digest protocol identified MAN2B1 and MAN2B2 in the sample labeled by ABP 6 at 
pH 4.5, and all five GH38 α-mannosidases in the sample labeled at pH 6.0 (Table 6.2). No other 
glycosidases were detected in these samples. 
Table 6.2. List of identified glycosidases by LC-MS-based proteomics in samples of mouse testis 
extracts incubated with ABP 6. PLGS, ProteinLynx Global Server. 
 
 To shed definitive light on the labeled mannosidases, in a final experiment all five 
human GH38 α-mannosidases were individually cloned and expressed in HEK293T cells, and 
the cell lysates were labeled at various pHs with ABP 5. Lysates of  cells transfected with 
MAN2A1 and MAN2A2 shown bands at around 140 kDa and labeled optimally at pH 5.5−6.0 
(Fig. 6.7). Lysates of  cells transfected with MAN2B1 showed multiple bands optimally labeled 
Table 8.2






O09159 MAN2B1_MOUSE 175 9 64 9
O54782 MAN2B2_MOUSE 306 28 57 20
pH 6.0
P27046 MAN2A1_MOUSE 391 28 84 22
Q8BRK9 MAN2A2_MOUSE 63 6 78 6
O09159 MAN2B1_MOUSE 175 6 64 9
O54782 MAN2B2_MOUSE 306 16 57 16
Q91W89 MAN2C1_MOUSE 119 12 63 14




at pH 4.0−5.5, with molecular weights of  130 kDa, 65 kDa, 45 kDa, and 30 kDa. This labeling 
pattern possibly reflects the complex processing and maturation of  MAN2B1 in the lysosome 
(Fig. 6.7). Lysates of  cells transfected with MAN2B2 showed a weaker 130 kDa band and a 
prominent 50 kDa band, both of  which had pH optimum around 4.0−5.5 (Fig. 6.7). Lysates of  
cells transfected with MAN2C1 showed a band just above 100 kDa and most prominently at pH 
6.5. It is also prominently labeled at pH 7.5, which is different from other GH38 enzymes 
expressed in HEK293T cells (Fig. 6.7). 
Figure 6.7. ABPP in lysates of HEK293T cells transfected with human GH38 α-mannosidases. 
 While it was not possible to discriminate MAN2A1 from MAN2A2 in the ABPP setup 
due to their similar pH range and molecular weight, the other four enzymes were readily 
identifiable by ABP labeling at different pH values. It was observed that MAN2A1/A2 were 
most prominently expressed in mouse testis and less in HEK203T cells and mouse brain and 
epididymis; MAN2B1 and MAN2B2 were expressed in all the samples, whilst MAN2C1 was 
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MAN2B1 seemed to have multiple forms that differ in molecular weights, in contrast to the 
sharp bands observed in mouse brain extracts. 
Figure 6.8. Assigning GH38 α-mannosidases in cell lysates and tissue extracts labeled with ABP 
5. 
6.2.4 In vitro activity of  compound 8−13 towards GH2 β-mannosidase 
 Next, the β-mannose configured compounds were characterized regarding inhibitory 
potency and labeling characteristics using commercially available GH2 β-mannosidase from 
Roman snail (Helix pomatia).54 Initial apparent IC50 measurements were performed by means of  
30 min incubation of  enzyme with compounds and the substrate 4-MU-β-D-(4-MU-β-Man) at 
pH 4.2, the optimum pH for the enzyme.55 However, none of  the compounds inhibited the 
enzyme, even at the highest concentration (50 μM). To verify this observation, labeling at various 
pH values was examined. In this experiment, 10 μM of  the Cy5 ABP 12 was incubated with the 
enzyme for 1 h across a range of  pH from 3.0 to 7.0 in the presence of  bovine serum albumin 
(BSA, which stabilized the enzyme at pH > 3.5 (Fig. 6.S3A, B)), and samples were subjected to 































































from pH 4.0 to 7.0 at just below 100 kDa (Fig. 6.9A, left, Fig. 6.S3C), which matched the known 
molecular weight (94 kDa) of  the snail GH2 enzyme.54 Band quantification showed that 
optimum labeling occurred at pH 5.5, and the labeling decreased rapidly at higher and lower pH 
(Fig. 6.9A, right, red). Similar to the α-mannose configured Cy5 ABP 5, the relative ABP labeling   
Figure 6.9. Labeling and inhibitory potency of compounds towards GH2 β-mannosidase from 
Roman snail (Helix pomatia). A) ABP 12 labeling at various pHs (left) and comparison of the quantified 
band intensity with relative enzymatic activity across pHs (right). B) Labeling of ABP 12 at various ABP 







































Compounds IC50 ( M)
8 (CWO466) > 50
9 (TB535) > 50
10 (TB429) 13.2 ± 1.78
11 (TB520) 6.16
12 (TB434) 3.59 ± 0.34














































intensity was lower than the enzymatic activity at acidic pH. This effect was not due to the 
instability of  the ABP at acidic pH, as labeling with ABPs pre-incubated at different pH values 
over a period of  0–60 min showed identical intensity (Fig. 6.S3D). At pH higher than 5.5, the 
relative labeling by ABP 12 generally matched the enzymatic activity. 
 Using the determined optimal labeling pH (5.5), ABP 12 was next incubated with the 
β-mannosidase at various ABP concentration and labeling time. Labeling increased with both 
ABP concentration and labeling time, and saturate labeling in the experiments was observed at 
10 μM ABP (1 h incubation) (Fig. 6.9B) and 120 min incubation (10 μM ABP) (Fig. 6.9C). 
Using these conditions (pH 5.5, 2 h incubation), IC50 measurement was performed again for all 
the β-mannose configured compounds. The results showed that at these reaction conditions, the 
compounds did inhibit the enzyme’s hydrolysis of  4-MU-β-man (Fig. 6.9D). ABP 12 was the 
most potent of  the series (apparent IC50 = 3.6 μM), followed by the BODIPY ABP 11, the biotin 
ABP 13, and the alkyl azide 10. The bare epoxide 8 and aziridine 9 turned out not to inhibit the 
enzyme at the highest compound concentration tested (50 μM) (Fig. 6.S3). 
6.2.3 Kinetic parameters determination for ABP 12 towards GH2 β-mannosidase 
 In previous chapters, a continuous method (simultaneous incubation of  inhibitor and 
fluorogenic substrate) has been utilized for assessing the kinetic parameters of  the β- 
glucuronidase ABP towards its target enzyme (Chapter 4, this thesis). However, due to its high 
potency and fast binding kinetics, only the pseudo-first order kinetic parameter (kinact./KI) could 
be obtained (Chapter 4, this thesis). A gel-based method has also been employed for the 
determination of  kinetic parameters KI (inhibition constant) and kinact (inactivation rate constant) 
for the slower-reacting α-iduronidase ABP (Chapter 5, this thesis). While it completely 
circumvented the influence of  added substrates, it was more laborious than the fluorogenic 
substrate assay. An alternative approach was used here, in which free ABP in the reaction mixture 
was removed by chromatography spin column, before the samples were added with 4-MU 
substrates and measured for fluorescence in 96-well plates. The extra step in removing free ABPs 
before adding substrates should theoretically prevent any influence from the substrates during 
ABP labeling, making the determination of  kinetic parameters more accurate.  
 To verify this approach in free ABP removal, the snail GH2 enzyme was firstly labeled 
with 10 μM ABP 12 for 2 h at pH 5.5, and subjected to polyacrylamide desalting spin column  




for two times. The extent of  removal of  unbound ABPs was checked by SDS-PAGE-based 
fluorescence detection. The gel showed that the unbound ABPs, which were migrated to the 
bottom of  the gel, were mostly removed after consecutive spin column (Fig. 6.10A). Interestingly, 
the first spin column removed 98.5 % of  the unbound ABPs in the samples, while the second 
column only removed less than half  of  the remaining unbound ABPs (Fig. 6.10A, right). The 
enzyme amount was partially affected by the spin columns, but a yield of  73 % was still obtained 
after the consecutive columns (Fig. 6.S4). With the method in place, the enzyme was next 
Figure 6.10. Determination of inhibitory kinetics of ABP 12 towards Helix pomatia GH2 β-
mannosidase. A) Assessing free-probe clearance by consecutive desalting columns using SDS-PAGE-
based fluorescence scanning (left); quantified relative band intensity from the free probe (right). Error 
ranges = SD from n = 2 experiments. B) Inverted logarithmic plot of relative enzymatic reaction rate of 
various ABP concentration at different incubation time C) Michaelis-Menten plot of the derived kobs at 
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103 to 104 times slower than GBA probe




incubated with ABP 12 at a range of  ABP concentrations (2−50 μM), each performed in a series 
of  incubation time (0−160 min). Calculation of  the observed inhibition rate constant (kobs) at 
each ABP concentration (Fig. 6.10B) and the subsequent plotting of  the kobs values at each ABP 
concentration (Fig. 6.10C) led to a KI (9.92 μM) and kinact (0.023 min-1) (Fig. 6.10D). The 
calculated pseudo first-order inhibition rate constant (kinact / KI) is 0.0023 μM-1 min-1 (Fig. 6.10D), 
which is 10-4 times lower than the values for the Cy5 ABP for β- glucuronidase but 1 order higher 
than the Cy5 ABP for α-iduronidase. The KI (9.92 μM) was 100-times lower than the KM of  the 
substrate 4-MU-β-man (0.91 mM)54, suggesting that ABP 12 has a much higher affinity than the 
fluorogenic substrate. 
6.2.5 Target detection and identification of  the β-mannose configured ABPs in mouse kidney 
homogenates 
 Chemical proteomics was firstly employed for target identification for the β-mannose 
configured biotin ABP 13 in mouse kidney extracts, a tissue that is high in MANBA mRNA 
expression (according to BioGPS dataset GeneAtlas MOE43056). The experiment was 
performed with or without 1 h pre-incubation with 5 μM ABP 11 (BODIPY green). A negative 
control was also included in which DMSO replaced the ABPs. Analysis of  the identified proteins 
showed that the β-mannosidase MANBA was the only glycosidase identified in samples 
incubated with ABP 13, while no glycosidases were detected in the DMSO sample (Table 6.3). 
The sample with ABP 11 pre-incubation showed a reduced PLGS (ProteinLynx Global Server) 
score and a reduced number of  total identified peptide assigned to MANBA, indicating that 
ABP 11 partially blocked the labeling of  the biotin ABP 13 towards MANBA at the tested 
incubation condition (5 μM, 1 h). 
 
Table 6.3. List of identified glycosidases by LC-MS-based proteomics in samples of mouse kidney 
extracts incubated with ABP 13. PLGS, ProteinLynx Global Server.  
Table 8.3






# 1 (ABP 13) Q8K2I4 MANBA_MOUSE 2825 32 72 33
# 2 (ABP 11
 ABP 13)
Q8K2I4 MANBA_MOUSE 733 18 72 22
# 3 (DMSO) N/A N/A N/A N/A N/A N/A
Protein amount: 5.6 mg protein per sample
ABP labeling condition: (1) Competition = pH 
5.5, 1 h 5 uM TB434 (2) Biotin-ABP labeling = 
pH 5.5, 3 h 10uM TB476
Beads: MyOne C1, 200 μL per sample




 Next, the Cy5 ABP 12 was incubated with mouse kidney extracts and followed by SDS-
PAGE-based fluorescence detection, to test if  MANBA can be specifically visualized. Various 
ABP concentration (pH 5.5, 2 h), incubation time (pH 5.5, 3 μM), and pH (3 μM, 2 h) were 
tested. The results showed a distinct band at just below 100 kDa, that was visible at over 1 μM 
12 (Fig. 6.11A), over 10 min incubation (Fig. 6.11B), and between pH 4.5 to 6.0 (optimally at 
pH 5.0 and 5.5) (Fig. 6.11C). The labeling did not saturate in intensity at 10 μM ABP and 120 
min incubation, consistent with the labeling and inhibitory potency results with the Helix pomatia 
Figure 6.11. cABPP in mouse kidney homogenates. Samples were pre-incubated with competitors or 
SDS, followed by incubation with ABP 12. CP, cyclophellitol. JJB75, cyclophellitol aziridine BODIPY-red 









































GH2 β-mannosidase. In addition to the ~100 kDa band, a minor band at ~55 kDa was also 
noted in the gels. To further verify the identity of  both bands, a cABPP experiment was 
conducted in which mouse kidney extracts were pre-incubated with inhibitors of  
glucocerebrosidase (GBA, which has a molecular weight of  around 55 kDa), retaining β-
glucosidases (including GBA2, that has a molecular weight at around 100 kDa), and compounds 
8−11 and 13, followed by ABP 12 incubation. The upper band was not abolished by pre-
incubation with the GBA and GBA2 inhibitor cyclophellitol (CP, Chapter 2, this thesis) as well 
as the GBA-specific ABP MDW94157, and only marginally reduced by compound 8, 9, 11; it was 
abolished by pre-incubation with the retaining β-glucosidase ABP JJB7552, 58, compound 10 and 
13, and SDS (Fig. 6.11). The labeling on the lower band was not intense enough in this 
experiment, but cABPP experiment and activity measurements in HEK293T lysates and 
recombinant enzymes revealed that GBA and GBA2 were both labeled by 12 (Fig. 6.S5). 
Together, these results suggest that the ~100 kDa band in mouse kidney homogenate was likely 
MANBA. Specific visualization of  MANBA was obtainable in samples relatively abundant in 
MANBA and low in GBA and GBA2, or with pre-incubation with GBA and GBA2 inhibitor. 
6.3 Discussion 
This chapter describes the characterization of  α- and β-mannose configured cyclophellitol 
aziridine ABPs’ activities towards the GH38 α-mannosidases and GH2 β-mannosidase. Both 
enzyme families are retaining exo-glycosidases, and are involved in metabolism within the protein 
N-linked glycan pathways. Continuous interest is placed on a number of  these enzymes in 
relation to diseases such as cancer and lysosomal storage disorders. As such, tools to visualize 
and profile the activity of  each of  these enzymes would be of  great value in laboratory and 
clinical studies. 
The α-mannose configured cyclophellitol and cyclophellitol aziridine compounds (except 
for the green BODIPY ABP 4), are low micromolar inhibitors towards the Jack bean (Canavalis 
ensiformis) GH38 α-mannosidase. The alkyl Cy5 ABP 5’s inhibitory potency increases with 
prolonged incubation time, and it labels the enzyme in a pH-, concentration-, and time-
dependent manner. Its labeling of  the enzyme is abolished by pre-incubation of  swainsonine 
and mannostatin A, both known inhibitors of  GH38 enzyme. These results suggest the ABP is 
a mechanism-based irreversible inhibitor of  GH38 α-mannosidases. This conclusion is further 




substantiated by structural analysis of  the Drosophila GH38 enzyme dGMII in complex with 
compound 2, which shows a glycosidic linkage between the anomeric carbon of  the compound 
and the enzymes catalytic nucleophile, and that the compound adopts the 1S5 conformation—
identical to the one adopted by the enzyme’s natural substrates. By gel-based fluorescent ABPP 
and chemical proteomics, it is shown that the ABPs offer in-class labeling of  all five of  the GH38 
α-mannosidases in mouse tissue extracts, and in HEK293T cells expressing each of  the cloned 
human GH38 enzymes. By tuning the labeling pH, individual mannosidases can be 
simultaneously profiled on gel in one experiment. The human MAN2B1 is optimally labeled at 
pH 4.0 to 5.5, and has multiple molecular weight forms (130 kDa, 65 kDa, 45 kDa, 30 kDa) 
which is likely a result of  its complex lysosomal processing.23, 32 The human MAN2B2 is 
processed from 130 kDa to 50 kDa. The 50 kDa form was not reported from previous literatures, 
which all isolated the enzyme in culture medium or tissue fluid instead of  from homogenates of  
cells or whole tissue. Here, it is shown that this 50 kDa form has a pH profile similar to MAN2B1, 
and is ubiquitously expressed in all mouse tissue tested, as well as in HEK293T cell. Therefore, 
it is likely that this 50 kDa form of  MAN2B2 is the mature lysosomal form, and conveniently, it 
can be readily distinguished from MAN2B1 based on an ABPP gel based on molecular weight—
the first assay that offers simultaneous activity readout of  the two enzymes in complex samples. 
The ABPP assay further identifies endogenous MAN2C1 in mouse brain extracts, which has a 
molecular weight of  around 100 kDa and a pH range between 5.0 to 7.5 (optimally at pH 6.5). 
It also identifies endogenous MAN2A1 and MAN2A2 in mouse testis and possibly liver extracts, 
but due to their similar molecular weight it is not possible to discriminate between the two. The 
best ABP concentration for labeling is 3 μM, as higher concentrations results in more aspecific 
labeling that complicates interpretation of  the results. 
The ability of  the α-mannose configured ABPs to label all five GH38 α-mannosidases 
invites two major applications. One would be gel-based fluorescent activity profiling for 
individual retaining exo-mannosidases across different sample types, to study the processing and 
activity of  these enzymes in different cell/tissue types and in healthy vs. disease context. For 
example, it could be used to study MAN2C1’s involvement in various cancer samples, or be used 
to monitor the bio-distribution and processing of  therapeutic MAN2B1 (or MAN2B1 induced 
by other potential therapies) in α-mannosidosis patients. Another application is the screening for 
inhibitors/activators that are specific towards one of  the five GH38 enzymes. For example, 
specific inhibitors for MAN2A1 would offer valuable leads for treating a number of  cancers, a 




research direction that has been actively pursued.59, 60 Chaperone/activators for MAN2B1, on 
the other hand, could lead to alternative therapies for α-mannosidosis. A setup involving 
fluorescence polarization (FluoPol) ABPP coupled to automated high-throughput screening is 
currently being investigated (Daniel Lahav, ongoing investigation). 
The N-alkylated β-mannose configured cyclophellitol and cyclophellitol aziridine 
compounds also inhibit their target enzyme—GH2 β-mannosidase—at low micromolar range. 
The bare cyclophellitol 9 and bare cyclophellitol aziridine 10, surprisingly, did not inhibit the 
GH2 β-mannosidase. On the other hand, the Cy5 ABP 12 labels the commercial GH2 enzyme 
from Helix pomatia in a mechanism-based manner., It is noted that the ABP does not avidly label 
the enzyme between pH 4.0 to 5.0, in contrast to activity measurement using the fluorogenic 
substrates. As both the enzyme (at 0.1 % (w/v) BSA) and the ABP are stable at this pH range, 
this noted difference might reflect the intrinsic difference of  the enzyme in its reactivity towards 
the two types of  artificial compounds under low pH. Proteomics with the biotin ABP 13 in 
mouse kidney extracts identified the mouse GH2 enzyme MANBA as the only glycosidase 
targets. ABPP with the Cy5 ABP 12 in mouse kidney homogenates confirmed that MANBA 
(around 96 kDa) is labeled, while ABPP in other sample types revealed that the β-glucosidases 
GBA and GBA2 are also targeted. Interestingly, MANBA in mouse kidney is also labeled by the 
β-glucose configured cyclophellitol aziridine ABP at the experimental condition (200 nM, 2 h 
incubation). Despite this, by pre-incubation of  specific β-glucosidase inhibitors such as 
cyclophellitol, MANBA can still be selectively visualized over the β-glucosidases. Next, a novel 
experimental protocol for determining inhibition kinetic parameters for irreversible inhibitors 
has also been setup, which is relatively free of  substrate during inhibitor incubation and thus 
should offer a better estimate of  inhibition kinetic parameters when compare to the commonly 
used continuous methods. Application of  the β-mannose configured ABPs might not be only 
restricted to the study in the rare lysosomal storage disorder β-mannosidosis. For instance, it 
could also be applied in studying other human diseases with abnormal MANBA activity, such as 
kidney disease.61 
 In conclusion, the presented study in this chapter established that the mannose 
configured cyclophellitol aziridine ABPs are valuable tools to profile individual retaining exo-
mannosidases in complex biological samples. They invite future application in laboratory and 
clinical investigation of  these enzymes in both health and disease. 




6.4 Experimental procedures 
6.4.1 General materials and methods 
All chemicals and reagents were purchased from Sigma Aldrich, if  not otherwise stated. 
HEK293T cells were purchased from ATCC and handled according to the published methods.62 
GH38 α-mannosidase from Jack bean (Canavalia ensiformis) and GH2 β-mannosidase from 
Roman snail (Helix pomatia) were purchased from Sigma Aldrich; recombinant GH38 α-
mannosidase from Drosophila melanogaster (dGMII) was generated according to the methods 
described in the Appendix section 6.S2.1 and 6.S2.2. Protein concentration in samples was 
determined using the PierceTM BCA kit from Thermo Fisher; for the commercial enzymes, the 
enzyme stocks were firstly desalted using PierceTM 7k polyacrylamide desalting spin column 
(Thermo Fisher) before subjecting to BCA assay; protein concentrations was 1.45 µg (13 pmol) 
µL-1 for C. e. α-mannosidase and 2.41 µg (25.6 pmol) µL-1 for H. p. β-mannosidase. DMSO 
concentration in samples was kept at 0.5 to 1 % (v/v) during inhibitor/ABP incubation. 
Coomassie stain were carried out as loading control for SDS-PAGE experiments. HEK293T 
cells (ATCC CRL-3216) were cultured in DMEM high glucose (Sigma-Aldrich) supplemented 
with 10 % FCS, 100 units/mL penicillin/streptomycin, and 1 mM Glutamax at 37 °C and at 7 
% CO2. 
6.4.2 IC50 determination for compound 1−7 towards Canavalia ensiformis GH38 α-mannosidase 
The enzyme (1.45 ng, or 13 fmol) was equilibrated in 12.5 μL McIlvaine buffer (150 mM citric 
acid/Na2HPO4, pH 4.5) for 5 min on ice, and incubated with 12.5 μL inhibitor dilutions 
(prepared in McIlvaine buffer) for 30 min at 37 °C in black flat-bottom medium-binding 96-well 
plates (Greiner) in triplicates. Samples were next incubated with 100 μL of  substrate mixture (10 
mM 4-methylumbelliferyl (4-MU)-α-D-mannopyranoside (4-MU-α-man) in McIlvaine buffer) 
for 30 min at 37 °C, or for 0−120 min for compound 5. Reaction was quenched by adding 200 
μL 1M Glycine-NaOH (pH 10.3) to the samples. 4-MU fluorescence was measured in the plates 
using a LS55 fluorometer (PerkinElmer) at λEx = 366 nm and λEm = 445 nm. Measured values 
were subtracted with background (no enzyme) values, normalized against control values (no 
inhibitor, with enzyme), and plotted against inhibitor concentrations. IC50 values were calculated 
with Prism 7.0 (GraphPad), using one-phase-exponential decay function. Standard deviations 
were obtained from 2 sets of  calculated IC50 values. 




6.4.3 Enzymatic activity measurement at various pH 
Canavalia ensiformis GH38 α-mannosidase (13 fmol) or Helix pomatia GH2 β-mannosidase (340 
fmol) were equilibrated in 25 μL McIlvaine buffer for 10 min at 37 °C at various pH (+ 1 mM 
ZnCl2 for Canavalia ensiformis GH38 α-mannosidase), followed by 30 min incubation with 100 μL 
substrate mixtures (10 mM 4-MU-α-D-mannosylpyranoside (Glycosynth) or 2 mM 4-
methylumbelliferyl (4-MU)-β-D-mannosylpyranoside (Glycosynth), 0.1 % (w/v) BSA) at 37 °C. 
After quenching the reaction by adding 200 μL stop buffer, fluorescence from samples were 
detected and quantified following methods in a previous section (6.4.2). 
6.4.4 ABPP with Canavalia ensiformis GH38 α-mannosidase 
13 fmol of  enzyme was equilibrated in 10 μL McIlvaine buffer (+ 1 mM ZnCl2; pH 5.5 if  not 
otherwise indicated) for 5 min on ice, and incubated with ABP 5 (3 μM during incubation, if  not 
otherwise indicated) or ABP 7 (0.1−10 μM during incubation) for 30 min (if  not otherwise 
indicated) at 37 °C. For cABPP experiment, same enzyme dilution was pre-incubated with 
swainsonine (Cayman Chemical) or mannostatin A (Santa Cruz) at 0.01−3,000 μM for 30 min 
at 37 °C, followed by ABP 5 incubation (3 μM) for 10 min at 37 °C. After ABP incubation, 
proteins were denatured and separated by SDS-PAGE, detected and analysed according to the 
previously described methods.62, 63 
6.4.5 ABPP with ABP 5 in mouse tissue extracts 
Mouse tissue extracts were generated by homogenizing mouse testis sample in four to five 
volumes of  KPi buffer (25 mM K2HPO4 / KH2PO4, pH 6.5, 0.1 % (v/v) Triton X-100, Protease 
inhibitor cocktail (EDTA-free, Roche)) in a 2.0 mL screw-cap Eppendorf  tube, using 1mm 
sterile glass beads and FastPrep 24 homogenizer (MP Biomedicals) at 6 m s-1 rpm for 20 sec for 
3 times. The homogenates were centrifuged at 16,000 rpm for 10 min at 4 °C, and the 
supernatant was collected and measured for protein concentration using BCA method. Samples 
were stored in aliquots at −20 °C. For ABPP, samples (40 μg protein) were diluted in 10 μL 
McIlvaine buffer (150 mM, pH 5.5, if  not otherwise stated) and incubated with 5 μL ABP 5 
(diluted in McIlvaine buffer) to a final ABP concentration of  3 μM (if  not otherwise stated) for 
30 min at 37 °C. For competitive ABPP, mouse testis extracts (40 μg protein) were diluted in 10 
μL McIlvaine buffer (pH 5.5) and pre-incubated with 0−1,000 μM swainsonine or mannostatin 




A in 12.5 μL volume for 30 min at 37 °C, followed by ABP 5 incubation (3 μM) in 15 μL volume 
for 10 min at 37 °C. Samples were denatured and analyzed by gel-based fluorescent ABPP as 
described previously. 
6.4.6 Proteomics 
For pull-down with ABP 6, 2.5 mg protein from mouse testis extracts were diluted with 
McIlvaine buffer (750 mM, pH 4.5 or 6.0) to a total volume of  500 μL, and incubated with 10 
μM ABP 6 at 37 °C for 1 h. For control, DMSO was used in place of  ABP. For pull-down with 
ABP 13, 4.0 mg total protein from the kidney extracts were diluted with McIlvaine buffer (750 
mM, pH 5.5) in a total volume of  500 μL, and incubated with 10 μM ABP 13 at 37 °C for 1 h, 
with or without prior pre-incubation with 5 μM ABP 11. After ABP incubation, samples were 
denatured with SDS, subjected to chloroform/methanol precipitation (C/M), 
reduction/alkylation, C/M again, and pull-down with 200 μL streptavidin beads in a volume of  
10.2 mL pull-down buffer for O/N at 4 °C following the previously described procedures.64 
Afterwards, half  of  the samples were subjected to on-bead digestion, and half  to in-gel digestion, 
and desalted using stage-tips according to the described procedures.64 For LC/MS analysis, 1 μL 
of  sample was injected with phase A (0.1 % (v/v) formic acid in MilliQ H2O) on a C18 column 
(Acquity UPLC M-Class 300 μm x 50 mm, packed with BEH C18 material of  1.7 μm diameter 
and 300 Å pore size particles), eluted with a 50 min gradient of  10 % to 60 % phase B (0.1 % 
(v/v) formic acid in ACN), followed by 10 min equilibration to 1% phase B at a flow of  0.4 
μL/min, hyphenated with Electro-spray ionization (ESI) via Nano-spray source with ESI 
emitters (New Objectives) fused silica tubing 360 μm OD x 25 μm ID tapered to 5 ± 0.5 μm (5 
nL/cm void volume) to a Synapt G2Si mass spectrometer (Waters) operating with Masslynx for 
acquisition and Ent3 software for polymer envelope signal deconvolution. The following settings 
in positive resolution mode were used: source temperature of  80 °C, capillary voltage 4.5 kV, 
nano flow gas of  0.25 Bar, purge gas 250 L/h, trap gas flow 2.0 ml/min, cone gas 100 L/h, 
sampling cone 25V, source offset 25, trap CE 32V, scan time 3.0 sec, mass range 400-2400 m/z. 
Lock mass acquiring was done with a mixture of  Leu Enk (556.2771) and Glu Fib (785.84265), 
lockspray voltage 3.5 kV, Glufib fragmentation was used as calibrant. The PLGS (Waters) 
program was used for data analysis, protein ID or extraction of  mgf  files for further Mascot 
(Matrix Science) search analysis. The identification results were exported as Excel file including 
protein accession numbers, mass of  the protein, pI, PLGS score, and % coverage of  the protein 




by amino acids identified by LC/MS. 
6.4.7 Cloning and transient expression of  human GH38 α-mannosidases in HEK203T cells 
The coding sequences from human GH38 α-mannosidases were PCR-amplified from total 
cDNA’s from human Gaucher spleen using primers listed in Table 6.S1. Primers were designed 
based on NCBI reference sequence NM_002372.3 (MAN2A1), NM_001320977.1 (MAN2A2), 
NM_000528.4 (MAN2B1), NM_001292038.1 (MAN2B2), and NM_006715.4 (MAN2C1), and 
cloned into pDNOR-221 and subcloned into pcDNA3.1/Zeo using the Gateway system 
(Invitrogen). Correctness of  the construct was verified by sequencing. Sub-confluent HEK293T 
cells were transfected with the generated plasmids (or vector plasmids) by the PEI method with 
a plasmid:PEI ratio 1:3. Media was refreshed 24 h later, and 72 h after transfection, cells were 
washed three times with phosphate buffered saline (PBS) buffer and collected in KPi buffer. The 
cell suspension was incubated on ice for 30 min, and stored at −80 °C. 
6.4.8 ABPP in lysates of  cells expressing the cloned GH38 α-mannosidases 
Lysates (20 μg protein) were diluted in 10 μL McIlvaine buffer (150 mM, pH 3.5−7.5, 1 mM 
ZnCl2), and incubated with 5 μL ABP 5 (diluted in DMSO and 150 mM McIlvaine buffer pH 
3.5−7.5, 1 mM ZnCl2) at a final ABP concentration of  3 μM for 30 min at 37 °C. Samples were 
denatured and analyzed by gel-based fluorescent ABPP as described previously. 
6.4.9 Stability test for Helix pomatia GH2 β-mannosidase 
For the effect of  supplements, 340 pmol enzyme was diluted in 25 µL McIlvaine buffer (150 
mM) with or without BSA (0.1 % (w/v)), Triton X-100 (0.1 % (v/v)), sodium taurocholate (0.2 
% (w/v)), or the combinations of  these for 0−120 min at pH 5.5, before subjecting to enzymatic 
assay (with 100 µL 2 mM 4-MU-β-D-mannopyranoside, 30 min incubation at 37 ºC, pH 5.5, 0.1 
% (w/v) BSA). For the effect of  pH, same enzyme dilutions were prepared in McIlvaine buffer 
(+ 0.1 % (w/v) BSA) at various pH values, and incubated for 0−60 min at 37 ºC. Samples were 
next subjected to the substrate assay (prepared with McIlvaine buffer at matching pH) before 
activity readout. 
6.4.10 ABPP with Helix pomatia GH2 β-mannosidase 
7.3−51.2 pmol of  enzyme was equilibrated in 10 μL McIlvaine buffer (+ 0.1 % w/v BSA, pH 




5.5, if  not otherwise indicated) for 5 min on ice, and incubated with ABP 12 (3 μM during 
incubation, if  not otherwise indicated) for 30 min (if  not otherwise indicated) at 37 °C. After 
ABP incubation, samples were subjected to SDS-PAGE-based fluorescence detection followed 
the previously described methods.62, 63 
6.4.11 IC50 determination for compound 8−13 towards Helix pomatia GH2 β-mannosidase 
The enzyme (32.2 ng, or 340 fmol) was equilibrated in 12.5 μL McIlvaine buffer (150 mM, pH 
5.5, + 0.1 % v/v Triton X-100) for 5 min on ice, and incubated firstly with the compounds (12.5 
μL) for 2 h at 37 °C and secondly with substrates (2 mM 4-MU-β-man) for 1 h at 37 °C. 
Fluorescence detection and data analysis followed the procedures described in a previous section 
(6.4.2). 
6.4.12 Determination of kinetic parameters of  ABP 12 towards helix pomatia GH2 β-
mannosidase 
0.9 μg (9.6 pmole) of  the enzyme was equilibrated in 120 μL McIlvaine buffer pH 5.5 (150mM, 
0.1% (v/v) Triton X-100) and pre-warmed to 37°C for 10 min. For inhibitor incubation, enzymes 
were combined with equal volume of  pre-warmed ABP (prepared in McIlvaine buffer) at 2−50 
μM ABP concentrations during incubation, and incubated on a thermoshaker at 37°C. 
Thereafter, 30 μL aliquots were taken at different time points (0−160 min) from each sample, 
and subjected to free-ABP removal using polyacrylamide desalting spin column (Pierce). The 
eluent were diluted 8x with McIlvaine buffer pH 4.5 (150 mM, 0.1% (v/v) Triton-X100), and 
loaded onto a 96-well plate in 25 μL triplicates. For substrate incubation, 100 μL of  pre-warmed 
substrate mixture (2mM 4-MU-β-D-mannosylpyranoside , dissolved in 150 mM McIlvaine buffer 
pH 4.5 + 0.1% (v/v) Triton X-100) was added to the samples, and allowed incubation at 37°C 
for 1 h before subsequent activity measurement. The measured activity was converted to −Ln 
(vt/v0), with vt being the rate of  substrate hydrolysis at the given time point for a given ABP 
concentration, and v0 being the rate at the given time point without ABP incubation. kobs was 
next determined from the −log (Vt/V0) vs time plot, using linear regression (GraphPad Prism 
7.0). The subsequent kobs vs [ABP 12] plot was used to determine kinact and KI for ABP 12 towards 
the enzyme, using the Michaelis-Menten curve-fitting (GraphPad Prism 7.0). For fluorescent gel-
based assessment in enzyme yield and free ABP removal, 153.6 pmol enzyme was diluted in 90 
µL McIlvaine buffer pH 5.5, and this was incubated with 40 µL ABP 12 for 2 h at 37 ºC, at a 




final ABP concentration of  10 µM or 1 µM. Thereafter, 100 µL from each sample was desalted 
using the spin column, and 90 µL from the eluate was desalted again. Next, 10 µL from the 
eluates (desalted once or twice) and the un-desalted sample were diluted with 140 µL McIlvaine 
buffer pH 5.5, and 15 µL from these were loaded onto 10 % polyacrylamide gels for SDS-PAGE 
and fluorescence detection. The electrophoresis was stopped when the dye front has migrated 
to about 1 cm from the bottom of  the gel. 
6.4.13 ABPP using ABP 12 in mouse kidney extracts 
25 μg total protein from mouse kidney extracts was diluted in McIlvaine buffer (150 mM, pH 
5.5, if  not otherwise stated) in a total volume of  10 μL, and incubated with 5 μL ABP 12 (diluted 
in DMSO and McIlvaine buffer) at final ABP concentration of  3 μM (if  not otherwise stated) 
for 2 h (if  not otherwise stated) at 37 °C. cABPP was performed with pre-incubating the extracts 
with SDS (2 % (w/v)), cyclophellitol (3 μM), ABP MDW94157 (3 μM), ABP JJB7552, 58 (3 μM), 
and compound 8−9 (50 μM), 10 (50 μM), 11 (3 μM), and 13 (50 μM) in a volume of  12.5 μL for 
2 h at 37 °C, followed by ABP 12 incubation (3 μM) in a volume of  15 μL for 2 h at 37 °C. 
Samples were denatured and analyzed by gel-based fluorescent ABPP as described previously. 
6.4.13 ABPP using ABP 12 in lysates of  GBA2-overexpressing HEK293T cells 
18.9 µg of  lysates from GBA2-overexpressing HEK293T cells (Chapter 2)62 were pre-incubated 
with 1 µM of  cyclophellitol, the cyclophellitol aziridine BODIPY-red ABP JJB75, compound 8, 
10, 11, 13, or 2 % (w/v) SDS (with 5 min boiling at 98 ºC when pre-incubation completed) at pH 
5.5 for 1 h at 37 ºC, and next incubated with 1 µM ABP 12 at pH 5.5 for 2 h at 37 ºC. Samples 
were denatured and subjected to SDS-PAGE and fluorescence detection. The gel was stained 
with Coomassie Brilliant Blue G250 for assessing total protein loading amount.  
6.4.14 Apparent IC50 values of  ABP 12 towards recombinant GBA or GBA2 
Assays were performed with recombinant GBA, or GBA2 from lysates of  overexpressing 
HEK293T cells using ABP 12 according to the described methods in Chapter 2.62 
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6.S1. Supporting Figures and Tables 
 
Figure 6.S1. Inhibition curves of compound 1−7 towards Jack bean (Canavalis ensiformis) GH38 
α-mannosidase for apparent IC50 determination. A) 30 min incubation. B) 30−120 min incubation. Error 





















































































































































Figure: [Inhibitor] vs activity plots on Canavalia ensiformis alpha-mannosidase. Assays were
performed at 37°C, pH 4.5, with 30 min inhibitor incubation and 30 min 4MU substrate (10mM) incubation.
















































































































































Figure: [Inhibitor] vs activity plots on Canavalia ensiformis alpha-mannosidase. Assays were
performed at 37°C, pH 4.5, with 30 min inhibitor incubation and 30 min 4MU substrate (10mM) incubation.
Total protein amount = 4 ng. Error bar = SD from 3 technical replicates.

















































































































































Figure: [Inhibitor] vs activity plots on anavalia ensifor is alpha- annosidase. ssays ere
perfor ed at 37° , p  4.5, ith 30 in inhibitor incubation and 30 in 4  substrate (10 ) incubation.
















































































































































Figure: [Inhibitor] vs activ ty plots on Canavalia ensiformis alpha-man osidase. Assays wer
performed at 37°C, pH 4.5, with 30 min inhib tor incubation and 30 min 4MU substrate (10mM) incubation.








































































































Figure 6.S2. Characterization of ABP labeling conditions for Helix pomatia GH2 β-mannosidase. 
A) Measured enzyme activity (30 min with 4-MU β-man substrate assay at pH 5.5) with or without 
supplements, over the indicated pre-incubation periods at pH 5.5. B) Effect of pH on enzymatic activity at 
various pH and over different pre-incubation periods, in the presence of 0.1 % (w/v) BSA. C) ABP 12 
labeling at various pH value, in the presence of 0.1 % (w/v) BSA. D) Effect of pre-incubating ABP 12 at 
pH 4.0, 5.5, and 6.5 for 0, 30, or 60 min at 37 ºC on its labeling towards the enzyme (at 10 µM [ABP], pH 
5.5, 1 h 37 ºC). Error range = ± SD (n = 3, technical replicates). 
 











































































































Figure 6.S3. Inhibition curves of compound 8−13 for apparent IC50 determination in snail (Helix 




Figure 6.S4. Activity of snail (Helix pomatia) GH2 β-mannosidase after desalting. Error range =   





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Yield: Helix p. β-Man on 










Figure 6.S5. Reactivity of ABP 12 towards retaining β-glucosidases. A) cABPP in lysates of GBA2-
overexpressed HEK293T cells, using pre-incubation of cyclophellitol (CP), ABP JJB75, compounds 8, 10, 
11, 13, and 2 % (w/v) SDS. CBB, Coomassie Brilliant Blue staining. B) Inhibition curves on GBA, GBA2, 
and GBA3. C) Apparent IC50 values. Error range = ± SD (n = 3 technical replicates).  
 
 








































































































































Enzyme IC50 ( M)
GBA 87.8 ± 19.4







































6.S2. Supporting experimental procedures for protein X-ray crystallography (University 
of  York) 
6.S2.1 Cloning and expression of  dGMII 
A plasmid containing cDNA encoding for the dGMII gene was obtained with kind permission 
from Dr. Sean Sweeny (University of  York). From this plasmid, cDNA encoding for amino acids 
76-1108 of  dGMII (to remove the N-terminal cytosolic, transmembrane, and stalk domains) was 
subcloned into the pOMNIBac vector (Geneva Biotech), behind a honeybee mellitin secretion 
peptide, 6xHis tag, and TEV cleavage site. Recombinant bacmid was produced using the Tn7 
transposition method in DH10EMBacY (Geneva Biotech)1, and purified using the PureLink 
miniprep kit (Invitrogen) following standard protocols. V1 baculovirus was produced by 
transfection of  bacmid into low passage adherent Sf21 cells (Invitrogen) using FuGENE HD 
transfection reagent (ProMega), at a ratio of  2 μg DNA to 4.5 μL FuGENE. V1V2 virus 
amplification was carried out using suspension Sf21 cells, using the YFP marker present in 
EMBacY baculovirus to determine optimum amplification prior to harvesting (typically ~60 % 
cells fluorescent). For expression, T. Ni cells (Invitrogen) were infected with V2 baculovirus at 
a multiplicity of  infection (MOI) > 1, and infection followed using the EMBacY YFP marker to 
determine optimum timepoint for harvesting (typically 72 h, with > 80 % cells fluorescent). All 
insect cells used tested negative for mycoplasma contamination. 
6.S2.2 Purification of  dGMII 
Harvested High Five cultures were spun for 15 minutes at 200 g to remove cells and spun again 
at 4000 g for 1 hour to remove insoluble cellular components. AEBSF (to a final concentration 
of  0.1 mM) and DDT (to a final concentration of  1 mM) were added to the supernatant. 
Clarified supernatant was loaded on to 2 x 5mL HiTrap Blue HP columns (GE Healthcare) pre-
equilibrated in blue agarose buffer A (20 mM HEPES pH 7.4, 100 mM NaCl, 1 mM DTT). 
Loaded columns were washed with 5 column volumes of  blue agarose buffer A and eluted using 
a linear gradient of  blue agarose buffer B (20 mM HEPES pH 7.4, 2 M NaCl, 1 mM DTT) over 
20 column volumes. HiTrap Blue fractions containing dGMII (as determined by SDS-PAGE) 
were pooled and diluted approximately 5-fold in HisTrap buffer A (50 mM HEPES pH 8.0, 0.5 
M NaCl, 30 mM Imidazole, 1 mM DTT) and loaded on to a 1 mL HisTrap FF Crude column 





buffer A and dGMII eluted using a linear gradient of  HisTrap buffer B (50 mM HEPES pH 8.0, 
0.5 M NaCl, 0.5 M imidazole, 1 mM DTT) over 20 column volumes, followed by 10 column 
volumes of  100 % Buffer B. HisTrap fractions containing dGMII were pooled and concentrated 
to less than 2 ml by centrifugation using VivaSpin 30,000 MW concentrator (GE Healthcare). 
Pooled dGMII was rediluted to ~2 mL in 1x AcTEV (Invitrogen) reaction buffer before addition 
of  5 μL AcTEV protease to remove the N-HisTEV tag. Digests were typically carried out 
overnight at ambient temperature, and reaction progress assessed by comparison to positive and 
negative controls using SDS-PAGE. Upon completion of  the AcTEV digest, as indicated by 
SDS-PAGE, dGMII was purified using a S200 16/600 size exclusion chromatography (SEC) 
column equilibrated in SEC buffer (50 mM HEPES pH 7.4, 200 mM NaCl, 1 mM DTT), at 1 
ml min-1. SEC fractions containing dGMII were pooled, concentrated to 10 mg ml-1 and stored 
in 20 μl aliquots at −80 °C. 
6.S2.3 3D Crystallography of  dGMII 
Initial crystallization conditions were screened using JCSG+ HT-96, PACT premier HT-96 (both 
Molecular Dimensions), Index HT and PEG/Ion HT (both Hampton Research) commercial 
screens. Hits were optimized, scaled up to maxi 48-well plates and a dGMII seed stock generated 
from crystals grown in 0.1 M imidazole pH 7.0 and 10 % (w/v) PEG 3350 using the Seed Bead 
protocol (Hampton Research). The above screens were repeated with seeding using an Oryx8 
(Douglas Instruments) and additional hits optimized further. Diffraction quality dGMII crystals 
were grown in maxi 48-well plates using sitting drop vapor diffusion in 0.1 M sodium succinate 
pH 7.0 and 10 % (w/v) PEG 3350. Crystals were cryoprotected using cryoprotectant solution 
(mother liquor supplemented with 25% v/v ethylene glycol) prior to flash freezing in liquid N2 
for data collection. Dataset collection and processing followed the previous methods.2 Apo 
dGMII was solved by molecular replacement with PDB model 1HWWmain text ref  30 using MolRep3, 
followed by alternating rounds of  manual model building and refinement using Coot and 
REFMAC5 respectively4, 5. For ligand complexes, dGMII crystals were soaked in solutions of  2 
(1 mM) in dGMII cryoprotectant solution for ~3 hours before flash freezing in liquid N2 for 
data collection. Complexes were solved by molecular replacement with the apo dGMII structure, 
followed by rounds of  manual model building and refinement using Coot and REFMAC5. 
Generation of  crystal structure figures and ligand coordinates followed the described methods.2 




6.S3. Synthetic strategies for compounds used in this chapter (Department of  Bio-organic 




Scheme 6.S1. Synthetic strategy of compound 2−7. Reagents and conditions: a) PPh3 polymer-bound 
on styrene-divinylbenzene copolymer, CH3CN, reflux, overnight, 54 %; b) Li, THF, NH3 (l), −60  C, 75 min; 
c) 1-azido-8-iodooctane (see Chapter 6), K2CO3, DMF, 80  C, overnight, 38 % over 2 steps; d) 17
6, 187 
or 198, Cu.SO4·5H2O, sodium ascorbate, DMF, RT, 4 35 %, 5 8.5 %, 6 16 %; e) 20
6, EEDQ, DMF, 0  C, 
2.5 h, 8 % over 2 steps. 
 
 
Scheme 6.S2. Synthetic strategy of compound 9−13. Reagents and conditions: a) 1-azido-8-
iodooctane (see Chapter 4), K2CO3, DMF, 80  C, overnight, 64 %; b) 17
6, 187 or 198, Cu.SO4·5H2O, 
sodium ascorbate, 11 17 %, 12 36 % and 13 32 %. 
Scheme 8.S2
Reagents and conditions: a) 1-azido-8-iodooctane (see Chapter 
3), K2CO3, DMF, 80 °C, overnight, 64%; b) 7 (see Chapter 2), 
825 or 926, Cu.SO4·5H2O, sodium ascorbate, 4 17%, 5 36% 
and 6 32%. 
17 18 19
9 10
11 R = BODIPY
12 R = Cy5
13 R = biotin
Scheme 8.S1
Reagents and conditions: a) PPh3 polymer-bound on styrene-divinylbenzene 
copolymer, CH3CN, reflux, ov rnight, 54%; b) Li, THF, NH3 (l , - 60 °C, 75 min; 
c) 1-azido-8-iodooctane (see Chapter 3), K2CO3, DMF, 80 °C, overnight, 38% 
over 2 steps; d) 11 (see Chapter 2), 1225 or 1326, Cu.SO4·5H2O, sodium ascorbate, 
DMF, rt, 4 35%, 5 8.5%, 6 16%; e) 14 (see Chapter 2), EEDQ, DMF, 0 °C, 2.5 h, 
8% over 2 steps.
314 15 16  R = Bn
2 R = OH
7  R = Cy5
4  R = BODIPY
5 R = Cy5
6 R = biotin
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β-Galactose Configured Cyclophellitol Aziridine as Activity-
Based Probes for Retaining exo-β-Galactosidases 
Based on: 
Kuo CL, Beenakker TJM, Profijt R, Marques ARA, Groenewegen N, Offen WA, Sarris AJC, Boot RG, 
Codée JDC, van der Marel GA, Davies GJ, Overkleeft HS & Aerts JMFG. To be submitted.  





The enzymes β-galactosidase (GLB1) and galactocerebrosidase (GALC) are both retaining exo-
glycosidases important in glycoconjugate metabolism, and their hereditary deficiency in man can 
lead to lysosomal storage disorders with still unmet medical needs. Chemical tools to study these 
enzymes have been developed in the past, including the cyclophellitol-based activity-based 
probes (ABPs) for GALC, and broad spectrum (4-deoxy) cyclophellitol aziridine ABPs for both 
β-glucosidases and β-galactosidases. However, β-galactose-configured N-tagged cyclophellitol 
aziridines—which might offer specific ABPs for β-galactosidases—have not been generated due 
to earlier synthetic challenges. Here, ABPs containing such scaffold are evaluated for their 
reactivities. The analysis shows that the ABPs exhibit expected mechanism-based inhibition and 
labeling of  recombinant bacterial GLB1 homologue, and both GLB1 and GALC in cell lysates, 
culture medium, and tissue extracts. The Cy5-tagged ABP additionally labels in mouse intestine 
extracts the dietary enzyme lactase-phlorizin hydrolase (LPH). Pull-down experiments with 
biotin conjugated ABP and mouse kidney extracts, followed by LC-MS analysis identified GLB1 
and GALC as major glycosidase targets, as well as two other putative β-galactosidases GLB1-lile 
protein 1 and 2 (GLB1L and GLB1L2) that have yet unknown biological functions. The β-
galactose-configured N-tagged cyclophellitol aziridine ABPs still label β-glucosidases with 
considerable affinity, illustrating the limitation of  this scaffold for specific β-galactosidase 
labeling. Nevertheless, by pre-incubating samples with β-glucosidase inhibitors, different β-
galactosidases can be simultaneously visualized by gel-based ABP detection. The novel ABPs 






7.1 Introduction  
he monosaccharide galactose is incorporated by higher eukaryotes into a variety of 
glycoconjugates such as glycoproteins, glycolipids, and glycosaminoglycans 
(GAGs). Among the two possible galactose anomers in glycoconjugates, the 
predominant one is β-galactose. In humans and other mammals, β-galactose is 
transferred from UDP-α-galactose to specific acceptors in the Golgi apparatus by the action of 
dedicated β-1,3- and β-1,4-galactosyltransferases.1 It is removed from glycoconjugates 
predominantly by two distinct lysosomal β-galactosidase: acid β-galactosidase (GLB1, E.C. 
3.2.1.24) degrading oligosaccharides (glycosaminoglycans and glycoproteins) and gangliosides 
(such as GM1a and GA1),2 and galactocerebrosidase (GALC, E.C. 3.2.1.46) degrading mainly 
galactosylceramide.3 
GLB1 belongs to Glycoside Hydrolase (GH) family 35.4 Synthesized as glycosylated 85 
kDa precursor, it is targeted to the lysosome through the mannose-6-phosphate (M6P) 
dependent pathway; proteolytic cleavage at its C terminus results in the mature enzyme 
containing a large 64 kDa subunit and a small 20 kDa subunit that remain associated with each 
other without disulfide linkage.5, 6 The 64 kDa subunit contains a TIM barrel domain containing 
the catalytic glutamates Glu188 and Glu268, while the 20 kDa subunit is required for the 
stabilization and functioning of the enzyme.6, 7, 8 Similar to other lysosomal glycosidases, GLB1’s 
catalysis of glycolipids is assisted by activator proteins, in this case both saposin B and the GM2 
activator protein.9 GLB1 forms in lysosomes a complex together with cathepsin A (PPCA, 
CSTA gene) and neuraminidase (NEU1), resulting in a stable and efficient catalytic machinery 
for degrading the glycosphingolipid GM1 ganglioside.10 Alternative splicing of the GLB1 gene 
produces a protein named elastin-binding protein (EBP), which does not possess catalytic 
activity and is instead transported to the extracellular matrix to act as a lectin that modulates 
elastin fiber formation.11, 12 Another lysosomal β-galactosidase, GALC, belongs to the GH59 
family.4 It is synthesized as an 80 kDa precursor containing four N-linked glycans, and targeted 
either directly to the lysosomes via the M6P-mediated pathways or by re-uptake of the secreted 
proteins through M6P-dependent or -independent pathways.13, 14 In the lysosome, it is processed 
to mature enzyme consisting of an N-terminal 50 kDa subunit (containing the TIM barrel 
domain harboring catalytic residues glu198 and Glu274) and a C-terminal 30 kDa subunit 
comprising the lectin domain bound with a calcium ion.13, 15, 16 With the assistance by saposin A, 
T 




17, 18 GALC specifically degrades galactosylceramide that is particularly abundant in myelin, 
kidney, and epithelial cells of intestine and colon.19 
The importance of GLB1 and GALC activity is illustrated by diseases caused by their 
deficiency. Deficiency in GLB1 may result in three distinct lysosomal storage disorders, namely 
GM1 gangliosidosis, Morquio B syndrome, and galactosialidosis. GM1 gangliosidosis is caused 
by mutations in the GLB1 gene and is characterized by an elevated cellular level of GM1 
ganglioside, causing lysosomal vacuolization in lymphocytes and neuronal cells, which in turn 
leads to demyelination and neuronal cell death in the periphery as well as in the central nervous 
system.20 Patients are classified into infantile (type I, OMIM # 230500), late infantile/juvenile 
(type two, OMIM # 230600), and adult onset forms (type III, OMIM # 230650) according to 
disease feature and progression.20 Disease severity is inversely related to residual GLB1 activity.21 
Although the molecular mechanisms leading to disease pathogenesis is not completely 
understood, it has been suggested that abnormal accumulation of GM1 ganglioside in the 
membranes linking the ER and mitochondria can drive Ca2+ efflux from the ER to mitochondria, 
leading to unfolded protein response (UPR) and mitochondrial stress, followed by apoptosis and 
ultimately neuronal death.22-24 Different mutations in GLB1 gene may lead to another disease 
entity named Morquio B syndrome (mucopolysaccharidosis type IVB, MPSIVB, OMIM # 
253010), where the primary accumulated substrates are oligosaccharides deriving from keratin 
sulfate and glycoproteins.2 No central nervous system involvement is observed in these patients, 
and the major affected tissues is the skeletal system.2 The third disease related to GLB1 
deficiency is galactosialidosis (OMIM # 256540), and is in fact caused by primary deficiency of 
cathepsin A (PPCA, gene = CTSA) that normally forms a protein complex with GLB1 and 
neuraminidase (NEU1) in the lysosome. Cathepsin A deficiency causes premature degradation 
of both GLB1 and NEU1, leading to their secondary deficiencies in patients.10 Deficiency in 
GALC or its activator protein saposin A, forms the basis of Krabbe disease (globoid cell 
leukodystrophy, GLD, OMIM # 245200).3, 25 About 85 % of Krabbe disease patients develop 
the infantile-onset form that presents with developmental delay and severe neurological damages, 
with death usually within a few years.26 Later-onset forms have higher residual GALC activity 
and milder symptoms, and may have life spans up to the seventh decade of life. The primarily 
accumulated substrate is galactosylsphingosine (psychosine) in macrophages (globoid cells) and 
neural cells—particularly oligodendrocytes and Schwann cells, and this cytotoxic compound is 





system.27, 28 No therapy is yet available for these β-galactose-related lysosomal storage disorders 
besides bone marrow transplantation (BMT) and hematopoietic stem cell transplantation (HCT) 
of Krabbe disease, which is only effective before the onset of symptoms (which is usually not 
the case). Several therapeutic approaches are presently studied including substrate reduction 
therapies (SRT),29 enzyme replacement therapies (ERT),30, 31 pharmacological chaperon 
therapies (PCT),32, 33 gene therapies,34-36 and lysosomal re-acidification therapy37. 
Mechanistically, both GLB1 and GALC are retaining exo-glycosidases using the Koshland 
double-displacement catalytic mechanism. A covalent glycosidic bond is formed during the 
reaction itinerary, which makes both enzymes amenable to activity-based glycosidase profiling 
(general introduction, this thesis). In the past, activity-based probes (ABPs) based on the β-
galactose configured cyclophellitol scaffold have been generated (Fig. 7.1A, LWA487) and 
enabled specific labeling of GALC in mouse tissues extracts at high micromolar ABP 
concentration.38 
Figure 7.1 Strategies for activity-based labeling towards exo-galactosidases. A) Inhibitor and ABP 
for GALC (LWA480 and LWA487) and potential inhibitor and ABPs for β-galactosidases B) Proposed 
reaction mechanism of the β-galactose configured cyclophellitol aziridines towards β-galactosidases.  
 On the other hand, ABPs based on the 4-deoxy cyclophellitol aziridine scaffold offers 
broad spectrum ABPs (Fig. 7.2, SYD215) that label both β-glucosidases and β-galactosidases.39 
To develop ABPs specifically towards β-galactosidases, attempts have been made to synthesize 
the N-alkylated or N-acylated β-galactose configured cyclophellitol aziridines (Fig. 7.1A). This 
was initially hampered by instability of compound intermediates during synthesis.40 This chapter 
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Figure 7.1. Strate ies for activity-based abeling towards exo-
galactosidases. (A) (Potential) inhibitors and activity based probes (B)
Proposed reaction mechanism of the towards β-galactose configured
cyclophellitol aziridines towards β-galactosidases.




Figure 7.2. Structures of compounds used in this chapter. 
aziridine compounds. These ABPs were ultimately generated through an alternative click 
chemistry involving the reaction between the norbornene-bearing cyclophellitol aziridine and 
the tetrazine-bearing reporter groups. This chapter reports on a detailed investigation of these 
compounds regarding inhibitory potency, glycosidase labeling, and target specificity.   
7.2 Results 
7.2.1 Synthetic strategies for β-galactose configured cyclophellitol aziridines 
 Compounds were synthesized at the Department of  Bio-organic Synthesis, Leiden 
University. The synthesis of  β-galactose configured cyclophellitol 1 and cyclophellitol aziridine 
2 has been previously described.40, 41 Acylation of  2 was unsuccessful due to the rapid 
decomposition of  the products, but alkylation with 8-iodooctylazide was successful, leading to 
the N-alkylated compound 3. However, normal Cu(I) catalyzed click reaction with an alkyne-
fluorophore did not yield the expected products.41 Therefore, an alternative strategy was tested, 
based on the inverse electron demand Diels-Alder (IEEDA) reaction between a norbornene and 
Figur  9.2
1 (LWA480) 2 (TB562) 3 (TB422) R = a
a b c d
7 (LWA247) X =f
8 (LWA206B) X = g
9 (LWA206A) X =h
4 (TB582) R = c
5 (TB652) R = d, X = e
e f g
6 (R3391) = 4 + 9
JJB367 R = b, X = e
(ref 41)
SYD215 R = b, X = e
(ref 41)
h





a tetrazine.42 Following this alternative approach, the cyclophellitol aziridine N-alkyl norbornene 
4 was firstly synthesized by alkylation of  2 with a norbornene handle, and subsequent click 
reaction with tetrazine conjugates afforded the desired Cy5 ABP 541 and biotin ABP 6. In 
addition, due to the initial unavailability of  5 and 6, the BODIPY-FL, BODIPY-TMR, and the 
biotin probe were generated in situ by incubation of  4 with compound 7, 8, or 9 in DMSO at RT 
for some period (30 min to overnight), and the mixture was used for several labeling experiments. 
7.2.2 In vitro inhibition and labeling of  compounds 2-7 towards β-galactosidases 
Compounds were tested for inhibitory potency towards GLB1 (present in human 
fibroblasts lysates) and mouse GALC (collected culture medium of HEK293T cells 
overexpressing this protein).38 The presence of GLB1 and GALC in these materials was first 
tested with 4-methylumbelliferyl β-D-galactopyranoside (4-MU-β-gal) substrate assay at various 
pH, and by using 11 μM AgNO3 to selectively inhibit GLB1 over GALC.43 The β-galactosidase 
activity in both materials had a pH optimum of 4.5, but at pH 6.0 the culture medium retained 
60 % activity, in contrast to the 20 % retained by β-galactosidase in the fibroblast lysates (Fig. 
7.S1A). In the presence of AgNO3, no activity remained in the fibroblast lysates, while the culture 
medium retained full β-galactosidase activity (Fig. 7.S1B), indicating that the fibroblast lysates 
contained only GLB1 and that the culture medium contained only GALC. Compounds were 
next assessed for their inhibitory potency on both enzymes using 4-MU β-gal assay. The GLB1 
and GALC enzyme preparations were incubated with substrate and compounds. Compounds 2 
and 3 exhibited low nanomolar IC50 values towards both GLB1 and GALC; the epoxide 144 and 
bulkier compound 4, 5, and 6 were about ten-fold less potent, but were still nanomolar inhibitors 
(Table 7.1, Fig. 7.S2). For comparison, the 4-deoxy Cy5 ABP SYD215 was a high nanomolar 
inhibitor for both enzymes, and was eight- to ten-fold less potent than the Cy5 ABP 5; the β-
glucose configured Cy5 ABP JJB367 was a further 50- to 100-fold less reactive, showing apparent 
IC50 values in the micromolar range (Table 7.1, Fig. 7.S2). 
The compounds also inhibited the bacterial GH35 β-galactosidase from Cellvibrio japonicus 
(CjGH35A, an homologue to human GLB145) with high potency (Table 7.S1, Fig. 7.S2C)), and 
kinetic studies of the compounds towards this enzyme revealed that the N-alkyl azide compound 
2 has the highest affinity (lowest KI) towards the enzyme and the highest inactivation rate 
constant (kinact / KI) of 21.71 min-1 μM-1 (Table 7.2, Fig. 7.S3, S4), with the later value 
comparable to that of cyclophellitol ABPs towards glucocerebrosidase (GBA).46 It was also 




Table 7.1. Apparent IC50 values (nM) of compounds towards retaining exo  β-galactosidases. 
Error range = ± SD, n = 2 biological replicates. 
 
 







observed that while the maximum potential reaction rate (kinact) of compound 2-5 was similar, 
their affinity (KI) towards CjGH35A was quite different—with the bare aziridine 2 and the N-
alkyl norbornene 4 less favorable than the N-alkyl azide 3 and the Cy5 ABP 5 (Table 7.2). 
A crystal structure of CjGH35A soaked with compound 2 was resolved and revealed that 
the compound bound to the enzyme at its catalytic nucleophile and adopted a 4C1 conformation 
(Fig. 7.3). 
Next, ABP labeling was attempted in human fibroblast lysates and the culture medium of 
GALC-overexpressing HEK293T cells. Due to the initial unavailability of the Cy5 ABP 5, the 
experiment was performed by firstly pre-incubating the norbornene compound 4 with the 
tetrazine-BODIPY compounds 8, and incubating the mixture with the culture medium of  
GLB1 GALC
JJB367 7,270  658 53,500  2,770
SYD215 138  24.5 472  37.6
1 (LWA480) 21.7 (ref 44) 39.1 (ref 44)
2 (TB562) 2.55  0.59 5.57  0.36
3 (TB422) 2.55  0.47 12.0  2.27
4 (TB582) 57.8  3.05 98.6  20.8
5 (TB652) 14.6  0.98 61.0  6.89
6 (R3391) 4.79  4.09 9.95  5.73
Table 7.1
Table 7.1. Apparent IC50 values (nM) of compounds towards
retaining exo β-galactosidases. Error range = ± SD, n = 2
biological replicates.
Kinact (min
-1) KI (μM) kinact/KI 
(min-1 μM-1)
2 (TB562) 0.99  0.11 1.90  0.39 0.52  0.06
3 (TB422) 0.56  0.11 0.03  0.01 21.71  4.08
4 (TB582) 2.19  0.55 3.37  1.20 0.65  0.16
5 (TB652) 2.03  0.63 0.11  0.04 18.98  5.88
Table 9.2
Table 9.2. Kinetic data for compounds 2-5 towards CjGH35A.






Figure 7.3. Crystal structure of CjGH35A in complex with 2. The map shown is a Fo-Fc map, with 
phases calculated prior to the inclusion of ligand in the refinement, contoured at 3σ. Carbon atoms are 
colored green for the ligand and ice blue for the side chains. The interacting residues are annotated, 







Figure 7.4. In vitro ABP labeling using in situ generated probe (4 + 8) at different probe 
concentration. A) Labeling in culture medium of HEK293T cells overexpressing mouse GALC. B) 
Labeling in human fibroblast (NHDF) lysates.  
GALC-overexpressing cells. A band of about 80 kDa in size was observed, (Fig. 7.4A), which 
could correspond to the secreted form of mouse GALC. In human fibroblast lysates, a smear of 
bands between 50 and 75 kDa was detected (Fig. 7.4B), which indicated the labeling of 
glycoprotein(s). 
 Because this labeling pattern resembled that of cyclophellitol ABPs towards GBA 
(Chapter 1 and 2, this thesis), the reactivity of compound 2-6 was also examined towards the 
recombinant human GBA (Imiglucerase) by enzymatic assay. The results showed that all 
compounds inhibited GBA with nanomolar potency, except for the aziridine compound 2 and 
the norbornene compound 4, both being low micromolar inhibitors of GBA (Table. 7.S1, Fig. 
7.S5). The compounds were also tested for their reactivity towards another retaining β- 
glucosidase, GBA2. It turned out that they were about two- to ten-fold less potent towards 
GBA2 compared to GBA (Table. 7.S1, Fig. 7.S5). The labeling by the in situ generated 
Figure 9.3
Figure 9.3. Crystal struct re of CjGH35A in complex with 2.
The map shown is a Fo-Fc map, with phases calculated prior to
the inclusion of ligand in the refinement, contoured at 3σ. Carbon
atoms are coloured green for the ligand and ice blue for the side
chains. The interacting residues are annotated, including catalytic
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Figure 9.4. In vitro ABP labeling using in situ generated
probe (4 + 8) at different probe concentration. (A) Labeling in
culture medium of HEK293T cells overexpressing mouse GALC.
(B) Labeling in human fibroblast (NHDF) lysates.




BODIPY-TMR probe (4 + 8) towards GBA was confirmed in NHDF lysates using a 
competitive ABPP (cABPP) setup, where its labeling was partially abrogated by pre-incubating 
the lysates with the GBA-specific ABP ME569 (chapter 3, this thesis) (Fig. 7.S6). To further 
verify if GLB1 and GALC were labeled by the probe, an additional cABPP was performed in 
mouse tissue extracts (expected to express both GLB1 and GALC) pre-incubated with 
cyclophellitol (known β-glucosidase inhibitor), compound 3 (inhibitor for both β-glucosidase 
and β-galactosidase) or 4 (β-galactosidase inhibitor at lower concentrations), subsequently 
labeled with the GBA-specific ABP ME569, and finally with the in situ generated probe. The 
probe labeled a ~50 kDa band and a ~60 kDa band that overlapped with GBA labeling by 
ME569 (lane 2 of both gels, Fig. 7.5A). Pre-incubation with 3 or 4 (the later at 500 nM), but not 
cyclophellitol, abolished the labeling by the in situ generated BODIPY-FL probe (Fig. 7.5A). 
Contrastingly, cyclophellitol and 3, but not 4, abolished the labeling by ME569 (Fig. 7.5A). In 
Figure 7.5. Labeling on GLB1 and GBA by the in situ generated probe (4 + 8) in extracts of mouse 
kidney (left) or brain (right). A) Competitive ABPP pre-incubated firstly with cyclophellitol (CP), 3, or 4, 
and secondly with ABP ME569. B) GLB1 activity in the identically treated samples measured by 






1. Generally in agree with cABPP results, with CP not affecting GLB1 activity, and both TB422 
and TB582 do. Only TB582 seems to have less inhibitory effect on GLB1 in 4MU assay than 
on the gel. Could be contamination of 4MU
enzymes (e.g. GBA or GBA2).
Cy3 Fluor. Cy3 Fluor.
Cy5 Fluor. Cy5 Fluor.











































































B Kidney extracts Brain extracts
Figure 9.5. Labeling on GLB1 and GBA by the in situ generated probe (4 + 8)
in extracts of mouse kidney (l ft) or brain (right). (A) Competitive ABPP with
firstly cyclophelitol (CP), 3, or 4, and secondly with ABP ME569. (B) GLB1 activity
in the identically treated samples measured by fluorogenic substrate assay. Error





parallel, enzymatic assay performed in the identically-treated samples showed that GLB1 activity 
was abolished by 3 and (at 500 nM) 4 (Fig. 7.5B), but not by cyclophellitol. Together, these 
results strongly suggested that the β-galactose-configured N-tagged cyclophellitol aziridine ABP 
allows gel-based fluorescence detection for both GLB1 (known size = 64 kDa) and GALC 
(known size = 50 kDa). 
 Next, the β-galactose-configured Cy5 ABP 5 was employed for evaluating with mouse 
kidney extracts (known to contain both GALC and GLB1) its labeling properties. The labeling 
was performed in samples pre-incubated with the broad-spectrum β-glucosidase BODIPY ABP 
JJB70, in order to specifically visualize the β-galactosidases (over GBA and GBA2). Labeling 
occurred in an irreversible and mechanism-based manner: optimal labeling for both GLB1 and 
GALC occurred at 1 µM ABP 5 (Fig. 7.6A), 30 min incubation time (Fig. 7.6 B), and at pH 
from 4.0 to 5.0 (Fig. 7.6 C). The labeling was partially abrogated by pre-incubating the samples 
with 4-MU β-gal, consistent with labeling occurring in the active site of the enzymes (Fig. 7.6D).  
 
Figure 7.6. Labeling of ABP 5 in mouse kidney extracts. (A) Concentration-dependent labeling. (B) 
Time-dependent labeling. (C) pH-dependent labeling. (D) Competitive ABPP with 4-MU-β-gal. 
7.2.3 Glycosidase target analysis by chemical proteomics and gel-based ABPP in mouse tissue 
extracts 
Glycosidase targets of the biotin ABP 6 in mouse kidney extracts were next examined. For 
Figure 3. Labeling of 5 in mouse kidney homogenates. A) Concentration-dependent 
labeling. B) Time-dependent labeling. C) pH-dependent labeling. D) Competitive ABPP 



























Figure 9.6. Labeling of ABP 5 in mouse kidney extracts. (A) Concentration-
dependent labeling. (B) Time-dependent labeling. (C) pH-dependent labeling. (D)
Competitive ABPP with 4-MU-β-gal.




this purpose, biotin ABP 6 was generated from a mixture of 5 µM 4 and 10 µM 9 reacted O/N. 
The ABP was with mouse kidney extracts at pH 4.5, and samples were subjected to LC/MS-
based protein identification form the streptavidin-enriched and on-bead trypsin-digested 
peptides. Five glycosidases were identified in samples incubated with the in situ generated biotin 
probe (4 and 9), and none in the control (no probe) or the competitive sample (pre-incubated 
with the Cy5 ABP 5). The identified glycosidases included the expected targets GALC, GLB1, 
the β-glucosidase GBA, as well as two other targets: the GLB1-like protein 1 and 2 (GLB1L and 
GLB1L2, respectively) (Table 7.3). The latter two proteins are putative enzymes that are also 
classified onto GH35 family but with yet unknown biological functions. Both proteins contain 
catalytic amino acids identical to those of GLB1 (Fig. 7.S7). Despite having similar molecular 
weight to the GLB1 precursor protein (around 70 kDa without N-glycosylation), their post-
translational processing, cellular localizations, and tissue-dependent expression are predicted to 
be different to those of GLB1 (Table 7.S3). To examine whether these features would allow 
their visualization by the β-galactose configured Cy5 ABP 5, mouse tissue extracts from brain, 
epididymis, testis, duodenum, and colon were pre-incubated with the broad-spectrum β-
glucosidase ABP JJB70 (to prevent labeling on β-glucosidases by ABP 5), and next incubated 
with ABP 5 for gel-based fluorescence detection. The gel showed that each tissue had a distinct 
labeling profile, and that additional bands were identified at molecular weight or pH range 
different from those of GLB1 and GALC. In extracts of mouse brain, epididymis, 
Table 7.3. List of identified glycosidases in mouse kidney extracts labeled and pulled-down with 
ABP 6 by LC-MS. 
 
Table 9.3
Do On-bead digest in mouse epididymis, 
brain, and H4 cell lysates (later)
Rank Accession Entry Description PLGS Score Coverage (%)




13 P23780 BGAL_MOUSE Beta-galactosidase OS=Mus 
musculus GN=Glb1 PE=1 
SV=1
2851 31
22 Q8VC60 GLB1L_MOUSE Beta-galactosidase-1-lile 
protein OS=Mus musculus
GN=Glb1l PE =1 SV=1
1783 22
47 P17439 GLCM_MOUSE Glucosylceramidase OS=Mus 
musculus GN=Gba PE=1 
SV=1
634 27
62 Q3UPY5 GLBL2_MOUSE Bet-galactosidase-1-lile
protein 2 OS=Mus musculus
GN=Glb1l2 PE=1 SV=1
367 23
Table 9.3. List of identified glycosidases in mouse kidney extracts labeled and





testis, duodenum, and colon, a number of bands at around 60 to 70 kDa displayed pH optimum 
at 6.0, instead of 4.5 from the one in kidney extracts (Fig. 7.7A). In duodenum extracts, an 
additional band between 150 and 250 kDa was detected optimally at pH 6.0, but it was not 
presented in extracts of colon. It was reasoned that the later higher band could be the intestinal 
dietary enzyme lactase phlorizin-hydrolase (LPH), as it contains a lactase pocket that hydrolyzes 
a β-galactose from the disaccharide lactose.47 Labeling with ABP 5 in cells expressing either the 
wild-type human LPH, or LPH mutated at the catalytic nucleophile of phlorizin hydrolase 
(pocket III) or lactase (IV) revealed that indeed LPH was labeled, and that the labeling largely 
occurred at the lactase pocket (Fig. 7.S8). 
 The bands detected in mouse kidney, brain, epididymis, and testis were further examined 
by treating the samples with or without PNGase F, an enzyme that removes the protein N-linked 
glycans. The treatment in kidney extracts shifted the 64 kDa band (putatively GLB1) to just 
above 50 kDa, and the 50 kDa band (GALC) to duplet bands at around 40 kDa (Fig. 7.7B). In 
brain extracts, deglycosylation of the 64 kDa band resulted in two bands just above kDa (Fig. 
7.7B). In testis and epididymis extracts, the ~70 kDa band was not affected by deglycosylation, 
as well as the prominent ~64 kDa band in the epididymis extracts (Fig. 7.7B). Together with 
the pH experiment, these results suggested that the Cy5 ABP 5 also likely labeled the GLB1-like 
proteins, as some of the bands between 50 kDa and 75 kDa either has a pH optimum of 6.0 
(suggesting non-lysosomal localization), or were not N-glycosylated (GLB1L2 and possibly 
GLB1L3, also points to non-lysosomal localization). In agreement with these observation, 
bioinformatics analysis (Fig. 7.7C and Table 7.S3) predicts that in contrast to GLB1L (which 
is likely secreted to the extracellular milieu), the other two GLB1-like proteins are not N-
glycosylated. GLB1L2 is predicted to contain no signal peptide, but instead a short 
transmembrane domain close to its N-terminus. Accordingly, it could be an one-pass plasma 
membrane protein having its catalytic pocket (C-terminal) facing the extracellular side. GLB1L3 
is also predicted to have no signal peptide, and could be a cytosolic/peroxisomal protein; it does 
have possible N-glycan sites, but if it does not contain an ER-targeting signal, N-glycosylation is 
not likely to occur. Furthermore, since the GLB1-like proteins are possibly not targeted to the 
lysosomes, they are unlikely to undergo a similar lysosomal proteolytic cleavage as that of GLB1. 
This would make their molecular weight larger than the mature, deglycosylated GLB1. The latter 
corresponds to the band observed just above 50 kDa seen in the PNGase F + lanes in Fig. 7.7B. 
In all the tested tissue homogenates at least one band with higher molecular weight was observed 




that was insensitive to PNGase F treatment. These bands are possibly GLB1-like proteins. 
Figure 7.7. In vitro labeling with ABP 5 in mouse tissue extracts. A) pH-dependent labeling in mouse 
tissue extracts. B) Labeling in mouse tissue extracts (pH 6.0) with or without deglycosylation by PNGaseF. 
C) Comparing domain structure, catalytic sites, and N-glycosylation sites for mouse GLB1 and GLB1-like 
proteins. Sp, signal peptide; T, transmembrane domain; *, acid/base; **, nucleophile; downward arrows, 
N-glycan sites; GH35 TIM barrel, Glycohydrolase family 35 domain (pfam01301); Jelly roll, β-
galactosidase 4_5 domain (pfam13364). 
7.3 Discussion 
In this chapter, the newly synthesized β-galactose configured cyclophellitol aziridine ABPs 
were examined for their mechanism-based labeling of  GLB1 and GALC—two retaining exo-β-
galactosidases whose lysosomal deficiency underlies the lysosomal storage diseases such as 













































Cy5 Fluor. Cy5 Fluor.
Figure 7.7. Iden ifying β-galactosid ses b ABP 5 labeling in mouse tissue
extracts. (A) pH-dependent labeling in mouse tissue extracts. (B) Labeling in
mouse tissue extracts with or without deglycosylation by PNGaseF. (C)
Comparing domain structure, catalytic sites, and N-glycosylation sites for
mouse GLB1 and GLB1-like proteins. Sp, signal peptide; T, transmembrane
domain; *, acid/base; **, nucleophile; downward arrows, N-glycan sites;
GH35 TIM barrel, Glycohydrolase family 35 domain (pfam01301); Jelly roll, β-
galactosidase 4_5 domain (pfam13364).






























































It is shown that the ABPs successfully label both GLB1 and GALC in mouse kidney 
extracts in a mechanism-based manner. They exhibit nanomolar inhibitory potency against both 
enzymes, as well as the bacterial GH35 enzyme CjGH35A. Towards the later enzyme, they also 
exhibit fast inhibition kinetics, resembling the values of  previously reported cyclophellitol-based 
inhibitors and ABPs towards GBA.46 When incubated with crystals of  CjGH35A, Compound 2 
forms a glycosidic bond with the enzyme, as seem in the resolved structure. This further verified 
its mechanism-based labeling towards β-galactosidases. While all the novel compounds 
(including the ABPs) also concomitantly inhibited GBA, compound 4 (β-galactose configured 
cyclophellitol aziridine N-alkyl norbornene) is relatively inactive towards this enzyme (IC50 ratio 
of  GBA/GLB1 = 200, highest among the tested compounds). This allows it to be used as a tool 
to selectively block β-galactosidase activity over β-glucosidases (at a carefully chosen 
concentration, such as 0.5 μM), a feature exploited in this chapter to verify targets of  the newly-
generated ABPs. With its concomitant inhibition of  β-glucosidases in mind, GLB1 and GALC 
can be visualized by the Cy5 ABP after pre-incubation of  GBA inhibitor, as demonstrate in this 
chapter. Thus, the Cy5 ABP can be used to rapidly and simultaneously profile GLB1 and GALC 
activity, as well as their post-translational modification and proteolytic processing. This would 
make it a very useful tool in the study and diagnosis of  lysosomal storage disorders caused by 
GLB1 or GALC deficiency. 
Chemical proteomics with the biotin ABP 6 in mouse kidney extracts revealed that, besides 
the expected target GLB1, GALC, and GBA, two other putative GH35 β-galactosidases were 
identified. These are the GLB1-like protein 1 and 2 (GLB1L and GLB1L2), which share 
homology to GLB1 and contain highly-conserved amino acid sequences near and at the catalytic 
residues (Fig. 7.S7). Gel-based ABPP in a variety of  mouse tissue extracts also identifies several 
proteins labeled by the Cy5 ABP 5 that exhibits properties distinct from the lysosomal protein 
GLB1 and GALC, such as a more neutral pH optimum (around 6.0), no N-linked glycosylation, 
and different tissue-dependent expression profile. These observations are corroborated with 
bioinformatics analysis, which shows that both the mouse and human GLB1L and GLB1L2 are 
likely not lysosomal proteins, and that GLB1L2 lacks a signal peptide nor possesses any N-
glycosylation sites (Table 7.S3). It is noteworthy that there exists another GH35 protein, the 
GLB1-like protein 3 (GLB1L3) in both mouse and human, predicted to be located in the cytosol, 
mitochondria, or peroxisomes (Table 7.S3). This protein was not identified by chemical 
proteomics in mouse kidney extracts, where it is probably poorly expressed (according to 




BioGPS expression database48, MOE430 dataset49). Nevertheless, due to the presence of  
conserved amino acid sequence at regions homologous to the GLB1’s catalytic site (Table 7.S3), 
it is envisioned that future pull-down experiment in tissues highly expressing this protein (such 
as testis49) might also reveal that GLB1L3 also is a bona fide β-galactosidase.  
Previously, a so-called senescence-associated β-galactosidase (SA-β-gal) is reported in a 
wide range of  senescent cells, from which the β-galactosidase activity can be selectively detected 
over the non-senescent cells at pH 6.0.50 The detected pH optimum at 6.0 for GLB1L and 
GLB1L2 (and possibly also GLB1L3) makes one to speculate the possibility that they might be 
the SA-β-gal. However, it has been shown with compelling evidence that the identity of  SA-β-
gal is in fact the lysosomal GLB1, and that upon its upregulation (both mRNA and protein) 
during senescence its suboptimal activity at pH 6.0 can be readily detected.51 In fact, such 
senescence-dependent upregulation is not unique to GLB1, as other lysosomal glycosidases, 
such as α-L-fucosidase and β-glucuronidase, are also similarly upregulated.52 Recently, a cell-
permeable tellurophene-containing ABP labeling proximal nucleophile has been developed for 
measuring SA-β-gal activity using an MS-based detection method.53 It can be envisioned that the 
here-described cyclophellitol aziridine fluorescent ABPs could also be used to simultaneous 
profile activity from multiple β-galactosidase across a pH range during senescence, using the 
simpler gel-based method. 
Because the molecular processing, enzymatic activity, and biology of  GLB1-like proteins 
are still largely unknown, the ability of  ABP 5 and 6 to profile their activity could offer exciting 
research directions. These include understanding their cell biology and biochemistry, and 
potential involvement senescence and in the lysosomal storage diseases caused by GLB1 or 
GALC deficiency. Additionally, the Cy5 ABP labels the dietary enzyme lactose-phlorizin 
hydrolase (LPH) in mouse duodenum extracts and in lysates of  cells overexpressing this protein. 
This probe might be also useful to monitor the activity of  this enzyme in other research context, 
such as its age-dependent expression54 and in diseases such as lactose-intolerance.55 
To conclude, the novel β-galactose configured cyclophellitol aziridine compounds are true 
mechanism-based irreversible inhibitors for both GLB1 and GALC. They concomitantly 
inactivate GBA and GBA2 at higher concentrations, but by pre-incubating the samples with β-
glucosidase inhibitors their visualization with the β-galactose ABPs can be prevented. The 





cell lysates and tissue homogenates. They also labeled the dietary enzyme LPH, and additionally 
revealed that the GLB1-like proteins are functional β-galactosidases that have different post-
translational processing, pH optimum, and tissue-dependent expression to that of  GLB1. They 
should be valuable tools in the future study of  β-galactosidases in health and disease.  




7.4 Experimental procedures 
7.4.1 Chemicals for biological assays 
Cyclophellitol (CP) and the β-glucosidase ABPs were synthesized as described earlier.39, 46 
Chemicals were obtained from Sigma-Aldrich, if  not otherwise indicated. Protein concentration 
was measured using PierceTM BCA assay kit (Thermo Fisher). 
7.4.2 Cell culture 
HEK293T cells (ATCC, CRL-3216) were cultured in DMEM high glucose (Sigma-Aldrich) 
supplemented with 10 % FCS, 0.1 (w/v) penicillin/streptomycin, and 1 % (v/v) Glutamax at 37 
°C at 7 % CO2, and sub-cultured at 1:10 ratio twice a week. Normal human dermal fibroblasts 
(NHDF, Cambrex-Lona, CC-2511) were cultured in HAMF12-DMEM medium (Sigma-Aldrich) 
supplemented with 10 % FCS and 0.1 (w/v) penicillin/streptomycin at 5 % CO2, and sub-
cultured at 1:3 ratio once per 1-2 weeks. Culture medium was refreshed every 2-3 days for NHDF. 
7.4.3 Enzyme activity assays 
Recombinant murine GALC was cloned and expressed in HEK293 cells following previously 
described procedures.38 The produced protein which was secreted to the culture medium 
(DMEM high glucose, Gibco) was directly used (5 μL volume) in enzyme activity studies. 
Human fibroblast lysates were prepared in KPi buffer (25 mM K2HPO4/KH2PO4, pH 6.5, 0.1 
% (v/v) Triton X-100, protease inhibitor cocktail (Roche, version 12, EDTA-free)), and 5.5 μg 
total protein was used. β-galactosidase from Cellvibrio japonicus (CjGH35A)45 was prepared in KPi 
buffer, and 8.9 ng protein was used. Enzyme activity assays were performed in 96-well plates 
(Greiner, black, flat-bottomed, medium-binding). All samples were diluted in McIlvaine buffer 
(150 mM citrate/Na2HPO4, pH 4.5) in a total volume of 25 μL, before incubated with 100 μL 
substrate mixture (1 mM 4-methylumbelliferyl β-D-galactopyranoside (4-MU-β-gal) in 150 mM 
McIlvaine buffer (pH 4.5) with 0.2 M NaCl) for 30 min at 37 °C. Reactions were stopped and 
analyzed as described earlier.56 To discriminate GLB1 and GALC activity, samples were 
incubated with McIlvaine buffer with or without 11 μM AgNO343, before incubated with 
substrates. To determine the apparent IC50 values, enzymes were equilibrated in 12.5 μL 
McIlvaine buffer (pH 4.5) and incubated with a range of inhibitor dilutions (12.5 μL) for 30 min 
at 37 °C, before subsequent incubation with substrates. All assays were performed in triplicate 





IC50 values were calculated as described earlier.56 KPi buffer and culture medium form control 
HEK293T cells were used as negative control for GLB1 and GALC, respectively. 
7.4.4 Inhibition kinetics 
An enzyme stock was prepared by diluting CjGH35A to 0.71 ng/µL in McIlvaine buffer (pH 
4.5, 0.1 % (w/v) BSA), and pre-warmed at 37 ̊C for 10 min in a thermoshaker. A series of  2 mL 
Eppendorf  tubes containing compounds 2-5 (162.5 µL, various compound concentrations) was 
added with 4-MU-β-gal (1300 µL, reaction [4-MU-β-gal] = 2345 µM), and identically pre-warmed. 
The t=0 samples were prepared by taking 112.5 μL from the [compound + 4-MU-β-gal] to the 
first two columns of  a 96-well plate (duplo for each compound concentration), after which stop 
buffer (200 µL, glycine-NaOH 1M, pH 10.3) and lastly the enzyme (12.5 μL) was added. Then, 
enzyme (137.5 µL) was added (t=0) to each of  the 2 mL Eppendorf  tubes (containing mixtures 
of  compounds and substrates). At t=2, 4, 6, 8 and 10 min, an aliquot of  125 µL from each of  
the reaction mixture was taken in duplo and added to the plate containing stop buffer. After 10 
minutes, the plate was measured with a LS-55 Fluorescence Spectrometer (PerkinElmer) using 
BL Studio with excitation at 366 nm and emission at 445 nm. Kinetic experiments were 
performed in duplo sets, each set with technical duplicates. Obtained values were plotted against 
incubation time, and fitted with one phase exponential association function to derive kobs values. 
The obtained kobs values were plotted against compound concentration in a second graph, and 
curve-fitted with Michaelis-Menten function to derive KI’ and kinact. KI was derived from KI’ 
using the function KI (1 + [4-MU-β-gal]/KM) = KI’, where [4-MU-β-gal] = 2345 µM and KM = 
487.4 µM. The KM was determined in a separate experiment by incubating the enzyme (same 
concentration as the kinetic experiments) with a series of  substrate concentrations for 10 
minutes at 37 °C. The reaction was stopped by adding stop buffer and samples were measured 
for 4-MU fluorescence. The results were plotted against substrate concentration, and KM was 
determined with Michaelis-Menten equation. Results were processed and analyzed using 
GraphPad Prism 7.0. 
7.4.5 Labeling using in situ generated probes 
The in situ generated probe was prepared by incubating 1 mM 4 (in DMSO) with 1 mM 7 or 8 
(both in DMSO) for at least 15 min at RT, unless otherwise stated. The produced probe had a 
concentration of  0.5 mM, assuming the click reaction proceeded to completion. Human 




fibroblast lysates (5 μg protein) and culture medium of  HEK293T cells (5 μL volume) were 
diluted in 150 mM McIlvaine buffer (pH 4.5) in a total volume of  10 μL, followed by incubation 
with 5 μL of  the in situ generated probe mixture (diluted in McIlvaine buffer) for 30 min at 37 
°C, at a final probe concentration of  1 μM. For competitive activity-based protein profiling 
(cABPP), human fibroblasts lysates were diluted as described above, and pre-incubated with 2.5 
μL ME56957 or the in situ generated probe mixture for 30 min at 37 °C at a final probe 
concentration of  100 nM for ME569 and 1 μM for the in situ generated probe. Samples were 
subsequently incubated with the second probe (ME569 for samples pre-incubated with the in 
situ generated probe, and vice versa) for another 30 min at 37 °C with identical probe 
concentration during pre-incubation. Samples were denatured, resolved by SDS-PAGE, and 
scanned for fluorescence as described previously.56 
7.4.6 Competitive ABPP in extracts of  mouse kidney or brain 
25 μg protein from extracts of mouse kidney or brain (prepared as described in chapter 8) was 
diluted in 10 μL McIlvaine buffer (150 mM, pH 4.5), and pre-incubated with 2 μL cyclophellitol, 
3, or 4 (diluted in DMSO and McIlvaine buffer) for 30 min at 37 °C at 50 or 500 nM 
concentration for compound during incubation. Samples were subsequently incubated with 2 
μL ME569 (100 nM during incubation) for 30 min at 37 °C, then with 2 μL in situ generated 
probe (4 + 8, 1 μM of  the clicked product during incubation, assuming complete reaction) or 8 
(1 μM during incubation, as negative control) for 30 min at 37 °C. Samples were denatured, 
resolved by SDS-PAGE, and scanned for fluorescence as described previously.56 
7.4.7 Characterization of  labeling by ABP 5 in mouse kidney extracts 
25 μg total protein from mouse kidney extracts was diluted in McIlvaine buffer (150 mM, various 
pH) in a total volume of  10 μL, and incubated with 5 μL ABP 5 prepared at different 
concentrations and pHs. For labeling at varying pH, kidney extracts were incubated with 
McIlvaine buffer (pH 3.0 – 7.0) for 15 min at 37 °C, followed by incubating with MDW93346 
(prepared in McIlvaine buffer pH 3.0 - 7.0, 5 μM during incubation) for 30 min at 37 °C to label 
all GBA, then with 1 μM ABP 5 (prepared in McIlvaine buffer pH 3.0 -7.0, 1 μM during 
incubation) for 30 min at 37 °C. For labeling at varying ABP concentration, mouse kidney 
extracts were equilibrated in McIlvaine buffer pH 4.5 for 5 min on ice, incubated with 5 μM 





ABP 5 (end concentration = 10nM -10μM; pH 4.5) for 30 min at 37 °C. For labeling at varying 
incubation time, mouse kidney extracts were prepared as above, and incubated with 1 μM ABP 
5 (end concentration; pH 4.5) at 37 °C for 1 min to 2 h without MDW933 pre-incubation. 
7.4.8 Chemical proteomics 
3.5 mg protein from mouse kidney extracts was diluted with McIlvaine buffer (750 mM, pH 4.5) 
in a total volume of  500 μL. Three samples were prepared, the first incubated with DMSO only, 
the second firstly with 5 μM ABP 5 and secondly with 10 μM in situ generated ABP 6 (1 mM 4 
+ 2 mM 9, O/N incubation at RT in DMSO), and the third with firstly DMSO and secondly 
the 10 μM in situ generated ABP 6. All incubation step was performed at 37 °C for 1 h. Samples 
were denatured and subjected to pull-down, on-bead tryptic digest, and LC-MS protein 
identification as described in Chapter 6. 
7.4.9 ABPP in mouse tissue extracts with ABP 5 
20 μg total protein from extracts of  mouse kidney, brain, epididymis, testis, duodenum, and 
intestine were diluted in 10 μL McIlvaine buffer (150 mM, various pH from 3.0 to 7.0). Samples 
were then pre-incubated with 2.5 μL ABP JJB7058 (diluted in McIlvaine buffer pH 3.0 – 7.0, 200 
nM during incubation) for 30 min at 37 °C, and then 2.5 μL ABP 5 (diluted in McIlvaine buffer 
pH 3.0 – 7.0, 1 μM during incubation) for 30 min at 37 °C, before subjected to SDS-PAGE-
based fluorescent detection. For deglycosylation analysis, ABP labeled samples (60 μg protein 
diluted consecutively in 20 μL McIlvaine buffer pH 6.0 (5 min on ice), 5 μL ABP JJB70 (30 min, 
37 °C) and 5 μL ABP 5 (30 min, 37 °C), at identical ABP concentrations as described) were 
firstly desalted using Pierce 7K polyacrylamide spin column (Thermo Fisher), and a 10 μL 
aliquot was treated with PNGase F according to the manufacturer’s protocol (New England 
BioLabs). Non-treated samples (20 μg protein diluted in 10 μL McIlvaine buffer pH 6.0) were 
similarly labeled with ABPs. Both the non-treated and PNGase F-treated samples were subjected 
to SDS-PAGE and fluorescence detection. For labeling on recombinant LPH, wild-type of  
catalytic mutant LPH constructs59 were expressed in HEK293T cells using the PEI method 
(Chapter 6). Cells were lysed in lysis buffer, and 20 µg total protein from the resulting lysates 
were labeled with 10 µM ABP 5 at pH 6.0 for 30 min at 37°C, before subjecting to SDS-PAGE 
and fluorescence detection. 
 





Amino acid sequences (human GLB1: NP_000395.3, GLB1L: NP_001273352.1, GLB1L2: 
NP_612351.2, GLB1L3: NP_001073876.2; mouse (Mus musculus) GLB1: NP_033882.1, GLB1L: 
NP_083286.1, GLB1L2: NP_722498.1, GLB1L3: NP_001106794.1) were retrieved from NCBI. 
Multiple sequence alignment was performed with CLUSTALW.60 Signal peptide prediction was 
based on SignalP 5.061 (DTU Bioinformatics). Transmembrane domain prediction was 
performed with XtalPred-RF.62 N-glycosylation sites were predicted using NetNGlyc 1.063 (DTU 
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7.S1. Supplementary Tables and Figures 
Table 7.S1. Apparent IC50 values for compounds towards CjGH35A, GBA, and GBA2. Error range = 
  SD, n = 2 biological replicates. 
 
Table 7.S2. Structural determination and refinement statistics for CjGH35A in complex with 2 











2 21.55  2.14
3 1.22  0.66
4 27.16  1.57
5 33.9  2.15
Table 9.S1. Apparent IC50 values for compounds towards CjGH35A, GBA, and
GBA2. Error range = ± SD, n = 2 biological replicates.
Table 9.S2





a, b, c (Å) 98.9, 115.8, 116.0
α, β, γ ( ) 90.2, 90.2, 90.4




I /σI 6.0 (1.2)















Bond lengths (Å) 0.018
Bond angles ( ) 1.927
*Values in parentheses are for highest-resolution shell.
Table 9.S2. Data for structural determination and
refinements for CjGH35A in complex with 2.




Table 7.S3. Comparison between GLB1 and GLB1-like proteins in A) mouse and B) human. 
 
Protein GLB1 GLB1-like 1 GLB1-like 2 GLB1-like 3
Gene GLB1 GLB1L GLB1L2 GLB1L3
Animo acid 677 (isoform a) 654 (isoform 1) 636 653
Molecular weight 76.075 74.158 72.079 74.823
N-terminal signal 
peptide
1-23 1-27 No No
Transmembrane 
domain
No No 13-32 No

















Protein GLB1 GLB1-like 1 GLB1-like 2 GLB1-like 3
Gene Glb1 Glb1l Glb1l2 Glb1l3
Animo acid 647 (isoform 1) 646 652 (isoform 1) 662
Molecular weight 73.12 73.28 73.96 75.59
N-terminal signal 
sequence
1-24 1-23 No No
Transmembrane 
domain
No No 13-35 No
N-glycan sites Asn27, Asn248, 
Asn500, Asn504, 
Asn510
Asn93, Asn239 No No
Cellular 
localization





Table 9.S3. Comparison between GLB1 and GLB1-like








Figure 7.S1. Discriminating activities from GLB1 and GALC in different samples by enzymatic 
assay. A) pH-dependent β-galactosidase activity (relative to the highest measured activity). B) Effect of 






























































































































NHDF lysates Culture medium (GALC-
overexpressing HEK293T)
NHDF lysates Culture medium (GALC-
overexpressing HEK293T)
Figure 9.S1. Discriminating activities from GLB1 and GALC in different
samples by enzymatic assay. (A) pH-dependent β-galactosidase activity
(relative to the highest measured activity). (B) Effect of AgNO3 (11 µM). Error
range = ± SD, n = 3 technical replicates.





Figure 7.S2. (Continued, 1 of 2). 
figure 7.S2
Figure 7.S2. Inhibition curves by compounds towards human GLB1
(hGLB1, NHDF lysates), mouse GALC (mGALC, from culture medium of
HEK293T cells overexpressing the protein), and CjGH79. Error range = ±
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Figure 7.S2. Inhibition curves by compounds towards A) human GLB1 (hGLB1, NHDF lysates), B) 
mouse GALC (mGALC, from culture medium of HEK293T cells overexpressing the protein), and 



















Figure 7.S2. Inhibition curves by compounds towards human GLB1
(hGLB1, NHDF lysates), mouse GALC (mGALC, from culture medium of
HEK293T cells overexpressing the protein), and CjGH79. Error range = ±
SD, n = 2 biological replicates.






















































































































































Figure 7.S3. Measurement of inhibition kinetic parameters by compounds 4-5 towards CjGH79. A) 
Processing curves. Error range =   SD, n = 3 technical replicates. B) kobs vs [I] plots, fitted with Michaelis-



































































































































































































































2 set #1 2 set #2 2 set #3 2
3 set #1 3 set #2 3 set #3 3
4 set #1 4 set #2 4
5 set #1 5 set #2 5 set #3 5
Figure 9.S3. Mesaurement of inhibition kinetic parameters by compounds
4-5 towards CjGH79. (A) Processing curves. Error range = ± SD, n = 3
technical replicates. (B) kobs vs [I] plots, fitted with Michaelis-Menten equation.






















































Km = 487.4 M
Figure 9.S4. Michaelis-Menten plot of 4-MU-β-gal towards CjGH35. Error
range = ± SD, n = 3 technical replicates.





Figure 7.S5. Inhibition curves by compounds towards A) GBA (imiglucerase) and B) GBA2 (lysates 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 9.S5. Inhibition curves by compounds towards (A) GBA
(imiglucerase) and (B) GBA2 (lysates of HEK293T cells overexpressing






Figure 7.S6. Labeling by the in situ generated probe (4 + 8) in human fibroblast (NHDF) lysates 
with or without pre-incubation with the GBA-specific ABP ME569. CBB, Coomassie Brilliant Blue 














Figure 9.S6. Labeling by the in situ generated probe (4 + 8) in human
fibroblast (NHDF) lysates with or without pre-incubation with the GBA-
specific ABP ME569. CBB, coomassie blue staining for assessing total protein
loading.





Figure 7.S7. Comparing amino acid sequences between GLB1 and GLB1-like proteins. Red, signal 
peptide of GLB1. Green, TIM barrel domain of GLB1. Cyan, TIM- β1 loop. Magenta, β-sheet domain 1 of 
GLB1. Dark yellow, cleaved peptide in mature GLB1. Yellow, β-sheet domain 2 of GLB1. Black, N-linked 
glycan sites of GLB1. Light gray, catalytic acid/base. Dark gray, catalytic nucleophile. Domain structures 







Figure 7.S8. ABP 5 labeling in HEK293T lysates containing expressed human wild-type or mutant 
LPH.  
7.S2. Synthetic strategies for compounds used in this chapter (Department of  Bio-Organic 
Synthesis, Leiden University) 
 
Scheme 7.S1. Synthesis of compounds 2 and 3. Reagents and conditions: a) Li, NH3, -60  C, b) 10, 
K2CO3, DMF, 80  C, overnight, 25 %; c) NaN3, DMF, 80  C, quant; d) PPh3, imidazole, I2, THF, -20  C to 









Cell lysates (HEK293T 
overexpressing human LPH)
In vitro labeling: ABP 5 (10 µM, 






11 12 13 14
Scheme 7.S1. Synthesis of compounds 2 and 3. Reagents and conditions: a)
Li, NH3, -60 °C, b) 10, K2CO3, DMF, 80 °C, overnight, 25 %; c) NaN3, DMF, 80
°C, quant; d) PPh3, imidazole, I2, THF, -20 °C to rt, 15 min, 69 %.





Scheme 7.S2. Synthesis of compounds 4 and 5. Reagents and conditions: a) 1,6-hexanediol, pyridine, 
CH2Cl2, RT, 90 min, 95 %; b) imidazole, PPh3, I2, Et2O, CH3CN, RT, overnight, 80 %; c) NaN3, DMF, 80 
 C, overnight, quant; d) PPh3 on beads, H2O, THF, 48 h, quant; e) norbornene-OSu
1, DIPEA, DCE, RT, 
overnight, 19 28 %, 20 68 %; f) p-toluenesulfonic acid, CH2Cl2, MeOH, RT, overnight, 86 %; g) PPh3, I2, 
imidazole, THF, reflux, 1.5 h, 73 %. h) 22, K2CO3, DMF, 75  C, overnight, 12 %. i) Cy5 tetrazine 23, MeOH, 
overnight, 87 %. 
7.S3 Protein crystallography (University of  York) 
The gene for CjGH35A, cloned into a pET28a vector modified for Ligation Independent 
Cloning, was expressed, and the protein purified and crystallized as described previouslymain text 
ref  45, in 2.7 M sodium acetate pH 7.2 (protein at 30 mg/ml, drop 1.2:1 μL over well). A crystal 
was soaked in the presence of  a speck of  powder of  compound 2 for 70 h. The crystal was 
fished directly into liquid nitrogen without the need for additional cryoprotectant. Data were 
collected on beamline IO2 at the Diamond Light Source at wavelength 0.97950 Å, and were 
processed using DIALS2 and scaled with AIMLESS3 to 1.6 Å (Table 7.S2). The space group was 
P1 and the unit cell dimensions, 98.9, 115.8, 116.0 Å, and angles, 90.2, 90.2, 90.4°. The structure 
was solved using programs from the CCP4I2 suite. Molecular replacement was performed using 





Scheme 7.S2. Synthesis of compounds 4 and 5. Reagents and conditions: a)
1,6-hexanediol, pyridine, CH2Cl2, RT, 90 min, 95 %; b) imidazole, PPh3, I2,
Et2O, CH3CN, RT, overnight, 80 %; c) NaN3, DMF, 80 °C, overnight, quant; d)
PPh3 on beads, H2O, THF, 48 h, quant; e) norbornene-OSu
38, DIPEA, DCE,
RT, overnight, 20 28 %, 21 68 %; f) p-toluenesulfonic acid, CH2Cl2, MeOH, RT,
overnight, 86 %; g) PPh3, I2, imidazole, THF, reflux, 1.5 h, 73 %. h) 21, K2CO3,













in Coot5, followed by repeated cycles of  REFMAC6 employing twin refinement using observed 
intensities. The structure was annotated in PDB (5JAW). 
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General Discussion and Future Prospects 
Activity-based probes for retaining exo-glycosidases: novel 
research tools for lysosomal storage disorders 
  




he central theme of  this thesis are molecular probes labeling retaining exo-
glycosidases implicated in health and diseases such as lysosomal storage disorders 
(LSDs). The structure of  these so-called activity-based probes (ABPs) is based on 
configurational isomers of  a cyclophellitol or cyclophellitol aziridine scaffold, to 
which a reporter tag (e.g. a fluorophore or a biotin) is attached. When incubated with sample, 
their substrate mimicry and the latent electrophilic trap (epoxide or aziridine) allow them to react 
upon proximity-driven protonation with their target glycosidase’s catalytic nucleophile, resulting 
in a stable ester bond that irreversibly inactivates the enzyme. Through the grafted reporter tag 
on the probe, the covalent ABP-enzyme complex can be readily visualized or affinity-enriched, 
allowing quantitative and qualitative analysis on the spatiotemporal distribution of  the labeled 
enzyme in vitro, in situ, and in vivo by the activity-based protein profiling (ABPP) platform 
(General Introduction, this thesis). 
 This thesis aims to explore novel applications of  glycosidase ABPs to study these enzymes’ 
role in health and disease, in particular in the inherited lysosomal storage diseases (LSDs). It 
further aims to expand the ABPP platform to other retaining exo-glycosidases such as α-
glucosidase, β-glucuronidase, α-L-iduronidase, α/β-mannosidases, and β-galactosidases. 
Different goals for the thesis work were formulated and reached: (1) setting up ABP profiling 
protocols for glycosidases (Chapter 1), (2) developing two novel in vivo applications for ABPs in 
LSD research (Chapter 2-3), and (3) characterizing in detail the mechanism of  action, potency, 
target specificity, and potential applications of  six novel classes of  ABPs (Chapter 4-7). The 
described work builds on past research utilizing cyclophellitol ABPs labeling the lysosomal 
glucocerebrosidase (GBA)1 and galactocerebrosidase (GALC)2, and cyclophellitol aziridine N-
acyl or N-alkyl variants targeting either retaining exo-β-glucosidases (GBA, GBA2, GBA3, and 
LPH), retaining exo-α-galactosidases, or retaining exo-α-L-fucosidases3–6. These ABPs, via the 
afore-mentioned reaction mechanism, allow sensitive and specific visualization of  target 
enzymes across species and sample types (recombinant enzyme, cell lysates, tissue homogenates, 
whole cells, and tissue sections) using detection methods such as SDS-PAGE-based fluorescence 
scanning, fluorescence-activated cell sorting (FACS), fluorescence microscopy, and mass 
spectrometry (LC-MS/MS). Demonstrated applications include the diagnostic confirmation of  
LSDs (Gaucher disease, Fabry disease, and Krabbe disease),1–3 the assessment of  bodily 
distribution of  labeled enzymes,7, 8 the investigation of  active-site pocket occupancy of  GBA by 






labeled enzymes.9  
 The first part of  the thesis concerns Gaucher disease. Chapter 1 systematically describes 
ABP protocols for gel-based and microscopy-based detection for GBA; these can be adapted to 
detect other lysosomal glycosidases with ABPs. Next are presented two novel in vivo applications 
of  ABPs, being: (1) assessing target specificity of  existing pharmacological agents for inducing 
cell/animal models of  Gaucher disease (Chapter 2), and (2) generating such cell/animal models 
using compounds modified from the cyclophellitol-based ABPs (Chapter 3). Both applications 
exploit the cell and tissue permeability of  ABPs and their highly selective inactivation of  GBA 
by binding to the catalytic nucleophile E340. The first study established the relevance and 
limitations of  conduritol B epoxide (CBE) and cyclophellitol (CP) in generating Gaucher 
cell/animal models, while the second investigation led to the identification of  superior GBA 
inhibitors (CPs with installed biphenyl or adamantly moiety at C8).  
 The second part of  the thesis reports on the characterization of  novel cyclophellitol 
aziridine ABPs with a differentially configured cyclophellitol core. For this use was made of  
enzymatic assays to establish potency of  inhibition and kinetic parameters; gel-based ABPP to 
assess target specificity and labeling at various conditions (concentration of  ABP, incubation 
time, pH, temperature, sample types; chemical proteomics to identify the labeled targets, and 
protein X-ray crystallography (performed at the University of  York) to acquire structural insights 
regarding the ABP-enzyme complex. It is demonstrated that the examined ABPs allow 
mechanism-based labeling and activity-based protein profiling (ABPP) for the corresponding 
LSD-relevant glycosidases, including GH31 lysosomal α-glucosidase (GAA) (Chapter 4), GH2 
β-glucuronidase (GUSB) (Chapter 4), GH39 α-L-iduronidase (IDUA) (Chapter 5), GH38 
lysosomal α-mannosidase (MAN2B1) (Chapter 6), GH2 β-mannosidase (MANBA) (Chapter 
6), and GH35/GH59 lysosomal β-galactosidase/galactocerebrosidase (GLB1/GALC) 
(Chapter 7). For all ABPs, Cy5- and biotin-tagged variants are available and both variants 
successfully label their target enzymes. Besides the α-L-iduronidase ABPs that are less potent 
than other ABP classes, all ABPs are able to visualize glycosidases in the context of  complex 
biological samples. Additional in-class (or similar class) glycosidase targets were identified for 
several ABPs, consistent with previous findings that cyclophellitol aziridine ABPs are broad-
spectrum probes: the in-class targets for the α-glucosidase ABPs were the other GH31 α-
glucosidases ER α-glucosidase II (GANAB), maltase-glucoamylase (MGAM), and sucrose-




isomaltase (SI); GH79 heparanase (HPSE) for the β-glucuronidase ABPs; four other GH38 α-
mannosidases (MAN2A1, MAN2A2, MAN2B2, and MAN2C1) for the α-mannosidase ABPs; 
two other GH35 proteins GLB1-like protein 1 and 2 (GLB1L and GLB1L2) for the β-
galactosidase ABPs. Of  note, all cyclophellitol aziridine ABPs at high concentrations tend to 
also label GBA, with the exception of  the α-L-iduronidase and α-mannosidase ABPs. Specific  
visualization of  the target enzyme class may be achieved by pre-blocking of  GBA with selective 
inhibitors/ABPs for this enzyme.  
I. Unique research possibilities and applications offered by the glycosidase ABPs 
a. Superior spatial detection 
 One important feature of  the studied ABPs is that they allow one to directly visualize 
active glycosidase molecules. As such ABP labeling fundamentally differs from detecting an 
enzyme through measurement of  its activity towards fluorogenic substrates or natural substrates. 
When applied in situ to detect the spatial distribution of  active glycosidase molecules, the ABP 
method provides better resolution than zymography based on enzyme activity assays. A recent 
study reported on detection of  active GBA molecules by fluorescent ABPs in human skin 
sections with higher resolution compared to fluorogenic substrate-based zymography10 This 
study established that active GBA molecules largely reside in the extracellular lipid matrix 
between the viable epidermis and the lower part of  stratum corneum. The in situ ABP detection 
technique, conceivably combined with the gel-based detection procedure, may be used to 
elucidate the (patho)physiological roles of  GBA in diseases such as atopic dermatitis,11 multiple 
myeloma,12 and neurological diseases such as amyotrophic lateral sclerosis,13 Lewy-body 
Dementia,14 and Parkinson disease.15 
b. In situ and in vivo labeling 
 The amphiphilic ABPs readily cross cellular membranes, which allows in situ and in vivo 
labeling of  lysosomal glycosidases that can be coupled to either gel-based, FACS, or fluorescence 
microscopy-based detection.1, 16 This approach is superior to detection of  enzymes using 
antibodies, which do not crosses cellular membranes and report glycosidase activity. Recently, 
cell permeable fluorescence-quenched substrates were developed by the group of  Vocadlo and 
shown to reveal the in situ activities by GBA17, 18 Similar probes are designed by the same 





inactivation/labeling, ABPs offer several unique applications. One example is to be found in 
studying the life cycle of  glycosidases in cells by pulse-chase experiment,19, 20 in which the 
formation, post-translational modification, and degradation can be monitored. Proof  of  
principle in this connection has been obtained for GBA.1  It can be envisioned that pulse-chase 
labeling with ABPs can be exploited to systematically examine the effect of  different mutations, 
modifier genes, or other cellular factors on the life cycle of  GBA. Such studies may shed further 
light on Gaucher disease and Parkinson disease. The approach could be extended to other 
lysosomal glycosidases for which ABPs are available. 
c. Distinguishing between isozymes 
 When coupled to gel-based detection, distinction among different enzymes or isoforms 
labeled by the same ABP is feasible, obviously provided that these differ in molecular weights 
(Chapter 1). Examples are the β-glucosidases GBA and GBA2, where the former is about 50-
65 kDa, and the latter is about 100 kDa.3, 9, 21 Isoforms of  GBA differ in glycan composition, i.e. 
there are distinct GBA glycoforms between 50-65 kDa),8 Isoforms may reflect the glycosidase’s 
cellular location (e.g. ER, Golgi, or lysosome). Isoforms may also stem from proteolytic 
processing, for example the 85 kDa vs. 64 kDa mature forms of  GLB122, 23. In general, 
combining the three approaches to detect enzymes (activity assay, ABP labeling, and antibody 
labeling) offers the most comprehensive assessment at both protein and activity level. The 
combination of  these three methods also assists best the biochemical confirmation of  diagnosis 
of  lysosomal storage diseases caused by defects in glycosidases.  
d. Sophisticated analysis of  therapeutic enzymes 
 Another unique advantage offered by ABPs is their potential use to track the cellular 
uptake and bodily distribution of  therapeutic enzymes, as in enzyme replacement therapy (ERT) 
for LSDs. The labeling of  a therapeutic enzyme with ABP is elegant and targeted, taking place 
at a well-defined catalytic nucleophile in the catalytic pocket. One study has compared head-to-
head two registered therapeutic enzymes for ERT of  Gaucher disease, imiglucerase and 
velaglucerase for their receptor-binding and uptake in cultured dendritic cells and macrophage, 
and for their bodily distribution in treated mice.8 The enzymes were labeled with similar ABPs 
with distinct fluorophores, next mixed equimolar after which the uptake and bodily distribution 
of  each was assessed in parallel.8 In this thesis, the α-L-iduronidase ABPs was successfully 




employed to monitor the cellular uptake and lysosomal targeting of  labeled therapeutic IDUA 
molecules in cultured fibroblasts from patients of  Hurler disease, mucolipidosis type II, and type 
III disease, using both fluorescence microscopy and gel-based methods (Chapter 5).24 Similarly, 
a recently discovered non-glycosylated α-galactosidase from plant was pre-labeled by α-galactose 
configured ABPs, and the uptake and delivery to lysosomes of  the fluorescent enzyme by 
cultured fibroblasts from a Fabry patient—via a lectin-independent pathway—was visualized.25 
More recently, correlative light and electron microscopy (CLEM) has been utilized to visualize 
endocytosed ABP-labeled imiglucerase in treated human fibroblasts expressing mannose 
receptors, revealing efficient delivery in individual lysosomes that contained endogenous GBA 
molecules as visualized with ABPs with other fluorophores.26 The newly available ABPs for 
different LSD-related glycosidases, described in this thesis, may facilitate the assessment of  
distribution, processing, and efficacy of  therapeutic enzymes following their administration to 
cells or animal models. Future installation of  detection tags compatible with infrared-red or 
radioisotopic detection may even allow real-time monitoring of  bodily distribution of  the labeled 
enzymes in animal models or in patients. Existing examples are cysteine protease ABPs 
containing a 64Co tag (with or without an additional Cy5 tag),27–29 a serine protease ABP coupled 
to an 111In tag,30 and a GBA ABP having a 2-deoxy-2-18F group.31 
e. Multiplexing  
 An advantage of  ABPs is the possibility offered to design multiplex readouts. Careful 
selection of  ABPs with distinct fluorophores allows simultaneous profiling of  multiple 
glycosidases, even in living cells or animals. Elegant simultaneous ABP profiling of  
endocannabinoid hydrolases in the mouse brain has been demonstrated.32 Chapter 2 of  this 
thesis provides examples of  multiplex ABP detection for active retaining exo-β-glucosidases, α-
glucosidases, and β-glucuronidase in cultured cells. Cells were incubated with ABPs having 
distinct fluorophores (BODIPY green, BODIPY red, or Cy5) that label the above mentioned 
enzymes. Upon cell lysis and subsequent gel-based fluorescence detection, different glycosidases 
labeled in vivo were visualized in parallel. In this manner, decrease in active enzyme molecules 
can be simultaneously assessed. By adding a subcellular fractionation step prior to gel-based 
detection, it is conceivable that one can also visualize the comparable/distinct subcellular 
localization of  different glycosidases. Furthermore, the multiplex setup coupled to gel-based 





N-linked glycosylation, proteolytic processing) for multiple enzymes. One potential application 
for the multiplex ABPP setup is to elucidate the molecular mechanisms underlying cellular 
processes affecting the transport and function of  lysosomal glycosidases. For example, it has 
been noted that the presence of  HEPES, a common pH-buffering additive to cell culture 
medium, could cause in cultured cells lysosomal stress and abnormality in GBA’s glycosylation 
status.33 The multiplex ABP incubation, coupled to subcellular fractionation technique and gel-
based readout, may thereby be applied to investigate whether upon HEPES treatment GBA is 
specifically affected in its glycosylation status, compared to other lysosomal glycosidases (for 
which ABPs are available). Furthermore, it can also be used to screen for the impact of  other 
types of  stressors on the lysosomal routing and lysosomal processing/stability of  GBA, 
compared to other lysosomal glycosidases. Impact of  different types of  enzyme mutations may 
be similarly examined in the context of  delineating genotype-phenotype correlation in LSDs. 
Furthermore, the multiplex readout may also be used in applied research. It is in principle 
compatible with different types  of  sample, such as cells, tissues, urine and plasma, thus 
assisting screening and diagnostic confirmation of  LSDs. 
f. Investigating in vivo target engagement of  glycosidase inhibitors 
 One of  the most powerful applications of  the cell permeable glycosidase ABPs is their 
use in assessing in vivo target engagement of  (covalent) inhibitors. The in vivo target engagement 
of  a drug is crucial to elicit proper therapeutic responses. The same holds for enzyme inhibitors 
used to induce authentic pharmacological cell/animal models of  human disease. Lack of  
awareness of  off-targets of  a given small molecule can be fatal,34 and ABPs are an excellent tool 
to profile potential off-targets of  covalent enzyme inhibitors.35 As mentioned, the irreversible 
GBA inhibitor conduritol B epoxide (CBE) with conceived specificity for GBA is commonly 
used for generating Gaucher disease models. It was closely examined in this thesis in cell and 
animal models to which extent there is interaction in vivo of  CBE with off-target glycosidases 
(other β-glucosidases, α-glucosidases and β-glucuronidase; enzymes for which ABPs were 
available) (Chapter 2). Observed competition by CBE of  the ABP labeling of  off-target 
glycosidases provides evidence for undesirable co-inhibition of  these enzymes. The investigation 
identified GBA2 and GAA as major off-target glycosidases at higher CBE concentrations. A 
narrow window for selective GBA inactivation exists, but when using CBE to induce a Gaucher 
disease model the experimenter should better check for potential concomitant inhibition of  




GBA2 and GAA. The same investigation revealed that cyclophellitol (CP), a closer mimic of  
glucose than CBE, inhibits GBA and GBA2 with equal affinity in all the studied models.21 
 The assessment of  in vivo target engagement is not necessarily restricted to covalent, 
mechanism-based inhibitors. For example, highly potent (nanomolar) reversible iminosugar 
inhibitors of  GBA2 based could be examined for their in vivo selectivity for GBA2, GBA and 
GBA3.36 Apparently, active-site targeted inhibitors with high affinity stay associated with the 
enzyme upon lysis of  cells and freeze-thawing of  lysates, and their ongoing active-site pocket 
occupancy can be readily visualized by in vitro applied ABPs. Obviously, such assays require 
considerable fine-tuning based on the features of  the inhibitor tested and ABP employed in the 
read-out. 
g. Use as mechanism-based inhibitors to inactivate enzymes on demand 
 The cyclophellitol and cyclophellitol aziridine ABPs can be used to selectively inhibit 
certain glycosidase in vitro or in vivo. The installation of  the flexible hydrophobic linker (with or 
without a fluorophore) in fact often enhances the inhibitory potency of  the compound towards 
their targeted glycosidases compared to just the cyclophellitol or cyclophellitol aziridine core 
alone;1, 3 sometimes the specificity profile also improves as in the case of  ABPs for GBA (where 
a bulky, hydrophobic moiety at the C8 position of  cyclophellitol prevents the labeling towards 
GBA2).37 For example, the cyclophellitol ABPs can be used as a more specific GBA inhibitor 
compared to CBE; the cyclophellitol aziridine ABPs can inhibit besides GBA also GBA2 and 
GBA3, while not inhibiting glucosylceramide synthase (GCS), a common off-targets by 
iminosugar inhibitors aiming at GBA2.38 When combined, these potent, specific, and cell-
permeable ABPs would offer convenient tools for studying the role of  GBA and GBA2 in 
sphingolipid metabolism in healthy and disease state. 
 In addition, the GBA-specific ABPs have been explored as a pharmacological agent in 
inducing Gaucher-like models (Chapter 3).37 Past research has found that the BODIPY-
containing cyclophellitol ABP does not penetrate the brain well of  treated mice,7 and this is 
consistent with the finding in adult zebrafish (Chapter 3). Thus, this ABP can only generates 
type 1 (non-neuropathic) Gaucher model at best. Due to GBA’s association with other 
neurological disorders such as Parkinson’s disease and Lewy-Body Dementia, and that current 





inactivation in the animal brain is desired. Although this has been achieved with genetic GBA 
knockout mice41 and fish models42, 43, pharmacological perturbation still offers several 
advantages, including the experimental simplicity, tunability of  the extent of  GBA inactivation, 
and that it allows one to simply start and stop enzyme inactivation and examine the response in 
the starting and recovering phase.44 Currently, only the cyclophellitol ABPs/inhibitors labeling 
GBA are suitable for generating an LSD model, as all others label multiple enzyme targets. The 
galactose configured cyclophellitol aziridine ABPs2 might be a potential lead in creating Krabbe 
disease animal model. Future studies might consider replace its BODIPY fluorophore with other 
hydrophobic moieties (such as biphenyl or adamantyl) to achieve better brain penetration. 
However, due to the much lower in vitro inhibitory potency, the in vivo efficacy and concomitant 
inhibition towards other enzymes in animals should be thoroughly examined. 
h. Discovery of  novel glycosidases, including cross species  
 The ability of  gel-based ABPP to simultaneously visualize multiple labeled targets having 
similar reactivity but distinct molecular properties (molecular weight, pH profile, and 
glycosylation status) provides a convenient platform for discovering novel glycosidases in given 
samples. Labeled bands (with or without affinity-enrichment by biotin ABP) can be further 
excised, tryptic digested, and identified by proteomics using LC-MS/MS instruments. The same 
approach has been widely applied in the case of  ABPs targeting proteases.45, 46 The α-galactose 
configured cyclophellitol aziridine ABPs were also used to investigate reactive α-galactosidases 
in plants, which in Nicotiana benthamiana led to the identification of  A1.1, a non-glycosylated 
enzyme stable across a broad pH range, and found to degrade the non-plant sphingolipids Gb3 
and lysoGb3 elevated in Fabry patients.25 Similarly, the broad substrate specificity of  some 
glycosidase ABPs have been be used to “fish out” novel glycosidases in other organisms such as 
plants.47, 48 In this thesis, the β-galactose configured cyclophellitol aziridine ABPs identified in 
the mouse kidney extracts two putative β-galactosidases in the GH35 family: the GLB1-like 
protein 1 and 2 (GLB1L and GLB1L2) (Chapter 7). This is substantiated by the occurrence of  
ABP-labeled bands in other mouse tissue extracts showing distinct molecular weights, 
glycosylation profile, and pH range than GLB1 and GALC. In the future, the biology and 
potential contribution of  GLB1-like proteins to LSDs stemming from β-galactosidase deficiency 
(e.g. GM1 gangliosidosis, Morquio B syndrome, Krabbe disease) should be carefully examined.  
i. Detecting interaction partners of  glycosidases 




 For proteomics identification of  glycosidases, biotin-tagged ABPs are commonly used to 
allow enrichment of  labeled enzyme with streptavidin carriers. In most of  the present 
biotinylated glycosidase ABPs, the biotin moiety is embedded in the catalytic pocket of  the 
enzyme and binding to streptavidin is only feasible upon denaturation of  the enzyme. An 
exception in this connection forms one GBA ABP that is a cyclophellitol-epoxide with an 
extended linker preceding the biotin moiety: likely when this ABP is bound to native enzyme the 
biotin is accessible to streptavidin, allowing pull-down.49 This ABP additionally contains an 
internal BODIPY fluorophore within the linker, making detection of  the affinity-enriched ABP-
enzyme complex compatible with fluorescence scanning on wet slab-gels, and thus facilitates 
their subsequent in-gel tryptic digest and proteomic analysis. It is conceived that such extended, 
dual functional extensions may be installed on other configurational isomers of  cyclophellitol 
and cyclophellitol aziridine cores. Such novel probes could be employed to pull down native 
enzymes and co-purify interacting protein partners. Combined with prior sub-cellular 
fractionation, this could provide valuable information on the protein interaction partners for 
each of  the glycosidases at distinct cellular locations. Identification of  interacting proteins is 
particularly warranted for the non-lysosomal glucosylceramidase (GBA2). The exact mode of  its 
membrane association, its precise localization, and biological functions is still enigmatic. Poorly 
understood is the reported association between GBA2 mutation and with locomotor dysfunction 
whilst pharmacological inhibition of  GBA2 activity in Miglustat-treated Gaucher disease and 
Niemann-Pick type C patients is well tolerated.50, 51 In the case of  the lysosomal GBA, protein 
interaction partners that should be identified with native ABP pull-downs as positive controls 
include LIMP2 and saposin C. Discovery of  novel GBA interacting proteins might be of  interest 
to generate new insights and clues in the pathophysiology of  Gaucher and Parkinson disease. 
j. Discovery of  small molecule interactors of  glycosidases 
 ABPs can in principle be also used to identify small molecules (including peptides)  
interacting with the catalytic pocket. Such interactors might be developed into pharmacological 
chaperones to stabilize (mutant) enzyme.52 Recently, a high-throughput in vitro screening 
platform has been developed using the glycosidase ABPs coupled to fluorescence polarization 
(FluoPol) assay, in which the ratio of  free ABP and bound ABP can be measured by reading out 
the extent of  polarized fluorescence (where the bound ABP emits more polarized 





and the same approach is presently extended to GBA, α-glucosidase, and α-mannosidase 
(unpublished work by Daniel Lahav, Dep. Bio-organic Synthesis, Leiden University). The 
screening can in principle also be performed in living cells, given the cell-permeability of  some 
ABPs. Alternatively, the fluorescent quench glycosidase substrates developed by Vocadlo and co-
workers provides another useful tools that is compatible with high-throughput microscopy-
based screening in living cells.17, 18 Nevertheless, no matter the type of  initial screen, ABP can be 
used as a confirmation tool to assess the amount of  active glycosidase molecules in different 
tissues of  treated animals, where in vivo imaging techniques for glycosidase activity are not yet 
available. This can be performed with gel-based detection for tissue homogenates and 
microscopy-based detection in tissue sections, as earlier discussed. The existing FluoPol and gel-
based ABPP platforms are presently used to identify selective inhibitors for various glycosidases 
(ongoing work Daniel Lahav, Dep. Bio-organic Synthesis, Leiden University). Finally, 
crystallography studies on the formed Michaelis complex and covalent complex of  the ABP 
towards the target glycosidase may provide a structural-guided design of  specific inhibitors 
towards a given glycosidase, for example to create a better inhibitor/ABP towards GH39 α-L-
iduronidase (Chapter 5).24  
k. Confirming LSD diagnosis 
 Diagnosis of  LSDs is primary based on clinical symptoms. It is often combined with 
genotyping and demonstration of  reduced enzyme activity in the case of  enzymopathies.53 
Additionally used for confirmation of  diagnosis is demonstration of  accumulating metabolites 
or elevated biomarkers.54 For several LSDs there are now (newborn) screening programs in some 
parts of  the world,55 largely based on genotyping followed by metabolite analysis and/or enzyme 
activity assays. The cyclophellitol and cyclophellitol aziridine ABPs can assist in some cases in 
the biochemical confirmation of  the diagnosis of  an LSD caused by deficiency of  a 
corresponding glycosidase. Available ABPs include those labeling GBA (Gaucher disease),1 GLA 
(Fabry disease),4 FUCA1 (fucosidosis),5 GALC (Krabbe disease),2 GAA (Pompe disease) 
(Chapter 4),56 GUSB (Sly syndrome) (Chapter 4),57 MAN2B1 (α-mannosidosis) (Chapter 6), 
MANBA (β-mannosidosis)(Chapter 6), and GLB1 (GM1 gangliosidosis and Morquio B 
syndrome) (Chapter 7). Of  note, ABP labeling can not only visualize lack of  active enzyme 
molecules, but also abnormalities in post-translational processing (such as glycosylation and 
proteolytic cleavage). The latter abnormalities can also be detected with antibodies but these are 




not always available. Proof  of  concept for the diagnostic potential of  ABPs has been provided 
for Gaucher disease,1 Fabry disease,4 Krabbe disease,2 and Pompe disease (Chapter 4)56 with 
patient fibroblasts. Future application might exploit the use of  ABPs in other patient materials, 
such as dried blood spots and urine, to assist in the confirmation of  LSD diagnosis. 
  Finally, an attractive potential application for α-galactose configured ABPs to discuss 
warrants discussion, that is their use to identify female heterozygotes of  Fabry disease that may 
develop an attenuated form of  the disease. Fabry disease (α-galactosidase (GLA) deficiency) is 
an X-linked disorder, and as the result of  random X-chromosome inactivation some cells of  
Fabry disease heterozygotes lack the normal enzyme whereas other cells are entirely normal 
depending on which copy of  the X-chromosome was inactivated.58 Reliable diagnosis of  Fabry 
disease carriers by simple enzyme activity assays is virtually impossible59: only the measurement 
of  isolated hair root cells, showing random X-chromosome inactivation) allows confirmation of  
the status of  carriers.60 The labeling of  cellular GLA with appropriate ABP might offer a 
convenient solution for carrier detection. Labeled cells can be sorted by FACS: concomitant 
demonstration of  cells with normal labeling intensity and cells lacking label would point to a 
heterozygote. A complication is that the presently available GLA ABP also labels the enzyme N-
acetylgalactosaminidase (NAGA) that is not affected in Fabry disease. A more specific ABP for 
GLA should be ideally designed. 
II. Current limitations and future prospects 
The electrophilic trap (warhead) 
 The broad-specificity cyclophellitol aziridine ABPs offer mechanism-based labeling of  in 
class glycosidases. This makes them excellent tools for simultaneous gel-based profiling and for 
discovery of  novel glycosidases. However, the high reactivity of  aziridine with nucleophiles, even 
beyond in-class targets, also makes them unattractive for microscopic imaging, as multiple 
enzymes may be labeled. Cyclophellitol epoxides allow highly specific labeling of  GBA and 
GALC. Unfortunately, its α-galactose configurational isomers did not react with retaining exo-
α-galacosidases.61 The same was observed for exo-α-glucosidase (unpublished data, Dep. Bio-
organic Synthesis, Leiden University). Future studies could investigate whether the C8-tagged 
cyclophellitol epoxide with other extensions would offer better target specificity. Also worth 





reactive than aziridine but are still compatible with installing a linker/tag at the aglycon position. 
The recognition element/linker 
 The β-glucosidases (GBA and GBA2) are prone to become labeled by higher 
concentrations of  cyclophellitol aziridine ABPs with various configurations of  the cyclophellitol 
core. This was observed for ABPs with α-glucose (Chapter 4),56 β-glucuronic acid (Chapter 
4),57 β-mannose (Chapter 6), and β-galactose (Chapter 7) configurations. For the α-glucose 
configured ABPs, their labeling of  β-glucosidases has been attributed to the half  chair (4H3) 
conformational mimicry of  cyclophellitol aziridine to β-glucosidases’ substrates at the transition-
state.62 Another explanation for the aziridine ABPs’ cross-reactivity with β-glucosidases might 
be the presence of  the N-alkyl extension (with or without a fluorophore) at the aglycon side. 
The major substrate of  both GBA and GBA2, glucosylceramide, contains such flexible alkyl 
chains at the aglycon side, and it has been noted that these are important for the hydrophobic 
interaction of  the substrate glucosylceramide with GBA during catalysis.63 Indeed, it was noted 
that the bare β-galactose configured cyclophellitol aziridine core is a much weaker β-glucosidase 
inhibitor when compared to its N-alkylated analogues. In the future, structural modification on 
the alkyl chain might prevent these ABP’s concomitant labeling on β-glucosidases, such as 
increasing the hydrophilicity, or decreasing the structural flexibility. 
 Interestingly, a conceptually new compound, cyclophellitol with a cyclic sulfate 
electrophilic warhead, has recently been developed as a selective inhibitor of  α-glucosidases over 
β-glucosidases by mimicking the 4C1 chair conformation of  the Michaelis complex observed in 
α-glucosidases.62 In the future, other types of  nucleophilic trap favoring the 4C1 chair 
conformation and allowing the attachment of  a reporter tag at the reducing-end aglycon side 
should be explored for the synthesis of  selective ABPs.  
The detection tag 
 Currently used fluorophores have their limitations. The BODIPY fluorophores, while 
providing excellent quantum yield,64 are usually inferior to the Cy5 fluorophore when used in 
samples such as cell lysates or animal tissue homogenates, as these often contain background 
fluorescence at overlapping wavelength. They are also not always synthetically attainable, and 
sometimes they are unstable during purification and storage.65 In addition, ABPs with the 
BODIPY fluorophores are less brain-penetrant, which may be due to the presence and action 




of  p-glycoprotein or multidrug resistance protein pumps that actively excrete BODIPY-
containing molecules across the blood-brain barrier.66, 67 The Cy5 fluorophore offers better 
signal-to-noise ratio, but on the other hand appears less soluble in aqueous solution, and is prone 
to label non-specifically, particularly in cells and zebrafish (observations Dep. Medical 
Biochemistry, Leiden University). Similarly, oligonucleotides modified with the positively-
charged Cy3 or Cy5 dye, but not the non-charged Alexa fluorophores, have been found to 
aspecifically accumulate at the mitochondrial membrane.68 All of  these issues might underlie the 
poor labeling and inactivation of  enzyme by Cy5 cyclophellitol ABP in zebrafish (Chapter 3). 
Taken together, a non-charged fluorophore with good solubility in aqueous solution would be 
ideal for visualizing purposes. Another way to improve sensitivity of  ABP detection under 
fluorescence microscopy is to use a two-step labeling strategy. For example, cells can be firstly 
treated with ABPs containing a norbornene tag (Chapter 7), and after fixation these can be 
covalently attached with tetrazene-Cy5 fluorophores via inverse electron-demand Diels-Alder 
reaction (IEDDA, Chapter 7). In this manner, issues concerning Cy5’s solubility and aspecificity 
in cells might be overcome. The tetrazine can in principle also be coupled to structures 
containing multiple fluorophores, thus allowing signal amplification. The ABPs can also be 
installed with a isotopic tag, allowing real-time imaging of  labeled therapeutic glycosidases using 
techniques such as positron emission tomography (PET)27–29, 31 or single-photon emission 
computed tomography (SPECT)30 in living animals.  
 For affinity-enrichment using biotinylated ABPs, the described methods in this thesis only 
allow enrichment of  denatured proteins. As mentioned above, this is due to the inaccessibility 
of  the biotin tag to streptavidin resin, when the glycosidase is in its native conformation. 
Replacing the biotin moiety with the dual functional tag with an extended linker (described in an 
earlier section) might allow native pull-down of  glycosidases in cell lysates or tissue homogenates. 
The conceived advantages of  this setup include: (1) “cleaner” enrichment, as endogenous 
biotinylated proteins would not be enriched by the streptavidin resin when they are in the native 
conformation (unpublished data); (2) easier confirmation of  the enrichment results. After pull-
down, samples can be resolved by SDS-PAGE, and the labeled glycosidases can be easily 
detected by fluorescence scanning. Sample resolved by SDS-PAGE can be directly used for in-
gel tryptic digestion for subsequent LC-MS/MS detection; (3) co-affinity enrichment of  other 
associated proteins with the labeled glycosidase (discussed in an earlier section). The proposed 






 Over the past years, carefully designed and characterized small molecules tailored for 
specific proteins, such as the herein described activity-based probes labeling retaining exo-
glycosidases, have opened up new research possibilities in the traditional medical biochemistry 
field. In the future, further development of  these chemical biology tools will no doubt continue 
to offer novel insights on the physiological and pathological roles of  relevant enzymes, as well 
as facilitate the development of  therapies and improvement of  disease diagnosis, as exemplified 
in this thesis for the lysosomal storage disorders. 
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his thesis describes the characterization and application of  activity-based probes 
(ABPs) labeling lysosomal glycosidases in mechanism-based manner. Lysosomal 
glycosidases are acid hydrolases that fragment glycoconjugates in lysosomes. 
Several inherited diseases in man concern deficiencies of  lysosomal glycosidase. 
The corresponding lysosomal storage disorders (LSDs) show characteristic lysosomal 
accumulation of  undegraded substrates. The General introduction provides an overview of  
lysosomal glycosidases and the associated LSDs. Described are the present therapeutic options 
and diagnostic methods for these LSDs. Attention is paid to the current knowledge on the life 
cycle of  lysosomal glycosidases and their catalytic mechanisms. Understanding on the latter 
has allowed generation of  activity-based probes (ABPs) irreversibly labeling lysosomal 
glycosidases in mechanism-based manner. Present ABPs for lysosomal glycosidases are based 
on cyclophellitol and cyclophellitol aziridine scaffolds. This thesis describes how these probes 
can be employed as versatile research tools to study the disease-relevant enzymes. 
Chapter 1 describes developed protocols for gel-based and microscopy-based detection of  
lysosomal glycosidases, in particular the β-glucosidase GBA, labeled with ABPs in vitro and in 
vivo. Cyclophellitol-type ABPs with an electrophilic epoxide group and a BODIPY fluorophore 
allow specific and sensitive visualization of  active GBA molecules following their irreversible 
labeling. Labeling can be performed in vitro using enzyme preparations or cell and tissue 
extracts. Due to the amphiphilic nature of  the ABP in situ labeling and detection of  active 
GBA in cells and organisms is also feasible. The described protocols for ABP labeling of  GBA 
can be extended to other cyclophellitol- and cyclophellitol aziridine-based ABPs labeling 
distinct glycosidases. 
Chapter 2 investigates the in vivo target engagement of  conduritol B epoxide (CBE) and 
cyclophellitol (CP) in cells and animals using a gel-based competitive activity-based protein 
profiling (cABPP) approach. CBE and CP are mechanism-based irreversible GBA inhibitors and 






may have additional in vivo glycosidase targets beyond GBA, depending on the applied dose and 
treatment duration. For the candidate off-target glycosidases a suite of  glycosidase ABPs is 
available which allow the investigation of  potential interaction of  CBE and CP with these 
enzymes. Investigation of  CBE-treated cells and zebrafish larvae revealed that at higher 
concentrations CBE also interacts in vivo with non-lysosomal glucosylceramidase (GBA2) and 
lysosomal α-glucosidase (GAA). A tight, but acceptable window for selective inhibition of  GBA 
in the brain of  mice is observed. On the other hand, CP was found to inactivate with equal 
affinity GBA and GBA2 and therefore is not suitable to generate genuine GD-like models. 
Chapter 3 reports on novel irreversible inhibitors of  GBA that are superior in selectivity towards 
the enzyme. This class of  inhibitors carries a bulky hydrophobic substituent at C8, such as 
adamantyl and biphenyl-moieties. By gel-based ABPP experiments, it is shown that the novel 
compounds are far more potent and selective irreversible inhibitors of  GBA as compared to 
CBE in vitro, in cultured cells, and in zebrafish larvae. The novel inhibitor with an adamantyl 
moiety was found to be brain-permeable and to allow generation of  an authentic neuropathic 
GD model in zebrafish by exposure of  animals to the compounds via food uptake.  
Crucial for optimal application of  novel glycosidase ABPs in LSD research is a careful 
biochemical characterization, which includes mechanism of  action, inhibition kinetics, in vitro 
and in vivo potency, and identification of  off-target glycosidases. 
Chapter 4 describes the characterization of  newly developed ABPs for the lysosomal 
glycosidases α-glucosidase (GAA) and β-glucuronidase (GUSB), enzymes deficient in Pompe 
disease and mucopolysaccharidosis type VII (MPSVII; Sly Syndrome), respectively. The ABPs 
label their respective target enzymes (GAA and GUSB) potently and in mechanism-based 
manner. The α-glucose configured ABP labels not only the lysosomal α-glucosidase GAA, but 
also the ER α-glucosidase II (GANAB). It was observed that at higher concentration GBA is a 
major off-target of  both ABPs. By altering the labeling pH, and by pre-incubating samples with 
a specific GBA inhibitor, GAA and GUSB can be specifically visualized with the corresponding 
ABPs in vitro as well as in lysates of  cells treated in situ with the ABPs. The diagnostic potential 
of  the GAA ABP for Pompe disease is demonstrated with cultured fibroblasts from patients. 
Chapter 5 documents the development and characterization of  α-L-iduronide configured 
cyclophellitol aziridine ABPs for human α-L-iduronidase, whose inherited deficiency leads to 




mucopolysaccharidosis type I (MPS I, Hurler syndrome). The new ABPs are shown to react 
irreversibly in mechanism-based manner with human recombinant α-L-iduronidase (rIDUA, 
Aldurazyme®). They exhibit lower potency and slower inhibitory kinetics compared to previous 
ABPs designed for other retaining glycosidases, possibly due to conformational constraints. The 
relative low affinity of  the present ABP makes detection of  endogenous IDUA in cells and 
tissues challenging. The fluorescent Cy5 ABP can efficiently label therapeutic iduronidase ex vivo 
and the enzyme’s delivery to lysosomes—as intended in enzyme replacement therapy (ERT)—
was successfully monitored by fluorescence microscopy of  MPS I patient fibroblasts. 
Chapter 6 reports on the biochemical evaluation of  α- and β-mannose configured cyclophellitol 
aziridine ABPs for the retaining exo-α-mannosidases (Glycoside Hydrolase (GH) family 38) and 
exo-β-mannosidase (GH family 2)—enzymes implicated in diverse pathologies including cancer 
and LSDs. The ABPs label their respective target mannosidases in mechanism-based manner 
and are micromolar inhibitors. All five GH38 α-mannosidases are labeled by α-mannose 
configured ABPs in mouse testis homogenates. Each enzyme was labeled in lysates of  cells upon 
overexpression. The unique molecular weight and pH optimum of  each mannosidase allows 
their simultaneous activity-based profiling in complex biological samples, and should assist 
future screening for small molecule inhibitors/activators of  these highly relevant enzymes. 
β-Mannose configured ABPs label the GH2 β-mannosidase (MANBA) in mouse kidney extracts. 
Co-labeling of  GBA occurs that can be prevented by pre-incubating samples with a GBA 
inhibitor.  
Chapter 7 provides the biochemical characterization of  β-galactose configured cyclophellitol 
aziridine ABPs, intended to label lysosomal β-galactosidase (GLB1) and galactocerebrosidase 
(GALC). The deficiency of  GLB1 causes GM1 gangliosidosis (and Morquio B syndrome) whilst 
deficiency of  GALC leads to Krabbe disease. The examined ABPs inhibit and label in 
mechanism-based manner recombinant and endogenous GLB1 and GALC. GLB1-like protein 
1 and 2 (GLB1L and GLB1L2) are additionally labeled, two putative β-galactosidases with poorly 
understood physiological roles. The β-glucosidases GBA and GBA2 are major off-targets of  β-
galactose configured cyclophellitol aziridine ABPs. These new ABPs can assist in future 






The thesis is concluded with a discussion summarizing the most important findings and 
highlighting the current and future applications of  cyclophellitol and cyclophellitol aziridine-
based ABPs in LSD research.  
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it proefschrift beschrijft de karakterisering en de toepassing van activity-based 
probes (ABPs) die lysosomale glycosidases labelen op een mechanism-based
wijze. Lysosomale glycosidases zijn zure hydrolases die glycoconjugaten 
fragmenteren in lysosomen. Verschillende erfelijke stofwisselingsziekten 
worden veroorzaakt door de deficiëntie in een lysosomaal glycosidase. De bijbehorende 
lysosomale stapelingsziekten (LSDs) vertonen een karakteristieke lysosomale stapeling van niet 
afgebroken substraten. De algemene inleiding biedt een overzicht betreffende lysosomale 
glycosidases en hiermee verbonden LSDs. Beschreven worden huidige 
behandelingsmogelijkheden en diagnostiek. Aandacht wordt besteed aan de kennis over de 
levenscyclus van lysosomale glycosidases en hun katalytische mechanisme. Begrip van dat 
laatste heeft mogelijk gemaakt het ontwikkelen van activity-based probes (ABPs), verbindingen 
die selectief  en irreversibel lysosomale glycosidases labelen in mechanism-based manner. De 
huidige ABPs voor lysosomale glycosidases zijn gebaseerd op cyclophellitol en cyclophellitol 
aziridine scaffolds. Dit proefschrift beschrijft hoe deze probes worden benut in het onderzoek 
aan ziekte-relevante enzymen. 
Hoofdstuk 1 beschrijft de ontwikkelde protocollen voor detectie in gel en met microscopie 
van lysosomale glycosidases, in het bijzonder het β-glucosidase GBA, na zijn labeling in vitro 
en in vivo met een fluorescent ABP. Cyclophellitol-type ABPs met een electrofiel epoxide en 
een BODIPY-fluorofoor visualiseren zeer specifiek en sensitief  actieve GBA-moleculen 
middels irreversibele labeling hiervan. Labeling kan worden uitgevoerd in vitro met 
enzympreparaten ofwel cel- en weefsel-extracten. Vanwege de amfifiele aard van de gebruikte 
ABPs is in situ labeling en detectie van actieve GBA-moleculen mogelijk in cellen en 
organismen. De beschreven protocollen voor ABP labeling van GBA kunnen verbreed worden 
naar andere cyclophellitol- en cyclophellitol aziridine-based ABPs die andersoortige 
glycosidases labelen. 




(CBE) en cyclophellitol (CP) in cellen en proefdieren. Gebruikt is gemaakt hierbij van een gel-
based ‘competitive activity-based protein profiling’ (cABPP) benadering. CBE en CP zijn 
mechanism-based irreversibele GBA remmers die volop gebruikt worden voor het genereren 
van modellen van de ziekte van Gaucher in cellen en proefdieren. Deze remmers kunnen echter 
in vivo additionele glycosidases naast GBA remmen, afhankelijk van gehanteerde dosis en 
incubatietijd. Voor kandidaat off-target glycosidases is een scala aan glycosidase ABPs 
beschikbaar waarmee de mogelijke interactie van CBE en CP hiermee kan worden aangetoond. 
Bestudering van CBE-behandelde cellen en zebravis larven liet zien dat bij hogere concentraties 
de remmer CBE in vivo ook reageert met niet-lysosomaal glucosylceramidase (GBA2) en 
lysosomaal α-glucosidase (GAA). Een nauw, maar acceptabel, window voor selectieve remming 
van GBA in het brein van de muis werd waargenomen. Anderzijds, CP bleek met eenzelfde 
affiniteit GBA en GBA2 te inactiveren en is derhalve ongeschikt voor het genereren van echte 
modellen van de ziekte van Gaucher. 
Hoofdstuk 3 beschrijft nieuwe irreversibele remmers van GBA met een superieure selectiviteit. 
Deze klasse verbindingen bevat een relatief  grote hydrofobe substituent op C8, zoals adamantyl 
en bifenyl-groepen. Aangetoond kon worden met gel-based ABPP experimenten dat de nieuwe 
verbindingen veel krachtigere en selectievere irreversibele remmers zijn van GBA dan CBE, 
zowel in vitro, in gekweekte cellen als in zebravis larven. De remmer met een adamantyl groep 
bleek goed brein-permeabel en maakt het mogelijk om een authentiek model de voor 
neuropathische vorm van de ziekte van Gaucher te genereren in de zebravis door een 
blootstelling van de dieren aan de verbinding gedrenkt in het voedsel.  
Cruciaal voor het optimale gebruik van nieuwe glycosidase ABPs in LSD onderzoek is een 
grondige biochemische karakterisering van hun eigenschappen, behelzend onderzoek aan het 
werkingsmechanisme, bepaling van kinetiek van remming, potentie in vitro en in vivo, en 
identificatie van off-target glycosidases. 
Hoofstuk 4 beschrijft de karakterisering van nieuw ontwikkelde ABPs voor de  lysosomale 
glycosidases α-glucosidase (GAA) en β-glucuronidase (GUSB), enzymen die deficiënt zijn bij de 
ziekte van Pompe en mucopolysaccharidosis type VII (MPSVII; Sly Syndroom), respectievelijk. 
Deze ABPs labelen hun respectievelijke target enzymen (GAA en GUSB) met hoge affiniteit en 
op mechanism-based wijze. Het α-glucose geconfigureerde ABP labelt niet alleen het lysosomale 





hogere concentratie van het ABP het β-glucosidase GBA een off-target is. Door het veranderen 
van de pH tijdens de labeling, en het pre-incuberen van monsters met een specifieke GBA 
remmer, kan GAA en GUSB specifiek gevisualiseerd worden met ABPs, zowel in vitro als in 
lysaten van cellen die in situ behandeld zijn met de ABPs. De potentieel diagnostische waarde 
van het GAA ABP voor de biochemische bevestiging van de diagnose van de ziekte van Pompe 
is aangetoond met gekweekte huidfibroblasten van patiënten. 
Hoofdstuk 5 documenteert α-L-iduronide geconfigureerde cyclophellitol aziridine ABPs voor 
human α-L-iduronidase, waarvan een erfelijke deficiëntie leidt tot mucopolysaccharidosis type I 
(MPS I, Hurler syndroom). De nieuwe ABPs blijken irreversibel te reageren op mechanism-
based wijze met recombinant α-L-iduronidase (rIDUA, Aldurazyme®). De probes vertonen een 
relatief  lage affiniteit van remming in vergelijking tot eerdere ABPs voor andere glycosidases, 
mogelijk vanwege conformatie beperkingen. The relatief  lage affiniteit van de huidige ABP 
verhindert de detectie van endogeen IDUA in cellen en weefsels. Omdat met de fluorescent Cy5 
ABP therapeutisch iduronidase ex vivo goed gelabeld kan worden, bleek het mogelijk de afvoer 
van dit enzym naar lysosomen van fibroblasten van MPS I patiënten goed te vervolgen. Een 
goede delivery naar lysosomen werd waargenomen, het beoogde doel van enzyme replacement 
therapy (ERT). 
Hoofdstuk 6 rapporteert de biochemische evaluatie van α- en β-mannose geconfigureerde 
cyclophellitol aziridine ABPs voor retaining exo-α-mannosidases (Glycoside Hydrolase (GH) 
familie 38) en exo-β-mannosidase (GH familie 2)—enzyme geïmpliceerd in verschillende ziekten 
zoals kanker en LSDs. De ABPs labelen mannosidases op mechanism-based wijze en zijn 
micromolaire remmers. Alle vijf  GH38 α-mannosidases aanwezig in homogenaten van muis-
testis worden gelabeld door de α-mannose geconfigureerde ABPs. Elk van de vijf  enzyme werd 
gelabeld in lysaten van cellen waarin het tot over-expressie was gebracht. Het unieke molecuul 
gewicht en pH optimum van elk mannosidase staat een simultane activity-based profiling toe in 
complexe biologische monsters. Die nieuwe probes kunnen van grote dienst zijn bij toekomstige 
screening voor small molecule inhibitors/activators van deze zeer relevante mannosidases. 
β-Mannose geconfigureerde ABPs labelen het GH2 β-mannosidase (MANBA) in muis-nier 
extracten. Een co-labeling van GBA treedt op met de probes die voorkomen kan worden door 
pre-incubatie van monsters met een GBA-remmer. 
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Hoofdstuk 7 biedt een overzicht van de biochemische karakterisering β-galactose 
geconfigureerde cyclophellitol aziridine ABPs, beoogd om de lysosomale β-galactosidase (GLB1) 
en galactocerebrosidase (GALC) te labelen. Deficiëntie van GLB1 veroorzaakt GM1 
gangliosidosis (en Morquio B syndroom) terwijl deficiëntie van GALC resulteert in de ziekte van 
Krabbe. De bestudeerde ABPs remmen en labelen in mechanism-based manner recombinant en 
endogeen GLB1 en GALC. Eveneens gelabeld worden GLB1-like protein 1 en 2 (GLB1L en 
GLB1L2), twee putatieve β-galactosidases met een grotendeels onbekende fysiologische rol. De 
β-glucosidases GBA en GBA2 zijn majeure off-targets van β-galactose geconfigureerde 
cyclophellitol aziridine ABPs. De nieuwe ABPs kunnen toekomstig fundamenteel en toegepast 
onderzoek aan humane β-galactosidases ondersteunen. 
Dit proefschrift eindigt met een beschrijving van de voornaamste resultaten en bevindingen. Tot 
slot worden de huidige en toekomstige toepassingen voor cyclophellitol en cyclophellitol 







及這些水解酶的缺陷，而其導致的溶小體儲積症（lysosomal storage disorder, LSD）則
會顯示在溶小體內積累了特定的未降解底物。緒論綜述了溶小體糖苷水解酶和相關
的 LSD，以及這些 LSD 現有的治療選項和診斷方法。文中更整理了關於溶小體糖苷
水解酶的生命週期及其催化機制的最新知識；對後者的知識尤其使得能固定標記溶
小體糖苷水解酶的活性探針（ABPs）因此得以被開發及合成。目前，環殼醇
(cyclophellitol)和環殼醇氮丙啶(cyclophellitol aziridine)為建構這些 ABP 的骨架。本論文
闡述了在研究這些與疾病相關的水解酶上如何來多元應用這些 ABP。 
第 1 章描述了利用凝膠電泳和螢光顯微鏡，在活體外或活體內用 ABP 標記溶小體糖
苷水解酶(特別是β-葡萄糖苷酶(GBA))的實驗步驟。這些環殼醇型 ABP 具有親電環
氧基團和 BODIPY 螢光團，能專一及靈敏地顯示被固定標記的活性 GBA 分子。標
記能在活體外(in vitro)進行，樣本包括酶製劑、細胞提取物、和組織提取物。而由於
ABP 的兩親性質，在細胞和生物體中來原位標記(in situ labeling)和檢測活性 GBA 也
均可行。另外，本章 ABP 標記 GBA 的實驗步驟還可以進一步擴展到其他環殼醇和
六元環多醇氮丙啶(configurational isomers of  cyclophellitol aziridine)的 ABP，來標記其
他不同類型的糖苷水解酶。 
第 2 章使用了凝膠電泳來進行競爭活性蛋白質分析（cABPP），研究了脫水肌醇（CBE）
和環殼醇（cyclophellitol, CP）在細胞和動物體內的目標接合作用。CBE 和 CP 是 GBA
依反應機制型的不可逆抑制劑，已被用於在細胞和動物中產生高雪氏症（Gaucher 
disease, GD）疾病模型。根據施用的劑量和持續時間，這兩種抑制劑在活體內(in vivo)則
可能有 GBA 以外的糖苷水解酶接合物。對於這些可能的額外接合物，一系列的 ABP
已被開發，並能被用於研究這些酶與 CBE 和 CP 的潛在交互作用。本研究顯示，在對





於 GBA則有窄小但卻足夠的選擇性抑制窗口。另一方面，本研究還發現 CP對於 GBA
和 GBA2的親和力相同，因此其不適合用於產生真正的 GD相關疾病模型。 












ABP能依酶反應機制來有效地標記它們各自的目標酶（GAA和 GUSB）。而 α -葡萄糖
構型的 ABP 不僅標記了溶小體α-葡糖苷酶 GAA，還標記了內質網 α -葡糖苷酶 II
（GANAB）。觀察顯示，在較高濃度下，兩種 ABP 的主要非目標酶為 GBA。而通過
改變標記時的酸鹼值，和通過使用特定 GBA抑制劑來預先混入樣品，相應的 ABP則
可用於活體外(包括用 ABP原位標記的細胞之裂解液)來選擇性地檢測GAA和GUSB。
另外，利用體外培養的患者纖維母細胞(fibroblasts)，針對 GAA的 ABP 顯示了其對龐
貝氏症有診斷潛力。 
第 5 章詳載了α-L-艾杜糖苷構型之六元環多醇氮丙啶 ABP 的開發和特性分析。此類
ABP為針對人類α-L-艾杜醣醛酸酶而開發，而此酶的遺傳缺陷能導致粘多醣貯積症第









第 6 章介紹了α-和β-甘露糖構型的六元環多醇氮丙啶 ABP 對保留型外切-α-甘露糖
苷酶（糖苷水解酶（GH）家族 38）和外切-β-甘露糖苷酶（GH家族 2）的生化分析。
這些酶與不同的疾病相關，包括癌症和 LSD。而甘露糖構型的 ABP 則顯示能以依酶
反應機制的方式標記它們各自的目標甘露糖苷酶，並且是微摩爾抑制劑。於小鼠睾丸




β-甘露糖構型的 ABP則標記了小鼠腎提取物中的 GH2 β-甘露糖苷酶（MANBA）。
通過用 GBA抑制劑預先混入樣品，則可被避免 GBA被此 ABP共標記。 
第 7章提供了對β-半乳糖構型的六元環多醇氮丙啶 ABP的生化特性分析，這些 ABP
旨在用於標記溶酶體β-半乳糖苷酶（GLB1）和半乳糖腦苷脂酶（GALC）。GLB1的缺
陷能導致 GM1神經節苷脂儲積症（和莫奎歐氏症(Morquio syndrome)B型），而 GALC
缺陷導致克拉伯病(Krabbe Disease)。據檢測，這些 ABP是以依酶反應機制的方式抑制
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